
<html lang="en"     class="pb-page"  data-request-id="a45e6c91-dd3b-4b6f-b97d-fc5e63a44800"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";issue:issue:10.1021/jmcmar.2012.55.issue-7;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;article:article:10.1021/jm300126x;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Design and Synthesis of Novel DFG-Out RAF/Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Inhibitors. 1. Exploration of [5,6]-Fused Bicyclic Scaffolds" /></meta><meta name="dc.Creator" content="Masanori  Okaniwa" /></meta><meta name="dc.Creator" content="Masaaki  Hirose" /></meta><meta name="dc.Creator" content="Takashi  Imada" /></meta><meta name="dc.Creator" content="Tomohiro  Ohashi" /></meta><meta name="dc.Creator" content="Youko  Hayashi" /></meta><meta name="dc.Creator" content="Tohru  Miyazaki" /></meta><meta name="dc.Creator" content="Takeo  Arita" /></meta><meta name="dc.Creator" content="Masato  Yabuki" /></meta><meta name="dc.Creator" content="Kazuyo  Kakoi" /></meta><meta name="dc.Creator" content="Juran  Kato" /></meta><meta name="dc.Creator" content="Terufumi  Takagi" /></meta><meta name="dc.Creator" content="Tomohiro  Kawamoto" /></meta><meta name="dc.Creator" content="Shuhei  Yao" /></meta><meta name="dc.Creator" content="Akihiko  Sumita" /></meta><meta name="dc.Creator" content="Shunichirou  Tsutsumi" /></meta><meta name="dc.Creator" content="Tsuneaki  Tottori" /></meta><meta name="dc.Creator" content="Hideyuki  Oki" /></meta><meta name="dc.Creator" content="Bi-Ching  Sang" /></meta><meta name="dc.Creator" content="Jason  Yano" /></meta><meta name="dc.Creator" content="Kathleen  Aertgeerts" /></meta><meta name="dc.Creator" content="Sei  Yoshida" /></meta><meta name="dc.Creator" content="Tomoyasu  Ishikawa" /></meta><meta name="dc.Description" content="To develop RAF/VEGFR2 inhibitors that bind to the inactive DFG-out conformation, we conducted structure-based drug design using the X-ray cocrystal structures of BRAF, starting from an imidazo[1,2-..." /></meta><meta name="Description" content="To develop RAF/VEGFR2 inhibitors that bind to the inactive DFG-out conformation, we conducted structure-based drug design using the X-ray cocrystal structures of BRAF, starting from an imidazo[1,2-..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="March 14, 2012" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm300126x" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2012 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm300126x" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm300126x" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm300126x" /></link>
        
    
    

<title>Design and Synthesis of Novel DFG-Out RAF/Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Inhibitors. 1. Exploration of [5,6]-Fused Bicyclic Scaffolds | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm300126x" /></meta><meta property="og:title" content="Design and Synthesis of Novel DFG-Out RAF/Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Inhibitors. 1. Exploration of [5,6]-Fused Bicyclic Scaffolds" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0028.jpeg" /></meta><meta property="og:description" content="To develop RAF/VEGFR2 inhibitors that bind to the inactive DFG-out conformation, we conducted structure-based drug design using the X-ray cocrystal structures of BRAF, starting from an imidazo[1,2-b]pyridazine derivative. We designed various [5,6]-fused bicyclic scaffolds (ring A, 1–6) possessing an anilide group that forms two hydrogen bond interactions with Cys532. Stabilizing the planarity of this anilide and the nitrogen atom on the six-membered ring of the scaffold was critical for enhancing BRAF inhibition. The selected [1,3]thiazolo[5,4-b]pyridine derivative 6d showed potent inhibitory activity in both BRAF and VEGFR2. Solid dispersion formulation of 6d (6d-SD) maximized its oral absorption in rats and showed significant suppression of ERK1/2 phosphorylation in an A375 melanoma xenograft model in rats by single administration. Tumor regression (T/C = −7.0%) in twice-daily repetitive studies at a dose of 50 mg/kg in rats confirmed that 6d is a promising RAF/VEGFR2 inhibitor showing potent anticancer activity." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm300126x"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm300126x">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm300126x&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm300126x&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm300126x&amp;href=/doi/10.1021/jm300126x" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2012</span><span class="cit-fg-volume">, 55</span><span class="cit-fg-issue">, 7</span><span class="cit-fg-pageRange">, 3452-3478</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/55/7" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm300101n" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm3001373" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Design and Synthesis of Novel DFG-Out RAF/Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Inhibitors. 1. Exploration of [5,6]-Fused Bicyclic Scaffolds<a class="ref internalNav" href="#pdb" aria-label=""></a></span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Masanori++Okaniwa">Masanori Okaniwa</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Masaaki++Hirose">Masaaki Hirose</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Takashi++Imada">Takashi Imada</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tomohiro++Ohashi">Tomohiro Ohashi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Youko++Hayashi">Youko Hayashi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tohru++Miyazaki">Tohru Miyazaki</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Takeo++Arita">Takeo Arita</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Masato++Yabuki">Masato Yabuki</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kazuyo++Kakoi">Kazuyo Kakoi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Juran++Kato">Juran Kato</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Terufumi++Takagi">Terufumi Takagi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tomohiro++Kawamoto">Tomohiro Kawamoto</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shuhei++Yao">Shuhei Yao</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Akihiko++Sumita">Akihiko Sumita</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Shunichirou++Tsutsumi">Shunichirou Tsutsumi</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tsuneaki++Tottori">Tsuneaki Tottori</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Hideyuki++Oki">Hideyuki Oki</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Bi-Ching++Sang">Bi-Ching Sang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jason++Yano">Jason Yano</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Kathleen++Aertgeerts">Kathleen Aertgeerts</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sei++Yoshida">Sei Yoshida</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Tomoyasu++Ishikawa">Tomoyasu Ishikawa</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-symbol">‡</span> <span class="aff-text">Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-Chome, Fujisawa, Kanagawa 251-8555, Japan</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">§</span> <span class="aff-text">CMC Center, Takeda Pharmaceutical Company Limited, 17-85, Jusohonmachi 2-Chome, Yodogawa-ku, Osaka 532-8686, Japan</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">∥</span> <span class="aff-text">Structural Biology, Takeda California, Inc., 10410 Science Center Drive, San Diego, California 92121, United States</span></div><div class="corresp-info"><strong>*</strong>For M.O.: phone, +81-466-32-1158; fax, +81-466-29-4449; e-mail, <a href="/cdn-cgi/l/email-protection#ddb0bcaebcb3b2afb4f3b2b6bcb3b4aabc9da9bcb6b8b9bcf3beb2b0"><span class="__cf_email__" data-cfemail="9bf6fae8faf5f4e9f2b5f4f0faf5f2ecfadbeffaf0fefffab5f8f4f6">[email protected]</span></a>. For T.I.: phone, +81-466-32-1155; fax, +81-466-29-4449; e-mail, <a href="/cdn-cgi/l/email-protection#bcc8d3d1d3c5ddcfc992d5cfd4d5d7ddcbddfcc8ddd7d9d8dd92dfd3d1"><span class="__cf_email__" data-cfemail="3b4f545654425a484e1552485352505a4c5a7b4f5a505e5f5a15585456">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm300126x&amp;href=/doi/10.1021%2Fjm300126x" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2012</span></span><span class="cit-volume">, 55</span><span class="cit-issue">, 7</span><span class="cit-pageRange">, 3452–3478</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">February 29, 2012</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>29 January 2012</li><li><span class="item_label"><b>Published</b> online</span>14 March 2012</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 12 April 2012</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm300126x" title="DOI URL">https://doi.org/10.1021/jm300126x</a></div><div class="article_header-article-copyright"><strong>Copyright © 2012 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D3452%26pageCount%3D27%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DMasanori%2BOkaniwa%252C%2BMasaaki%2BHirose%252C%2BTakashi%2BImada%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D55%26issueNum%3D7%26contentID%3Djm300126x%26title%3DDesign%2Band%2BSynthesis%2Bof%2BNovel%2BDFG-Out%2BRAF%252FVascular%2BEndothelial%2BGrowth%2BFactor%2BReceptor%2B2%2B%2528VEGFR2%2529%2BInhibitors.%2B1.%2BExploration%2Bof%2B%255B5%252C6%255D-Fused%2BBicyclic%2BScaffolds%26numPages%3D27%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D3478%26publicationDate%3DApril%2B2012">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm300126x"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">4275</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">41</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm300126x" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Design and Synthesis of Novel DFG-Out RAF/Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Inhibitors. 1. Exploration of [5,6]-Fused Bicyclic Scaffolds&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Masanori&quot;,&quot;last_name&quot;:&quot;Okaniwa&quot;},{&quot;first_name&quot;:&quot;Masaaki&quot;,&quot;last_name&quot;:&quot;Hirose&quot;},{&quot;first_name&quot;:&quot;Takashi&quot;,&quot;last_name&quot;:&quot;Imada&quot;},{&quot;first_name&quot;:&quot;Tomohiro&quot;,&quot;last_name&quot;:&quot;Ohashi&quot;},{&quot;first_name&quot;:&quot;Youko&quot;,&quot;last_name&quot;:&quot;Hayashi&quot;},{&quot;first_name&quot;:&quot;Tohru&quot;,&quot;last_name&quot;:&quot;Miyazaki&quot;},{&quot;first_name&quot;:&quot;Takeo&quot;,&quot;last_name&quot;:&quot;Arita&quot;},{&quot;first_name&quot;:&quot;Masato&quot;,&quot;last_name&quot;:&quot;Yabuki&quot;},{&quot;first_name&quot;:&quot;Kazuyo&quot;,&quot;last_name&quot;:&quot;Kakoi&quot;},{&quot;first_name&quot;:&quot;Juran&quot;,&quot;last_name&quot;:&quot;Kato&quot;},{&quot;first_name&quot;:&quot;Terufumi&quot;,&quot;last_name&quot;:&quot;Takagi&quot;},{&quot;first_name&quot;:&quot;Tomohiro&quot;,&quot;last_name&quot;:&quot;Kawamoto&quot;},{&quot;first_name&quot;:&quot;Shuhei&quot;,&quot;last_name&quot;:&quot;Yao&quot;},{&quot;first_name&quot;:&quot;Akihiko&quot;,&quot;last_name&quot;:&quot;Sumita&quot;},{&quot;first_name&quot;:&quot;Shunichirou&quot;,&quot;last_name&quot;:&quot;Tsutsumi&quot;},{&quot;first_name&quot;:&quot;Tsuneaki&quot;,&quot;last_name&quot;:&quot;Tottori&quot;},{&quot;first_name&quot;:&quot;Hideyuki&quot;,&quot;last_name&quot;:&quot;Oki&quot;},{&quot;first_name&quot;:&quot;Bi-Ching&quot;,&quot;last_name&quot;:&quot;Sang&quot;},{&quot;first_name&quot;:&quot;Jason&quot;,&quot;last_name&quot;:&quot;Yano&quot;},{&quot;first_name&quot;:&quot;Kathleen&quot;,&quot;last_name&quot;:&quot;Aertgeerts&quot;},{&quot;first_name&quot;:&quot;Sei&quot;,&quot;last_name&quot;:&quot;Yoshida&quot;},{&quot;first_name&quot;:&quot;Tomoyasu&quot;,&quot;last_name&quot;:&quot;Ishikawa&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2012&quot;,&quot;month&quot;:&quot;03&quot;,&quot;day&quot;:&quot;14&quot;,&quot;issue&quot;:&quot;7&quot;,&quot;volume&quot;:&quot;55&quot;,&quot;pages&quot;:&quot;3452-3478&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm300126x&quot;},&quot;abstract&quot;:&quot;To develop RAF/VEGFR2 inhibitors that bind to the inactive DFG-out conformation, we conducted structure-based drug design using the X-ray cocrystal structures of BRAF, starting from an imidazo[1,2-b]pyridazine derivative. We designed various [5,6]-fused bicyclic scaffolds (ring A, 1–6) possessing an anilide group that forms two hydrogen bond interactions with Cys532. Stabilizing the planarity of this anilide and the nitrogen atom on the six-membered ring of the scaffold was critical for enhancing BRAF inhibition. The selected [1,3]thiazolo[5,4-b]pyridine derivative 6d showed potent inhibitory activity in both BRAF and VEGFR2. Solid dispersion formulation of 6d (6d-SD) maximized its oral absorption in rats and showed significant suppression of ERK1/2 phosphorylation in an A375 melanoma xenograft model in rats by single administration. Tumor regression (T/C = −7.0%) in twice-daily repetitive studies at a dose of 50 mg/kg in rats confirmed that 6d is a promising RAF/VEGFR2 inhibitor showing potent anticancer act&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm300126x&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm300126x" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm300126x&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm300126x" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm300126x&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm300126x" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm300126x&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm300126x&amp;href=/doi/10.1021/jm300126x" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm300126x" /></input><a href="/doi/pdf/10.1021/jm300126x" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm300126x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm300126x%26sid%3Dliteratum%253Aachs%26pmid%3D22376051%26genre%3Darticle%26aulast%3DOkaniwa%26date%3D2012%26atitle%3DDesign%2Band%2BSynthesis%2Bof%2BNovel%2BDFG-Out%2BRAF%252FVascular%2BEndothelial%2BGrowth%2BFactor%2BReceptor%2B2%2B%2528VEGFR2%2529%2BInhibitors.%2B1.%2BExploration%2Bof%2B%255B5%252C6%255D-Fused%2BBicyclic%2BScaffolds%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D55%26issue%3D7%26spage%3D3452%26epage%3D3478%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=291651" title="Anions">Anions</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291788" title="Reaction products">Reaction products</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/55/7" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jmcmar.2012.55.issue-7/production/jmcmar.2012.55.issue-7.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_null" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/medium/jm-2012-00126x_0028.gif" alt="" id="_i1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300126x&amp;id=f_null"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">To develop RAF/VEGFR2 inhibitors that bind to the inactive DFG-out conformation, we conducted structure-based drug design using the X-ray cocrystal structures of BRAF, starting from an imidazo[1,2-<i>b</i>]pyridazine derivative. We designed various [5,6]-fused bicyclic scaffolds (ring A, <b>1</b>–<b>6</b>) possessing an anilide group that forms two hydrogen bond interactions with Cys532. Stabilizing the planarity of this anilide and the nitrogen atom on the six-membered ring of the scaffold was critical for enhancing BRAF inhibition. The selected [1,3]thiazolo[5,4-<i>b</i>]pyridine derivative <b>6d</b> showed potent inhibitory activity in both BRAF and VEGFR2. Solid dispersion formulation of <b>6d</b> (<b>6d-SD</b>) maximized its oral absorption in rats and showed significant suppression of ERK1/2 phosphorylation in an A375 melanoma xenograft model in rats by single administration. Tumor regression (<i>T</i>/<i>C</i> = −7.0%) in twice-daily repetitive studies at a dose of 50 mg/kg in rats confirmed that <b>6d</b> is a promising RAF/VEGFR2 inhibitor showing potent anticancer activity.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div class="extra-info-sec articleNote withdrawn"><h4><span>†</span> Accession Codes</h4><p class="last">PDB accession codes are <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4DBN">4DBN</a> for the BRAF cocrystal structure and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3VNT">3VNT</a> for the VEGFR2 cocrystal structure.</p></div><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_30471" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_30471" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Signal transduction in the mitogen-activated protein kinase (MAPK) or Ras/RAF/MEK/ERK pathway plays critical roles in cellular activities, including proliferation, differentiation, and survival. The pathway is controlled by extracellular signals through membrane receptors such as receptor tyrosine kinases (RTK)<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> and is activated by oncogenic mutations in many types of cancer.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> For example, there are many reports demonstrating the correlation between RAS mutations and malignant tumors.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> According to these reports, the RAS gene is activated by mutations at codon 12, 13, or 61 in various carcinomas, including pancreatic cancer (∼90%), non-small-cell lung cancer (∼35%), and liver cancer (∼30%), and so on. It is also known that BRAF mutation, particularly V600E, occurs in various carcinomas, including malignant melanoma (∼60%), thyroid cancer (∼30%), and colon cancer (∼15%).<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4, 5)</a> BRAF(V600E) kinase has approximately 13-fold more potent MEK phosphorylation activity than does wild-type BRAF kinase, and the BRAF mutation is deeply involved in the growth of these cancers.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Hence, targeting the Ras/RAF/MEK/ERK pathway may be a legitimate approach to cancer treatment.<a onclick="showRef(event, 'ref7 ref8'); return false;" href="javascript:void(0);" class="ref ref7 ref8">(7, 8)</a></div><div class="NLM_p">However, angiogenesis is also a critical process in solid tumor progression because the tumors require significantly more oxygen, glucose, and other nutrients to sustain their rapid growth than do normal tissues.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> Many cancer tissues secrete vascular endothelial growth factor (VEGF) to promote angiogenesis from adjacent blood vessels.<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> The VEGF receptor 2 (VEGFR2) is expressed on the surface of blood vessels, and it plays an important role in tumor angiogenesis. VEGF/VEGFR2 inhibition has been demonstrated as a cancer treatment method by using bevacizumab,<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a>a monoclonal antibody against VEGF, and several small molecule inhibitors of VEGFR2, such as sunitinib,<a onclick="showRef(event, 'ref12'); return false;" href="javascript:void(0);" class="ref ref12">(12)</a> axitinib,<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> and pazopanib.<a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(14)</a></div><div class="NLM_p">Sorafenib<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>) was initially developed as a C-RAF (RAF-1) inhibitor, although its actual profile is a multikinase inhibitor against VEGFR2, VEGFR3, and PDGFR-β kinases involved in angiogenesis. Efficacy in the clinical studies was thought to be primarily derived from inhibition of tumor angiogenesis.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Sorafenib was approved by the Food and Drug Administration (FDA) for the treatment of hepatocellular carcinoma and renal cell carcinoma with its efficacy likely due to its antiangiogenesis activity.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> However, sorafenib showed insufficient efficacy in metastatic melanoma phase 3 clinical trials, most likely because of insufficient RAF inhibition in melanoma tissues.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> One possible explanation may be that metastatic melanoma is independent of angiogenesis. Another explanation may be that the potency of sorafenib is insufficient for RAF inhibition in melanoma tissues. Therefore, more potent dual inhibitors against RAF and VEGFR2 may be beneficial for patients suffering from various tumors, including metastatic melanoma.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/medium/jm-2012-00126x_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Various BRAF inhibitors and their binding to the BRAF protein.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300126x&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Over the past decade, efforts have been made to develop drugs and optimize the effects of RAF kinase inhibitors by using X-ray cocrystal structures of the BRAF protein with various ligands. Sorafenib is the first reported RAF kinase inhibitor that binds to the DFG-out “inactive” conformation of BRAF and BRAF(V600E).<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> Another RAF inhibitor, RAF265, has also been reported as a RAF/VEGFR dual kinase inhibitor.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> These two compounds are classified as type II inhibitors,<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> which bind to the DFG-out “inactive” conformation at the ATP binding site and occupy the hydrophobic “back pocket” in kinases. In contrast, vemurafenib (PLX4032)<a onclick="showRef(event, 'cit8b ref22'); return false;" href="javascript:void(0);" class="ref cit8b ref22">(8b, 22)</a> and SB-590885<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> are classified as type I inhibitors, which bind to the DFG-in “active” conformation of the ATP binding site. These type I inhibitors of RAF are highly BRAF selective against other kinases, particularly VEGFR2.</div><div class="NLM_p">Imidazo[1,2-<i>b</i>]pyridazine derivative <b>1a</b><a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> was identified as a hit compound by kinase screening of our chemical library (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>A). Compound <b>1a</b> showed significant inhibitory activities against BRAF and VEGFR2, with IC<sub>50</sub> values of 43 nM and 3.1 nM, respectively. A molecular model was constructed using the docking program GOLD, version 3.2,<a onclick="showRef(event, 'cit25a'); return false;" href="javascript:void(0);" class="ref cit25a">(25a)</a> and the cocrystal structure model of sorafenib<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> with BRAF(V600E) was used to examine the binding mode of imidazo[1,2-<i>b</i>]pyridazines. Although the pyranyl group of <b>1a</b> did not fit in this model (vide infra), the simplified acetyl derivative <b>1b</b> overlapped well with sorafenib in the DFG-out conformation of BRAF(V600E) (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>B). An amide proton at the 2-position and a nitrogen atom at the N-1 position of 2-aminoimidazo[1,2-<i>b</i>]pyridazine were considered significant because they could interact with the backbone C═O and NH of Cys532 in the kinase hinge region of the BRAF(V600E) protein. On the basis of this modeling, novel DFG-out RAF inhibitors bearing [5,6]-fused bicyclic rings (ring A, <b>1</b>–<b>6</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>) were designed. An acyl group (R<sup>1</sup>), which is smaller than pyran (<b>1a</b>), was considered suitable because of space constraints in the binding site between the indole side chain of Trp531 and Gly534. Additionally, the benzamide moiety (ring C) linked to a central phenoxy group (ring B) was also thought to be significant for binding with the DFG-out conformation of BRAF. The amide NH between rings B and C can interact with the carboxylate side chain of Glu501, and the C═O group of the amide interacts with the backbone NH of Asp594 in the DFG motif. The benzamide group (ring C) should occupy the hydrophobic back-pocket region, where the phenyl group of Phe595 exists in the DFG-in conformation (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>).</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/medium/jm-2012-00126x_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Design concept: (A) structures of hit compound <b>1a</b> and its analogue <b>1b</b>; (B) overlap modeling of <b>1b</b> (yellow) and sorafenib (purple) bound to BRAF(V600E) (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1UWJ">1UWJ</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300126x&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/medium/jm-2012-00126x_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Design of our DFG-out-type RAF inhibitors (left). Design of the [5,6]-fused bicyclic ring A (right).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300126x&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In this paper, the synthesis and structure–activity relationships (SARs) of novel DFG-out RAF/VEGFR2 inhibitors bearing various [5,6]-fused bicyclic scaffolds will be described.</div></div><div id="sec1_1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_52087" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_52087" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Imidazo[1,2-<i>b</i>]pyridazine<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> derivatives <b>1a</b>–<b>n</b> were prepared as shown in Schemes <a class="ref internalNav" href="#sch1" aria-label="1">1</a> and <a class="ref internalNav" href="#sch2" aria-label="2">2</a>. Compounds <b>1a</b>–<b>g</b> with various acyl groups (R<sup>1</sup>) were synthesized using the commercially available ethyl 6-iodoimidazo[1,2-<i>b</i>]pyridazine-2-carboxylate <b>7</b> as the starting material. S<sub>N</sub>Ar displacement reaction of <b>7</b> with3-aminophenol in the presence of potassium carbonate gave the phenoxylated derivative <b>8</b> in 50% yield. Condensation of <b>8</b>with 3-(trifluoromethyl)benzoic acid using (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide) hydrochloride (EDCI) and 1-hydroxybenzotriazole (HOBt) as coupling reagents afforded benzamide <b>9</b> in 86% yield. Hydrolysis of <b>9</b> with 8 N NaOH gave the corresponding carboxylic acid in 91% yield. Subsequent Curtius rearrangement of the resulting carboxylic acid using diphenylphosphorylazide (DPPA) and <i>tert-</i>butanol gave the Boc-protected amine in 89% yield. The Boc group was deprotected using 4 N HCl in EtOAc to provide 2-aminoimidazo[1,2-<i>b</i>]pyridazine derivative <b>10</b> in 67% yield. Finally, the 2-amino group was acylated by the corresponding carboxylic acids (<b>a</b>, <b>c</b>, and <b>d</b>) using EDCI and HOBt as the coupling agents or the corresponding acid chlorides (<b>b</b>, <b>e</b>, <b>f</b>, and <b>g</b>) to give the desired acylated 2-aminoimidazo[1,2-<i>b</i>]pyridazine derivatives <b>1a</b>–<b>g</b> in 42–81% yield (Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a>).</div><figure id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/medium/jm-2012-00126x_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0018.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of N-Acylated 2-Aminoimidazo[1,2-<i>b</i>]pyridazines <b>1a</b>–<b>f</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300126x&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 3-aminophenol, K<sub>2</sub>CO<sub>3</sub>, DMF, 150 °C, 5 h (50%); (b) 3-(trifluoromethyl)benzoic acid, EDCI·HCl, HOBt, DMF, room temp, 3 h (86%); (c) 8 N NaOH aq, MeOH, H<sub>2</sub>O, room temp, 4 h (91%); (d) DPPA, Et<sub>3</sub>N, <sup><i>t</i></sup>BuOH, 100 °C, 14 h (89%); (e) 4 N HCl/EtOAc, MeOH, room temp, 14 h (67%); (f) R<sup>1</sup>CO<sub>2</sub>H (<b>a</b>, <b>c</b>, and <b>d</b>), EDCI·HCl, HOBt, DMF, room temp (42–81%); (g) R<sup>1</sup>COCl (<b>b</b>, <b>e</b>, <b>f</b>, and <b>g</b>), Et<sub>3</sub>N, THF, room temp (54–75%).</p></p></figure><figure id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/medium/jm-2012-00126x_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0019.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Cyclopropyl Carbonylated 2-Aminoimidazo[1,2-<i>b</i>]pyridazines <b>1g</b>–<b>n</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300126x&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) ethyl (chloroacetyl)carbamate, Na<sub>2</sub>HPO<sub>4</sub>, DMF, 110 °C, 4 h (76%); (b) Ba(OH)<sub>2</sub>·8H<sub>2</sub>O, H<sub>2</sub>O, NMP, 120 °C, 12 h (71%); (c) cyclopropanecarbonyl chloride, DMA, room temp, 16 h (98%); (d) 3-aminophenol, K<sub>2</sub>CO<sub>3</sub>, DMF, 150 °C, 24 h (80%); (e) R<sup>3</sup>-C<sub>6</sub>H<sub>4</sub>CO<sub>2</sub>H (<b>h</b>, <b>l</b>, and <b>n</b>), EDCI, HOBt, DMF, room temp (68–77%); (f) R<sup>3</sup>-C<sub>6</sub>H<sub>4</sub>COCl (<b>i</b>, <b>j</b>, and <b>k</b>), NMP, room temp (43–75%); (g) 1.4 M methylmagnesium bromide in THF, toluene, room temp, 12 h (19%).</p></p></figure><div class="NLM_p">Cyclopropylcarbonyl-2-aminoimidazo[1,2-<i>b</i>]pyridazine derivatives <b>1h</b>–<b>n</b> were synthesized via a different route, for efficiently introducing various substituents (R<sup>3</sup>) (Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>). The reaction of commercially available 6-iodopyridazine-3-amine <b>11</b>with ethyl (chloroacetyl)carbamate in the presence of disodium hydrogen phosphate gave ethyl 6-iodoimidazo[1,2-<i>b</i>]pyridazine-2-carbamate <b>12</b> in 76% yield. Hydrolysis of ethyl carbamate with aqueous barium hydroxide, followed by acylation of the resulting amine with cyclopropanecarbonyl chloride, was performed in two steps to afford 2-cyclopropylcarbonylamino-6-iodoimidazo[1,2-<i>b</i>]pyridazine <b>13</b> in 70% yield. The reaction of <b>13</b> with3-aminophenol in the presence of potassium carbonate afforded the 6-phenoxylated derivative <b>14</b> in 80% yield. Amide-forming reactions of <b>14</b> with the corresponding benzoic acids were carried out in the presence of EDCI and HOBt to give <b>1h</b>, <b>1l</b>, and <b>1n</b> in 68–77% yield or with the corresponding acid chlorides to give <b>1i</b>, <b>1j</b>, and <b>1k</b> in 43–75% yield. The tertiary alcohol derivative <b>1m</b> was synthesized in 19% yield by the treatment of methyl ester <b>1l</b> with methylmagnesium bromide.</div><div class="NLM_p">Benzoic acids <b>15n</b>–<b>q</b> were prepared by the method shown in Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>. The synthesis of 3-(1-cyano-1-methylethyl)benzoic acid <b>15n</b> began with cyanation of the corresponding commercially available methyl-3-(bromomethyl)benzoate <b>16</b> with potassium cyanide in the presence of 18-crown-6, and benzyl cyanide <b>17</b> was obtained in 91% yield. Compound <b>17</b> was dimethylated using iodomethane in the presence of sodium hydride, followed by hydrolysis with aqueous lithium hydroxide, to give the desired benzoic acid <b>15n</b> in 77% yield in two steps. Cyclopropyl derivative <b>15o</b> was synthesized in two steps from benzyl cyanide <b>17</b> by a similar method using 1,2-dibromoethane; the obtained yield was 46% yield. 2-Chlorobenzoic acid (R<sup>3a</sup> = Cl) derivatives <b>15p</b> and <b>15q</b>were synthesized using similar methods adopted for <b>15n</b> and <b>15o</b>. Bromination of the commercially available 3-methylbenzoate derivative <b>18</b> with <i>N</i>-bromosuccinimide (NBS) in the presence of 2,2′-azobis(2-methylpropionitrile) (AIBN) gave the benzyl bromide derivative <b>19</b> in 66% yield. Cyanation of <b>19</b> using sodium cyanide in <i>N</i>,<i>N</i>-dimethylformamide afforded benzyl cyanide <b>20</b> in 79% yield. Subsequent alkylation of <b>20</b> with iodomethane or 1,2-dibromoethane in the presence of sodium hydride afforded the corresponding alkylated derivatives, which were hydrolyzed using aqueous lithium hydroxide to give the desired benzoic acids <b>15p</b> and <b>15q</b> in 52–80% yield in two steps.</div><figure id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/medium/jm-2012-00126x_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0020.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Benzoic Acids <b>15n</b>–<b>q</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300126x&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) potassium cyanide, 18-crown-6, CH<sub>3</sub>CN, room temp, 3 days (91%) or sodium cyanide, DMF, 80 °C, 1 h (79%); (b) NaH, DMSO, room temp, then MeI, room temp (79–88%); (c) NaH, DMSO, room temp, then 1,2-dibromoethane, room temp (57–76%); (d) LiOH·H<sub>2</sub>O, THF, MeOH, H<sub>2</sub>O, room temp (61–98%); (e) NBS, AIBN, CH<sub>3</sub>CN, 90 °C, 26 h (66%).</p></p></figure><div class="NLM_p">Imidazo[1,2-<i>a</i>]pyridine derivative<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a><b>2</b> was synthesized using the method described in Scheme <a class="ref internalNav" href="#sch4" aria-label="4">4</a>. The reaction of 5-bromo-2-nitropyridine <b>21</b> with 3-nitrophenol in the presence of cesium carbonate and subsequent hydrogenation using 10% palladium/carbon provided aminophenoxylated aminopyridine <b>22</b> as the dihydrochloride salt (yield of 54%, two steps) after treatment of the product with 4 N HCl in EtOAc. Regioselective amide formation between <b>22</b> and 3-(1-cyano-1-methylethyl)benzoyl chloride, prepared in situ from <b>15n</b> using oxalyl chloride, gave benzamide <b>23</b> in 66% yield. Tosylation of the 2-amino group on the pyridine ring, followed by alkylation with 2-iodoacetamide at the nitrogen atom on the pyridine ring, provided the precursor <b>24</b> (yield, 63%) for the imidazo[1,2-<i>a</i>]pyridine scaffold in two steps. The ring formation reaction of <b>24</b> proceeded in the presence of trifluoroacetic anhydride (TFAA) in dichloromethane to give imidazo[1,2-<i>a</i>]pyridine-2-trifluoroacetamide <b>25</b> in 52% yield. Cleavage of the trifluoroacetyl group with 1 N NaOH and subsequent acylation of the resulting amino group using cyclopropanecarbonyl chloride gave the desired compound <b>2</b> (yield, 43%) in two steps.</div><figure id="sch4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/medium/jm-2012-00126x_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0021.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Imidazo[1,2-<i>a</i>]pyridine <b>2</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300126x&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 3-nitrophenol, Cs<sub>2</sub>CO<sub>3</sub>, DMF, room temp, 12 h (54%); (b) H<sub>2</sub>, 10% Pd/C, MeOH, THF, EtOAc, room temp, 20 h, then 4 N HCl/EtOAc (quant); (c) 3-(1-cyano-1-methylethyl)benzoyl chloride, DMA, room temp, 18 h (66%); (d) 4-methylbenzenesulfonyl chloride, pyridine, 80 °C, 2 days (99%); (e) 2-iodoacetamide, DIEA, DMF, room temp, 48 h (63%); (f) TFAA, CH<sub>2</sub>Cl<sub>2</sub>, room temp, 16 h (52%); (g) 1 N NaOH aq, EtOH, 45 °C, 12 h (quant); (h) cyclopropanecarbonyl chloride, DMA, room temp, 8 h (43%).</p></p></figure><div class="NLM_p">Benzimidazole derivatives<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a><b>3a</b>,<b>b</b> were synthesized as shown in Scheme <a class="ref internalNav" href="#sch5" aria-label="5">5</a>. For synthesis of the N-methylated compound <b>3b</b>, introduction of a methyl group was regiocontrolled at the first step by the regioselective S<sub>N</sub>Ar displacement of 2,4-difluoronitrobenzene <b>26</b> using 40% aqueous methylamine solution. When <i>N</i>,<i>N</i>-dimethylformamide was used as a cosolvent in this reaction, methylamine was allowed to react with the 2- and 4-fluorine groups of <b>26</b> to provide a complex mixture of 2-methylamino, 4-methylamino, and 2,4-bis(methylamino) products. However, in the absence of <i>N</i>,<i>N</i>-dimethylformamide, the desired 2-methylamino derivative <b>27b</b> precipitated from the reaction mixture. Thus, the N-methylated starting material <b>27b</b> could be selectively synthesized in 99% yield. Commercially available 2-amino-4-fluoronitrobenzene <b>27a</b> and the prepared <b>27b</b> were allowed to react with <i>tert-</i>butyl (3-hydroxyphenyl)carbamate in the presence of potassium carbonate to afford phenoxylated derivatives <b>28a</b>,<b>b</b> in 69% and 100% yields, respectively. Hydrogenation of the nitro group in <b>28a</b>,<b>b</b> using palladium/carbon gave the corresponding diamines in quantitative yield. Subsequent treatment of the resulting diamines with cyanogen bromide provided benzimidazol-2-amines in 69–100% yield, which were acylated using cyclopropanecarbonyl chloride to afford cyclopropyl carbonylated 2-aminobenzimidazoles <b>29a</b>,<b>b</b> in 98% and 65% yields, respectively. After the Boc groups of <b>29a</b>,<b>b</b> were cleaved by TFA (88% yield), an amide coupling reaction between the deprotected compounds and <b>15n</b> was carried out in the presence of EDCI and 4-(<i>N</i>,<i>N</i>-dimethylamino)pyridine (DMAP) to obtain the target benzimidazole derivatives <b>3a</b>,<b>b</b> in 69% and 38% yields, respectively.</div><figure id="sch5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/medium/jm-2012-00126x_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0022.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of 1<i>H</i>-Benzimidazole <b>3a</b>,<b>b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300126x&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 40% methylamine solution, 0 °C, 1.5 h (99%); (b) <i>tert</i>-butyl (3-hydroxyphenyl)carbamate, K<sub>2</sub>CO<sub>3</sub>, DMF, 80–100 °C (69–100%); (c) H<sub>2</sub>, 10% Pd/C, THF, MeOH, room temp (quant); (d) BrCN, THF, room temp (69–100%); (e) cyclopropanecarbonyl chloride, DMAP, pyridine, room temp (65–98%); (f) TFA, reflux (88%); (g) <b>15n</b>, EDCI·HCl, DMAP, pyridine (38–69%).</p></p></figure><div class="NLM_p">The synthesis of imidazo[4,5-<i>b</i>]pyridine derivatives<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a><b>4a</b>,<b>b</b> is shown in Scheme <a class="ref internalNav" href="#sch6" aria-label="6">6</a>. Substituted benzoyl chloride, prepared by the reaction of <b>15n</b> with oxalyl chloride in situ, was allowed to react with 3-aminophenol under Schotten–Baumann conditions to provide the intermediate phenol <b>30</b> in 95% yield in two steps. The regioselective reaction of 2,6-dichloro-3-nitropyridine <b>31</b> with <i>tert-</i>butylamine proceeded at the 2-position to give the <i>tert-</i>butylaminated compound <b>32a</b> in 99% yield. Subsequent coupling of <b>32a</b> with <b>30</b> in the presence of potassium carbonate afforded the coupled product <b>33a</b> in 72% yield. The nitro group of <b>33a</b> was hydrogenated using palladium/carbon, and the resulting aniline was treated with cyanogen bromide to provide the imidazo[4,5-<i>b</i>]pyridine-2-amine derivative <b>34a</b> in 82% yield in two steps. Subsequent acylation of the 2-amino group of <b>34a</b> with cyclopropanecarbonyl chloride, followed by cleavage of the <i>tert</i>-butyl group with TFA, provided the desired imidazo[4,5-<i>b</i>]pyridine derivative <b>4a</b> in 79% yield in two steps. The corresponding N-methylated derivative <b>4b</b> was prepared using a method similar to that used to generate <b>4a</b>. Regioselective amination of 2,6-dichloro-3-nitropyridine <b>31</b> with methylamine provided the 2-methylaminated product <b>32b</b> in 78% yield. The coupling reaction of <b>32b</b> with <b>30</b> in the presence of potassium carbonate gave <b>33b</b> in 88% yield. Reduction of the nitro group of <b>33b</b> and subsequent treatment with cyanogen bromide provided the 1-methylimidazo[4,5-<i>b</i>]pyridine-2-amine derivative <b>34b</b> in 80% yield in two steps. Finally, acylation of <b>34b</b> with cyclopropanecarbonyl chloride provided the desired N-methylated imidazo[4,5-<i>b</i>]pyridine derivative <b>4b</b> in 56% yield.</div><figure id="sch6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/medium/jm-2012-00126x_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0023.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Imidazo[4,5-<i>b</i>]pyridine <b>4</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300126x&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (COCl)<sub>2</sub>, cat. DMF, THF, room temp; (b) 3-aminophenol, NaHCO<sub>3</sub>, H<sub>2</sub>O, THF, room temp (96% in two steps); (c) <i>tert</i>-butylamine, toluene, or methylamine, THF, room temp (78–99%); (d) <b>30</b>, K<sub>2</sub>CO<sub>3</sub>, DMF, room temp, 18 h (72–88%); (e) H<sub>2</sub>, 10% Pd/C, MeOH, THF, room temp, 12 h; (f) BrCN, THF, room temp, 18 h (80–82% in two steps); (g) cyclopropanecarbonyl chloride, DMAP, pyridine, room temp (56–96%); (h) TFA, 80 °C, 2 h (82%).</p></p></figure><div class="NLM_p">The synthesis of 1,3-benzothiazole derivative<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a><b>5</b> is shown in Scheme <a class="ref internalNav" href="#sch7" aria-label="7">7</a>. The reaction of 4-fluoronitrobenzene <b>35</b> with 3-aminophenol in the presence of potassium carbonate gave the phenoxylated aniline derivative <b>36</b> in 95% yield. Condensation of <b>36</b> with <b>15n</b> using EDCI in the presence of DMAP in pyridine provided benzamide <b>37</b> in 99% yield. Reduction of the nitro group of <b>37</b> under hydrogenation conditions using palladium/carbon gave aniline <b>38</b> in 98% yield. The thiazole ring was constructed by the reaction of <b>38</b> with potassium thiocyanate and bromine in acetic acid, and the obtained yield was 87%. The obtained 2-amino-1,3-benzothiazole derivative was acylated using cyclopropanecarbonyl chloride to afford the desired 1,3-benzothiazole derivative <b>5</b> in 88% yield.</div><figure id="sch7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/medium/jm-2012-00126x_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0024.jpeg" id="gr16" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of 1,3-Benzothiazole <b>5</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300126x&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 3-aminophenol, K<sub>2</sub>CO<sub>3</sub>, DMF, 80 °C, 8 h (95%); (b) <b>15n</b>, EDCI·HCl, DMAP, pyridine, room temp, 4 h (99%); (c) H<sub>2</sub>, 10% Pd/C, THF, MeOH, room temp, 14 h (98%); (d) KSCN, Br<sub>2</sub>, AcOH, room temp, 4 h (87%); (e) cyclopropanecarbonyl chloride, DMAP, pyridine, room temp, 6 h (88%).</p></p></figure><div class="NLM_p">The synthesis of thiazolo[5,4-<i>b</i>]pyridine<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> derivatives <b>6a</b>–<b>c</b>is shown in Scheme <a class="ref internalNav" href="#sch8" aria-label="8">8</a>. Reaction of commercially available 2-chloro-5-nitropyridine <b>39</b> with Boc-protected aminophenol in the presence of potassium carbonate provided a coupled product, and subsequent reduction of the nitro group under standard hydrogenation conditions provided the corresponding aniline <b>40</b> in 77% yield in two steps. Fused 1,3-thiazole ring constructionusing potassium thiocyanate and bromine under conditions similar to those used to generate 1,3-benzothiazole afforded the 2-aminothiazolo[5,4-<i>b</i>]pyridine derivative <b>41</b> in 88% yield. Acylation of the 2-amino group with cyclopropanecarbonyl chloride in pyridine gave the precursor <b>42</b> for introducing benzamide moieties, in 86% yield. Deprotection of the Boc group using TFA and subsequent condensation using benzoic acid derivatives <b>15n</b>–<b>p</b>under the standard conditions provided the desired thiazolo[5,4-<i>b</i>]pyridine derivatives <b>6a</b>–<b>c</b> in 46–87% yield.</div><figure id="sch8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/medium/jm-2012-00126x_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0025.jpeg" id="gr17" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthesis of [1,3]Thiazolo[5,4-<i>b</i>]pyridine <b>6a</b>–<b>c</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300126x&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <i>tert</i>-butyl (3-hydroxyphenyl)carbamate, K<sub>2</sub>CO<sub>3</sub>, DMF, 70 °C, 2 h; (b) H<sub>2</sub>, 10% Pd/C, EtOH, THF, room temp, 7 h (77% in two steps); (c) KSCN, Br<sub>2</sub>, AcOH, room temp, 1.5 h (88%); (d) cyclopropanecarbonyl chloride, pyridine, room temp, 1 h (86%); (e) TFA, anisole, 0 °C, 1 h (79%); (f) <b>15n</b>,<b>o</b>, SOCl<sub>2</sub>, DMAP, toluene, then pyridine (46–58%), or <b>15p</b>, HATU, pyridine, room temp (87%).</p></p></figure><div class="NLM_p">Compound <b>6d</b> was synthesized using a method similar to that used for <b>6a</b>–<b>c</b> in Scheme <a class="ref internalNav" href="#sch9" aria-label="9">9</a>. Compound <b>15q</b> was converted into the corresponding acid chloride in situ using oxalyl chloride, and the obtained acid chloride was allowed to react with 3-amino-4-fluorophenol in the presence of aqueous sodium bicarbonate to give an intermediate phenol <b>43</b> in 100% yield. Compound <b>43</b> was allowed to react with 2-chloro-5-nitropyridine <b>39</b> in the presence of potassium carbonate to give a coupled product in 93% yield, and subsequent reduction of the nitro group using reduced iron and calcium chloride in aqueous ethanol provided aniline <b>44</b> in 69% yield. Cyclization of <b>44</b> using potassium thiocyanate and bromine in acetic acid gave thiazolo[5,4-<i>b</i>]pyridin-2-amine <b>45</b> in 69% yield. Acylation of <b>45</b> with cyclopropanecarbonylchloride afforded the desired compound <b>6d</b> in 96% yield.</div><figure id="sch9" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/medium/jm-2012-00126x_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0026.jpeg" id="gr18" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Synthesis of [1,3]Thiazolo[5,4-<i>b</i>]pyridine <b>6d</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300126x&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (COCl)<sub>2</sub>, cat. DMF, THF, room temp, 2.5 h, then 3-amino-4-fluorophenol, NaHCO<sub>3</sub>, THF, H<sub>2</sub>O, room temp, 1 h (100%); (b) <b>39</b>, K<sub>2</sub>CO<sub>3</sub>, DMF, room temp, 4 h (93%); (c) Fe(0), CaCl<sub>2</sub>, EtOH, H<sub>2</sub>O, 80 °C, 18 h (69%); (d) KSCN, Br<sub>2</sub>, AcOH, room temp, 6 h (69%); (e) cyclopropanecarbonyl chloride, pyridine, THF, room temp, 3 h (96%).</p></p></figure><div class="NLM_p">Compound <b>6e</b>, which was chlorinated at ring B, was prepared by the synthetic route shown in Scheme <a class="ref internalNav" href="#sch10" aria-label="10">10</a>. Reaction of <b>39</b> with 3-amino-4-chlorophenol in the presence of potassium carbonate provided the phenoxylated compound <b>46</b> in 85% yield. Protection of the anilino group of <b>46</b> by a trifluoroacetyl group using trifluoroacetic anhydride, followed by reduction of the nitro group using reduced iron in acetic acid, gave the trifluoroacetylated compound <b>47</b> in 79% yield in two steps. Cyclization of <b>47</b> using potassium thiocyanate and bromine in acetic acid and subsequent acylation with cyclopropanecarbonyl chloride provided the 2-acylated aminothiazolo[5,4-<i>b</i>]pyridine derivative <b>48</b> in 42% yield in two steps. Deprotection of the trifluoroacetyl group was achieved using sodium borohydride in mixed solvent of methanol and ethanol to give the corresponding aniline in 75% yield. Condensation with <b>15q</b> under standard conditions provided the desired thiazolo[5,4-<i>b</i>]pyridine derivative <b>6e</b> in 64% yield.</div><figure id="sch10" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/medium/jm-2012-00126x_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0027.jpeg" id="gr19" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 10. Synthesis of [1,3]Thiazolo[5,4-<i>b</i>]pyridine <b>6e</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300126x&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 3-amino-4-chlorophenol, K<sub>2</sub>CO<sub>3</sub>, DMF, room temp, 16 h (85%); (b) TFAA, THF, room temp, 1 h (87%); (c) Fe(0), AcOH, 60 °C, 3 h (91%); (d) KSCN, Br<sub>2</sub>, AcOH, room temp, 16 h (72%); (e) cyclopropanecarbonyl chloride, pyridine, room temp, 1 h (59%); (f) NaBH<sub>4</sub>, MeOH, EtOH, room temp, 1 h (75%); (g) <b>15q</b>, (COCl)<sub>2</sub>, DMF, THF, then DMA, room temp, 2 h (64%).</p></p></figure></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_36078" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_36078" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">To develop novel RAF/VEGFR2 inhibitors, we identified an initial lead compound imidazo[1,2-<i>b</i>]pyridazine<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> derivative <b>1a</b> from screening. Compound <b>1a</b> showed good potency against VEGFR2 and BRAF(V600E), with IC<sub>50</sub> values of 3.1 and 43 nM, respectively. However, Western blotting assay for assessing the phosphorylation level of the downstream MEK1/2 (pMEK) in HT-29 colon cancer cells revealed that its cellular activity based on BRAF(V600E) inhibition was insufficient (IC<sub>50</sub> = 3800 nM). Thus, our initial medicinal chemistry efforts were directed at exploring the alkylamide side chain (R<sup>1</sup>) and hydrophobic “back pocket” benzamide moiety (R<sup>3</sup>) using the imidazo[1,2-<i>b</i>]pyridazine scaffold <b>1</b> to enhance both BRAF(V600E) and cellular pMEK inhibitory activities.</div><div class="NLM_p">Imidazo[1,2-<i>b</i>]pyridazines <b>1a</b>–<b>g</b>, with various <i>N</i>-acyl groups (R<sup>1</sup>) at the 2-position, were evaluated as shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>. BRAF(V600E) modeling suggested that the R<sup>1</sup> group exists in the narrow space formed by the indole ring of Trp531 and Gly534 and that the optimal size of the R<sup>1</sup> group for fitting into this narrow space would be smaller than that of a pyranyl group. Therefore, we examined the SAR of R<sup>1</sup> groups to determine their BRAF preference and their potency against cellular pMEK activity. Replacement of the pyranyl group in <b>1a</b> with a methyl group in <b>1b</b> resulted in significantly increased BRAF(V600E) inhibitory activity, with an IC<sub>50</sub> of 4.1 nM. Compounds bearing alkyl groups larger than those in <b>1b</b>, such as ethyl (<b>1c</b>) and isopropyl (<b>1d</b>) groups, exhibited decreased BRAF(V600E) inhibitory activities, with IC<sub>50</sub> values of 6.9 and 31 nM, respectively. Thus, <b>1b</b> and <b>1c</b> revealed more potent cellular pMEK activity than did <b>1a</b>. These results are consistent with those of our modeling studies, suggesting that decreasing the size of the <i>N</i>-acyl groups (R<sup>1</sup>) generally increased BRAF and the cellular pMEK inhibitory activity. Because the R<sup>1</sup> group is located near a hinge in our BRAF model, bulky groups may be unfavorable for binding the BRAF protein.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Structure–Activity Relationship of <i>N</i>-Acyl Groups at 2-Amino Position (R<sup>1</sup>)</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/medium/jm-2012-00126x_0010.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/medium/jm-2012-00126x_0011.gif" alt="" id="fx2" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last"><i>n</i> = 2. Values in parentheses indicate the 95% confidence interval.</p></div><div class="footnote" id="t1fn2"><sup>Table b</sup><p class="last">Concentration producing 50% inhibition (IC<sub>50</sub>) values against RAF substrate MEK phosphorylation in HT-29 (<i>BRAF</i><sup>V600E</sup>) cultured human colon cancer cell lines.</p></div><div class="footnote" id="t1fn3"><sup>Table c</sup><p class="last">Not determined.</p></div></div><div></div></div><div class="NLM_p">Compounds <b>1e</b>–<b>g</b> having a cycloalkyl group as R<sup>1</sup> were further evaluated. Similar to the alkyl side chain in <b>1b</b>–<b>d</b>, decreasing the ring size from cyclopentyl (<b>1g</b>) to cyclopropyl (<b>1e</b>) enhanced the BRAF(V600E) inhibitory activity. Additionally, the cyclopropyl derivative <b>1e</b> showed potent cellular pMEK activity with an IC<sub>50</sub> of 310 nM. However, substitution of the <i>N</i>-acyl group (R<sup>1</sup>) had negligible impact on the VEGFR2 inhibition, with compounds <b>1a</b>–<b>g</b> showing nanomolecular-order inhibitory activity against VEGFR2. Since the acetyl group of <b>1b</b> was found to be sensitive to deacetylation<a onclick="showRef(event, 'cit32a'); return false;" href="javascript:void(0);" class="ref cit32a">(32a)</a> by liver microsomes in an in vitro metabolism study (data not shown, but this result was utilized in our next prodrug study<a onclick="showRef(event, 'cit32b'); return false;" href="javascript:void(0);" class="ref cit32b">(32b)</a>), we chose the cyclopropyl group (<b>1e</b>) as the representative R<sup>1</sup> group.</div><div class="NLM_p">Next, we investigated the effect of substituting R<sup>3</sup> groups in the “back pocket” of the benzene ring (ring C); the results are summarized in Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>. Our initial goal was to examine the substitution position of the trifluoromethyl group against BRAF(V600E). Alternating between the meta (<b>1e</b>), para (<b>1h</b>), and ortho (<b>1i</b>) positions resulted in decreased BRAF inhibitory activity, suggesting that meta substitution may be favorable for inhibiting the BRAF protein.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Structure–Activity Relationship of Back Pocket Region (R<sup>3</sup>)</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/medium/jm-2012-00126x_0012.gif" alt="" id="fx3" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/medium/jm-2012-00126x_0013.gif" alt="" id="fx4" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>Table a</sup><p class="last"><i>n</i> = 2. Values in parentheses indicate the 95% confidence interval.</p></div><div class="footnote" id="t2fn2"><sup>Table b</sup><p class="last">Concentration producing 50% inhibition (IC<sub>50</sub>) values against RAF substrate MEK phosphorylation in HT-29 (<i>BRAF</i><sup>V600E</sup>) cultured human colon cancer cell lines.</p></div><div class="footnote" id="t2fn3"><sup>Table c</sup><p class="last">Not determined.</p></div></div><div></div></div><div class="NLM_p">Replacement of the trifluoromethyl group with methoxy (<b>1j</b>) and <i>tert-</i>butoxy (<b>1k</b>) groups helped in maintaining strong BRAF(V600E) inhibitory activities comparable to that of <b>1e</b>. Additionally, <b>1k</b> showed slightly increased cellular pMEK inhibition, with an IC<sub>50</sub> of 120 nM. In our model, wherein <b>1k</b> was bound to BRAF, the <i>tert</i>-butoxy group of <b>1k</b> could occupy the lipophilic space formed by Val504, Leu505, Ile513, Leu514, and Thr508 in the back pocket to result in lipophilic van der Waals interactions with the BRAF protein. On the basis of BRAF inhibition studies, we assumed that bulky lipophilic groups may stabilize the DFG-out binding conformation and increase cellular activity. Therefore, to confirm our assumption, we examined the introduction of bulky 1-hydroxy-1-methylethyl (<b>1m</b>) and 1-cyano-1-methylethyl (<b>1n</b>) groups. Although <b>1m</b> showed reduced cellular pMEK inhibitory activity compared to <b>1k</b>, the more lipophilic 1-cyano-1-methylethyl derivative <b>1n</b> demonstrated the most potent cellular activity among all the derivatives in the imidazo[1,2-<i>b</i>]pyridazine series, with an IC<sub>50</sub> of 55 nM. These results indicated that the lipophilic back pocket moiety is a key pharmacophore of the DFG-out type BRAF inhibitor for its potent pMEK inhibitory activity.</div><div class="NLM_p">All the imidazo[1,2-<i>b</i>]pyridazine derivatives <b>1e</b>–<b>n</b> showed more potent activities against VEGFR2 than against BRAF(V600E). These results implied that VEGFR2 has a wider range of molecular recognition in the back pocket than does BRAF(V600E). Therefore, we moved to the exploration of alternative [5,6]-fused bicyclic scaffolds to strengthen the BRAF inhibitory activity.</div><div class="NLM_p">To identify the appropriate scaffolds (ring A), novel [5,6]-fused bicyclic derivatives <b>2</b>–<b>6</b>, which had the same phenoxylated back pocket moiety as does <b>1n</b>, were designed and evaluated (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>). Replacement of imidazo[1,2-<i>b</i>]pyridazine (<b>1n</b>) with imidazo[1,2-<i>a</i>]pyridine (<b>2</b>) resulted in approximately 3-fold reduction of the BRAF(V600E) and cellular pMEK inhibitory activities. Similar tendencies were observed between benzimidazole (<b>3a</b>) and imidazo[4,5-<i>b</i>]pyridine (<b>4a</b>) as well as between 1,3-benzothiazole (<b>5</b>) and [1,3]thiazolo[5,4-<i>b</i>]pyridine (<b>6a</b>). These results suggested that the nitrogen atom adjacent to the phenoxy group contributes to the enhanced BRAF(V600E) inhibitory activities.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Structure–Activity Relationship of Novel [5,6]-Fused Bicyclic Ring A</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/medium/jm-2012-00126x_0014.gif" alt="" id="fx5" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/medium/jm-2012-00126x_0015.gif" alt="" id="fx6" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>Table a</sup><p class="last"><i>n</i> = 2. Values in parentheses indicate the 95% confidence interval.</p></div><div class="footnote" id="t3fn2"><sup>Table b</sup><p class="last">Concentration producing 50% inhibition (IC<sub>50</sub>) values against RAF substrate MEK phosphorylation in HT-29 (<i>BRAF</i><sup>V600E</sup>) cultured human colon cancer cell lines.</p></div><div class="footnote" id="t3fn3"><sup>Table c</sup><p class="last">Not determined.</p></div></div><div></div></div><div class="NLM_p">Additionally, alternating the fusion position of the imidazole rings, such as <b>2</b> to <b>3a</b> or <b>1n</b> to <b>4a</b>, maintained the BRAF(V600E) inhibitory activity but reduced the cellular pMEK inhibitory activity. Since the additional proton doner (NH) at the N-3 position in <b>3a</b> and <b>4a</b> plausibly diminish those cellular permeability, we examined the introduction of a methyl group at the N-3 position to mask the proton donor. However, the N-methylated derivatives <b>3b</b> and <b>4b</b> showed dramatically decreased BRAF(V600E) inhibitory activity, with IC<sub>50</sub> values of 960 and 200 nM, respectively. Because the intermediate N-methylated imidazo[5,4-<i>d</i>]pyridine-2-amine <b>34b</b> showed stronger BRAF(V600E) inhibitory activity (IC<sub>50</sub> = 35 nM) than did <b>4b</b>, we assumed that the steric hindrance between the <i>N</i>-3-methyl group and the 2-cyclopropylcarboxamide moiety of <b>4b</b> disrupted the planarity of the <i>C</i>-2 carboxamide with ring A and might reduce BRAF inhibition. To confirm our hypothesis, we calculated the stable dihedral angles of the amides in <b>3a</b>,<b>b</b> and <b>4a</b>,<b>b</b> using the MOE program<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> (see <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a>) to determine their minimum potential energies (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>). We found that the N-methylated derivatives <b>3b</b> and <b>4b</b> preferred torsional conformations (energy, 3.2–4.2 kcal/mol) to the planar conformations of <b>3a</b> and <b>4a</b>. Accordingly, we focused on identifying scaffolds that could stabilize the planarity of the <i>C</i>-2 carboxamide group with ring A to enhance the BRAF inhibitory activity.</div><figure id="fig4" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/medium/jm-2012-00126x_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Stable dihedral angles of amides linked to ring A (<b>3</b>, <b>4</b>) are calculated using ligand-based analysis to determine their minimal potential energies. Compounds calculated are simplified analogues without the phenoxy moiety. Fused imidazoles without the methyl group (<b>3a</b>, <b>4a</b>) are categorized in the planar group. Fused imidazoles with a methyl group (<b>3b</b>, <b>4b</b>) are categorized in the torsional group owing to steric hindrance between 3-methyl and carbonyl. Dihedral angles (deg) and their internal energy gains (Δ<i>E</i>*) from their planar conformations are shown.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300126x&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To stabilize this planarity, we designed fused 1,3-thiazole scaffolds, 1,3-benzothiazole (<b>5</b>) and [1,3]thiazolo[5,4-<i>b</i>]pyridine (<b>6</b>). On the basis of the intramolecular interactions between the carbonyl group and sulfur by using the d-orbital of the sulfur atom,<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> we hypothesized that the planar conformations of the <i>C</i>-2 carboxamide with their scaffolds may be stabilized more effectively than those of the scaffolds <b>1</b>–<b>4</b>. As expected, <b>5</b> and <b>6a</b> showed greater BRAF(V600E) inhibitory activity than did the corresponding imidazole derivatives <b>3a</b> and <b>4a</b>. Particularly, the [1,3]thiazolo[5,4-<i>b</i>]pyridine derivative <b>6a</b> demonstrated the most potent BRAF(V600E) and cellular pMEK activities, with IC<sub>50</sub> values of 5.6 and 6.2 nM, respectively. The inhibitory potency of <b>6a</b> against BRAF(V600E) reached a level comparable to that against VEGFR2. Thus, we selected [1,3]thiazolo[5,4-<i>b</i>]pyridine scaffold <b>6</b> as one of the most appropriate scaffolds for dual inhibition against BRAF(V600E) and VEGFR2.</div><div class="NLM_p">Because <b>6a</b> showed sufficient in vitro potency to act as a BRAF(V600E) and VEGFR2 dual kinase inhibitor, the pharmacokinetic (PK) profile of this compound was evaluated in mice (Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>). However, <b>6a</b> showed poor drug exposure, with an AUC<sub>0–8h</sub> of 0.393 μg h/mL, after oral administration at a dose of 10 mg/kg in mice. To improve this poor oral absorption, we initially substituted the dimethylcyanomethyl group (<b>6a</b>) with a cyanocyclopropyl group (<b>6b</b>) so that the metabolized site was blocked. The BRAF/VEGFR2 inhibitory activities remained high, and this transformation was effective in enhancing oral absorption in mice while improving metabolic stability and slightly increasing the solubility for <b>6b</b>. Additionally, we attempted to introduce an R<sup>3a</sup> group at the ortho position between benzamide and the R<sup>3b</sup> group to increase the solubilities of <b>6a</b>,<b>b</b> by twisting the plane of benzamide (ring B) with ring C. As expected, <b>6c</b>, with a chlorine atom at the 2-position of benzamide (ring C), showed improved solubility and oral absorption in mice while maintaining the in vitro potency. Introduction of chlorine at R<sup>3a</sup> proved to be effective for enhancing the poor solubility.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Structure–Activity Relationship of [1,3]Thiazolo[5,4-<i>b</i>]pyridine Derivatives <b>6a</b>–<b>e</b></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/medium/jm-2012-00126x_0016.gif" alt="" id="fx7" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/medium/jm-2012-00126x_0017.gif" alt="" id="fx8" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>Table a</sup><p class="last"><i>n</i> = 2. Values in parentheses indicate the 95% confidence interval.</p></div><div class="footnote" id="t4fn2"><sup>Table b</sup><p class="last">Concentration producing 50% inhibition (IC<sub>50</sub>) values against RAF substrate MEK phosphorylation in HT-29 (<i>BRAF</i><sup>V600E</sup>) cultured human colon cancer cell lines.</p></div><div class="footnote" id="t4fn3"><sup>Table c</sup><p class="last">10 mmol/L solution of the compound in DMSO was evaluated using the JP second fluid in the disintegration test (pH 6.8) containing bile acid. The sample solution was shaken at 37 °C for 24 h, and its solubility was evaluated after filtration.</p></div><div class="footnote" id="t4fn4"><sup>Table d</sup><p class="last">Metabolism clearance of each compound was examined using liver microsomes and NADPH.</p></div><div class="footnote" id="t4fn5"><sup>Table e</sup><p class="last">Cassette dosing of five compounds. Values shown are the mean of data from three mice. Compounds (10 mg/kg) were administered in 0.5% methylcellulose in distilled water.</p></div></div><div></div></div><div class="NLM_p">Finally, we optimized the substituents (R<sup>2</sup>) at the para or 6-position of the phenoxyl group (ring B) to enhance the metabolic stability of <b>6c</b> by blocking the metabolically labile site. The results of our modeling studies showed that because of steric restriction around the 4-position, smaller R<sup>2</sup> groups could be more favorable to be introduced. The 6-chlorinated [1,3]thiazolo[5,4-<i>b</i>]pyridine derivative <b>6e</b> showed reduced in vitro potency against BRAF(V600E), but the 6-fluorinated [1,3]thiazolo[5,4-<i>b</i>]pyridine derivative <b>6d</b> maintained sufficient in vitro potency to act as a BRAF(V600E) and VEGFR2 dual kinase inhibitor. Furthermore, <b>6d</b> showed significantly improved metabolic stability against human liver microsomes and good PK profiles in mice. Therefore, we selected <b>6d</b> as a promising candidate for further evaluation.</div><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i20" class="anchor-spacer"></div><h3 class="article-section__title" id="_i20"> X-ray Cocrystal Structural Analysis of <b>6d</b> with BRAF and VEGFR2</h3><div class="NLM_p">We determined the X-ray cocrystal structures of <b>6d</b> with BRAF and VEGFR2 proteins, respectively.<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> The BRAF cocrystal structure (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4DBN">4DBN</a>) revealed that <b>6d</b> occupies the ATP-binding site and stabilizes the inactive DFG-out conformation of BRAF by being accommodated to the back pocket region (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>A). As expected, the [1,3]thiazolo[5,4-<i>b</i>]pyridine-2-amine moiety is located in front of the hinge region of BRAF and forms two significant hydrogen bonds between the carbonyl of Cys532 and the NH of the 2-amide (2.7 Å) and between the NH of Cys532 and the N-3 nitrogen (3.2 Å). The cocrystal structure of BRAF supports our hypothesis that the planar conformation of the 2-amide group with the [1,3]thiazolo[5,4-<i>b</i>]pyridine scaffold may be stabilized through sulfur–carbonyl interactions because the measured distance (2.8 Å) between the sulfur and oxygen atoms is shorter than the sum of the corresponding van der Waals radii of the oxygen and sulfur atoms (3.32 Å).<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> Interestingly, the indole side chain of Trp531 is located near the 2-amide bond of <b>6d</b> and possibly forms π–π stacking interactions with the 2-amide. This type of interaction is not observed in the cocrystal structure<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> of sorafenib, and it may be critical for enhancing the BRAF inhibition of <b>6d</b>. Structural differences of adenine sites between <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4DBN">4DBN</a> (<b>6d</b>) and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1UWJ">1UWJ</a> (sorafenib) is discussed in detail using the figure that describes the overlapped structures in <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>. Additionally, the biphenyl amide moiety between rings B and C of <b>6d</b> forms two significant hydrogen bond interactions with the backbone NH of Asp594 (3.0 Å) and the side chain carboxylate of Glu501 in the C-helix (3.0 Å). These interactions may be important for stabilizing the DFG-out inactive conformation of BRAF. Furthermore, the 2-chloro-3-(1-cyanocyclopropyl)benzene ring is located in a back pocket that is twisted away from the carbonyl surface by 44.4° (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>B). The bulky cyanocyclopropyl group occupies the hydrophobic back pocket formed by Val504, Thr508, Leu567, His574, and Ile592 (indicated by the green area in Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>B); this hydrophobic interaction plays an important role enhancing the BRAF(V600E) cellular activity.</div><figure id="fig5" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/medium/jm-2012-00126x_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Cocrystal structure of <b>6d</b> with BRAF (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4DBN">4DBN</a>, 3.1 Å resolution) and VEGFR2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3VNT">3VNT</a>, 1.64 Å resolution): (A) DFG-out conformation of BRAF (green cartoon) is stabilized by <b>6d</b>; (B) back pocket region of BRAF (surface); (C) DFG-out conformation of VEGFR2 (magenta cartoon) is stabilized by <b>6d</b>; (D) back pocket region of VEGFR2 (surface).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300126x&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The cocrystal structure of VEGFR2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3VNT">3VNT</a>) also revealed that <b>6d</b> occupies the ATP binding site of VEGFR2 and stabilizes the DFG-out conformation of VEGFR2 (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>C). Since similar hydrogen bond interactions (depicted in the red dotted lines in Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>C), compared to those of BRAF, and occupation of the 3-(1-cyanocyclopropyl)benzene moiety in the back pocket region of VEGFR2 (Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>D) were observed, <b>6d</b> was proved to be a DFG-out type RAF/VEGFR2 inhibitor.</div><div class="NLM_p last">The stabilized planar conformation of the 2-amide group with the [1,3]thiazolo[5,4-<i>b</i>]pyridine scaffold by the sulfur–carbonyl interaction was also observed in the VEGFR2 cocrystal structure. However, because of the replacement of the indole ring (Trp531) in BRAF with the phenyl ring (Phe918) in VEGFR2, the VEGFR2 pocket appears to be spacious and more accommodating to the various bicyclic fused rings with diversified and less planar amide conformations compared to BRAF in Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> Kinase Inhibitory Profiles of <b>6d</b></h3><div class="NLM_p">The inhibitory profiles of <b>6d</b> against 26 different kinases are summarized in Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>. Compound <b>6d</b> exhibited potent inhibitory activity against not only BRAF(V600E) (IC<sub>50</sub> = 7.0 nM) but also wild-type BRAF (12 nM) and C-RAF (1.5 nM). Additionally, other kinases related to angiogenesis,<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> such as FGFR3, PDGFRα, PDGFRβ, were inhibited with IC<sub>50</sub> values comparable to that of VEGFR2 inhibition. Several kinases, including Aurora B and Src, were moderately inhibited with IC<sub>50</sub> values ranging from 240 to 420 nM, and no significant inhibition was observed against the remaining 19 kinases. Therefore, <b>6d</b> was considered to have a character as a pan-RAF and angiogenesis-related kinases inhibitor.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Kinase Selectivity of <b>6d</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">kinase</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">kinase</th><th class="colsep0 rowsep0" align="center">IC<sub>50</sub> (nM)<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">BRAF(wt)</td><td class="colsep0 rowsep0" align="left">12</td><td class="colsep0 rowsep0" align="left">PKA</td><td class="colsep0 rowsep0" align="left">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">C-RAF</td><td class="colsep0 rowsep0" align="left">1.5</td><td class="colsep0 rowsep0" align="left">PKCθ</td><td class="colsep0 rowsep0" align="left">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">FGFR3</td><td class="colsep0 rowsep0" align="left">22</td><td class="colsep0 rowsep0" align="left">CHK1</td><td class="colsep0 rowsep0" align="left">6300</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PDGFRα</td><td class="colsep0 rowsep0" align="left">12</td><td class="colsep0 rowsep0" align="left">CK1δ</td><td class="colsep0 rowsep0" align="left">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">PDGFRβ</td><td class="colsep0 rowsep0" align="left">5.5</td><td class="colsep0 rowsep0" align="left">ERK1</td><td class="colsep0 rowsep0" align="left">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">EGFR</td><td class="colsep0 rowsep0" align="left">>10000</td><td class="colsep0 rowsep0" align="left">CDK1</td><td class="colsep0 rowsep0" align="left">2200</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Her2</td><td class="colsep0 rowsep0" align="left">>10000</td><td class="colsep0 rowsep0" align="left">CDK2</td><td class="colsep0 rowsep0" align="left">2700</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">TIE2</td><td class="colsep0 rowsep0" align="left">>10000</td><td class="colsep0 rowsep0" align="left">Aurora B</td><td class="colsep0 rowsep0" align="left">240</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">c-Met</td><td class="colsep0 rowsep0" align="left">>10000</td><td class="colsep0 rowsep0" align="left">p38α</td><td class="colsep0 rowsep0" align="left">1100</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">c-Kit</td><td class="colsep0 rowsep0" align="left">>10000</td><td class="colsep0 rowsep0" align="left">JNK1</td><td class="colsep0 rowsep0" align="left">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Src</td><td class="colsep0 rowsep0" align="left">420</td><td class="colsep0 rowsep0" align="left">GSK3β</td><td class="colsep0 rowsep0" align="left">2900</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IR</td><td class="colsep0 rowsep0" align="left">>10000</td><td class="colsep0 rowsep0" align="left">MEK1</td><td class="colsep0 rowsep0" align="left">>10000</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">IKKβ</td><td class="colsep0 rowsep0" align="left">>10000</td><td class="colsep0 rowsep0" align="left">MEKK1</td><td class="colsep0 rowsep0" align="left">>10000</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last"><i>n</i> = 2.</p></div></div></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> In Vitro Pharmacology of <b>6d</b></h3><div class="NLM_p">To determine the potency of <b>6d</b> as a BRAF(V600E) inhibitor, we investigated the in vitro MAPK signal suppression effect of <b>6d</b> in various cancer cells harboring the <i>BRAF</i><sup>V600E</sup> mutation (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>). In several types of colon, melanoma, and thyroid cancer cells, <b>6d</b> suppressed both phospho-MEK1/2 and phospho-ERK1/2 levels in a concentration-dependent manner. Reflecting the inhibition of the downstream molecules in MAPK signal transduction, <b>6d</b> demonstrated antiproliferative activities among these cell lines, with GI<sub>50</sub> of 130–820 nM.</div><figure id="fig6" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/medium/jm-2012-00126x_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. MAPK signal suppression effect by 2 h treatment of <b>6d</b> (Western blotting) and its antiproliferative activity (GI<sub>50</sub>) in various cancer cell lines possessing the <i>BRAF</i><sup>V600E</sup> mutated gene.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300126x&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Next, the cellular VEGFR2 inhibitory activity of <b>6d</b> was evaluated in VEGFR2-overexpressing 293/KDR cells<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>). Compound <b>6d</b> significantly inhibited the VEGFR2 phosphorylation induced by treatment with vascular endothelial growth factor A (VEGF-A), with an IC<sub>50</sub> of 0.53 nM. Furthermore, <b>6d</b> potently inhibited the VEGF-induced proliferation of HUVEC at a GI<sub>50</sub> of 19 nM. These results indicated that the cellular antiangiogenesis activity of <b>6d</b> resulted in enhanced in vivo antitumor efficacy against various types of cancers.</div><figure id="fig7" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/medium/jm-2012-00126x_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. VEGF signal suppression effect by 2 h treatment of <b>6d</b> (Western blotting) in 293/KDR cell lines. The 293/KDR cells were untreated (−) or treated (+) with VEGF-A (final concentration of 50 ng/mL) for 10 min.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300126x&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> Pharmacokinetic Profiles and in Vivo Studies of <b>6d</b> in Rats</h3><div class="NLM_p">To maximize the oral bioavailability of <b>6d</b>, we applied a spray-dried solid dispersion (SD) formulation<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> to this compound using hydroxypropyl methylcellulose phthalate (HPMCP, HP-55). The obtained <b>6d-SD</b> showed sufficient oral bioavailability (<i>F</i> = 70.5%) at a dose of 10 mg/kg for <b>6d</b> in rats (Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>).</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Mean<a class="ref internalNav" href="#t6fn1" aria-label="a">a</a> Pharmacokinetic Parameters for <b>6d</b> in Rats</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">dose (mg/kg)</th><th class="colsep0 rowsep0" align="center">route</th><th class="colsep0 rowsep0" align="center">CL<sub>total</sub>(mL h<sup>–1</sup> kg<sup>–1</sup>)</th><th class="colsep0 rowsep0" align="center"><i>V</i><sub>dss</sub>(mL/kg)</th><th class="colsep0 rowsep0" align="center">MRT (h)</th><th class="colsep0 rowsep0" align="center">AUC<sub>0–24h</sub>(μg h/mL)</th><th class="colsep0 rowsep0" align="center"><i>C</i><sub>max</sub>, po (μg/mL)</th><th class="colsep0 rowsep0" align="center"><i>F</i> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">1<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a></td><td class="colsep0 rowsep0" align="left">iv</td><td class="colsep0 rowsep0" align="left">886 ± 203</td><td class="colsep0 rowsep0" align="left">1655 ± 493</td><td class="colsep0 rowsep0" align="left">1.86 ± 0.24</td><td class="colsep0 rowsep0" align="left">1.167 ± 0.25</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">10<a class="ref internalNav" href="#t6fn3" aria-label="c">c</a></td><td class="colsep0 rowsep0" align="left">oral</td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">4.38 ± 0.43</td><td class="colsep0 rowsep0" align="left">8.23 ± 1.04</td><td class="colsep0 rowsep0" align="left">1.29 ± 0.07</td><td class="colsep0 rowsep0" align="left">70.5 ± 8.9</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>a</sup><p class="last">Values shown are the mean ± SD of data from three rats.</p></div><div class="footnote" id="t6fn2"><sup>b</sup><p class="last">Delivered in polyethylene glycol/DMA (1/1).</p></div><div class="footnote" id="t6fn3"><sup>c</sup><p class="last">Solid dispersion (SD) powder, prepared by spray dry method using hydroxypropylmethylcellulose (HP-55) (<b>6d</b>/HP-55 (1:4)); delivered in distilled water.</p></div></div></div><div class="NLM_p">Reflecting the sufficient oral bioavailability, <b>6d-SD</b> demonstrated significantly decreased phosphorylation levels of ERK1/24 h after oral administration in an A375 (<i>BRAF</i><sup>V600E</sup> mutant) human melanoma xenograft model in rats (Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a>).</div><figure id="fig8" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/medium/jm-2012-00126x_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Mean (<i>n</i> = 2) phosphorylated ERK1/2 levels in F344 nude rats bearing A375 (<i>BRAF</i><sup>V600E</sup> mutant) human melanoma xenograft tumors after treatment with single dose of <b>6d-SD</b>. Footnotes in the table portion indicate the following: (b) detected by Western blotting; (c) delivered in distilled water; (d) solid dispersion formulation was delivered in distilled water; (e) dose of <b>6d</b> is described.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300126x&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Finally, we examined the antitumor efficacy of <b>6d-SD</b> administered orally twice daily in an A375 melanoma xenograft model in rats (Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a>). Two weeks after administration at a dose of 10 mg/kg for <b>6d</b>, we observed tumor regression with <i>T</i>/<i>C</i>of −7.0% without severe toxicity. Since <b>6d</b> also shows potent VEGFR2 inhibitory activity (Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>, Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>), this tumor regression should include the efficacy based on the antiangiogenesis potency and BRAF inhibitory activity.</div><figure id="fig9" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/medium/jm-2012-00126x_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Mean (<i>n</i> = 3) tumor volumes and body weights in F344 nude rats bearing A375 human melanoma xenograft tumors dosed with <b>6d-SD</b> or vehicle. Footnotes in the table portion indicate the following: (b) compound <b>6d-SD</b> was administered orally twice daily for 14 days; (c) delivered in distilled water; (d) dolid dispersion formulation was delivered in distilled water; (e) dose of <b>6d</b> is described. <i>P</i> ≤ 0.05 vs control at day 14 (<i>t</i>-test).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300126x&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i26">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_26320" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_26320" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">We designed and developed RAF/VEGFR2 inhibitors bearing a novel [1,3]thiazolo[5,4-<i>b</i>]pyridine scaffold <b>6</b> on the basis of structure-based drug design using docking models of our lead imidazo[1,2-<i>b</i>]pyridazines <b>1a</b>,<b>b</b> with BRAF. Target compounds were designed as DFG-out type binders for binding the inactive conformation of BRAF. X-ray cocrystal structural analysis of the representative compound <b>6d</b> indicated that the two hydrogen bonds in benzamide between rings B and C with Asp594 and Glu501 play a key role in stabilizing the DFG-out conformation. Furthermore, the sulfur–carbonyl interactions were important for the planar conformation of the 2-amide, together with coordination of the π–π interaction with the indole ring of Trp531, which was significant for enhancing BRAF inhibition. The optimal compound <b>6d</b> showed excellent in vitro potency as a BRAF(V600E) and VEGFR2 dual kinase inhibitor.</div><div class="NLM_p last">In vitro pharmacologycal evaluation of <b>6d</b> revealed potent MAPK cascade suppression in various <i>BRAF</i><sup>V600E</sup> mutant tumor cell lines. Furthermore, <b>6d</b> showed antiangiogenesis by suppressing the VEGFR2 pathway in 293/KDR and VEGF-stimulated HUVEC cells. Compound <b>6d-SD</b>, prepared using a spray-dried SD formulation, demonstrated a mechanism-based in vivo PD effect as well as regressive antitumor efficacy in an A375 human melanoma xenograft model in rats. These results suggest that dual inhibition of BRAF(V600E) and VEGFR2 may provide strong antitumor efficacy and that <b>6d</b> is a promising candidate for the treatment of various human cancers harboring the <i>BRAF</i><sup>V600E</sup> mutation.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i27">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_43185" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_43185" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> General Chemistry Information</h3><div class="NLM_p last">The starting materials, reagents, and solvents for reactions were reagent-grade and were used as purchased. Thin-layer chromatography (TLC) was carried out using Merck Kieselgel 60, 63–200 mesh, F254 plates, or Fuji Silysia Chemical Ltd., 100–200 mesh, NH plates. Chromatographic purification was carried out using silica gel (Merck, 70–230 mesh) or basic silica gel (Fuji Silysia Chemical Ltd., DM1020, 100–200 mesh). Melting points were obtained using an OptiMelt melting point apparatus MPA100 and used uncorrected. Proton nuclear magnetic resonance <sup>1</sup>H NMR spectra were recorded using a Bruker AVANCE II (300 MHz) spectrometer with tetramethylsilane (TMS) as an internal standard. The NMR data are given as follows: chemical shift (δ) in ppm, multiplicity (where applicable), coupling constants (<i>J</i>) in Hz (where applicable), and integration (where applicable). Multiplicities are indicated by s (singlet), d (doublet), t (triplet), q (quartet), dd (double doublets), dt, (double triplet), ddd (double double doublet), br s (broad singlet), or m (multiplet). MS spectra were collected with a Waters LC–MS system (ZMD-1) and were used to confirm ≥95% purity of each compound. The column used was an L-column 2 ODS (3.0 mm × 50 mm i.d., CERI, Japan) with a temperature of 40 °C and a flow rate of 1.2 mL/min. Mobile phase A was 0.05% TFA in ultrapure water. Mobile phase B was 0.05% TFA in acetonitrile which was increased linearly from 5% to 90% over 2 min, 90% over the next 1.5 min, after which the column was equilibrated to 5% for 0.5 min. Elemental analyses (Anal.) and high-resolution mass spectrometry (HRMS) were carried out at Takeda Analytical Laboratories, Ltd. Yields were not optimized.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> <i>N</i>-{6-[3-({[3-(Trifluoromethyl)phenyl]carbonyl}amino)phenoxy]imidazo[1,2-<i>b</i>]pyridazin-2-yl}tetrahydro-2<i>H</i>-pyran-4-carboxamide (<b>1a</b>)</h3><div class="NLM_p last">To a solution of <i>N</i>-{3-[(2-aminoimidazo[1,2-<i>b</i>]pyridazin-6-yl)oxy]phenyl}-3-(trifluoromethyl)benzamide <b>10</b> (150 mg, 0.36 mmol) in <i>N</i>,<i>N</i>-dimethylformamide (5 mL) were successively added tetrahydro-2<i>H</i>-pyran-4-carboxylic acid (70.8 mg, 0.54 mmol), EDCI·HCl (104 mg, 0.54 mmol), HOBt (73.6 mg, 0.54 mmol), and triethylamine (76 μL, 0.54 mmol), and the reaction mixture was stirred at room temperature for 14 h. The mixture was partitioned between ethyl acetate (10 mL) and saturated aqueous NaHCO<sub>3</sub> (5 mL). The organic layer was dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, filtered, and evaporated. The oily residue was purified with silica gel column chromatography (50–100% ethyl acetate in <i>n</i>-hexane). Desired fractions were evaporated in vacuo and the oily residue was crystallized with ethyl acetate/<i>n</i>-hexane (1:4) to give <b>1a</b> (155 mg, 81%) as a pale yellow amorphous solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 1.52–1.81 (m, 4H), 2.56–2.83 (m, 1H), 3.25–3.40 (m, 2H), 3.80–3.97 (m, 2H), 7.03 (dd, <i>J</i> = 2.1, 7.7 Hz, 1H), 7.08 (d, <i>J</i> = 9.4 Hz, 1H), 7.46 (t, <i>J</i> = 8.1 Hz, 1H), 7.58–7.71 (m, 1H), 7.74 (t, <i>J</i> = 2.1 Hz, 1H), 7.75–7.86 (m, 1H), 7.98 (d, <i>J</i> = 8.1 Hz, 1H), 8.01–8.12 (m, 2H), 8.17–8.38 (m, 2H), 10.60 (s, 1H), 10.81 (s, 1H). HRMS (ESI) calcd for C<sub>26</sub>H<sub>22</sub>F<sub>3</sub>N<sub>5</sub>O<sub>4</sub> [M + H]<sup>+</sup> 526.1697. Found: 526.1659.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> <i>N</i>-(3-{[2-(Propionylamino)imidazo[1,2-<i>b</i>]pyridazin-6-yl]oxy}phenyl)-3-(trifluoromethyl)benzamide (<b>1c</b>)</h3><div class="NLM_p last">Compound <b>1c</b> (116 mg) was prepared in a similar manner to that described for <b>1a</b> from <b>10</b> (150 mg, 0.363 mmol), using propionic acid (40 μL, 0.544 mmol), EDCI·HCl (104 mg, 0.544 mmol), HOBt (73 mg, 0.544 mmol), triethylamine (76 μL, 0.544 mmol), and <i>N</i>,<i>N</i>-dimethylformamide (5 mL). Yield 68%, white crystals; mp 190–194 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 1.07 (t, <i>J</i> = 7.5 Hz, 3H), 2.37 (q, <i>J</i> = 7.5 Hz, 2H), 7.01–7.11 (m, 2H), 7.46 (t, <i>J</i> = 8.2 Hz, 1H), 7.65–7.83 (m, 3H), 7.94–8.00 (m, 1H), 8.02 (s, 1H), 8.05 (d, <i>J</i> = 9.6 Hz, 1H), 8.22–8.30 (m, 2H), 10.59 (s, 1H), 10.75 (s, 1H). HRMS (ESI): calcd for C<sub>23</sub>H<sub>18</sub>F<sub>3</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup> 470.1435. Found: 470.1457.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> <i>N</i>-(3-{[2-(Isobutyrylamino)imidazo[1,2-<i>b</i>]pyridazin-6-yl]oxy}phenyl)-3-(trifluoromethyl)benzamide (<b>1d</b>)</h3><div class="NLM_p last">Compound <b>1d</b>(74 mg) was prepared in a similar manner to <b>1a</b> from <b>10</b> (150 mg, 0.363 mmol), using 2-methylpropanoic acid (50 μL, 0.544 mmol), EDCI·HCl (104 mg, 0.544 mmol), HOBt (73 mg, 0.544 mmol), triethylamine (76 μL, 0.544 mmol), and <i>N</i>,<i>N</i>-dimethylformamide (5 mL). Yield 42%, pale green crystals; mp 193 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 1.08 (d, <i>J</i> = 7.0 Hz, 6H), 2.65–2.77 (m, 1H), 7.00–7.11 (m, 2H), 7.46 (t, <i>J</i> = 8.1 Hz, 1H), 7.63–7.83 (m, 3H), 7.94–8.09 (m, 3H), 8.22–8.30 (m, 2H), 10.59 (s, 1H), 10.75 (s, 1H). MS (ESI) <i>m</i>/<i>z</i> 484.15 (M + H)<sup>+</sup>. Anal. Calcd for C<sub>24</sub>H<sub>20</sub>F<sub>3</sub>N<sub>5</sub>O<sub>3</sub>: C, 59.63; H, 4.17; N, 14.49. Found: C, 59.53; H, 4.25; N, 14.55.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> <i>N</i>-{3-[(2-Acetamidoimidazo[1,2-<i>b</i>]pyridazin-6-yl)oxy]phenyl}-3-(trifluoromethyl)benzamide (<b>1b</b>)</h3><div class="NLM_p last">To a solution of <b>10</b> (150 mg, 0.362 mmol) in pyridine (3 mL) was added acetyl chloride (31 μL, 0.435 mmol), and the reaction mixture was stirred at room temperature for 5 h. The reaction mixture was concentrated in vacuo. The resulting slurry was triturated with water (10 mL). The resulting precipitate was collected and recrystallized from ethanol to give compound <b>1b</b> (99 mg, 60%) as pale yellow crystals, mp 224–226 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 2.07 (s, 3H), 7.01–7.11 (m, 2H), 7.46 (t, <i>J</i> = 8.1 Hz, 1H), 7.63–7.83 (m, 3H), 7.95–8.01 (m, 2H), 8.06 (d, <i>J</i> = 9.6 Hz, 1H), 8.22–8.30 (m, 2H), 10.59 (s, 1H), 10.80 (s, 1H). HRMS (ESI): calcd for C<sub>22</sub>H<sub>16</sub>F<sub>3</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup> 456.1278. Found: 456.1283.</div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> <i>N</i>-[3-({2-[(Cyclopropylcarbonyl)amino]imidazo[1,2-<i>b</i>]pyridazin-6-yl}oxy)phenyl]-3-(trifluoromethyl)benzamide (<b>1e</b>)</h3><div class="NLM_p last">Compound <b>1e</b> (132 mg) was prepared in a similar manner to <b>1b</b> from <b>10</b>, using cyclopropanecarbonyl chloride (45.5 mg, 0.44 mmol) and pyridine (3 mL). Yield 75%, colorless crystals; mp 203–204 °C. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 0.61–1.04 (m, 4H), 1.67–2.04 (m, 1H), 7.03 (dd, <i>J</i> = 2.1, 7.6 Hz, 1H), 7.08 (d, <i>J</i> = 9.6 Hz, 1H), 7.46 (t, <i>J</i> = 8.1 Hz, 1H), 7.67 (d, <i>J</i> = 8.1 Hz, 1H), 7.73 (t, <i>J</i> = 2.1 Hz, 1H), 7.75–7.86 (m, 1H), 7.87–8.02 (m, 2H), 8.06 (d, <i>J</i> = 9.6 Hz, 1H), 8.19–8.41 (m, 2H), 10.59 (s, 1H), 11.09 (s, 1H). MS (ESI): <i>m</i>/<i>z</i> 482.2 (M + H)<sup>+</sup>. Anal. Calcd for C<sub>24</sub>H<sub>18</sub>F<sub>3</sub>N<sub>5</sub>O<sub>3</sub>: C, 59.88; H, 3.77; N, 14.55. Found: C, 59.91; H, 3.88; N, 14.37.</div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> <i>N</i>-[3-({2-[(Cyclobutylcarbonyl)amino]imidazo[1,2-<i>b</i>]pyridazin-6-yl}oxy)phenyl]-3-(trifluoromethyl)benzamide (<b>1f</b>)</h3><div class="NLM_p last">Compound <b>1f</b> (98 mg) was prepared in a similar manner to <b>1b</b> from <b>10</b> (150 mg, 0.362 mmol), using cyclobutanecarbonyl chloride (50 μL, 0.435 mmol), triethylamine (75 μL, 0.544 mmol), and tetrahydrofuran (5 mL). Yield 54%, white amorphous solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 1.83–2.11 (m, 2H), 2.15–2.46 (m, 4H), 3.14–3.28 (m, 1H), 6.88 (d, <i>J</i> = 9.4 Hz, 1H), 7.00–7.06 (m, 1H), 7.42–7.48 (m, 2H), 7.60–7.68 (m, 1H), 7.69–7.85 (m, 4H), 7.91–7.98 (m, 1H), 8.04–8.09 (m, 1H), 8.13 (s, 1H), 8.19 (s, 1H). HRMS (ESI): calcd for C<sub>25</sub>H<sub>20</sub>F<sub>3</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup> 496.1591. Found: 496.1588.</div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> <i>N</i>-[3-({2-[(Cyclopentylcarbonyl)amino]imidazo[1,2-<i>b</i>]pyridazin-6-yl}oxy)phenyl]-3-(trifluoromethyl)benzamide (<b>1g</b>)</h3><div class="NLM_p last">Compound <b>1g</b> (105 mg) was prepared in a manner similar to <b>1b</b> from <b>10</b> (150 mg, 0.362 mmol), using cyclopentanecarbonyl chloride (53 μL, 0.435 mmol), triethylamine (75 μL, 0.544 mmol), and tetrahydrofuran (5 mL).Yield 57%, white crystals; mp 215–217 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 1.47–1.90 (m, 8H), 2.81–2.95 (m, 1H), 7.00–7.10 (m, 2H), 7.46 (t, <i>J</i> = 8.2 Hz, 1H), 7.63–7.83 (m, 3H), 7.94–8.09 (m, 3H), 8.21–8.30 (m, 2H), 10.59 (s, 1H), 10.77 (s, 1H). HRMS (ESI): calcd for C<sub>26</sub>H<sub>22</sub>F<sub>3</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup> 510.1748. Found: 510.1711.</div></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> <i>N</i>-[3-({2-[(Cyclopropylcarbonyl)amino]imidazo[1,2-<i>b</i>]pyridazin-6-yl}oxy)phenyl]-4-(trifluoromethyl)benzamide (<b>1h</b>)</h3><div class="NLM_p last">Compound <b>1h</b> (110 mg) was prepared in a similar manner to <b>1a</b>from <i>N</i>-[6-(3-aminophenoxy)imidazo[1,2-<i>b</i>]pyridazin-2-yl]cyclopropanecarboxamide <b>14</b> (100 mg, 0.32 mmol), using, 4-(trifluoromethyl)benzoic acid <b>15h</b> (63 mg, 0.33 mmol), EDCI·HCl (65 mg, 0.34 mmol), HOBt (46 mg, 0.34 mmol), and <i>N</i>,<i>N</i>-dimethylformamide (5 mL). Yield 68%, white crystals; mp 240–241 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 0.62–0.94 (m, 4H), 1.76–2.06 (m, 1H), 6.99–7.05 (m, 1H), 7.08 (d, <i>J</i> = 9.6 Hz, 1H), 7.45 (t, <i>J</i> = 8.1 Hz, 1H), 7.63–7.71 (m, 1H), 7.74 (t, <i>J</i> = 2.1 Hz, 1H), 7.92 (d, <i>J</i> = 8.2 Hz, 2H), 7.98 (s, 1H), 8.06 (d, <i>J</i> = 9.6 Hz, 1H), 8.13 (d, <i>J</i> = 8.2 Hz, 2H), 10.60 (s, 1H), 11.09 (s, 1H). MS (ESI): <i>m</i>/<i>z</i> 482.02 (M + H)<sup>+</sup>. Anal. Calcd for C<sub>24</sub>H<sub>18</sub>F<sub>3</sub>N<sub>5</sub>O<sub>3</sub>: C, 59.88; H, 3.77; N, 14.55. Found: C, 59.92; H, 3.88; N, 14.43.</div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> <i>N</i>-[3-({2-[(Cyclopropylcarbonyl)amino]imidazo[1,2-<i>b</i>]pyridazin-6-yl}oxy)phenyl]-2-(trifluoromethyl)benzamide (<b>1i</b>)</h3><div class="NLM_p last">To a solution of 2-(trifluoromethyl)benzoic acid <b>15i</b> (110 mg, 0.581 mmol) in tetrahydrofuran (5 mL) was added oxalyl chloride (84 μL, 0.969 mmol) followed by <i>N</i>,<i>N</i>-dimethylformamide (5 μL) at 4 °C. The reaction mixture was stirred at room temperature for 1.5 h and evaporated in vacuo. The residue was diluted with NMP (5 mL), and to the mixture was added <b>14</b> (150 mg, 0.484 mmol). The reaction mixture was stirred at room temperature for 2 h. The mixture was diluted with ethyl acetate (20 mL), washed with saturated NaHCO<sub>3</sub> (20 mL) and brine (20 mL) successively, dried over anhydrous MgSO<sub>4</sub>, filtered, and evaporated in vacuo. The residue was purified by silica gel column chromatography (0–100% ethyl acetate in <i>n-</i>hexane) to give compound <b>1i</b> (176 mg, 75%) as a white amorphous solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 0.77–0.84 (m, 4H), 1.86–1.98 (m, 1H), 6.98–7.04 (m, 1H), 7.07 (d, <i>J</i> = 9.6 Hz, 1H), 7.43 (t, <i>J</i> = 8.1 Hz, 1H), 7.51–7.57 (m, 1H), 7.64 (t, <i>J</i> = 2.1 Hz, 1H), 7.67–7.76 (m, 2H), 7.76–7.88 (m, 2H), 7.98 (s, 1H), 8.05 (d, <i>J</i> = 9.6 Hz, 1H), 10.71 (s, 1H), 11.07 (s, 1H). HRMS (ESI): calcd for C<sub>24</sub>H<sub>18</sub>F<sub>3</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup> 482.1435. Found: 482.1432.</div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> <i>N</i>-[3-({2-[(Cyclopropylcarbonyl)amino]imidazo[1,2-<i>b</i>]pyridazin-6-yl}oxy)phenyl]-3-methoxybenzamide (<b>1j</b>)</h3><div class="NLM_p last">Compound <b>1j</b> (49 mg) was prepared in a similar manner to <b>1i</b> from <b>14</b> (80 mg, 0.26 mmol) using 3-methoxybenzoic acid <b>15j</b> (48 mg, 0.32 mmol), oxalyl chloride (32 μL, 0.37 mmol), <i>N</i>,<i>N</i>-dimethylformamide (5 μL), tetrahydrofuran (2 mL), and NMP (2 mL). Yield 43%, white crystals; mp 186–187 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 0.77–0.85 (m, 4H), 1.85–1.99 (m, 1H), 3.83 (s, 3H), 6.95–7.03 (m, 1H), 7.07 (d, <i>J</i> = 9.6 Hz, 1H), 7.12–7.21 (m, 1H), 7.37–7.49 (m, 3H), 7.48–7.56 (m, 1H), 7.61–7.70 (m, 1H), 7.73 (t, <i>J</i> = 2.1 Hz, 1H), 7.98 (s, 1H), 8.05 (d, <i>J</i> = 9.6 Hz, 1H), 10.34 (s, 1H), 11.09 (s, 1H). MS (ESI): <i>m</i>/<i>z</i> 444.02 (M + H)<sup>+</sup>. Anal. Calcd for C<sub>24</sub>H<sub>21</sub>N<sub>5</sub>O<sub>4</sub>: C, 65.00; H, 4.77; N, 15.79. Found: C, 64.73; H, 4.87; N, 15.69.</div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> 3-<i>tert</i>-Butoxy-<i>N</i>-[3-({2-[(cyclopropylcarbonyl)amino]imidazo[1,2-<i>b</i>]pyridazin-6-yl}oxy)phenyl]benzamide (<b>1k</b>)</h3><div class="NLM_p last">Compound <b>1k</b> (160 mg) was prepared in a similar manner to <b>1i</b> from <b>14</b> (150 mg, 0.49 mmol), using 3-<i>tert</i>-butoxybenzoic acid <b>15k</b> (110 mg, 0.58 mmol), oxalyl chloride (63 μL, 0.73 mmol), <i>N</i>,<i>N</i>-dimethylformamide (5 μL), tetrahydrofuran (4 mL), and NMP (4 mL). Yield 57%, white crystals; mp 206–207 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 0.74–0.87 (m, 4H), 1.33 (s, 9H), 1.85–1.98 (m, 1H), 6.90–7.03 (m, 1H), 7.07 (d, <i>J</i> = 9.6 Hz, 1H), 7.16–7.27 (m, 1H), 7.36–7.48 (m, 2H), 7.48–7.53 (m, 1H), 7.61–7.70 (m, 2H), 7.73 (t, <i>J</i> = 2.1 Hz, 1H), 7.98 (s, 1H), 8.05 (d, <i>J</i> = 9.6 Hz, 1H), 10.34 (s, 1H), 11.09 (s, 1H). MS (ESI): 486.25 (M + H)<sup>+</sup>. Anal. Calcd for C<sub>27</sub>H<sub>27</sub>N<sub>5</sub>O<sub>4</sub>: C, 66.79; H, 5.61; N, 14.42. Found: C, 66.68; H, 5.56; N,14.41.</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> Methyl 3-({[3-({2-[(Cyclopropylcarbonyl)amino]imidazo[1,2-<i>b</i>]pyridazin-6-yl}oxy)phenyl]amino}carbonyl)benzoate (<b>1l</b>)</h3><div class="NLM_p last">Compound <b>1l</b> (270 mg) was prepared by a similar manner to <b>1a</b> from <b>14</b> (250 mg, 0.81 mmol), using 3-(methoxycarbonyl)benzoic acid <b>15l</b> (150 mg, 0.83 mmol), EDCI·HCl (160 mg, 0.84 mmol), HOBt (110 mg, 0.81 mmol), and <i>N</i>,<i>N</i>-dimethylformamide (8 mL). Yield 72%, white crystals; mp 216–217 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 0.74–0.85 (m, 4H), 1.84–1.98 (m, 1H), 3.91 (s, 3H), 6.97–7.05 (m, 1H), 7.08 (d, <i>J</i> = 9.6 Hz, 1H), 7.45 (t, <i>J</i> = 8.1 Hz, 1H), 7.63–7.79 (m, 3H), 7.98 (s, 1H), 8.06 (d, <i>J</i> = 9.6 Hz, 1H), 8.12–8.19 (m, 1H), 8.19–8.26 (m, 1H), 8.52 (t, <i>J</i> = 1.5 Hz, 1H), 10.59 (s, 1H), 11.09 (s, 1H). Anal. Calcd for C<sub>25</sub>H<sub>21</sub>N<sub>5</sub>O<sub>5</sub>: C, 63.69; H, 4.49; N, 14.85. Found: C, 63.48; H, 4.51; N, 14.76.</div></div><div id="sec4_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> <i>N</i>-[3-({2-[(Cyclopropylcarbonyl)amino]imidazo[1,2-<i>b</i>]pyridazin-6-yl}oxy)phenyl]-3-(1-hydroxy-1-methylethyl)benzamide (<b>1m</b>)</h3><div class="NLM_p last">To a solution of methyl 3-({[3-({2-[(cyclopropylcarbonyl)amino]imidazo[1,2-<i>b</i>]pyridazin-6-yl}oxy)phenyl]amino}carbonyl)benzoate <b>1l</b> (100 mg, 0.212 mmol) in tetrahydrofuran (5 mL) was added dropwise a solution of 1.4 M methylmagnesium bromide in tetrahydrofuran/toluene (0.76 mL, 1.1 mmol) under ice-cooling. After addition, the reaction mixture was stirred at room temperature for 12 h. To the mixture was added water (10 mL), and the mixture was treated with 1 N HCl (5 mL). The mixture was extracted with ethyl acetate (30 mL), and the organic layer was washed with brine (30 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and filtered. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography (40–100% ethyl acetate in <i>n-</i>hexane) to give compound <b>1m</b> (19 mg, 19%) as a white amorphous solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 0.75–0.85 (m, 4H), 1.46 (s, 6H), 1.85–1.97 (m, 1H), 5.14 (s, 1H), 6.96–7.03 (m, 1H), 7.07 (d, <i>J</i> = 9.6 Hz, 1H), 7.37–7.50 (m, 2H), 7.67 (m, 2H), 7.73 (t, <i>J</i> = 2.1 Hz, 1H), 7.75–7.81 (m, 1H), 7.98 (s, 1H), 8.01 (t, <i>J</i> = 1.5 Hz, 1H), 8.05 (d, <i>J</i> = 9.6 Hz, 1H), 10.35 (s, 1H), 11.09 (s, 1H). HRMS (ESI): calcd for C<sub>26</sub>H<sub>25</sub>N<sub>5</sub>O<sub>4</sub>[M + H]<sup>+</sup> 472.1979. Found: 472.1941.</div></div><div id="sec4_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> 3-(1-Cyano-1-methylethyl)-<i>N</i>-[3-({2-[(cyclopropylcarbonyl)amino]imidazo[1,2-<i>b</i>]pyridazin-6-yl}oxy)phenyl]benzamide (<b>1n</b>)</h3><div class="NLM_p last">Compound <b>1n</b> (120 mg) was prepared by a similar manner to <b>1a</b> from <b>14</b> (100 mg, 0.32 mmol), using 3-(1-cyano-1-methylethyl)benzoic acid <b>15n</b> (62 mg, 0.33 mmol), EDCI·HCl (65 mg, 0.34 mmol), HOBt (46 mg, 0.34 mmol), and <i>N</i>,<i>N</i>-dimethylformamide (5 mL). Yield 77%, white crystals; mp 225–226 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 0.73–0.86 (m, 4H), 1.74 (s, 6H), 1.83–1.98 (m, 1H), 6.99–7.04 (m, 1H), 7.08 (d, <i>J</i> = 9.6 Hz, 1H), 7.45 (t, <i>J</i> = 8.1 Hz, 1H), 7.54–7.69 (m, 2H), 7.69–7.80 (m, 2H), 7.92 (dt, <i>J</i> = 7.8, 1.2 Hz, 1H), 7.98 (s, 1H), 8.00–8.10 (m, 2H), 10.45 (s, 1H), 11.09 (s, 1H). HRMS (ESI): calcd for C<sub>27</sub>H<sub>24</sub>N<sub>6</sub>O<sub>3</sub> [M + H]<sup>+</sup> 481.1983. Found: 481.1969.</div></div><div id="sec4_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> 3-(1-Cyano-1-methylethyl)-<i>N</i>-[3-({2-[(cyclopropylcarbonyl)amino]imidazo[1,2-<i>a</i>]pyridin-6-yl}oxy)phenyl]benzamide (<b>2</b>)</h3><div class="NLM_p">To a solution of 3-(1-cyano-1-methylethyl)-<i>N</i>-[3-({2-[(trifluoroacetyl)amino]imidazo[1,2-<i>a</i>]pyridin-6-yl}oxy)phenyl]benzamide <b>25</b> (400 mg, 0.788 mmol) in ethanol (4.0 mL) was added 1 N NaOH (8.0 mL), and the reaction mixture was stirred at 45 °C for 12 h. To the reaction mixture was added water (100 mL), and the mixture was extracted with ethyl acetate (200 mL). The organic layer was washed with brine (100 mL) and dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. The insoluble material was filtered off, and the filtrate was concentrated under reduced pressure. The obtained residue was purified by basic silica gel column chromatography (0–20% methanol in ethyl acetate), and the desired fractions were combined and concentrated under reduced pressure to give <i>N</i>-{3-[(2-aminoimidazo[1,2-<i>a</i>]pyridin-6-yl)oxy]phenyl}-3-(1-cyano-1-methylethyl)benzamide (0.35 g, quantitative yield) as colorless amorphous solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 1.73 (s, 6H), 5.08 (s, 2H), 6.78 (dd, <i>J</i> = 2.1, 8.1 Hz, 1H), 6.87 (dd, <i>J</i> = 2.1, 9.6 Hz, 1H), 7.01 (s, 1H), 7.22 (d, <i>J</i> = 9.6 Hz, 1H), 7.34 (t, <i>J</i> = 8.2 Hz, 1H), 7.44 (s, 1H), 7.50–7.62 (m, 2H), 7.74 (d, <i>J</i> = 8.1 Hz, 1H), 7.88 (d, <i>J</i> = 7.5 Hz, 1H), 7.98 (s, 1H), 8.34 (d, <i>J</i> = 2.1 Hz, 1H), 10.34 (s, 1H). MS (ESI): <i>m</i>/<i>z</i> 412.05 (M + H)<sup>+</sup>.</div><div class="NLM_p last">To a solution of <i>N</i>-{3-[(2-aminoimidazo[1,2-<i>a</i>]pyridin-6-yl)oxy]phenyl}-3-(1-cyano-1-methylethyl)benzamide (200 mg, 0.486 mmol) in <i>N</i>,<i>N</i>-dimethylacetamide (2.0 mL) was added cyclopropanecarbonyl chloride (46 μL, 0.510 mmol), and the reaction mixture was stirred at room temperature for 8 h. The reaction mixture was diluted with ethyl acetate (100 mL), washed with 5% aqueous NaHCO<sub>3</sub> (50 mL) and brine (50 mL), and dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. The insoluble material was filtered off, and the filtrate was concentrated under reduced pressure. The residue was purified by basic silica gel column chromatography (50–100% ethyl acetate in <i>n-</i>hexane). The desired fractions were combined and concentrated under reduced pressure, and the residue was triturated with ethyl acetate and <i>i</i>-Pr<sub>2</sub>O to give <b>2</b> (100 mg, 43%) as colorless crystals, mp 138–140 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 0.73–0.85 (m, 4H), 1.73 (s, 6H), 1.86–2.03 (m, 1H), 6.81 (dd, <i>J</i> = 2.4, 8.1 Hz, 1H), 7.10 (dd, <i>J</i> = 2.4, 9.6 Hz, 1H), 7.36 (t, <i>J</i> = 8.1 Hz, 1H), 7.44–7.52 (m, 2H), 7.57 (t, <i>J</i> = 7.8 Hz, 2H), 7.69–7.78 (m, 1H), 7.89 (d, <i>J</i> = 8.4 Hz, 1H), 7.98 (t, <i>J</i> = 1.5 Hz, 1H), 8.07 (s, 1H), 8.59 (d, <i>J</i> = 2.4 Hz, 1H), 10.35 (s, 1H), 10.98 (s, 1H). MS (ESI): <i>m</i>/<i>z</i> 480.2 (M + H)<sup>+</sup>. Anal. Calcd for C<sub>28</sub>H<sub>25</sub>N<sub>5</sub>O<sub>3</sub>: C, 70.13; H, 5.25; N, 14.60. Found: C, 70.26; H, 5.46; N, 14.56.</div></div><div id="sec4_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> 3-(1-Cyano-1-methylethyl)-<i>N</i>-[3-({2-[(cyclopropylcarbonyl)amino]-1<i>H</i>-benzimidazol-6-yl}oxy)phenyl]benzamide (<b>3a</b>)</h3><div class="NLM_p">A mixture of <i>tert</i>-butyl [3-({2-[(cyclopropylcarbonyl)amino]-1<i>H</i>-benzimidazol-6-yl}oxy)phenyl]carbamate <b>29a</b> (1.58 g, 3.88 mmol) and trifluoroacetic acid (50 mL) was refluxed at 80 °C for 1 h. The reaction mixture was cooled at room temperature and evaporated in vacuo. The residue was diluted with ethyl acetate (200 mL), washed with 0.1 N HCl (100 mL) and saturated NaHCO<sub>3</sub> (100 mL) successively, and dried over anhydrous MgSO<sub>4</sub>. The solvent was evaporated in vacuo. The residue was crystallized from methanol to give <i>N</i>-[6-(3-aminophenoxy)-1<i>H</i>-benzimidazol-2-yl]cyclopropanecarboxamide (1.06 g, 88%) as pale brown crystals, mp 213-214 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 0.90–0.92 (m, 4H), 1.91–2.01 (m, 1H), 5.13 (br s, 2H), 6.07–6.10 (m, 2H), 6.22–6.26 (m, 1H), 6.79 (dd, <i>J</i> = 2.4, 8.7 Hz, 1H), 6.91–7.12 (m, 2H), 7.40 (br d, <i>J</i> = 8.4 Hz, 1H), 11.81 (br s, 1H), 11.99 (br s, 1H). HRMS (ESI): calcd for C<sub>17</sub>H<sub>16</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> 309.1346. Found: 309.1327.</div><div class="NLM_p last">Compound <b>3a</b> (168 mg) was prepared in a similar manner to <b>1a</b> from <i>N</i>-[6-(3-aminophenoxy)-1<i>H</i>-benzimidazol-2-yl]cyclopropanecarboxamide (156 mg, 0.506 mmol), using 3-(1-cyano-1-methylethyl)benzoic acid <b>15n</b> (195 mg, 1.03 mmol), pyridine (5 mL), EDCI·HCl (407 mg, 2.12 mmol), DMAP (58.2 mg, 0.476 mmol). Yield 69%, colorless crystals; mp 139–141 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 0.91–0.93 (m, 4H), 1.73 (s, 6H), 1.94–2.00 (m, 1H), 6.74 (dd, <i>J</i> = 1.8, 7.8 Hz, 1H), 8.85 (dd, <i>J</i> = 2.4, 8.4 Hz, 1H), 7.05–7.18 (m, 1H), 7.32 (t, <i>J</i> = 8.1 Hz, 1H), 7.41–7.59 (m, 4H), 7.72–7.75 (m, 1H), 7.88 (d, <i>J</i> = 7.8 Hz, 1H), 7.97–7.98 (m, 1H), 10.31 (br s, 1H), 11.84 (br s, 1H), 12.03 (br s, 1H). HRMS (ESI): calcd for C<sub>28</sub>H<sub>25</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup> 480.2030. Found: 480.1995.</div></div><div id="sec4_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> 3-(1-Cyano-1-methylethyl)-<i>N</i>-[3-({2-[(cyclopropylcarbonyl)amino]-1-methyl-1<i>H</i>-benzimidazol-6-yl}oxy)phenyl]benzamide (<b>3b</b>)</h3><div class="NLM_p"><i>N</i>-[6-(3-Aminophenoxy)-1-methyl-1<i>H</i>-benzimidazol-2-yl]cyclopropanecarboxamide (1.02 g) was prepared in a similar manner to intermediate of <b>3a</b>, <i>N</i>-[6-(3-aminophenoxy)-1<i>H</i>-benzimidazol-2-yl]cyclopropanecarboxamide from using <i>tert</i>-butyl [3-({2-[(cyclopropylcarbonyl)amino]-1-methyl-1<i>H</i>-benzimidazol-6-yl}oxy)phenyl]carbamate <b>29b</b> (1.52 g, 3.60 mmol), using trifluoroacetic acid (50 mL). Yield 88%, pink amorphous solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 0.93–0.98 (m, 2H), 1.11–1.13 (m, 2H), 1.94–1.99 (m, 1H), 3.68 (s, 3H), 6.34 (t, <i>J</i> = 2.1 Hz, 1H), 6.38–6.41 (m, 1H), 6.46–6.49 (m, 1H), 6.96 (d, <i>J</i> = 2.1 Hz, 1H), 7.03 (dd, <i>J</i> = 2.1, 8.4 Hz, 1H), 7.14 (t, <i>J</i> = 8.1 Hz, 1H), 7.28–7.37 (m, 1H). HRMS (ESI): calcd for C<sub>18</sub>H<sub>18</sub>N<sub>4</sub>O<sub>2</sub> [M + H]<sup>+</sup> 323.1503. Found: 323.1487.</div><div class="NLM_p last">Compound <b>3b</b> (97.3 mg) was prepared in a similar manner to <b>1a</b> from <i>N</i>-[6-(3-aminophenoxy)-1-methyl-1<i>H</i>-benzimidazol-2-yl]cyclopropanecarboxamide (166 mg, 0.514 mmol), using 3-(1-cyano-1-methylethyl)benzoic acid <b>15n</b> (316 mg, 1.67 mmol), pyridine (5 mL), EDCI·HCl (456 mg, 2.38 mmol), and DMAP (38.9 mg, 0.318 mmol). Yield 38%, colorless crystals; mp 129–130 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 0.82–0.92 (m, 4H), 1.73 (s, 6H), 1.90–2.05 (m, 1H), 3.54 (s, 3H), 6.76 (dd, <i>J</i> = 1.8, 7.8 Hz, 1H), 6.94 (d, <i>J</i> = 8.1 Hz, 1H), 7.31–7.37 (m, 2H), 7.41–7.60 (m, 4H), 7.72–7.75 (m, 1H), 7.90 (d, <i>J</i> = 7.8 Hz, 1H), 7.98–8.00 (m, 1H), 10.35 (br s, 1H), 10.89 (br s, 1H). HRMS (ESI): calcd for C<sub>29</sub>H<sub>27</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup> 494.2187. Found: 494.2171.</div></div><div id="sec4_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> 3-(1-Cyano-1-methylethyl)-<i>N</i>-[3-({2-[(cyclopropylcarbonyl)amino]-3<i>H</i>-imidazo[4,5-<i>b</i>]pyridin-5-yl}oxy)phenyl]benzamide (<b>4a</b>)</h3><div class="NLM_p">A mixture of <i>N</i>-{3-[(2-amino-3-<i>tert</i>-butyl-3<i>H</i>-imidazo[4,5-<i>b</i>]pyridin-5-yl)oxy]phenyl}-3-(1-cyano-1-methylethyl)benzamide <b>34a</b>(0.23 g, 0.5 mmol), cyclopropanecarbonyl chloride (0.21 g, 2.0 mmol), and DMAP (0.24 g, 2.0 mmol) in pyridine (2.0 mL) was stirred at room temperature for 18 h. The reaction mixture was partitioned between ethyl acetate (50 mL) and water (50 mL). The organic layer was dried over anhydrous MgSO<sub>4</sub> and filtered. The filtrate was concentrated in vacuo, and the residue was purified by silica gel column chromatography (0–100% ethyl acetate in <i>n-</i>hexane) to give <i>N</i>-[3-({3-<i>tert-</i>butyl-2-[(cyclopropylcarbonyl)amino]-3<i>H</i>-imidazo[4,5-<i>b</i>]pyridin-5-yl}oxy)phenyl]-3-(1-cyano-1-methylethyl)benzamide (0.15 g, 0.28 mmol, 56%) as a colorless amorphous solid. The overreacted bis-(cyclopropylcarbonyl)derivative was treated by 1 N NaOH and methanol (5:1) to give additional <i>N</i>-[3-({3-<i>tert-</i>butyl-2-[(cyclopropylcarbonyl)amino]-3<i>H</i>-imidazo[4,5-<i>b</i>]pyridin-5-yl}oxy)phenyl]-3-(1-cyano-1-methylethyl)benzamide (0.11 g, 40%) as a colorless amorphous solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 0.77–0.86 (m, 2H), 1.01–1.11 (m, 2H), 1.67–1.73 (m, 1H), 1.76 (s, 15H), 6.74 (d, <i>J</i> = 8.5 Hz, 1H), 6.94 (dt, <i>J</i> = 6.8, 1.1 Hz, 1H), 7.31–7.55 (m, 4H), 7.59 (t, <i>J</i> = 2.1 Hz, 1H), 7.69 (d, <i>J</i> = 7.2 Hz, 1H), 7.78 (d, <i>J</i> = 7.9 Hz, 1H), 7.98 (t, <i>J</i> = 1.7 Hz, 1H), 8.11 (br s, 1H), 12.86 (br s, 1H). MS (ESI): <i>m</i>/<i>z</i> 537 (M + H)<sup>+</sup>.</div><div class="NLM_p last">A solution of <i>N</i>-[3-({3-<i>tert-</i>butyl-2-[(cyclopropylcarbonyl)amino]-3<i>H</i>-imidazo[4,5-<i>b</i>]pyridin-5-yl}oxy)phenyl]-3-(1-cyano-1-methylethyl)benzamide (0.23 g, 0.48 mmol) in trifluoroacetic acid (2 mL) was stirred at 80 °C for 2 h. The mixture was cooled at room temperature and evaporated in vacuo. The residue was partitioned between ethyl acetate (50 mL) and 0.1 N NaOH (50 mL). The organic layer was dried over anhydrous MgSO<sub>4</sub> and filtered. The filtrate was concentrated in vacuo. The residue was crystallized with acetone to give compound <b>4a</b> (188 mg, 82%) as colorless crystals, mp 180–181 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 0.41–1.19 (m, 4H), 1.74 (s, 6H), 2.53–2.60 (m, 1H), 6.77 (d, <i>J</i> = 8.3 Hz, 2H), 7.22–7.35 (m, 1H), 7.42–7.54 (m, 2H), 7.56–7.79 (m, 3H), 7.91 (d, <i>J</i> = 7.9 Hz, 1H), 8.03 (t, <i>J</i> = 1.8 Hz, 1H), 9.60 (br s, 1H), 11.65 (br s, 1H), 13.23 (br s, 1H). HRMS (ESI): calcd for C<sub>27</sub>H<sub>24</sub>N<sub>6</sub>O<sub>3</sub> [M + H]<sup>+</sup> 481.1983. Found: 481.1966.</div></div><div id="sec4_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> 3-(1-Cyano-1-methylethyl)-<i>N</i>-[3-({2-[(cyclopropylcarbonyl)amino]-3-methyl-3<i>H</i>-imidazo[4,5-<i>b</i>]pyridin-5-yl}oxy)phenyl]benzamide (<b>4b</b>)</h3><div class="NLM_p last">To a solution of <b>34b</b> (170 mg, 0.40 mmol) in pyridine (2 mL) were added cyclopropanecarbonyl chloride (105 mg, 1.0 mmol) and DMAP (120 mg, 1.0 mmol) successively. The reaction mixture was stirred at room temperature for 18 h. The mixture was partitioned between ethyl acetate (50 mL) and water (50 mL). The organic layer was dried over anhydrous MgSO<sub>4</sub>, filtered, and evaporated in vacuo. The residue was purified by silica gel column chromatography (0–100% ethyl acetate in <i>n-</i>hexane) to give compound <b>4b</b> (110 mg, 56%) as colorless crystals, mp 132–134 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 0.85–0.90 (m, 2H), 1.01–1.14 (m, 2H), 1.76 (s, 6H), 1.79–1.91 (m, 1H), 3.60 (s, 3H), 6.73 (d, <i>J</i> = 8.3 Hz, 1H), 6.96 (dt, <i>J</i> = 7.5, 1.9 Hz, 1H), 7.34–7.48 (m, 2H), 7.47–7.64 (m, 3H), 7.69 (ddd, <i>J</i> = 1.0, 2.0, 7.9 Hz, 1H), 7.77 (dt, <i>J</i> = 7.7, 1.2 Hz, 1H), 7.97 (t, <i>J</i> = 1.8 Hz, 2H), 12.13 (br s, 1H). HRMS (ESI): calcd for C<sub>28</sub>H<sub>26</sub>N<sub>6</sub>O<sub>3</sub> [M + H]<sup>+</sup> 495.2139. Found: 495.2135.</div></div><div id="sec4_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> 3-(1-Cyano-1-methylethyl)-<i>N</i>-[3-({2-[(cyclopropylcarbonyl)amino]-1,3-benzothiazol-6-yl}oxy)phenyl]benzamide (<b>5</b>)</h3><div class="NLM_p">Potassium thiocyanate (8.09 g, 83.2 mmol) was added to acetic acid (150 mL). To the solution was added a solution of <i>N</i>-[3-(4-aminophenoxy)phenyl]-3-(1-cyano-1-methylethyl)benzamide <b>38</b> (7.34 g, 19.8 mmol) in acetic acid (150 mL). The mixture was stirred at room temperature for 15 min. To the mixture was added a solution of bromine (4.0 g, 25.0 mmol) in acetic acid (100 mL) at room temperature over 30 min, and the reaction mixture was stirred at room temperature for 4 h. The resulting yellow precipitate was removed by filtration through a pad of Celite. The filtrate was concentrated under reduced pressure. The residue was diluted with tetrahydrofuran (100 mL) and ethyl acetate (200 mL), and the mixture was basified with 2 N NaOH (200 mL). The organic layer was washed with saturated NH<sub>4</sub>Cl (200 mL) and dried over anhydrous MgSO<sub>4</sub>. The solvent was evaporated in vacuo to give <i>N</i>-{3-[(2-amino-1,3-benzothiazol-6-yl)oxy]phenyl}-3-(1-cyano-1-methylethyl)benzamide (7.4 g, 87%) as a pale yellow amorphous solid. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 1.73 (s, 6H), 6.73–6.76 (m, 1H), 6.96 (dd, <i>J</i> = 2.7, 8.7 Hz, 1H), 7.31–7.36 (m, 2H), 7.42–7.60 (m, 6H), 7.72–7.75 (m, 1H), 7.89 (d, <i>J</i> = 8.1 Hz, 1H), 7.98 (t, <i>J</i> = 1.8 Hz, 1H), 10.33 (br s, 1H). MS (ESI): <i>m</i>/<i>z</i> 429.05 (M + H)<sup>+</sup>.</div><div class="NLM_p last">To a solution of <i>N</i>-{3-[(2-amino-1,3-benzothiazol-6-yl)oxy]phenyl}-3-(1-cyano-1-methylethyl)benzamide (5.13 g, 12.0 mmol) in pyridine (50 mL) were added cyclopropanecarbonyl chloride (2.5 mL, 27.6 mmol) and DMAP (89.3 mg, 0.731 mmol), successively, at 4 °C. The reaction mixture was stirred at room temperature for 6 h. To the mixture were added methanol (50 mL) and 2 N NaOH (10 mL) successively, and the mixture was stirred at room temperature for 3 h. The mixture was concentrated under reduced pressure, and the residue was diluted with ethyl acetate (300 mL). The mixture was washed with water (150 mL), 0.1 N HCl (100 mL), saturated NaHCO<sub>3</sub> (100 mL), and brine (100 mL), successively. The organic layer was dried over anhydrous MgSO<sub>4</sub>. The solvent was evaporated in vacuo. The residue was purified by silica gel column chromatography (5–50% ethyl acetate in <i>n-</i>hexane). Desired fractions were combined and evaporated in vacuo and the residue was crystallized from ethyl acetate/<i>i</i>-Pr<sub>2</sub>O to give compound <b>5</b> (4.40 g, 88%) as colorless crystals, mp 120–121 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 0.94–0.97 (m, 4H), 1.73 (s, 6H), 1.93–2.01 (m, 1H), 6.80 (dd, <i>J</i> = 1.8, 8.1 Hz, 1H), 7.17 (dd, <i>J</i> = 2.4, 8.7 Hz, 1H), 7.37 (t, <i>J</i> = 8.1 Hz, 1H), 7.48 (t, <i>J</i> = 2.1 Hz, 1H), 7.55–7.61 (m, 2H), 7.72–7.78 (m, 3H), 7.89 (d, <i>J</i> = 8.1 Hz, 1H), 7.98 (t, <i>J</i> = 1.8 Hz, 1H), 10.35 (br s, 1H), 12.63 (br s, 1H). HRMS (ESI): calcd for C<sub>28</sub>H<sub>24</sub>N<sub>4</sub>O<sub>3</sub>S [M + H]<sup>+</sup> 497.1642. Found: 497.1647.</div></div><div id="sec4_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> 3-(1-Cyano-1-methylethyl)-<i>N</i>-[3-({2-[(cyclopropylcarbonyl)amino][1,3]thiazolo[5,4-<i>b</i>]pyridin-5-yl}oxy)phenyl]benzamide (<b>6a</b>)</h3><div class="NLM_p last">Compound <b>6a</b> (111 mg) was prepared in a similar manner to <b>1i</b> from <i>N</i>-[5-(3-aminophenoxy)[1,3]thiazolo[5,4-<i>b</i>]pyridin-2-yl]cyclopropanecarboxamide <b>42</b> (126 mg, 0.387 mmol), using 3-(1-cyano-1-methylethyl)benzoic acid <b>15n</b> (147 mg, 0.778 mmol), thionyl chloride (100 μL, 1.37 mmol), toluene (5 mL), DMAP (10 mg, 0.0819 mmol), and pyridine (3 mL). Yield 58%, colorless crystals; mp 234 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 0.94–0.97 (m, 4H), 1.74 (s, 6H), 1.95–2.04 (m, 1H), 6.93 (ddd, <i>J</i> = 0.9, 2.4, 8.1 Hz, 1H), 7.15 (d, <i>J</i> = 8.1 Hz, 1H), 7.43 (t, <i>J</i> = 8.4 Hz, 1H), 7.57–7.65 (m, 3H), 7.75 (ddd, <i>J</i> = 0.9, 2.1, 7.8 Hz, 1H), 7.92 (dt, <i>J</i> = 7.2, 1.5 Hz, 1H), 8.02 (t, <i>J</i> = 1.8 Hz, 1H), 8.18 (d, <i>J</i> = 8.7 Hz, 1H), 10.41 (br s, 1H), 12.68 (br s, 1H). MS (ESI): <i>m</i>/<i>z</i> 498.15 (M + H)<sup>+</sup>. HRMS (ESI): calcd for C<sub>27</sub>H<sub>23</sub>N<sub>5</sub>O<sub>3</sub>S [M + H]<sup>+</sup> 498.1594. Found: 498.1580.</div></div><div id="sec4_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> 3-(1-Cyanocyclopropyl)-<i>N</i>-[3-({2-[(cyclopropylcarbonyl)amino][1,3]thiazolo[5,4-<i>b</i>]pyridin-5-yl}oxy)phenyl]benzamide (<b>6b</b>)</h3><div class="NLM_p last">Compound <b>6b</b> (82 mg) was prepared in a similar manner to <b>1i</b> from <i>N</i>-[5-(3-aminophenoxy)[1,3]thiazolo[5,4-<i>b</i>]pyridin-2-yl]cyclopropanecarboxamide <b>42</b> (118 mg, 0.362 mmol), using 3-(1-cyano-1-methylethyl)benzoic acid <b>15o</b> (151 mg, 0.808 mmol), thionyl chloride (200 μL, 2.74 mmol), toluene (5 mL), DMAP (10 mg, 0.0819 mmol), and pyridine (2 mL). Yield 46%, colorless crystals; mp 208–215 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 0.94–0.97 (m, 4H), 1.61 (dd, <i>J</i> = 5.4, 8.4 Hz, 2H), 1.81 (dd, <i>J</i> = 5.4, 8.4 Hz, 2H), 1.97–2.01 (m, 1H), 6.91–6.95 (m, 1H), 7.15 (d, <i>J</i> = 8.7 Hz, 1H), 7.42 (t, <i>J</i> = 8.4 Hz, 1H), 7.52–7.59 (m, 2H), 7.62–7.64 (m, 2H), 7.81 (br s, 1H), 7.86 (dt, <i>J</i> = 6.0, 2.4 Hz, 1H), 8.18 (d, <i>J</i> = 8.7 Hz, 1H), 10.40 (br s, 1H), 12.70 (br s, 1H). MS (ESI): <i>m</i>/<i>z</i> 495.46 (M + H)<sup>+</sup>. HRMS (ESI): calcd for C<sub>27</sub>H<sub>21</sub>N<sub>5</sub>O<sub>3</sub>S [M + H]<sup>+</sup> 496.1438. Found: 496.1406.</div></div><div id="sec4_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> 2-Chloro-3-(1-cyanocyclopropyl)-<i>N</i>-[3-({2-[(cyclopropylcarbonyl)amino][1,3]thiazolo[5,4-<i>b</i>]pyridin-5-yl}oxy)phenyl]benzamide (<b>6c</b>)</h3><div class="NLM_p last">Compound <b>6c</b> (169 mg) was prepared in a similar manner to <b>1a</b> from <i>N</i>-[5-(3-aminophenoxy)[1,3]thiazolo[5,4-<i>b</i>]pyridin-2-yl]cyclopropanecarboxamide <b>42</b> (120 mg, 3.68 μmol), using 2-chloro-3-(1-cyclopropyl)benzoic acid <b>15p</b> (90 mg, 405 μmol), HATU (154 mg, 405 μmol), and pyridine (3 mL). Yield 87%, colorless crystals; mp 226–227 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 0.88–0.99 (m, 4H), 1.38–1.49 (m, 2H), 1.78–1.84 (m, 2H), 1.93–2.04 (m, 1H), 6.93 (ddd, <i>J</i> = 0.9, 2.3, 8.1 Hz, 1H), 7.15 (d, <i>J</i> = 8.7 Hz, 1H), 7.41 (t, <i>J</i> = 8.1 Hz, 1H), 7.48 (t, <i>J</i> = 7.6 Hz, 1H), 7.51–7.56 (m, 1H), 7.58–7.63 (m, 2H), 7.66 (dd, <i>J</i> = 1.7, 7.6 Hz, 1H), 8.17 (d, <i>J</i> = 8.7 Hz, 1H), 10.70 (br s, 1H), 12.70 (br s, 1H). HRMS (ESI): calcd for C<sub>27</sub>H<sub>20</sub>ClN<sub>5</sub>O<sub>3</sub>S [M + H]<sup>+</sup> 530.1048. Found: 530.1033.</div></div><div id="sec4_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> 2-Chloro-3-(1-cyanocyclopropyl)-<i>N</i>-[5-({2-[(cyclopropylcarbonyl)amino][1,3]thiazolo[5,4-<i>b</i>]pyridin-5-yl}oxy)-2-fluorophenyl]benzamide (<b>6d</b>)</h3><div class="NLM_p last">To a mixture of <i>N</i>-{5-[(2-amino[1,3]thiazolo[5,4-<i>b</i>]pyridin-5-yl)oxy]-2-fluorophenyl}-2-chloro-3-(1-cyanocyclopropyl)benzamide <b>45</b> (9.0 g, 18.8 mmol) and pyridine (2.3 mL, 28.1 mmol) in tetrahydrofuran (90 mL) was added dropwise cyclopropanecarbonyl chloride (1.89 mL, 20.8 mmol) at 4 °C. The reaction mixture was stirred at room temperature for 3 h. An additional amount of cyclopropanecarbonyl chloride (0.063 mL, 0.69 mmol) was added to the mixture. The reaction mixture was stirred at room temperature for an additional 12 h. To the mixture were added water (100 mL) and saturated NaHCO<sub>3</sub> (100 mL), and the mixture was stirred at room temperature for 30 min. The resulting precipitate was collected by filtration, washed with water (200 mL), and dried under vacuum to give compound <b>6d</b> (9.85 g, 96%) as colorless crystals, mp 213 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 0.77–1.08 (m, 4H), 1.35–1.53 (m, 2H), 1.73–1.88 (m, 2H), 1.92–2.07 (m, 1H), 7.07 (dt, <i>J</i> = 8.7, 3.6 Hz, 1H), 7.17 (d, <i>J</i> = 8.7 Hz, 1H), 7.38 (dd, <i>J</i> = 9.1, 10.2 Hz, 1H), 7.43–7.50 (m, 1H), 7.55–7.69 (m, 2H), 7.78 (dd, <i>J</i> = 3.0, 6.4 Hz, 1H), 8.18 (d, <i>J</i> = 8.7 Hz, 1H), 10.57 (s, 1H), 12.70 (s, 1H). MS (ESI): <i>m</i>/<i>z</i> 548.0 (M + H)<sup>+</sup>. Anal. Calcd for C<sub>27</sub>H<sub>19</sub>ClFN<sub>5</sub>O<sub>3</sub>S: C, 59.18; H, 3.49; N, 12.78. Found: C, 59.01; H, 3.53; N, 12.65.</div></div><div id="sec4_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> 2-Chloro-<i>N</i>-[2-chloro-5-({2-[(cyclopropylcarbonyl)amino][1,3]thiazolo[5,4-<i>b</i>]pyridin-5-yl}oxy)phenyl]-3-(1-cyanocyclopropyl)benzamide (<b>6e</b>)</h3><div class="NLM_p">Under ice-cooling, to a suspension of sodium borohydride (5.63 g, 149 mmol) in methanol (66 mL) was added in small portions <i>N</i>-(5-{4-chloro-3-[(trifluoroacetyl)amino]phenoxy}[1,3]thiazolo[5,4-<i>b</i>]pyridin-2-yl)cyclopropanecarboxamide <b>48</b>(3.4 g, 7.44 mmol), and the reaction mixture was stirred at room temperature for 1 h. The reaction mixture was diluted with ethyl acetate (150 mL) and partitioned with water (200 mL). The organic layer was concentrated under reduced pressure. The residue was diluted with ethyl acetate (200 mL), washed with brine (100 mL), and the organic layer was dried over anhydrous MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residue was purified by basic silica gel column chromatography (eluent, ethyl acetate) and triturated with <i>i</i>-Pr<sub>2</sub>O to give <i>N</i>-[5-(3-amino-4-chlorophenoxy)[1,3]thiazolo[5,4-<i>b</i>]pyridin-2-yl]cyclopropanecarboxamide (2.00 g, 75%) as white crystals, mp 237–238 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 0.88–1.10 (m, 4H), 1.90–2.10 (m, 1H), 5.49 (br s, 2H), 6.32 (dd, <i>J</i> = 2.7, 8.6 Hz, 1H), 6.54 (d, <i>J</i> = 2.7 Hz, 1H), 7.08 (d, <i>J</i> = 8.6 Hz, 1H), 7.21 (d, <i>J</i> = 8.6 Hz, 1H), 8.15 (d, <i>J</i> = 8.6 Hz, 1H), 12.69 (br s, 1H). MS (ESI): <i>m</i>/<i>z</i> 361.0 (M + H)<sup>+</sup>.</div><div class="NLM_p last">Compound <b>6e</b> (151 mg) was prepared in a similar manner to <b>1i</b> from <i>N</i>-[5-(3-amino-4-chlorophenoxy)[1,3]thiazolo[5,4-<i>b</i>]pyridin-2-yl]cyclopropanecarboxamide (150 mg, 0.416 mmol), using 2-chloro-3-(1-cyanocyclopropyl)benzoic acid <b>15q</b> (184 mg, 0.830 mmol),oxalyl chloride (88 μL, 1.04 mmol), <i>N</i>,<i>N</i>-dimethylformamide (15 μL), tetrahydrofuran (4.6 mL), and <i>N</i>,<i>N</i>-dimethylacetamide (4.6 mL). Yield 64%, white crystals; mp 138–140 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 0.90–1.00 (m, 4H), 1.40–1.50 (m, 2H), 1.75–1.82 (m, 2H), 1.95–2.05 (m, 1H), 7.15 (dd, <i>J</i> = 3.0, 9.0 Hz, 1H), 7.21 (d, <i>J</i> = 8.7 Hz, 1H), 7.40–7.55 (m, 1H), 7.55–7.70 (m, 4H), 8.20 (d, <i>J</i> = 8.7 Hz, 1H), 10.38 (br s, 1H), 12.71 (br s, 1H). HRMS (ESI): calcd for C<sub>27</sub>H<sub>19</sub>Cl<sub>2</sub>N<sub>5</sub>O<sub>3</sub>S [M + H]<sup>+</sup> 564.0658. Found: 564.0660.</div></div><div id="sec4_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> Ethyl 6-(3-Aminophenoxy)imidazo[1,2-<i>b</i>]pyridazine-2-carboxylate (<b>8</b>)</h3><div class="NLM_p last">A mixture of ethyl 6-iodoimidazo[1,2-<i>b</i>]pyridazine-2-carboxylate <b>7</b> (13.6 g, 42.8 mmol), 3-aminophenol (7.02 g, 64.3 mmol), potassium carbonate (10.2 g, 64.3 mmol), and <i>N</i>,<i>N</i>-dimethylformamide (100 mL) was stirred at 150 °C for 5 h. After the mixture was cooled at room temperature, ethyl acetate (300 mL) and water (300 mL) were added to the reaction mixture, and the resulting insoluble material was filtered through a pad of Celite. The aqueous layer was extracted with ethyl acetate (5 × 200 mL). The combined organic layer was washed with saturated aqueous NaHCO<sub>3</sub> (300 mL) and dried over anhydrous MgSO<sub>4</sub>. The solvent was evaporated under reduced pressure and the residue was purified by basic silica gel column chromatography (0–50% ethyl acetate/<i>n-</i>hexane) to give <b>8</b> (6.41 g, 50%) as colorless crystals, mp 138–139 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 1.30 (t, <i>J</i> = 7.2 Hz, 3H), 4.29 (q, <i>J</i> = 7.2 Hz, 2H), 5.33 (br s, 2H), 6.32–6.50 (m, 3H), 7.07 (t, <i>J</i> = 8.0 Hz, 1H), 7.18 (d, <i>J</i> = 9.6 Hz, 1H), 8.20 (d, <i>J</i> = 9.6 Hz, 1H), 8.61 (s, 1H). MS (ESI): <i>m</i>/<i>z</i> 299.00 (M + H)<sup>+</sup>. Anal. Calcd for C<sub>15</sub>H<sub>14</sub>N<sub>4</sub>O<sub>3</sub>: C, 60.40; H, 4.73; N, 18.78. Found: C, 60.28; H, 4.65; N, 18.63.</div></div><div id="sec4_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> Ethyl 6-(3-{[3-(Trifluoromethyl)benzoyl]amino}phenoxy)imidazo[1,2-<i>b</i>]pyridazine-2-carboxylate (<b>9</b>)</h3><div class="NLM_p last">A mixture of <b>8</b>(4.63 g, 15.5 mmol), 3-(trifluoromethyl)benzoic acid (4.42 g, 23.2 mmol), HOBt (3.13 g, 23.2 mmol), EDCI·HCl (4.44 g, 23.2 mmol) in <i>N</i>,<i>N</i>-dimethylformamide (90 mL) was stirred at room temperature for 3 h. Saturated aqueous ammonium chloride (90 mL) was added to the reaction mixture, and the mixture was extracted with ethyl acetate (300 mL). The separated organic layer was dried over anhydrous MgSO<sub>4</sub> and filtered through a pad of basic silica gel using ethyl acetate as eluting solvent. The filtrate was concentrated under reduced pressure. The resulting slurry was triturated with ethyl acetate/<i>i</i>-Pr<sub>2</sub>O (1:1) and the resulting precipitate was collected by filtration to give <b>9</b> (6.31 g, 86%) as colorless crystals, mp 218–219 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 1.29 (t, <i>J</i> = 7.1 Hz, 3H), 4.29 (q, <i>J</i> = 7.1 Hz, 2H), 7.10 (dd, <i>J</i> = 2.0, 8.2 Hz, 1H), 7.30 (d, <i>J</i> = 9.8 Hz, 1H), 7.49 (t, <i>J</i> = 8.2 Hz, 1H), 7.66–7.73 (m, 1H), 7.76–7.84 (m, 2H), 7.95–8.01 (m, 1H), 8.23–8.31 (m, 3H), 8.62 (s, 1H), 10.63 (s, 1H). MS (ESI): <i>m</i>/<i>z</i> 471.10 (M + H)<sup>+</sup>. Anal. Calcd for C<sub>23</sub>H<sub>17</sub>F<sub>3</sub>N<sub>4</sub>O<sub>4</sub>: C, 58.73; H, 3.64; N, 11.91. Found: C, 58.63; H, 3.78; N, 11.85.</div></div><div id="sec4_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> <i>N</i>-{3-[(2-Aminoimidazo[1,2-<i>b</i>]pyridazin-6-yl)oxy]phenyl}-3-(trifluoromethyl)benzamide (<b>10</b>)</h3><div class="NLM_p">A mixture of <b>9</b> (5.81 g, 12.3 mmol) and 8 N NaOH (20 mL) in methanol (100 mL) was stirred at room temperature for 4 h. The mixture was acidified with 5 N HCl to pH 5 and extracted with 25% tetrahydrofuran in ethyl acetate (3 × 300 mL). The combined organic layer was dried over anhydrous MgSO<sub>4</sub>. The insoluble was filtered off, and the filtrate was evaporated under reduced pressure to give 6-(3-{[3-(trifluoromethyl)benzoyl]amino}phenoxy)imidazo[1,2-<i>b</i>]pyridazine-2-carboxylic acid (4.95 g, 91%) as a colorless solid, mp 229–231 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 7.10 (dd, <i>J</i> = 1.8, 8.2 Hz, 1H), 7.27 (d, <i>J</i> = 9.8 Hz, 1H), 7.49 (t, <i>J</i> = 8.2 Hz, 1H), 7.70 (d, <i>J</i> = 8.2 Hz, 1H), 7.75–7.84 (m, 2H), 7.98 (d, <i>J</i> = 7.7 Hz, 1H), 8.21–8.32 (m, 3H), 8.52 (s, 1H), 10.62 (s, 1H), 12.87 (br s, 1H). MS (ESI): <i>m</i>/<i>z</i> 443.05 (M + H)<sup>+</sup>. Anal. Calcd for C<sub>21</sub>H<sub>13</sub>F<sub>3</sub>N<sub>4</sub>O<sub>4</sub>: C, 57.02; H, 2.96; N, 12.67. Found: C, 56.98; H, 3.02; N, 12.57.</div><div class="NLM_p">To a suspension of 6-(3-{[3-(trifluoromethyl)benzoyl]amino}phenoxy)imidazo[1,2-<i>b</i>]pyridazine-2-carboxylic acid (3.00 g, 6.78 mmol) in tetrahydrofuran (200 mL) and <i>tert</i>-butanol (200 mL) was added triethylamine (1.89 mL, 13.5 mmol) at room temperature, and the mixture was stirred at room temperature for 10 min. To the mixture was added diphenylphosphorylazide (2.17 mL, 10.1 mmol). The reaction mixture was stirred at room temperature for 10 min and then stirred at 100 °C for 14 h. After the mixture was cooled at room temperature, ethyl acetate (400 mL) was added to the mixture. The mixture was washed with saturated aqueous NaHCO<sub>3</sub> (200 mL), and the separated organic layer was washed with brine (200 mL) and dried over anhydrous MgSO<sub>4</sub>. The solvent was evaporated under reduced pressure and the residue was purified by silica gel column chromatography (0–95% ethyl acetate in <i>n</i>-hexane) to give <i>tert</i>-butyl [6-(3-{[3-(trifluoromethyl)benzoyl]amino}phenoxy)imidazo[1,2-<i>b</i>]pyridazin-2-yl]carbamate (3.10 g, 89%) as colorless crystals, mp 123–125 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 1.46 (s, 9H), 6.99–7.07 (m, 2H), 7.45 (t, <i>J</i> = 8.1 Hz, 1H), 7.64–7.83 (m, 4H), 7.94–8.05 (m, 2H), 8.22–8.30 (m, 2H), 10.05 (br s, 1H), 10.60 (br s, 1H). MS (ESI): <i>m</i>/<i>z</i> 514.15 (M + H)<sup>+</sup>. Anal. Calcd for C<sub>25</sub>H<sub>22</sub>F<sub>3</sub>N<sub>5</sub>O<sub>4</sub>·0.8H<sub>2</sub>O: C, 56.88; H, 4.51; N, 13.27. Found: C, 56.65; H, 4.55; N, 13.15.</div><div class="NLM_p last">A mixture of <i>tert</i>-butyl [6-(3-{[3-(trifluoromethyl)benzoyl]amino}phenoxy)imidazo[1,2-<i>b</i>]pyridazin-2-yl]carbamate (400 mg, 0.779 mmol), 4 N HCl in ethyl acetate (10 mL), and methanol (10 mL) was stirred at room temperature for 14 h. The solvent was neutralized with 8 N NaOH (5 mL). The resulting mixture was extracted with ethyl acetate (50 mL). The organic layer was washed with water (50 mL) and brine (50 mL), successively, and dried over anhydrous MgSO<sub>4</sub>. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography (50–100% ethyl acetate in <i>n</i>-hexane) to give <b>10</b> (215 mg, 67%) as pale green crystals, mp 158–160 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 5.29–5.35 (m, 2H), 6.80 (d, <i>J</i> = 9.4 Hz, 1H), 6.93–7.00 (m, 1H), 7.16 (s, 1H), 7.43 (t, <i>J</i> = 8.2 Hz, 1H), 7.62–7.68 (m, 2H), 7.70–7.82 (m, 2H), 7.97 (d, <i>J</i> = 7.9 Hz, 1H), 8.21–8.29 (m, 2H), 10.55 (s, 1H). MS (ESI): <i>m</i>/<i>z</i> 414.16 (M + H)<sup>+</sup>. Anal. Calcd for C<sub>20</sub>H<sub>14</sub>F<sub>3</sub>N<sub>5</sub>O<sub>2</sub>·0.3H<sub>2</sub>O: C, 57.36; H, 3.51; N, 16.72. Found: C, 57.36; H, 3.49; N, 16.62.</div></div><div id="sec4_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> Ethyl (6-Iodoimidazo[1,2-<i>b</i>]pyridazin-2-yl)carbamate (<b>12</b>)</h3><div class="NLM_p last">To a solution of 6-iodopyridazine-3-amine <b>11</b> (20.0 g, 90.5 mmol) in <i>N</i>,<i>N</i>-dimethylacetamide (160 mL) were added ethyl (chloroacetyl)carbamate (25.5 g, 153 mmol) and disodium hydrogenphosphate (32.1 g, 226 mmol), and the reaction mixture was stirred at 110 °C for 4 h. After the mixture was cooled at room temperature, water (700 mL) was added to the mixture, and the precipitated crystals were filtered and washed with water (200 mL), acetonitrile (100 mL), and <i>n-</i>hexane (200 mL), successively, to give compound <b>12</b> (22.8 g, 76%) as black crystals, mp 215–216 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 1.26 (t, <i>J</i> = 7.1 Hz, 3H), 4.17 (q, <i>J</i> = 7.1 Hz, 2H), 7.48 (d, <i>J</i> = 9.2 Hz, 1H), 7.71 (d, <i>J</i> = 9.2 Hz, 1H), 8.07 (s, 1H), 10.51 (s, 1H). MS (ESI): <i>m</i>/<i>z</i> 332.87 (M + H)<sup>+</sup>.</div></div><div id="sec4_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i58" class="anchor-spacer"></div><h3 class="article-section__title" id="_i58"> <i>N</i>-(6-Iodoimidazo[1,2-<i>b</i>]pyridazin-2-yl)cyclopropanecarboxamide (<b>13</b>)</h3><div class="NLM_p">To a solution of barium hydroxide octahydrate (28.5 g, 90.3 mmol) in water (400 mL) was added a solution of ethyl (6-iodoimidazo[1,2-<i>b</i>]pyridazin-2-yl)carbamate <b>12</b> (20.0 g, 60.2 mmol) in NMP (200 mL). The reaction mixture was stirred at 120 °C for 12 h. After cooling to 80 °C, the mixture was diluted with water (200 mL), tetrahydrofuran (200 mL), and ethyl acetate (400 mL). The mixture was stirred at room temperature for 20 min. The insoluble was filtered off, and the filtrate was washed with water (200 mL) and brine (200 mL), successively, and dried over anhydrous MgSO<sub>4</sub>. The solvent was evaporated under reduced pressure. The residual slurry was triturated with water (200 mL), and the resulting crystals were collected by filtration to give 6-iodoimidazo[1,2-<i>b</i>]pyridazine-2-amine (11.0 g, 71%) as orange crystalline needles, mp 173–175 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 5.59 (s, 2H), 7.23 (d, <i>J</i> = 8.9 Hz, 1H), 7.34–7.42 (m, 2H). MS (ESI): <i>m</i>/<i>z</i> 260.95 (M + H)<sup>+</sup>.</div><div class="NLM_p last">To a solution (10 mL) of 6-iodoimidazo[1,2-<i>b</i>]pyridazine-2-amine (10 g, 38.4 mmol) in <i>N</i>,<i>N</i>-dimethylacetamide (120 mL) was added cyclopropanecarbonyl chloride (4.20 mL, 46.1 mmol) at 4 °C. The reaction mixture was stirred at room temperature for 16 h. Water (240 mL)was added to the reaction mixture at 4 °C. The resulting precipitate was collected by filtration and washed with water (200 mL) to give compound <b>13</b> (12.3 g, 98%) as pale yellow crystals, mp 248–250 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 0.79–0.87 (m, 4H), 1.89–2.00 (m, 1H), 7.49 (d, <i>J</i> = 9.2 Hz, 1H), 7.73 (d, <i>J</i> = 9.2 Hz, 1H), 8.23 (s, 1H), 11.19 (s, 1H). MS (ESI): <i>m</i>/<i>z</i> 328.95 (M + H)<sup>+</sup>. Anal. Calcd for C<sub>10</sub>H<sub>9</sub>IN<sub>4</sub>O: C, 36.61; H, 2.76; N, 17.08. Found: C, 36.89; H, 2.84; N, 17.20.</div></div><div id="sec4_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> <i>N</i>-[6-(3-Aminophenoxy)imidazo[1,2-<i>b</i>]pyridazine-2-yl]cyclopropanecarboxamide (<b>14</b>)</h3><div class="NLM_p last">A mixture of <b>13</b> (12.3 g, 37.4 mmol), 3-aminophenol (8.18 g, 74.9 mmol), and potassium carbonate (11.9 g, 74.9 mmol) in <i>N</i>,<i>N</i>-dimethylformamide (120 mL) was stirred at 150 °C for 24 h. The mixture was cooled to room temperature and diluted with ethyl acetate (150 mL) and water (150 mL). The mixture was filtered through a pad of Celite. The filtrate was partitioned between ethyl acetate (150 mL) and saturated aqueous NaHCO<sub>3</sub>(150 mL). The aqueous layer was extracted with ethyl acetate (4 × 100 mL). The organic layers were combined and dried over anhydrous MgSO<sub>4</sub>, filtered, and evaporated in vacuo. The residue was purified by silica gel column chromatography (50–100% ethyl acetate in <i>n-</i>hexane) to give compound <b>14</b> (9.24 g, 80%) as pale brown crystals, mp 237–239 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 0.74–0.86 (m, 4H), 1.87–1.98 (m, 1H), 5.29 (s, 2H), 6.30 (dd, <i>J</i> = 1.7, 8.0 Hz, 1H), 6.35 (t, <i>J</i> = 1.7 Hz, 1H), 6.43 (dd, <i>J</i> = 1.7, 8.0 Hz, 1H), 6.95 (d, <i>J</i> = 9.8 Hz, 1H), 7.05 (t, <i>J</i> = 8.0 Hz, 1H), 7.92–8.04 (m, 2H), 11.06 (s, 1H). MS (ESI): <i>m</i>/<i>z</i> 328.94 (M + H)<sup>+</sup>. Anal. Calcd for C<sub>16</sub>H<sub>15</sub>N<sub>5</sub>O<sub>2</sub>·0.1H<sub>2</sub>O: C, 61.77; H, 4.92; N, 22.51. Found: C, 61.68; H, 4.93; N, 22.50.</div></div><div id="sec4_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i60" class="anchor-spacer"></div><h3 class="article-section__title" id="_i60"> 3-(1-Cyano-1-methylethyl)benzoic Acid (<b>15n</b>)</h3><div class="NLM_p">To a solution of methyl 3-(cyanomethyl)benzoate <b>17</b> (7.0 g, 40 mmol) in dimethylsulfoxide (80 mL) was slowly added sodium hydride (60% in oil, 4.8 g, 120 mmol) under ice-cooling. The reaction mixture was stirred at room temperature for 20 min. To the mixture was added iodomethane (7.5 mL, 120 mmol), and the mixture was stirred at room temperature for 16 h. Under ice-cooling, the reaction mixture was diluted with water (80 mL). The mixture was extracted with ethyl acetate (200 mL), and the organic layer was washed with water (100 mL) and brine (100 mL), dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>, and filtered. The solvent was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography (5–50% ethyl acetate in <i>n-</i>hexane) to give methyl 3-(1-cyano-1-methylethyl)benzoate (6.4 g, 79%) as a colorless oil. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 1.72 (s, 6H), 3.89 (s, 3H), 7.61 (t, <i>J</i> = 7.8 Hz, 1H), 7.84 (ddd, <i>J</i> = 1.2, 2.1, 7.8 Hz, 1H), 7.95 (dt, <i>J</i> = 7.8, 1.2 Hz, 1H), 8.08 (t, <i>J</i> = 1.5 Hz, 1H). MS (ESI): <i>m</i>/<i>z</i> 204.06 (M + H)<sup>+</sup>.</div><div class="NLM_p last">To a solution of methyl 3-(1-cyano-1-methylethyl)benzoate (2.8 g, 14 mmol) in tetrahydrofuran (30 mL) were added lithium hydroxide monohydrate (0.98 g, 24 mmol), methanol (10 mL), and water (10 mL), and the mixture was stirred at room temperature for 18 h. The solvent was evaporated under reduced pressure, and the residue was diluted with water (15 mL). The mixture was adjusted to pH 3 by adding 1 N HCl slowly. The resulting white precipitate was collected by filtration and washed with water (100 mL) to give the compound <b>15n</b> (2.5 g, 98%) as white crystals, mp 166–168 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 1.72 (s, 6H), 7.57 (t, <i>J</i> = 7.8 Hz, 1H), 7.78 (dt, <i>J</i> = 7.8, 1.5 Hz, 1H), 7.92 (dt, <i>J =</i> 7.8, 1.5 Hz, 1H), 8.08 (t, <i>J</i> = 1.5 Hz, 1H), 13.19 (s, 1H). Anal. Calcd for C<sub>11</sub>H<sub>11</sub>NO<sub>2</sub>: C, 69.83; H, 5.86; N, 7.40. Found: C, 69.64; H, 5.95; N, 7.34.</div></div><div id="sec4_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i61" class="anchor-spacer"></div><h3 class="article-section__title" id="_i61"> 3-(1-Cyanocyclopropyl)benzoic Acid (<b>15o</b>)</h3><div class="NLM_p">Methyl 3-(1-cyanocyclopropyl)benzoate (1.30 g) was prepared in a similar manner to the intermediate of <b>15n</b>, methyl 3-(1-cyano-1-methylethyl)benzoate from methyl 3-(cyanomethyl)benzoate <b>17</b> (1.5 g, 8.56 mmol), using sodium hydride (60% in oil, 1.03 g, 25.7 mmol), 1,2-dibromoethane (2.41 g, 12.84 mmol), and dimethylsulfoxide (30 mL). Yield 76%, colorless oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 1.38–1.56 (m, 2H), 1.74–1.82 (m, 2H), 3.93 (s, 3H), 7.40–7.49 (m, 1H), 7.55–7.62 (m, 1H), 7.88 (t, <i>J</i> = 1.5 Hz, 1H), 7.96 (dt, <i>J</i> = 7.8, 1.5 Hz, 1H).</div><div class="NLM_p last">Compound <b>15o</b> (0.73 g) was prepared in a similar manner to <b>15n</b> from methyl 3-(1-cyanocyclopropyl)benzoate (1.28 g, 6.36 mmol), using lithium hydroxide monohydrate (0.443 g, 10.8 mmol), tetrahydrofuran (12 mL), methanol (4 mL), and water (6 mL). Yield 61%, colorless crystals; mp 192–193 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 1.43–1.53 (m, 2H), 1.73–1.84 (m, 2H), 4.26 (br s, 1H), 7.49 (t, <i>J</i> = 7.8 Hz, 1H), 7.66 (dt, <i>J</i> = 7.8, 1.5 Hz, 1H), 7.94 (t, <i>J =</i> 1.5 Hz, 1H), 8.04 (dt, <i>J</i> = 7.8, 1.5 Hz, 1H). Anal. Calcd for C<sub>11</sub>H<sub>9</sub>NO<sub>2</sub>·0.3H<sub>2</sub>O: C, 68.60; H, 5.02; N, 7.27. Found: C, 68.64; H, 4.99; N, 7.34.</div></div><div id="sec4_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i62" class="anchor-spacer"></div><h3 class="article-section__title" id="_i62"> 2-Chloro-3-(1-cyano-1-methylethyl)benzoic Acid (<b>15p</b>)</h3><div class="NLM_p">Methyl 2-chloro-3-(1-cyanocyclopropyl)benzoate (1.99 g) was prepared in a similar manner to the intermediate of <b>15n</b>, methyl 3-(1-cyano-1-methylethyl)benzoate from methyl 2-chloro-3-(cyanomethyl)benzoate <b>20</b> (2.00 g, 9.54 mmol), using sodium hydride (60% in mineral oil, 1.14 g, 28.6 mmol), iodomethane (1.78 mL, 28.6 mmol), and dimethylsulfoxide (20 mL). Yield 88%, colorless oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 1.90 (s, 6H), 3.95 (s, 3H), 7.33–7.40 (m, 1H), 7.57–7.64 (m, 2H). MS (ESI): <i>m</i>/<i>z</i> 238.00 (M + H)<sup>+</sup>.</div><div class="NLM_p last">Compound <b>15p</b> (1.43 g) was prepared in a similar manner to <b>15n</b> from methyl 2-chloro-3-(1-cyanocyclopropyl)benzoate (1.67 g, 7.02 mmol), using lithium hydroxide monohydrate (501 mg, 11.9 mmol), tetrahydrofuran (24 mL), methanol (8 mL), and water (8 mL). Yield 91%, white crystals; mp 124–125 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 1.92 (s, 6H), 7.41 (t, <i>J</i> = 7.8 Hz, 1H), 7.67 (dd, <i>J</i> = 1.6, 7.8 Hz, 1H), 7.85 (dd, <i>J</i> = 1.6, 7.8 Hz, 1H). Anal. Calcd for C<sub>11</sub>H<sub>10</sub>ClNO<sub>2</sub>·0.1H<sub>2</sub>O: C, 58.60; H, 4.56; N, 6.21. Found: C, 58.56; H, 4.49; N, 6.14.</div></div><div id="sec4_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i63" class="anchor-spacer"></div><h3 class="article-section__title" id="_i63"> 2-Chloro-3-(1-cyanocyclopropyl)benzoic Acid (<b>15q</b>)</h3><div class="NLM_p">Methyl 2-chloro-3-(1-cyanocyclopropyl)benzoate (25.7 g) was prepared in a similar manner to the intermediate of <b>15n</b>, methyl 3-(1-cyano-1-methylethyl)benzoate from methyl 2-chloro-3-(cyanomethyl)benzoate <b>20</b> (40.0 g, 191 mmol), using sodium hydride (60% in mineral oil, 22.9 g, 573 mmol), 1,2-dibromoethane (34 mL, 395 mmol), and dimethylsulfoxide (400 mL). Yield 57%, colorless crystals; mp 63–64 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 1.33–1.39 (m, 2H), 1.76–1.83 (m, 2H), 3.95 (s, 3H), 7.32 (t, <i>J</i> = 7.7 Hz, 1H), 7.50 (dd, <i>J</i> = 1.7, 7.7 Hz, 1H), 7.74 (dd, <i>J</i> = 1.7, 7.7 Hz, 1H). MS (ESI): <i>m</i>/<i>z</i> 236 (M + H)<sup>+</sup>. Anal. Calcd for C<sub>12</sub>H<sub>10</sub>ClNO<sub>2</sub>: C, 61.16; H, 4.28; N, 5.94. Found: C, 60.97; H, 4.32; N, 5.93.</div><div class="NLM_p last">Compound <b>15q</b> (22.1 g) was prepared in a similar manner to <b>15n</b> from methyl 2-chloro-3-(1-cyanocyclopropyl)benzoate (25.7 g, 109 mmol), using lithium hydroxide monohydrate (6.69 g, 159 mmol), tetrahydrofuran (210 mL), methanol (70 mL), and water (70 mL). Yield 91%, white crystals; mp 155–156 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 1.32–1.42 (m, 2H), 1.79–1.87 (m, 2H), 4.47 (br s, 1H), 7.37 (t, <i>J</i> = 7.7 Hz, 1H), 7.56 (dd, <i>J</i> = 1.7, 7.7 Hz, 1H), 7.95 (dd, <i>J</i> = 1.7, 7.7 Hz, 1H). Anal. Calcd for C<sub>11</sub>H<sub>8</sub>ClNO<sub>2</sub>: C, 59.61; H, 3.64; N, 6.32. Found: C, 59.57; H, 3.66; N, 6.23.</div></div><div id="sec4_37" class="NLM_sec NLM_sec_level_2"><div id="ac_i64" class="anchor-spacer"></div><h3 class="article-section__title" id="_i64"> Methyl 3-(Cyanomethyl)benzoate (<b>17</b>)</h3><div class="NLM_p last">To a solution of methyl 3-(bromomethyl)benzoate <b>16</b> (10.0 g, 44 mmol) in acetonitrile (100 mL) were added potassium cyanate (5.7 g, 87 mmol) and 18-crown-6 (1.0 g), and the reaction mixture was stirred at room temperature for 3 days. The reaction mixture was filtered, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel column chromatography (5–30% ethyl acetate in <i>n-</i>hexane). The combined desired fractions were concentrated under reduced pressure to give compound <b>17</b> (7.0 g, 91%) as a colorless oil. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 3.88 (s, 3H), 4.17 (s, 2H), 7.57 (t, <i>J</i> = 7.6 Hz, 1H), 7.61–7.69 (m, 1H), 7.88–7.95 (m, 1H), 7.97 (br s, 1H). MS (ESI): <i>m</i>/<i>z</i> 176.03 (M + H)<sup>+</sup>.</div></div><div id="sec4_38" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> Methyl 3-(Bromomethyl)-2-chlorobenzoate (<b>19</b>)</h3><div class="NLM_p last">To a solution of methyl 2-chloro-3-methylbenzoate <b>18</b> (3.60 g, 19.4 mmol) in acetonitrile (60 mL) were added 1-bromopyrrolidine-2,5-dione (11.5 g, 64.3 mmol) and AIBN (960 mg, 5.84 mmol), and the reaction mixture was stirred at 90 °C for 26 h. The reaction mixture was concentrated under reduced pressure, and the insoluble material was filtered off. The filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (0–5% ethyl acetate in <i>n-</i>hexane) to give compound <b>19</b> (3.42 g, 66%) as a colorless oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 3.94 (s, 3H), 4.64 (s, 2H), 7.31 (t, <i>J</i> = 7.7 Hz, 1H), 7.58 (dd, <i>J</i> = 1.7, 7.7 Hz, 1H), 7.71 (dd, <i>J</i> = 1.7, 7.7 Hz, 1H). MS (ESI): <i>m</i>/<i>z</i> 264.90 (M + H)<sup>+</sup>.</div></div><div id="sec4_39" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> Methyl 2-Chloro-3-(cyanomethyl)benzoate (<b>20</b>)</h3><div class="NLM_p last">To a solution of <b>19</b> (748 mg, 2.84 mmol) in <i>N</i>,<i>N</i>-dimethylformamide (7 mL) was added sodium cyanate (412 mg, 8.41 mmol), and the reaction mixture was stirred at 80 °C for 1 h under nitrogen atmosphere. The reaction mixture was diluted with a mixed solvent of ethyl acetate and <i>n-</i>hexane (1:1, 200 mL). The mixture was washed with water (200 mL) and brine (200 mL), successively, dried over anhydrous MgSO<sub>4</sub>, and filtered. The filtrate was evaporated under reduced pressure, and the residue was purified by silica gel column chromatography (2–20% ethyl acetate in <i>n</i>-hexane) and recrystallized from ethyl acetate and <i>n</i>-hexane to give compound <b>20</b> (470 mg, 79%) as white crystals, mp 68–69 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 3.91 (s, 2H), 3.95 (s, 3H), 7.39 (t, <i>J</i> = 7.8 Hz, 1H), 7.66–7.72 (m, 1H), 7.76–7.81 (m, 1H). Anal. Calcd for C<sub>10</sub>H<sub>8</sub>ClNO<sub>2</sub>: C, 57.30; H, 3.85; N, 6.68. Found: C, 57.20; H, 3.80; N, 6.74.</div></div><div id="sec4_40" class="NLM_sec NLM_sec_level_2"><div id="ac_i67" class="anchor-spacer"></div><h3 class="article-section__title" id="_i67"> 5-(3-Aminophenoxy)pyridine-2-amine Dihydrochloride (<b>22</b>)</h3><div class="NLM_p">To a mixture of 5-bromo-2-nitropyridine <b>21</b> (20.5 g, 101 mmol) and cesium carbonate (50 g, 153 mmol) in <i>N</i>,<i>N</i>-dimethylformamide (200 mL) was added dropwise a solution of 3-nitrophenol (15.5 g, 111 mmol) in <i>N</i>,<i>N</i>-dimethylformamide (100 mL) over 1 h, and the reaction mixture was stirred at room temperature for 12 h. The reaction mixture was concentrated under reduced pressure, and the residue was diluted with water (300 mL) and extracted with ethyl acetate (600 mL). The organic layer was washed with 5% aqueous NaHCO<sub>3</sub> (300 mL) and brine (300 mL) and dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. The insoluble material was filtered off, and the filtrate was concentrated under reduced pressure. The residue was purified by basic silica gel column chromatography (10–40% ethyl acetate in <i>n-</i>hexane), and the desired fractions were concentrated under reduced pressure to give 2-nitro-5-(3-nitrophenoxy)pyridine (14.28 g, 54%) as colorless crystals, mp 113–114 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 7.69–7.87 (m, 3H), 8.10 (t, <i>J</i> = 2.1 Hz, 1H), 8.17 (dt, <i>J</i> = 7.7, 1.8 Hz, 1H), 8.38 (d, <i>J</i> = 9.0 Hz, 1H), 8.53 (d, <i>J</i> = 2.7 Hz, 1H). MS (ESI): <i>m</i>/<i>z</i> 262.07 (M + H)<sup>+</sup>. Anal. Calcd for C<sub>11</sub>H<sub>7</sub>N<sub>3</sub>O<sub>5</sub>: C, 50.58; H, 2.70; N, 16.09. Found: C, 50.51; H, 2.69; N, 16.06.</div><div class="NLM_p last">To a solution of 2-nitro-5-(3-nitrophenoxy)pyridine (14.0 g, 53.6 mmol) in methanol/tetrahydrofuran/ethyl acetate (5:1:1, 1.4 L) was added 10% palladium/carbon (1.4 g), and the reaction mixture was stirred at room temperature under hydrogen atmosphere (1.0 atm) for 20 h. The insoluble material was filtered off, and the filtrate was concentrated in vacuo. The residue was diluted with ethyl acetate (300 mL), and to the mixture was added dropwise slowly 4 N HCl in ethyl acetate (30 mL). The resulting colorless precipitate was collected by filtration, washed with <i>i</i>-Pr<sub>2</sub>O (100 mL) and <i>n-</i>hexane (100 mL), and dried under vacuum to give the compound <b>22</b> (15.2 g, quantitative yield) as colorless solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 6.69–6.83 (m, 2H), 6.85–6.95 (m, 1H), 7.09 (d, <i>J</i> = 9.6 Hz, 1H), 7.33 (t, <i>J</i> = 8.0 Hz, 1H), 7.86 (dd, <i>J</i> = 2.7, 9.6 Hz, 1H), 7.98 (d, <i>J</i> = 2.7 Hz, 1H), 8.15 (br s, 3H), 10.02 (br s, 3H).</div></div><div id="sec4_41" class="NLM_sec NLM_sec_level_2"><div id="ac_i68" class="anchor-spacer"></div><h3 class="article-section__title" id="_i68"> <i>N</i>-{3-[(6-Aminopyridin-3-yl)oxy]phenyl}-3-(1-cyano-1-methylethyl)benzamide (<b>23</b>)</h3><div class="NLM_p last">Compound <b>23</b> (3.44 g) was prepared in a similar manner to <b>1i</b> from 5-(3-aminophenoxy)pyridine-2-amine dihydrochloride <b>22</b> (3.5 g, 12.7 mmol), using 3-(1-cyano-1-methylethyl)benzoic acid <b>15n</b> (2.66 g, 14.0 mmol), oxalyl chloride (1.63 mL, 19.1 mmol), <i>N</i>,<i>N</i>-dimethylformamide (20 μL), tetrahydrofuran (28 mL), and <i>N</i>,<i>N</i>-dimethylacetamide (50 mL). Yield 66%, colorless crystals; mp 143–144 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 1.74 (s, 6H), 5.91 (s, 2H), 6.51 (d, <i>J</i> = 8.9 Hz, 1H), 6.66–6.77 (m, 1H), 7.23 (dd, <i>J</i> = 2.7, 8.9 Hz, 1H), 7.30 (t, <i>J</i> = 8.1 Hz, 1H), 7.38 (t, <i>J</i> = 2.1 Hz, 1H), 7.43–7.52 (m, 1H), 7.58 (t, <i>J</i> = 7.8 Hz, 1H), 7.68–7.82 (m, 2H), 7.84–7.94 (m, 1H), 7.99 (t, <i>J</i> = 1.8 Hz, 1H), 10.33 (s, 1H). MS (ESI): <i>m</i>/<i>z</i> 373.10 (M + H)<sup>+</sup>. Anal. Calcd for C<sub>22</sub>H<sub>20</sub>N<sub>4</sub>O<sub>2</sub>: C, 70.95; H, 5.41; N, 15.04. Found: C, 70.93; H, 5.46; N, 15.01.</div></div><div id="sec4_42" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> <i>N</i>-{3-[(1-(2-Amino-2-oxoethyl)-6-{[(4-methylphenyl)sulfonyl]imino}-1,6-dihydropyridin-3-yl)oxy]phenyl}-3-(1-cyano-1-methylethyl)benzamide (<b>24</b>)</h3><div class="NLM_p">To a solution of <b>23</b> (2.5 g, 6.71 mmol) in pyridine (60 mL) was added 4-methylbenzenesulfonyl chloride (1.34 g, 7.05 mmol) under ice-cooling, and the reaction mixture was stirred at 80 °C for 2 days. After the mixture was cooled at room temperature, water (200 mL) was added to the mixture. The mixture was extracted with ethyl acetate (300 mL). The organic layer was washed with brine (300 mL) and dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. The insoluble material was filtered off, and the filtrate was concentrated under reduced pressure to give 3-(1-cyano-1-methylethyl)-<i>N</i>-{3-[(6-{[(4-methylphenyl)sulfonyl]amino}pyridin-3-yl)oxy]phenyl}benzamide (3.48 g, 99%) as colorless crystals, mp 156–157 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 1.74 (s, 6H), 2.34 (s, 3H), 6.75 (dd, <i>J</i> = 2.4, 8.1 Hz, 1H), 7.15 (d, <i>J</i> = 9.0 Hz, 1H), 7.27–7.45 (m, 4H), 7.46–7.68 (m, 3H), 7.71–7.83 (m, 3H), 7.89 (d, <i>J</i> = 7.8 Hz, 1H), 7.99 (s, 1H), 8.02 (d, <i>J</i> = 3.0 Hz, 1H), 10.37 (s, 1H), 11.07 (br s, 1H). MS (ESI): <i>m</i>/<i>z</i> 527.2 (M + H)<sup>+</sup>. Anal. Calcd for C<sub>29</sub>H<sub>26</sub>N<sub>4</sub>O<sub>4</sub>S: C, 66.14; H, 4.98; N, 10.64. Found: C, 66.17; H, 5.01; N, 10.45.</div><div class="NLM_p last">To a solution of 3-(1-cyano-1-methylethyl)-<i>N</i>-{3-[(6-{[(4-methylphenyl)sulfonyl]amino}pyridin-3-yl)oxy]phenyl}benzamide (3.2 g, 6.08 mmol) in <i>N</i>,<i>N</i>-dimethylformamide (20 mL) was added <i>N</i>-ethyl-<i>N</i>-isopropylpropan-2-amine (1.11 mL, 6.38 mmol), and the reaction mixture was stirred at room temperature for 15 min. 2-Iodoacetamide (1.18 g, 6.38 mmol) was added to the reaction mixture, and the mixture was stirred at room temperature for 48 h. The reaction mixture was concentrated under reduced pressure, and to the residue was added 5% aqueous NaHCO<sub>3</sub> (150 mL). The mixture was extracted with ethyl acetate (300 mL). The organic layer was washed with brine (150 mL) and dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. The insoluble material was filtered off, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (50–100% ethyl acetate in <i>n-</i>hexane) and triturated with a mixed solvent of ethyl acetate, <i>i</i>-Pr<sub>2</sub>O, and <i>n-</i>hexane (1:1:1, 20 mL) to give compound <b>24</b> (2.23 g, 63%) as colorless crystals, mp 128–130 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 1.74 (s, 6H), 2.34 (s, 3H), 4.83 (s, 2H), 6.76 (dd, <i>J</i> = 2.4, 7.8 Hz, 1H), 7.28 (d, <i>J</i> = 8.1 Hz, 2H), 7.32–7.46 (m, 3H), 7.48 (t, <i>J</i> = 2.1 Hz, 1H), 7.59 (t, <i>J</i> = 7.8 Hz, 2H), 7.68 (d, <i>J</i> = 8.1 Hz, 2H), 7.71–7.82 (m, 3H), 7.86–7.94 (m, 1H), 8.01 (t, <i>J</i> = 1.8 Hz, 1H), 8.13 (d, <i>J</i> = 2.4 Hz, 1H), 10.41 (s, 1H). MS (ESI): <i>m</i>/<i>z</i> 584.15 (M + H)<sup>+</sup>. Anal. Calcd for C<sub>31</sub>H<sub>29</sub>N<sub>5</sub>O<sub>5</sub>S: C, 63.79; H, 5.01; N, 12.00. Found: C, 63.64; H, 5.24; N, 11.79.</div></div><div id="sec4_43" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> <i>N</i>-{3-[(2-Aminoimidazo[1,2-<i>a</i>]pyridin-6-yl)oxy]phenyl}-3-(1-cyano-1-methylethyl)benzamide (<b>25</b>)</h3><div class="NLM_p last">To a solution of <b>24</b> (1.00 g, 1.72 mmol) in dichloromethane (8 mL) was added trifluoroacetic acid anhydride (6 mL), and the reaction mixture was stirred at room temperature for 16 h. The reaction mixture was concentrated under reduced pressure, and to the mixture was added 5% aqueous NaHCO<sub>3</sub> (150 mL), and the mixture was extracted with ethyl acetate (150 mL). The organic layer was washed with brine (150 mL) and dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. The insoluble material was filtered off, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (30–60% ethyl acetate in <i>n-</i>hexane) and triturated with <i>i</i>-Pr<sub>2</sub>O and <i>n-</i>hexane to give compound <b>25</b> (450 mg, 52%) as colorless crystals, mp 130–132 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 1.73 (s, 6H), 6.84 (dd, <i>J</i> = 2.4, 7.5 Hz, 1H), 7.22 (dd, <i>J</i> = 2.4, 9.6 Hz, 1H), 7.38 (t, <i>J</i> = 8.1 Hz, 1H), 7.51 (t, <i>J</i> = 2.4 Hz, 1H), 7.54–7.68 (m, 3H), 7.70–7.79 (m, 1H), 7.89 (d, <i>J</i> = 8.1 Hz, 1H), 7.99 (t, <i>J</i> = 1.8 Hz, 1H), 8.27 (s, 1H), 8.66 (d, <i>J</i> = 2.4 Hz, 1H), 10.36 (s, 1H), 12.48 (s, 1H). MS (ESI): <i>m</i>/<i>z</i> 508.10 (M + H)<sup>+</sup>.</div></div><div id="sec4_44" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> 5-Fluoro-<i>N</i>-methyl-2-nitroaniline (<b>27b</b>)</h3><div class="NLM_p last">Methylamine solution (40%, 38.4 g) was added dropwise to 2,4-difluoro-1-nitrobenzene <b>26</b> (25.0 g, 157 mmol) at 0 °C over 15 min. After completion of the addition, the reaction mixture was stirred at 0 °C for 1.5 h. To the mixture was added water (500 mL) and the resulting crystals were collected by filtration to give compound <b>27b</b> (26.4 g, 99%) as a yellow crystalline solid, mp 105–106 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 2.94 (d, <i>J</i> = 4.8 Hz, 3H), 6.53 (ddd, <i>J</i> = 2.7, 7.8, 10.2 Hz, 1H), 6.78 (dd, <i>J</i> = 2.7, 12.3 Hz, 1H), 8.17 (dd, <i>J</i> = 6.3, 9.6 Hz, 1H), 8.32 (br s, 1H). Anal. Calcd for C<sub>7</sub>H<sub>7</sub>FN<sub>2</sub>O<sub>2</sub>: C, 49.41; H, 4.15; N, 16.46. Found: C, 49.15; H, 4.20; N, 16.45.</div></div><div id="sec4_45" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> <i>tert</i>-Butyl [3-(3-Amino-4-nitrophenoxy)phenyl]carbamate (<b>28a</b>)</h3><div class="NLM_p last">To a solution of <i>tert</i>-butyl (3-hydroxyphenyl)carbamate (6.89 g, 32.9 mmol) and 5-fluoro-2-nitroaniline <b>27a</b> (5.09 g, 32.6 mmol) in <i>N</i>,<i>N</i>-dimethylformamide (100 mL) was added potassium carbonate (11.2 g, 80.9 mmol), and the reaction mixture was stirred at 100 °C for 14 h. The mixture was cooled at room temperature and diluted with ethyl acetate/<i>n-</i>hexane (1:1, 250 mL). The mixture was washed with water (2 × 150 mL) and brine (100 mL), successively, and dried over anhydrous MgSO<sub>4</sub>. The solvent was evaporated in vacuo, and the residue was purified with silica gel column chromatography (2–30% ethyl acetate in <i>n-</i>hexane) to give compound <b>28a</b> (7.7 g, 69%) as yellow crystals, mp 130–131 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 1.54 (s, 9H), 6.13 (br s, 2H), 6.19 (d, <i>J</i> = 2.7 Hz, 1H), 6.35 (dd, <i>J</i> = 2.4, 6.3 Hz, 1H), 6.57 (br s, 1H), 6.74–6.78 (m, 1H), 7.11–7.16 (m, 1H), 7.28–7.35 (m, 2H), 8.12 (d, <i>J</i> = 9.6 Hz, 1H).</div></div><div id="sec4_46" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> <i>tert</i>-Butyl {3-[3-(Methylamino)-4-nitrophenoxy]phenyl}carbamate (<b>28b</b>)</h3><div class="NLM_p last">Compound <b>28b</b> (21.8 g) was prepared in a similar manner to <b>28a</b> from <b>27b</b> (8.58 g, 50.4 mmol), using <i>tert</i>-butyl (3-hydroxyphenyl)carbamate (11.0 g, 52.3 mmol), <i>N</i>,<i>N</i>-dimethylformamide (200 mL), and potassium carbonate (28.6 g, 207 mmol). Yield, quantitative; orange amorphous solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 1.51 (s, 9H), 2.92 (d, <i>J</i> = 5.1 Hz, 3H), 6.22 (dd, <i>J</i> = 2.7, 9.6 Hz, 1H), 6.29 (d, <i>J</i> = 2.4 Hz, 1H), 6.64 (br s, 1H), 6.75 (ddd, <i>J</i> = 0.9, 2.4, 8.1 Hz, 1H), 7.12 (d, <i>J</i> = 8.4 Hz, 1H), 7.27–7.33 (m, 2H), 8.14 (d, <i>J</i> = 9.6 Hz, 1H), 8.19 (br d, <i>J</i> = 4.8 Hz, 1H).</div></div><div id="sec4_47" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> <i>tert-</i>Butyl [3-({2-[(Cyclopropylcarbonyl)amino]-1<i>H</i>-benzimidazol-6-yl}oxy)phenyl]carbamate (<b>29a</b>)</h3><div class="NLM_p">A mixture of <b>28a</b>(5.51 g, 15.6 mmol), 10% palladium/carbon (875 mg), tetrahydrofuran (20 mL), and methanol (100 mL) was stirred at room temperature under hydrogen atmosphere for 18 h. The insoluble was filtered off and the filtrate was evaporated in vacuo to give <i>tert</i>-butyl [3-(3,4-diaminophenoxy)phenyl]carbamate (5.17 g, quant) as a purple amorphous solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 1.49 (s, 9H), 3.24 (br s, 2H), 3.49 (br s, 2H), 6.37–6.43 (m, 3H), 6.61 (ddd, <i>J</i> = 0.9, 2.4, 8.1 Hz, 1H), 6.66 (d, <i>J</i> = 8.1 Hz, 1H), 6.90 (t, <i>J</i> = 2.1 Hz, 1H), 7.07–7.11 (m, 1H), 7.17 (t, <i>J</i> = 8.1 Hz, 1H).</div><div class="NLM_p">To a solution of <i>tert</i>-butyl [3-(3,4-diaminophenoxy)phenyl]carbamate (3.00 g, 9.51 mmol) in tetrahydrofuran (150 mL) was added cyanogen bromide (2.93 g, 27.7 mmol). The reaction mixture was stirred at room temperature for 3 days. The reaction mixture was diluted with ethyl acetate (300 mL). The mixture was washed with saturated NaHCO<sub>3</sub> (2 × 100 mL) and brine (100 mL), successively, and dried over anhydrous MgSO<sub>4</sub>. The solvent was evaporated in vacuo to give <i>tert</i>-butyl {3-[(2-amino-1<i>H</i>-benzimidazol-6-yl)oxy]phenyl}carbamate (4.37 g, quant) as brown crystals, mp 117–119 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 1.44 (s, 9H), 4.16 (br s, 2H), 6.59–6.69 (m, 2H), 6.77–6.90 (m, 2H), 6.96–6.98 (m, 2H), 7.05 (d, <i>J</i> = 8.4 Hz, 1H), 7.14 (t, <i>J</i> = 8.1 Hz, 1H). MS (ESI): <i>m</i>/<i>z</i> 341.05 (M + H)<sup>+</sup>.</div><div class="NLM_p last">To a solution of <i>tert</i>-butyl {3-[(2-amino-1<i>H</i>-benzimidazol-6-yl)oxy]phenyl}carbamate (1.30 g, 3.82 mmol) in pyridine (50 mL) were added cyclopropanecarbonyl chloride (1 mL, 11.0 mmol) and DMAP (21.3 mg, 0.174 mmol). The reaction mixture was stirred at room temperature for 16 h. To the reaction mixture were added methanol (30 mL) and 8 N NaOH (3 mL), successively, and the mixture was stirred at room temperature for 2.5 h. The mixture was evaporated in vacuo, and the residue was dissolved in methanol (5 mL) and ethyl acetate (50 mL). The mixture was washed with 0.1 N HCl (50 mL) and saturated NaHCO<sub>3</sub> (50 mL), successively, and dried over anhydrous MgSO<sub>4</sub>. The solvent was evaporated in vacuo. The residue was crystallized from ethyl acetate and <i>i</i>-Pr<sub>2</sub>O to give the compound <b>29a</b> (1.53 g, 98%) as a colorless crystalline solid, mp 144–145 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 0.90–0.92 (m, 4H), 1.42 (s, 9H), 1.92–1.99 (m, 1H), 6.51–6.55 (m, 1H), 6.80 (dd, <i>J</i> = 2.1, 8.4 Hz, 1H), 7.02–7.21 (m, 3H), 7.36–7.41 (m, 2H), 9.36 (br s, 1H), 11.83 (br s, 1H), 12.01 (br s, 1H). MS (ESI): <i>m</i>/<i>z</i> 409.15 (M + H)<sup>+</sup>.</div></div><div id="sec4_48" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> <i>tert-</i>Butyl [3-({2-[(Cyclopropylcarbonyl)amino]-1-methyl-1<i>H</i>-benzimidazol-6-yl}oxy)phenyl]carbamate (<b>29b</b>)</h3><div class="NLM_p"><i>tert</i>-Butyl {3-[4-amino-3-(methylamino)phenoxy]phenyl}carbamate (10.1 g) was prepared in a similar manner to the intermediate of <b>29a</b>, <i>tert</i>-butyl [3-(3,4-diaminophenoxy)phenyl]carbamate from <b>28b</b> (10.9 g, 30.4 mmol), using 10% palladium/carbon (1.8 g), tetrahydrofuran (150 mL), ethanol (100 mL), and hydrogen (3 atm). <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 1.49 (s, 9H), 2.81 (s, 4H), 2.88 (s, 1H), 2.95 (s, 1H), 6.31 (dd, <i>J</i> = 2.7, 8.1 Hz, 1H), 6.37 (d, <i>J</i> = 2.4 Hz, 1H), 6.47 (br s, 1H), 6.60–6.67 (m, 2H), 6.89 (t, <i>J</i> = 2.1 Hz, 1H), 7.11–7.20 (m, 2H). MS (ESI): <i>m</i>/<i>z</i> 330.05 (M + H)<sup>+</sup>.</div><div class="NLM_p"><i>tert</i>-Butyl {3-[(2-amino-1-methyl-1<i>H</i>-benzimidazol-6-yl)oxy]phenyl}carbamate (7.46 g) was prepared in a similar manner to the intermediate of <b>29a</b>, <i>tert</i>-butyl {3-[(2-amino-1<i>H</i>-benzimidazol-6-yl)oxy]phenyl}carbamate from <i>tert</i>-butyl {3-[4-amino-3-(methylamino)phenoxy]phenyl}carbamate (10.1 g, 30.4 mmol), using tetrahydrofuran (200 mL) and cyanogen bromide (4.33 g, 40.9 mmol). Yield, 69% in two steps; black amorphous solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 1.43 (s, 9H), 3.33 (br s, 2H), 3.46 (s, 3H), 6.47–6.50 (m, 2H), 6.65 (dd, <i>J</i> = 2.4, 8.4 Hz, 1H), 6.92 (d, <i>J</i> = 2.4 Hz, 1H), 7.10–7.19 (m, 3H), 9.34 (br s, 1H). MS (ESI): <i>m</i>/<i>z</i> 355.05 (M + H)<sup>+</sup>.</div><div class="NLM_p last">Compound <b>29b</b> (1.89 g) was prepared in a similar manner to <b>29a</b> from <i>tert</i>-butyl {3-[(2-amino-1-methyl-1<i>H</i>-benzimidazol-6-yl)oxy]phenyl}carbamate (2.45 g, 6.91 mmol), using pyridine (100 mL), cyclopropanecarbonyl chloride (3.0 mL, 33.1 mmol), and DMAP (258 mg, 2.11 mmol). Yield 65%, pale brown amorphous solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 0.85–0.90 (m, 2H), 1.06–1.11 (m, 2H), 1.50 (s, 9H), 1.80–1.90 (m, 1H), 3.60 (m, 3H), 6.56 (br s, 1H), 6.64–6.68 (m, 1H), 6.90–6.94 (m, 2H), 7.08–7.11 (m, 2H), 7.20–7.33 (m, 2H), 8.63–8.65 (m, 1H). MS (ESI): <i>m</i>/<i>z</i> 423.15 (M + H)<sup>+</sup>.</div></div><div id="sec4_49" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> 3-(1-Cyano-1-methylethyl)-<i>N</i>-(3-hydroxyphenyl)benzamide (<b>30</b>)</h3><div class="NLM_p last">Compound <b>30</b> (13.0 g) was prepared in a similar manner to <b>1i</b> from 3-(1-cyano-1-methylethyl)benzoic acid <b>15n</b> (10.0 g, 52.8 mmol), using tetrahydrofuran (200 mL), <i>N</i>,<i>N</i>-dimethylformamide (80 μL), oxalyl chloride (6.28 mL, 72.0 mmol), 3-aminophenol (5.24 g, 48.0 mmol), NaHCO<sub>3</sub> (6.05 g, 72.0 mmol), and water (60 mL). Yield 96%, white crystals; mp 172 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 1.75 (s, 6H), 6.49–6.55 (m, 1H), 7.08–7.18 (m, 2H), 7.30–7.34 (m, 1H), 7.59 (t, <i>J</i> = 7.8 Hz, 1H), 7.72–7.77 (m, 1H), 7.88–7.93 (m, 1H), 8.01 (t, <i>J</i> = 1.7 Hz, 1H), 9.43 (s, 1H), 10.18 (s, 1H). MS (ESI): <i>m</i>/<i>z</i> 281 (M + H)<sup>+</sup>.</div></div><div id="sec4_50" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> <i>N</i>-<i>tert</i>-Butyl-6-chloro-3-nitropyridin-2-amine (<b>32a</b>)</h3><div class="NLM_p last">To a solution of 2,6-dichloro-3-nitropyridine <b>31</b> (25.2 g, 131 mmol) in toluene (150 mL) was added dropwise a solution of <i>tert-</i>butylamine (9.63 g) in toluene (100 mL) at 0 °C over 30 min. The reaction mixture was stirred at room temperature for 6 h. To the reaction mixture was added an additional amount of <i>tert</i>-butylamine (10.0 g), and the mixture was stirred at room temperature for an additional 8 h. To the reaction mixture was added water (300 mL). The organic layer was washed with saturated ammonium chloride (200 mL) and brine (200 mL), successively, dried over anhydrous MgSO<sub>4</sub>, filtered, and evaporated in vacuo to give compound <b>32a</b> (29.6 g, 99%) as an orange crystalline solid, mp 87 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 1.50 (s, 9H), 6.81 (d, <i>J</i> = 8.5 Hz, 1H), 8.28 (s, 1H), 8.44 (d, <i>J</i> = 8.7 Hz, 1H). Anal. Calcd for C<sub>9</sub>H<sub>12</sub>ClN<sub>3</sub>O<sub>2</sub>: C, 47.07; H, 5.27; N, 18.30. Found: C, 46.97; H, 5.22; N, 18.26.</div></div><div id="sec4_51" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> 6-Chloro-<i>N</i>-methyl-3-nitropyridin-2-amine (<b>32b</b>)</h3><div class="NLM_p last">To a solution of 2,6-dichloro-3-nitropyridine <b>31</b> (3.86 g, 20 mmol) was added dropwise 2 M methylamine solution in tetrahydrofuran (15 mL, 30 mmol) at 0 °C. The reaction mixture was stirred at room temperature for 1 h. The mixture was partitioned between ethyl acetate (300 mL) and water (300 mL). The organic layer was dried over anhydrous MgSO<sub>4</sub>, filtered, and evaporated in vacuo. The residue was purified by silica gel column chromatography (0–100% ethyl acetate in <i>n-</i>hexane) to give compound <b>32b</b> (2.94 g, 78%) as a yellow solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 3.18 (d, <i>J</i> = 4.9 Hz, 3H), 6.62 (d, <i>J</i> = 8.5 Hz, 1H), 8.25–8.40 (m, 2H). MS (ESI): <i>m</i>/<i>z</i> 187.95 (M + H)<sup>+</sup>.</div></div><div id="sec4_52" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79"> <i>N</i>-(3-{[6-(<i>tert</i>-Butylamino)-5-nitropyridin-2-yl]oxy}phenyl)-3-(1-cyano-1-methylethyl)benzamide (<b>33a</b>)</h3><div class="NLM_p last">A mixture of 2-<i>tert</i>-butylamino-3-nitro-6-chloropyridine <b>32a</b> (1.15 g, 5.0 mmol), 3-(1-cyano-1-methylethyl)-<i>N</i>-(3-hydroxyphenyl)benzamide <b>30</b>(1.40 g, 5.0 mmol), and potassium carbonate (0.69 g, 5.0 mmol) in <i>N</i>,<i>N</i>-dimethylformamide (5 mL) was stirred at room temperature for 18 h. The reaction mixture was partitioned between ethyl acetate (200 mL) and water (200 mL). The organic layer was dried over anhydrous MgSO<sub>4</sub> and filtered. The filtrate was concentrated in vacuo and the residue was purified by silica gel column chromatography (0–100% ethyl acetate in <i>n-</i>hexane) to give compound <b>33a</b> (1.70 g, 3.59 mmol, 72%) as a yellow solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 1.19 (s, 9H), 1.78 (s, 6H), 6.26 (d, <i>J</i> = 9.0 Hz, 1H), 6.77–7.04 (m, 1H), 7.34–7.50 (m, 2H), 7.50–7.59 (m, 1H), 7.65 (t, <i>J</i> = 2.1 Hz, 1H), 7.70 (ddd, <i>J</i> = 1.0, 2.0, 7.9 Hz, 1H), 7.77 (dt, <i>J</i> = 7.7, 1.4 Hz, 1H), 7.90 (s, 1H), 7.98 (t, <i>J</i> = 1.7 Hz, 1H), 8.43 (d, <i>J</i> = 9.0 Hz, 1H), 8.63 (s, 1H). MS (ESI): <i>m</i>/<i>z</i> 474 (M + H)<sup>+</sup>.</div></div><div id="sec4_53" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> 3-(1-Cyano-1-methylethyl)-<i>N</i>-(3-{[6-(methylamino)-5-nitropyridin-2-yl]oxy}phenyl)benzamide (<b>33b</b>)</h3><div class="NLM_p last">Compound <b>33b</b>(3.96 g) was prepared in a similar manner to <b>33a</b> from <b>32b</b> (1.88 g, 10 mmol), using <b>30</b> (2.80 g, 10 mmol), potassium carbonate (1.38 g, 10 mmol), and <i>N</i>,<i>N</i>-dimethylformamide (80 mL). Yield 88%, yellow amorphous solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 1.78 (s, 6H), 2.92 (d, <i>J</i> = 4.9 Hz, 3H), 6.21 (d, <i>J</i> = 9.0 Hz, 1H), 6.90–7.10 (m, 1H), 7.38–7.47 (m, 2H), 7.48–7.60 (m, 1H), 7.66–7.75 (m, 2H), 7.79 (dt, <i>J</i> = 7.7, 1.3 Hz, 1H), 7.93 (s, 1H), 7.99 (t, <i>J</i> = 1.7 Hz, 1H), 8.32–8.54 (m, 2H). MS (ESI): <i>m</i>/<i>z</i> 432.15 (M + H)<sup>+</sup>.</div></div><div id="sec4_54" class="NLM_sec NLM_sec_level_2"><div id="ac_i81" class="anchor-spacer"></div><h3 class="article-section__title" id="_i81"> <i>N</i>-{3-[(2-Amino-3-<i>tert</i>-butyl-3<i>H</i>-imidazo[4,5-<i>b</i>]pyridin-5-yl)oxy]phenyl}-3-(1-cyano-1-methylethyl)benzamide (<b>34a</b>)</h3><div class="NLM_p">A mixture of <i>N</i>-(3-{[6-(<i>tert</i>-butylamino)-5-nitropyridin-2-yl]oxy}phenyl)-3-(1-cyano-1-methylethyl)benzamide <b>33a</b> (1.42 g, 3.0 mmol) and 10% palladium/carbon (0.50 g) in methanol (10 mL) and tetrahydrofuran (5 mL) was stirred at room temperature under hydrogen atmosphere for 2 h. The catalyst was filtered through a pad of Celite. The filtrate was concentrated in vacuo, and the residue was partitioned between ethyl acetate (200 mL) and water (200 mL). The organic layer was dried over anhydrous MgSO<sub>4</sub> and filtered. The filtrate was concentrated in vacuo to give <i>N</i>-(3-{[5-amino-6-(<i>tert</i>-butylamino)pyridin-2-yl]oxy}phenyl)-3-(1-cyano-1-methylethyl)benzamide (1.33 g, quant) as a purple amorphous solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 1.29 (s, 9H), 1.77 (s, 6H), 2.85 (br s, 2H), 4.30 (br s, 1H), 6.07 (d, <i>J</i> = 7.9 Hz, 1H), 6.89 (d, <i>J</i> = 7.9 Hz, 2H), 7.28–7.40 (m, 2H), 7.40–7.57 (m, 2H), 7.65–7.81 (m, 3H), 7.95 (t, <i>J</i> = 1.8 Hz, 1H). MS (ESI): <i>m</i>/<i>z</i> 444.30 (M + H)<sup>+</sup>.</div><div class="NLM_p last">The obtained solid (1.33 g) was dissolved in tetrahydrofuran (10 mL). To the solution was added cyanogen bromide (0.74 g, 7.00 mmol), and the reaction mixture was stirred at room temperature for 18 h. The reaction was quenched by the addition of saturated NaHCO<sub>3</sub> (50 mL). The mixture was partitioned between ethyl acetate (200 mL) and water (200 mL). The organic layer was dried over anhydrous MgSO<sub>4</sub> and filtered. The filtrate was concentrated in vacuo. The residue was purified by silica gel column chromatography (0–100% ethyl acetate in <i>n-</i>hexane) to give compound <b>34a</b> (1.15 g, 2.45 mmol, 82% in two steps) as a pale black amorphous solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 1.76 (s, 15H), 4.78 (br s, 2H), 6.69 (d, <i>J</i> = 8.3 Hz, 1H), 6.92 (ddd, <i>J</i> = 1.0, 2.2, 8.1 Hz, 1H), 7.35 (t, <i>J</i> = 8.1 Hz, 1H), 7.40–7.54 (m, 3H), 7.56 (d, <i>J</i> = 8.3 Hz, 1H), 7.70 (ddd, <i>J</i> = 1.1, 2.1, 7.9 Hz, 1H), 7.76 (dt, <i>J</i> = 7.6, 1.4 Hz, 1H), 7.91 (s, 1H), 7.96 (t, <i>J</i> = 1.7 Hz, 1H). MS (ESI): <i>m</i>/<i>z</i> 469 (M + H)<sup>+</sup>.</div></div><div id="sec4_55" class="NLM_sec NLM_sec_level_2"><div id="ac_i82" class="anchor-spacer"></div><h3 class="article-section__title" id="_i82"> <i>N</i>-{3-[(2-Amino-3-methyl-3<i>H</i>-imidazo[4,5-<i>b</i>]pyridin-5-yl)oxy]phenyl}-3-(1-cyano-1-methylethyl)benzamide (<b>34b</b>)</h3><div class="NLM_p"><i>N</i>-(3-{[5-Amino-6-(methylamino)pyridin-2-yl]oxy}phenyl)-3-(1-cyano-1-methylethyl)benzamide (3.54 g) was prepared in a similar manner to the intermediate of <b>34a</b>, <i>N</i>-(3-{[5-amino-6-(<i>tert</i>-butylamino)pyridin-2-yl]oxy}phenyl)-3-(1-cyano-1-methylethyl)benzamide from compound <b>33b</b> (3.96 g, 8.83 mmol), using 10% palladium/carbon (1.0 g), tetrahydrofuran (5 mL), and methanol (10 mL) to give a purple amorphous solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 1.73 (s, 6H), 2.63–3.27 (m, 5H), 4.42 (br s, 1H), 5.95 (d, <i>J</i> = 7.9 Hz, 1H), 6.80–6.95 (m, 2H), 7.27–7.33 (m, 1H), 7.36 (t, <i>J</i> = 2.1 Hz, 1H), 7.40–7.51 (m, 2H), 7.62–7.71 (m, 1H), 7.75 (dd, <i>J</i> = 7.7, 1.7 Hz, 1H), 7.95 (t, <i>J</i> = 1.8 Hz, 1H), 8.12 (s, 1H). MS (ESI): <i>m</i>/<i>z</i> 402.15 (M + H)<sup>+</sup>.</div><div class="NLM_p last">Compound <b>34b</b> (0.34 g) was prepared in a similar manner to <b>34a</b> from <i>N</i>-(3-{[5-amino-6-(methylamino)pyridin-2-yl]oxy}phenyl)-3-(1-cyano-1-methylethyl)benzamide (0.40 g), using cyanogen bromide (0.53 g, 5.0 mmol) and tetrahydrofuran (10 mL). Yield, 80% in two steps; pale brown solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 1.73 (s, 6H), 3.53 (s, 3H), 4.82 (s, 2H), 6.64 (d, <i>J</i> = 8.3 Hz, 1H), 6.90 (dd, <i>J</i> = 2.1, 7.9 Hz, 1H), 7.29–7.38 (m, 1H), 7.38–7.44 (m, 1H), 7.48 (t, <i>J</i> = 7.2 Hz, 2H), 7.56 (d, <i>J</i> = 8.3 Hz, 1H), 7.67 (dd, <i>J</i> = 1.0, 7.8 Hz, 1H), 7.72–7.80 (m, 1H), 7.95 (t, <i>J</i> = 1.7 Hz, 1H), 8.21 (br s, 1H). MS (ESI): <i>m</i>/<i>z</i> 427.20 (M + H)<sup>+</sup>.</div></div><div id="sec4_56" class="NLM_sec NLM_sec_level_2"><div id="ac_i83" class="anchor-spacer"></div><h3 class="article-section__title" id="_i83"> 3-(4-Nitrophenoxy)aniline (<b>36</b>)</h3><div class="NLM_p last">Compound <b>36</b> (21.8 g) was prepared in a similar manner to <b>8</b> from 1-fluoro-4-nitrobenzene <b>35</b> (14.1 g, 100 mmol), using 3-aminophenol (11.2 g, 102 mmol), potassium carbonate (26.5 g, 191 mmol), and <i>N</i>,<i>N</i>-dimethylformamide (150 mL). Yield 95%, yellow crystalline solid; mp 79 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 5.39 (br s, 2H), 6.26 (ddd, <i>J</i> = 0.9, 2.4, 7.8 Hz, 1H), 6.31 (t, <i>J</i> = 2.1 Hz, 1H), 6.48 (ddd, <i>J</i> = 0.9, 2.1, 8.1 Hz, 1H), 7.07–7.14 (m, 3H), 8.24 (dt, <i>J</i> = 7.2, 3.6 Hz, 2H). MS (ESI): <i>m</i>/<i>z</i> 271.95 (M + H)<sup>+</sup>. Anal. Calcd for C<sub>12</sub>H<sub>10</sub>N<sub>2</sub>O<sub>3</sub>: C, 62.60; H, 4.38; N, 12.17. Found: C, 62.63; H, 4.39; N, 12.19.</div></div><div id="sec4_57" class="NLM_sec NLM_sec_level_2"><div id="ac_i84" class="anchor-spacer"></div><h3 class="article-section__title" id="_i84"> 3-(1-Cyano-1-methylethyl)-<i>N</i>-[3-(4-nitrophenoxy)phenyl]benzamide (<b>37</b>)</h3><div class="NLM_p last">Compound <b>37</b> (8.10 g) was prepared in a similar manner to <b>1i</b> from <b>36</b> (4.69 g, 20.4 mmol), using <b>15h</b> (3.98 g, 21.0 mmol), EDCI·HCl (4.69 g, 24.5 mmol), DMAP (151 mg, 1.24 mmol), and pyridine (100 mL). Yield 99%, yellow amorphous solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 1.75 (s, 6H), 6.97 (dd, <i>J</i> = 1.8, 8.4 Hz, 1H), 7.20 (dt, <i>J</i> = 10.5, 3.3 Hz, 2H), 7.49 (t, <i>J</i> = 7.8 Hz, 1H), 7.60 (t, <i>J</i> = 7.2 Hz, 1H), 7.67–7.71 (m, 2H), 7.76 (d, <i>J</i> = 8.7 Hz, 1H), 7.93 (d, <i>J</i> = 7.8 Hz, 1H), 8.02 (t, <i>J</i> = 1.5 Hz, 1H), 8.29 (dt, <i>J</i> = 10.5, 3.3 Hz, 2H), 10.49 (br s, 1H). MS (ESI): <i>m</i>/<i>z</i> 402.05 (M + H)<sup>+</sup>.</div></div><div id="sec4_58" class="NLM_sec NLM_sec_level_2"><div id="ac_i85" class="anchor-spacer"></div><h3 class="article-section__title" id="_i85"> <i>N</i>-[3-(4-Aminophenoxy)phenyl]-3-(1-cyano-1-methylethyl)benzamide (<b>38</b>)</h3><div class="NLM_p last">To a solution of <b>37</b> (8.10 g, 20.2 mmol) in tetrahydrofuran (50 mL) and methanol (50 mL) was added 10% palladium/carbon (555 mg), and the reaction mixture was stirred at room temperature under hydrogen atmosphere (2.5 atm) for 14 h. The insoluble was filtered off and the filtrate was concentrated in vacuo to give compound <b>38</b> (7.34 g, 98%) as a pale gray amorphous solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 1.74 (s, 6H), 5.00 (br s, 2H), 6.58–6.67 (m, 3H), 6.77–6.81 (m, 2H), 7.27 (t, <i>J</i> = 8.1 Hz, 1H), 7.37 (t, <i>J</i> = 2.1 Hz, 1H), 7.43–7.46 (m, 1H), 7.58 (t, <i>J</i> = 7.8 Hz, 1H), 7.74 (ddd, <i>J</i> = 0.9, 2.1, 7.8 Hz, 1H), 7.90 (dt, <i>J</i> = 8.1, 1.2 Hz, 1H), 7.99 (t, <i>J</i> = 1.5 Hz, 1H), 10.30 (br s, 1H). MS (ESI): <i>m</i>/<i>z</i> 372.10 (M + H)<sup>+</sup>.</div></div><div id="sec4_59" class="NLM_sec NLM_sec_level_2"><div id="ac_i86" class="anchor-spacer"></div><h3 class="article-section__title" id="_i86"> <i>tert</i>-Butyl {3-[(5-Aminopyridin-2-yl)oxy]phenyl}carbamate (<b>40</b>)</h3><div class="NLM_p last">To a suspension of <i>tert</i>-butyl (3-hydroxyphenyl)carbamate (3.02 g, 14.4 mmol) and potassium carbonate (2.99 g, 21.7 mmol) in <i>N</i>,<i>N</i>-dimethylformamide (35 mL) was added 2-chloro-5-nitropyridine <b>39</b> (2.52 g, 15.9 mmol), and the reaction mixture was stirred at 70 °C for 2 h. To the reaction mixture was added water (100 mL), and the mixture was extracted with ethyl acetate (100 mL, 50 mL). The combined extracts were washed with brine (20 mL) and dried over anhydrous MgSO<sub>4</sub>. The insoluble material was filtered off, and the filtrate was concentrated under reduced pressure to give <i>tert</i>-butyl {3-[(5-nitropyridin-2-yl)oxy]phenyl}carbamate as a yellow solid. To a solution of <i>tert</i>-butyl {3-[(5-nitropyridin-2-yl)oxy]phenyl}carbamate in ethanol/tetrahydrofuran (4:1, 100 mL) was added 10% palladium/carbon (1.54 g), and the reaction mixture was stirred at room temperature for 7 h under hydrogen atmosphere (1.0 atm). The insoluble material was filtered off, and the filtrate was concentrated under reduced pressure. The residue was recrystallized from methanol to give compound <b>40</b> (3.35 g, 77% in two steps from <b>39</b>) as brown crystalline solid, mp 166–167 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 1.45 (s, 9H), 5.11 (br s, 2H), 6.52 (dd, <i>J</i> = 1.5, 7.4 Hz, 1H), 6.74 (d, <i>J</i> = 8.7 Hz, 1H), 7.07 (dd, <i>J</i> = 2.2, 8.7 Hz, 1H), 7.10–7.23 (m, 3H), 7.55 (d, <i>J</i> = 2.2 Hz, 1H), 9.36 (br s, 1H).</div></div><div id="sec4_60" class="NLM_sec NLM_sec_level_2"><div id="ac_i87" class="anchor-spacer"></div><h3 class="article-section__title" id="_i87"> <i>tert</i>-Butyl {3-[(2-Amino[1,3]thiazolo[5,4-<i>b</i>]pyridin-5-yl)oxy]phenyl}carbamate (<b>41</b>)</h3><div class="NLM_p last">Compound <b>41</b> (3.51 g) was prepared in a similar manner to <b>5</b> from <b>40</b> (3.33 g, 11.1 mmol), using potassium thiocyanate (4.30 g, 44.2 mmol), AcOH (60 mL), and bromine (1.85 g, 11.6 mmol). Yield 88%, pale yellow crystals; mp 181–182 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 1.45 (s, 9H), 6.62–6.70 (m, 1H), 6.88 (d, <i>J</i> = 8.9 Hz, 1H), 7.18–7.29 (m, 3H), 7.62 (br s, 2H), 7.71 (d, <i>J</i> = 8.9 Hz, 1H), 9.43 (br s, 1H). MS (ESI): <i>m</i>/<i>z</i> 359.1 (M + H)<sup>+</sup>.</div></div><div id="sec4_61" class="NLM_sec NLM_sec_level_2"><div id="ac_i88" class="anchor-spacer"></div><h3 class="article-section__title" id="_i88"> <i>N</i>-[5-(3-Aminophenoxy)[1,3]thiazolo[5,4-<i>b</i>]pyridin-2-yl]cyclopropanecarboxamide (<b>42</b>)</h3><div class="NLM_p">The intermediate <i>tert</i>-butyl [3-({2-[(cyclopropylcarbonyl)amino][1,3]thiazolo[5,4-<i>b</i>]pyridin-5-yl}oxy)phenyl]carbamate (1.02 g) was prepared in a similar manner to <b>5</b> from <i>tert</i>-butyl {3-[(2-amino[1,3]thiazolo[5,4-<i>b</i>]pyridin-5-yl)oxy]phenyl}carbamate <b>41</b> (1.00 g, 2.79 mmol), using cyclopropanecarbonyl chloride (327 μL, 3.63 mmol) and pyridine (30 mL). Yield 86%, pale yellow crystals; mp 199 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 0.86–1.03 (m, 4H), 1.45 (s, 9H), 1.92–2.05 (m, 1H), 6.68–6.79 (m, 1H), 7.08 (d, <i>J</i> = 8.7 Hz, 1H), 7.20–7.38 (m, 3H), 8.15 (d, <i>J</i> = 8.7 Hz, 1H), 9.48 (br s, 1H), 12.66 (br s, 1H).</div><div class="NLM_p last">A solution of <i>tert</i>-butyl [3-({2-[(cyclopropylcarbonyl)amino][1,3]thiazolo[5,4-<i>b</i>]pyridin-5-yl}oxy)phenyl]carbamate (900 mg, 2.11 mmol) and anisole (1 mL) in trifluoroacetic acid (10 mL) was stirred at 0 °C for 1 h. The reaction mixture was concentrated under reduced pressure, and to the residue was added saturated aqueous NaHCO<sub>3</sub> (50 mL), and the mixture was extracted with tetrahydrofuran/ethyl acetate (1:1, 50 mL and then 15 mL). The combined organic layers were washed with brine (5 mL) and dried over anhydrous Na<sub>2</sub>SO<sub>4</sub>. The insoluble material was filtered off, and the filtrate was concentrated under reduced pressure. The residue was recrystallized from tetrahydrofuran/ethyl acetate to give compound <b>42</b> (542 mg, 79%) as pale yellow crystals, mp 261–263 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 0.87–1.03 (m, 4H), 1.92–2.05 (m, 1H), 5.25 (br s, 2H), 6.23 (ddd, <i>J</i> = 0.8, 2.4, 7.9 Hz, 1H), 6.28 (t, <i>J</i> = 2.4 Hz, 1H), 6.40 (ddd, <i>J</i> = 0.8, 2.4, 7.9 Hz, 1H), 6.97–7.08 (m, 2H), 8.11 (d, <i>J</i> = 8.7 Hz, 1H), 12.67 (br s, 1H). MS (ESI): <i>m</i>/<i>z</i> 327.1 (M + H)<sup>+</sup>. Anal. Calcd for C<sub>16</sub>H<sub>14</sub>N<sub>4</sub>O<sub>2</sub>S·0.1H<sub>2</sub>O: C, 58.56; H, 4.36; N, 17.07. Found: C, 58.55; H, 4.40; N, 17.03.</div></div><div id="sec4_62" class="NLM_sec NLM_sec_level_2"><div id="ac_i89" class="anchor-spacer"></div><h3 class="article-section__title" id="_i89"> 2-Chloro-3-(1-cyanocyclopropyl)-<i>N</i>-(2-fluoro-5-hydroxyphenyl)benzamide (<b>43</b>)</h3><div class="NLM_p last">Compound <b>43</b> (23.4 g) was prepared in a similar manner to <b>1i</b> from 2-chloro-3-(1-cyanocyclopropyl)benzoic acid <b>15q</b> (16.0 g, 72.2 mmol), using oxalyl chloride (7.2 mL, 84.0 mmol), <i>N</i>,<i>N</i>-dimethylformamide (0.1 mL), tetrahydrofuran (150 mL), 3-amino-4-fluorophenol (9.00 g, 70.8 mmol), NaHCO<sub>3</sub> (13.9 g, 166 mmol), water (100 mL), and tetrahydrofuran (50 mL). Yield 100%, brown crystals; mp 188–189 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 1.40–1.49 (m, 2H), 1.76–1.85 (m, 2H), 6.52–6.63 (m, 1H), 7.07 (dd, <i>J</i> = 9.0, 10.5 Hz, 1H), 7.39 (dd, <i>J</i> = 2.9, 6.5 Hz, 1H), 7.47 (d, <i>J</i> = 7.6 Hz, 1H), 7.53–7.60 (m, 1H), 7.64 (dd, <i>J</i> = 1.7, 7.6 Hz, 1H), 9.48 (s, 1H), 10.30 (s, 1H). MS (ESI): <i>m</i>/<i>z</i> 331.1 (M + H)<sup>+</sup>. Anal. Calcd for C<sub>17</sub>H<sub>12</sub>ClFN<sub>2</sub>O<sub>2</sub>: C, 61.73; H, 3.66; N, 8.47. Found: C, 61.68; H, 3.93; N, 8.15.</div></div><div id="sec4_63" class="NLM_sec NLM_sec_level_2"><div id="ac_i90" class="anchor-spacer"></div><h3 class="article-section__title" id="_i90"> <i>N</i>-{5-[(5-Aminopyridine-2-yl)oxy]-2-fluorophenyl}-2-chloro-3-(1-cyanocyclopropyl)benzamide (<b>44</b>)</h3><div class="NLM_p">A mixture of <b>43</b> (23.0 g, 69.6 mmol), 2-chloro-5-nitropyridine <b>39</b> (12.2 g, 77.1 mmol), and potassium carbonate (11.5 g, 83.1 mmol) in <i>N</i>,<i>N</i>-dimethylformamide (70 mL) was stirred at room temperature for 4 h. The mixture was diluted with <i>N</i>,<i>N</i>-dimethylformamide (130 mL). Water (250 mL) was added to the mixture. The mixture was stirred at room temperature for 1 h. The resulting precipitate was collected by filtration and washed with water (250 mL) to give 2-chloro-3-(1-cyanocycropropyl)-<i>N</i>-{2-fluoro-5-[(5-nitropyridin-2-yl)oxy]phenyl}benzamide (29.3 g, 93%) as gray crystals, mp 201–202 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 1.38–1.51 (m, 2H), 1.74–1.86 (m, 2H), 7.08–7.19 (m, 1H), 7.32 (d, <i>J</i> = 9.1 Hz, 1H), 7.42 (dd, <i>J</i> = 9.0, 10.3 Hz, 1H), 7.47 (t, <i>J</i> = 7.6 Hz, 1H), 7.56–7.62 (m, 1H), 7.65 (dd, <i>J</i> = 1.7, 7.6 Hz, 1H), 7.85 (dd, <i>J</i> = 2.8, 6.4 Hz, 1H), 8.65 (dd, <i>J</i> = 2.6, 9.1 Hz, 1H), 9.06 (d, <i>J</i> = 2.6 Hz, 1H), 10.62 (s, 1H). MS (ESI): <i>m</i>/<i>z</i> 453.1 (M + H)<sup>+</sup>. Anal. Calcd for C<sub>22</sub>H<sub>14</sub>ClFN<sub>4</sub>O<sub>4</sub>: C, 58.35; H, 3.12; N, 12.37. Found: C, 58.34; H, 3.32; N, 12.57.</div><div class="NLM_p last">A mixture of 2-chloro-3-(1-cyanocycropropyl)-<i>N</i>-{2-fluoro-5-[(5-nitropyridin-2-yl)oxy]phenyl}benzamide (6.60 g, 14.6 mmol), reduced iron (1.68 g, 30.0 mmol), calcium chloride (3.33 g, 30.0 mmol), water (80 mL), and ethanol (20 mL) was stirred at 80 °C for 18 h. The reaction mixture was cooled at room temperature. To the mixture were added water (250 mL), 1 N NaOH (250 mL), ethyl acetate (300 mL), and Celite (33 g), successively, and the mixture was stirred for 15 min. The mixture was filtered through a pad of Celite. The insoluble was washed with ethyl acetate (100 mL). The filtrate and washings were combined, and the separated organic layer was dried over anhydrous MgSO<sub>4</sub>. The solvent was evaporated in vacuo. The resulting slurry was triturated with diethyl ether to give compound <b>44</b> (4.23 g, 69%) as pale yellow crystals, mp 186–187 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 1.35–1.42 (m, 2H), 1.80–1.85 (m, 2H), 3.45–3.57 (br s, 2H), 6.82 (d, <i>J</i> = 8.4 Hz, 1H), 6.82–6.88 (m, 1H), 7.02 (d, <i>J</i> = 8.4 Hz, 1H), 7.12 (dd, <i>J</i> = 7.5, 8.4 Hz, 1H), 7.38 (t, <i>J</i> = 7.8 Hz, 1H), 7.50 (dd, <i>J</i> = 1.5, 7.5 Hz, 1H), 7.66 (dd, <i>J</i> = 1.8, 7.8 Hz, 1H), 7.70 (d, <i>J</i> = 3.0 Hz, 1H), 7.97–8.03 (br s, 1H), 8.28 (dd, <i>J</i> = 3.0, 6.6 Hz, 1H). MS (ESI): <i>m</i>/<i>z</i> 423.1 (M + H)<sup>+</sup>. Anal. Calcd for C<sub>22</sub>H<sub>16</sub>ClFN<sub>4</sub>O<sub>2</sub>·0.25H<sub>2</sub>O: C, 61.83; H, 3.89; N, 13.11. Found: C, 61.94; H, 3.84; N, 12.83.</div></div><div id="sec4_64" class="NLM_sec NLM_sec_level_2"><div id="ac_i91" class="anchor-spacer"></div><h3 class="article-section__title" id="_i91"> <i>N</i>-{5-[(2-Amino[1,3]thiazolo[5,4-<i>b</i>]pyridin-5-yl)oxy]-2-fluorophenyl}-2-chloro-3-(1-cyanocyclopropyl)benzamide (<b>45</b>)</h3><div class="NLM_p last">The mixture of potassium thiocyanate (3.89 g, 40 mmol) in acetic acid (50 mL) was stirred at room temperature for 10 min. To the mixture was added <b>44</b> (4.23 g, 10 mmol), and the mixture was stirred at room temperature for an additional 5 min. To the mixture was added a solution of bromine (2.40 g, 15 mmol) in acetic acid (50 mL) at 15 °C. The resulting mixture was stirred at room temperature for 6 h. The resulting yellow precipitate was removed by filtration through a pad of Celite and washed with acetic acid (50 mL). The filtrate and washings were combined and concentrated under reduced pressure. The residue was diluted with 0.1 N NaOH (100 mL), and the mixture was extracted with ethyl acetate (100 mL). The organic layer was dried over anhydrous MgSO<sub>4</sub>. The solvent was evaporated in vacuo. The residue was purified with silica gel column chromatography (0–100% ethyl acetate in <i>n-</i>hexane). Desired fractions were combined and evaporated in vacuo. And the resulting slurry was triturated with diethyl ether to give the compound <b>45</b> (3.32 g, 69%) as pale yellow crystals, mp 215–216 °C. <sup>1</sup>H NMR (300 MHz, DMSO-<i>d</i><sub>6</sub>): δ 1.41–1.49 (m, 2H), 1.75–1.85 (m, 2H), 6.95 (d, <i>J</i> = 8.5 Hz, 1H), 6.97–7.03 (m, 1H), 7.33 (dd, <i>J</i> = 9.3, 10.2 Hz, 1H), 7.46 (t, <i>J</i> = 7.6 Hz, 1H), 7.56–7.67 (m, 4H), 7.69 (dd, <i>J</i> = 2.9, 6.5 Hz, 1H), 7.73 (d, <i>J</i> = 8.5 Hz, 1H), 10.53 (s, 1H). HRMS (ESI): calcd for C<sub>23</sub>H<sub>15</sub>ClFN<sub>5</sub>O<sub>2</sub>S [M + H]<sup>+</sup> 480.0692. Found: 480.0692.</div></div><div id="sec4_65" class="NLM_sec NLM_sec_level_2"><div id="ac_i92" class="anchor-spacer"></div><h3 class="article-section__title" id="_i92"> 2-Chloro-5-[(5-nitropyridin-2-yl)oxy]aniline (<b>46</b>)</h3><div class="NLM_p last">To a solution of 2-chloro-5-nitropyridine <b>39</b> (4.76 g, 30 mmol) and 3-amino-4-chlorophenol (4.31 g, 30 mmol) in <i>N</i>,<i>N</i>-dimethylformamide (15 mL) was added potassium carbonate (4.15 g, 30 mmol), and the reaction mixture was stirred at room temperature for 16 h. To the reaction mixture was added ethyl acetate (80 mL), and the mixture was washed successively with water (50 mL) and saturated brine (50 mL). The organic layer was dried over anhydrous MgSO<sub>4</sub> and concentrated under reduced pressure. The residual solid was recrystallized from ethyl acetate/<i>n-</i>hexane (1:1) (30 mL), and the crystals were collected by filtration, washed with <i>i</i>-Pr<sub>2</sub>O (20 mL), and dried under vacuum to give compound <b>46</b> (6.74 g, 85%) as brown crystals, mp 123–124 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 4.19 (br s, 2H), 6.48 (dd, <i>J</i> = 2.7, 8.6 Hz, 1H), 6.58 (d, <i>J</i> = 2.7 Hz, 1H), 7.01 (d, <i>J</i> = 9.0 Hz, 1H), 7.29 (d, <i>J</i> = 8.6 Hz, 1H), 8.47 (dd, <i>J</i> = 2.7, 9.0 Hz, 1H), 9.05 (d, <i>J</i> = 2.7 Hz, 1H). MS (ESI): <i>m</i>/<i>z</i> 266.0 (M + H)<sup>+</sup>. Anal. Calcd for C<sub>11</sub>H<sub>8</sub>ClN<sub>3</sub>O<sub>3</sub>: C, 49.73; H, 3.04; N, 15.82. Found: C, 49.73; H, 3.13; N, 15.64.</div></div><div id="sec4_66" class="NLM_sec NLM_sec_level_2"><div id="ac_i93" class="anchor-spacer"></div><h3 class="article-section__title" id="_i93"> <i>N</i>-{5-[(5-Aminopyridin-2-yl)oxy]-2-chlorophenyl}-2,2,2-trifluoroacetamide (<b>47</b>)</h3><div class="NLM_p last">A solution of <b>46</b> (6.5 g, 24.5 mmol) in tetrahydrofuran (50 mL) and trifluoroacetic anhydride (3.73 mL, 26.9 mmol) was stirred at room temperature for 1 h. The reaction mixture was concentrated under reduced pressure, and the residue was dissolved in ethyl acetate (80 mL). The solution was washed with saturated NaHCO<sub>3</sub>(50 mL). The organic layer was dried over anhydrous MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residual solid was collected by filtration using <i>i</i>-Pr<sub>2</sub>O (30 mL) and dried under vacuum to give <i>N</i>-{2-chloro-5-[(5-nitropyridin-2-yl)oxy]phenyl}-2,2,2-trifluoroacetamide (7.73 g, 87%) as white crystals, mp 117–118 °C. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 6.95–7.19 (m, 2H), 7.52 (dd, <i>J</i> = 1.5, 9.0 Hz, 1H), 8.20–8.30 (m, 1H), 8.40–8.60 (m, 2H), 9.00–9.10 (m, 1H). MS (ESI): <i>m</i>/<i>z</i> 362.0 (M + H)<sup>+</sup>. Anal. Calcd for C<sub>13</sub>H<sub>7</sub>ClF<sub>3</sub>N<sub>3</sub>O<sub>4</sub>: C, 43.17; H, 1.95; N, 11.62. Found: C, 43.17; H, 2.06; N, 11.54. To a solution of <i>N</i>-{2-chloro-5-[(5-nitropyridin-2-yl)oxy]phenyl}-2,2,2-trifluoroacetamide (13 g, 35.9 mmol) in acetic acid (200 mL) was added reduced iron (10 g, 179 mmol). The mixture was stirred at 60 °C for 3 h. After cooling at room temperature, the reaction mixture was concentrated under reduced pressure. The concentrate was diluted with ethyl acetate (150 mL), and to the mixture was slowly added saturated NaHCO<sub>3</sub> (200 mL). The mixture was filtered through Celite. The organic layer of the filtrate was collected and dried over anhydrous MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residual oil was dissolved in toluene, and the solution was purified by silica gel column chromatography (20–80% ethyl acetate in <i>n-</i>hexane) to give compound <b>47</b> (10.9 g, 91%) as a brown oil. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 3.57 (br s, 2H), 6.83 (d, <i>J</i> = 8.7 Hz, 1H), 6.93 (dd, <i>J</i> = 2.8, 8.7 Hz, 1H), 7.11 (dd, <i>J</i> = 2.8, 8.7 Hz, 1H), 7.39 (d, <i>J</i> = 8.7 Hz, 1H), 7.69 (d, <i>J</i> = 3.0 Hz, 1H), 8.11 (d, <i>J</i> = 3.0 Hz, 1H), 8.41 (br s, 1H). MS (ESI): <i>m</i>/<i>z</i> 332.0 (M + H)<sup>+</sup>.</div></div><div id="sec4_67" class="NLM_sec NLM_sec_level_2"><div id="ac_i94" class="anchor-spacer"></div><h3 class="article-section__title" id="_i94"> <i>N</i>-(5-{4-Chloro-3-[(trifluoroacetyl)amino]phenoxy}[1,3]thiazolo[5,4-<i>b</i>]pyridin-2-yl)cyclopropanecarboxamide (<b>48</b>)</h3><div class="NLM_p">To a mixture of <b>47</b> (12 g, 36.2 mmol) and potassium thiocyanate (14.1 g, 145 mmol) in acetic acid (145 mL) was added dropwise bromine (8.67 g, 54.3 mmol) under ice-cooling. The reaction mixture was stirred at room temperature for 16 h. The reaction mixture was filtered through Celite, and the filtrate was concentrated under reduced pressure. The residual oil was dissolved in ethyl acetate (100 mL), and to the mixture was slowly added saturated NaHCO<sub>3</sub> (150 mL), and the mixture was partitioned. The organic layer was dried over anhydrous MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residual solid was collected by filtration using <i>i</i>-Pr<sub>2</sub>O (100 mL) and dried under vacuum to give <i>N</i>-{5-[(2-amino[1,3]thiazolo[5,4-<i>b</i>]pyridin-5-yl)oxy]-2-chlorophenyl}-2,2,2-trifluoroacetamide (10.1 g, 72%) as pale yellow crystals, mp 164–165 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 6.98 (d, <i>J</i> = 8.5 Hz, 1H), 7.16 (dd, <i>J</i> = 2.8, 8.8 Hz, 1H), 7.27 (d, <i>J</i> = 2.8 Hz, 1H), 7.61 (d, <i>J</i> = 8.8 Hz, 1H), 7.66 (br s, 1H), 7.75 (d, <i>J</i> = 8.5 Hz, 1H), 11.30 (br s, 1H). MS (ESI): <i>m</i>/<i>z</i> 389.0 (M + H)<sup>+</sup>. Anal. Calcd for C<sub>14</sub>H<sub>8</sub>ClF<sub>3</sub>N<sub>4</sub>O<sub>2</sub>S: C, 43.25; H, 2.07; N, 14.41. Found: C, 43.01; H, 2.17; N, 14.28.</div><div class="NLM_p last">To a solution of <i>N</i>-{5-[(2-amino[1,3]thiazolo[5,4-<i>b</i>]pyridin-5-yl)oxy]-2-chlorophenyl}-2,2,2-trifluoroacetamide (5.0 g, 12.86 mmol) in pyridine (25 mL) was added dropwise cyclopropanecarbonyl chloride (1.28 mL, 14.2 mmol) under ice-cooling, and the reaction mixture was stirred at room temperature for 1 h. The reaction mixture was treated with saturated NaHCO<sub>3</sub> (100 mL) and diluted with ethyl acetate (100 mL), and the organic layer was collected. The organic layer was dried over anhydrous MgSO<sub>4</sub>, filtered, and concentrated under reduced pressure. The residual solid was crystallized from ethyl acetate (30 mL), collected by filtration, and dried under vacuum to give compound <b>48</b> (3.46 g, 59%) as white crystals, mp 235–236 °C. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 300 MHz): δ 0.86–1.07 (m, 4H), 1.90–2.10 (m, 1H), 7.20 (d, <i>J</i> = 8.7 Hz, 1H), 7.26 (dd, <i>J</i> = 2.7, 8.9 Hz, 1H), 7.38 (d, <i>J</i> = 2.7 Hz, 1H), 7.66 (d, <i>J</i> = 8.9 Hz, 1H), 8.20 (d, <i>J</i> = 8.7 Hz, 1H), 11.34 (br s, 1H), 12.72 (br s, 1H). MS (ESI): <i>m</i>/<i>z</i> 457.0 (M + H)<sup>+</sup>.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i95"><a href="/doi/suppl/10.1021/jm300126x">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27338" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27338" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Information methods used in kinase enzyme assays, cellular assays, in vivo studies, computational studies, structural biology studies, solubility study, microsomal study, and pharmacokinetic studies. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm300126x/suppl_file/jm300126x_si_001.pdf">jm300126x_si_001.pdf (224.67 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm300126x" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_65246" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_65246" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Masanori Okaniwa</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi
2-Chome, Fujisawa, Kanagawa 251-8555, Japan</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#274a4654464948554e09484c46494e50466753464c4243460944484a0753484a485e465452094e544f4e4c4650466753464c4243460944484a"><span class="__cf_email__" data-cfemail="15787466747b7a677c3b7a7e747b7c62745561747e7071743b767a78">[email protected]</span> <span class="__cf_email__" data-cfemail="8efae1e3e1f7effdfba0e7fde6e7e5eff9efcefaefe5ebeaefa0ede1e3">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tomoyasu Ishikawa</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi
2-Chome, Fujisawa, Kanagawa 251-8555, Japan</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#335e5240525d5c415a1d5c58525d5a4452734752585657521d505c5e13475c5e5c4a5240461d5a405b5a58524452734752585657521d505c5e"><span class="__cf_email__" data-cfemail="a0cdc1d3c1cecfd2c98ecfcbc1cec9d7c1e0d4c1cbc5c4c18ec3cfcd">[email protected]</span> <span class="__cf_email__" data-cfemail="d5a1bab8baacb4a6a0fbbca6bdbcbeb4a2b495a1b4beb0b1b4fbb6bab8">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Masaaki Hirose</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi
2-Chome, Fujisawa, Kanagawa 251-8555, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Takashi Imada</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi
2-Chome, Fujisawa, Kanagawa 251-8555, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tomohiro Ohashi</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi
2-Chome, Fujisawa, Kanagawa 251-8555, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Youko Hayashi</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi
2-Chome, Fujisawa, Kanagawa 251-8555, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tohru Miyazaki</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi
2-Chome, Fujisawa, Kanagawa 251-8555, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Takeo Arita</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi
2-Chome, Fujisawa, Kanagawa 251-8555, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Masato Yabuki</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi
2-Chome, Fujisawa, Kanagawa 251-8555, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kazuyo Kakoi</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi
2-Chome, Fujisawa, Kanagawa 251-8555, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Juran Kato</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi
2-Chome, Fujisawa, Kanagawa 251-8555, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Terufumi Takagi</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi
2-Chome, Fujisawa, Kanagawa 251-8555, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tomohiro Kawamoto</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi
2-Chome, Fujisawa, Kanagawa 251-8555, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shuhei Yao</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi
2-Chome, Fujisawa, Kanagawa 251-8555, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Akihiko Sumita</span> - <span class="hlFld-Affiliation affiliation">CMC Center, Takeda Pharmaceutical Company
Limited, 17-85, Jusohonmachi 2-Chome, Yodogawa-ku, Osaka
532-8686, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shunichirou Tsutsumi</span> - <span class="hlFld-Affiliation affiliation">CMC Center, Takeda Pharmaceutical Company
Limited, 17-85, Jusohonmachi 2-Chome, Yodogawa-ku, Osaka
532-8686, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tsuneaki Tottori</span> - <span class="hlFld-Affiliation affiliation">CMC Center, Takeda Pharmaceutical Company
Limited, 17-85, Jusohonmachi 2-Chome, Yodogawa-ku, Osaka
532-8686, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Hideyuki Oki</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi
2-Chome, Fujisawa, Kanagawa 251-8555, Japan</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bi-Ching Sang</span> - <span class="hlFld-Affiliation affiliation">Structural
Biology, Takeda California, Inc., 10410
Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jason Yano</span> - <span class="hlFld-Affiliation affiliation">Structural
Biology, Takeda California, Inc., 10410
Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Kathleen Aertgeerts</span> - <span class="hlFld-Affiliation affiliation">Structural
Biology, Takeda California, Inc., 10410
Science Center Drive, San Diego, California 92121, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sei Yoshida</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi
2-Chome, Fujisawa, Kanagawa 251-8555, Japan</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d5024e8656-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i96">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_53241" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_53241" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The authors thank Naoki Tomita, Osamu Kurasawa, and Yuta Tanaka for their support in the synthesis reactions. The authors also thank Kouji Mori, Noriko Uchiyama, Hiroshi Miki, Taeko Yoshida, and Hidehisa Iwata for their assistance in evaluating the kinase inhibitory activities, and Akira Hori and Yuichi Kakoi for their assistance in evaluating the cellular VEGFR2 inhibitory activities. The authors are grateful to Garret Textor, Matt Kroeger, and Gyorgy Snell from Takeda San Diego for their assistance in determining the crystal structure of BRAF with <b>6d</b>. The authors acknowledge the Advanced Photon Source, an Office of Science User Facility operated for the U.S. Department of Energy (DOE) Office of Science by Argonne National Laboratory, supported by the U.S. DOE under Contract DE-AC02-06CH11357. Finally, the authors express their gratitude to Yukiko Watanabe for her assistance in PK evaluation.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i97" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i97"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i98" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i98"> Abbreviations Used</h2><tr><td class="NLM_term"><sup>1</sup>H NMR</td><td class="NLM_def"><p class="first last">proton nuclear magnetic resonance</p></td></tr><tr><td class="NLM_term">AUC</td><td class="NLM_def"><p class="first last">area under the blood concentration time curve</p></td></tr><tr><td class="NLM_term">CL<sub>total</sub></td><td class="NLM_def"><p class="first last">clearance</p></td></tr><tr><td class="NLM_term">ERK</td><td class="NLM_def"><p class="first last">extracellular signal-regulated kinase</p></td></tr><tr><td class="NLM_term">FDA</td><td class="NLM_def"><p class="first last">Food and Drug Administration</p></td></tr><tr><td class="NLM_term">FGFR</td><td class="NLM_def"><p class="first last">fibroblast growth factor receptor</p></td></tr><tr><td class="NLM_term">HPLC</td><td class="NLM_def"><p class="first last">high-performance liquid chromatography</p></td></tr><tr><td class="NLM_term">HUVEC</td><td class="NLM_def"><p class="first last">human umbilical vein endothelial cell</p></td></tr><tr><td class="NLM_term">MAPK</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase</p></td></tr><tr><td class="NLM_term">MEK</td><td class="NLM_def"><p class="first last">mitogen-activated protein kinase</p></td></tr><tr><td class="NLM_term">MS</td><td class="NLM_def"><p class="first last">mass spectrometry</p></td></tr><tr><td class="NLM_term">PD</td><td class="NLM_def"><p class="first last">pharmacodynamic</p></td></tr><tr><td class="NLM_term">PDB</td><td class="NLM_def"><p class="first last">Protein Data Bank</p></td></tr><tr><td class="NLM_term">PDGFR</td><td class="NLM_def"><p class="first last">platelet-derived growth factor receptor</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetic</p></td></tr><tr><td class="NLM_term">RTK</td><td class="NLM_def"><p class="first last">receptor tyrosine kinase</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">SD</td><td class="NLM_def"><p class="first last">solid dispersion</p></td></tr><tr><td class="NLM_term">SD</td><td class="NLM_def"><p class="first last">standard deviation</p></td></tr><tr><td class="NLM_term">VD<sub>ss</sub></td><td class="NLM_def"><p class="first last">steady state volume of distribution</p></td></tr><tr><td class="NLM_term">VEGF</td><td class="NLM_def"><p class="first last">vascular endothelial growth factor</p></td></tr><tr><td class="NLM_term">VEGFR2</td><td class="NLM_def"><p class="first last">vascular endothelial growth factor receptor 2</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i99">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_82301" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_82301" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 38 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Kolch, W.</span><span> </span><span class="NLM_article-title">Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">351</span><span class="NLM_x">, </span> <span class="NLM_fpage">289</span><span class="NLM_x">–</span> <span class="NLM_lpage">305</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=351&publication_year=2000&pages=289-305&author=W.+Kolch&title=Meaningful+relationships%3A+the+regulation+of+the+Ras%2FRaf%2FMEK%2FERK+pathway+by+protein+interactions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKolch%26aufirst%3DW.%26atitle%3DMeaningful%2520relationships%253A%2520the%2520regulation%2520of%2520the%2520Ras%252FRaf%252FMEK%252FERK%2520pathway%2520by%2520protein%2520interactions%26jtitle%3DBiochem.%2520J.%26date%3D2000%26volume%3D351%26spage%3D289%26epage%3D305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit1b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Peyssonnaux, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eychène, A.</span><span> </span><span class="NLM_article-title">The Raf/MEK/ERK pathway: new concepts of activation</span> <span class="citation_source-journal">Biol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">53</span><span class="NLM_x">–</span> <span class="NLM_lpage">62</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=16&amp;doi=10.1021%2Fjm300126x&amp;key=10.1016%2FS0248-4900%2801%2901125-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=8&amp;doi=10.1021%2Fjm300126x&amp;key=11730323" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=32&amp;doi=10.1021%2Fjm300126x&amp;key=1%3ACAS%3A528%3ADC%252BD3MXptVOju7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2001&pages=53-62&author=C.+Peyssonnauxauthor=A.+Eych%C3%A8ne&title=The+Raf%2FMEK%2FERK+pathway%3A+new+concepts+of+activation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1bR"><div class="casContent"><span class="casTitleNuber">1b</span><div class="casTitle"><span class="NLM_cas:atitle">The Raf/MEK/ERK pathway: New concepts of activation</span></div><div class="casAuthors">Peyssonnaux, Carole; Eychene, Alain</div><div class="citationInfo"><span class="NLM_cas:title">Biology of the Cell</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">1/2</span>),
    <span class="NLM_cas:pages">53-62</span>CODEN:
                <span class="NLM_cas:coden">BCELDF</span>;
        ISSN:<span class="NLM_cas:issn">0248-4900</span>.
    
            (<span class="NLM_cas:orgname">Editions Scientifiques et Medicales Elsevier</span>)
        </div><div class="casAbstract">A review.  The Raf/MEK/ERK signaling was the first MAP kinase cascade to be characterized.  It is probably one of the most well known signal transduction pathways among biologists because of its implication in a wide variety of cellular functions as diverse -and occasionally contradictory- as cell proliferation, cell-cycle arrest, terminal differentiation and apoptosis.  Discovery and understanding of this pathway have benefited from the combination of both genetic studies in worms and flies and biochem. studies in mammalian cells.  However, ten years after, this field is still under debate and new mol. partners in the cascade continue to increase the complexity of its regulation.  This review deals with the emergence of new concepts in the activation and regulation of the Raf/MEK/ERK module.  In particular, the preponderant role of B-Raf is underlined, and the role of novel regulators such as KSR is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyjiXSFlBQ6rVg90H21EOLACvtfcHk0li8YCLPjnlgEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXptVOju7s%253D&md5=cde3db5b205a1305dc2e6262deea65ec</span></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.1016%2FS0248-4900%2801%2901125-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0248-4900%252801%252901125-X%26sid%3Dliteratum%253Aachs%26aulast%3DPeyssonnaux%26aufirst%3DC.%26aulast%3DEych%25C3%25A8ne%26aufirst%3DA.%26atitle%3DThe%2520Raf%252FMEK%252FERK%2520pathway%253A%2520new%2520concepts%2520of%2520activation%26jtitle%3DBiol.%2520Cell%26date%3D2001%26volume%3D93%26spage%3D53%26epage%3D62" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit1c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">McKay, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrison, D. K.</span><span> </span><span class="NLM_article-title">Integrating signals from RTKs to ERK/MAPK</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">3113</span><span class="NLM_x">–</span> <span class="NLM_lpage">3121</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=3113-3121&author=M.+M.+McKayauthor=D.+K.+Morrison&title=Integrating+signals+from+RTKs+to+ERK%2FMAPK"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMcKay%26aufirst%3DM.%2BM.%26aulast%3DMorrison%26aufirst%3DD.%2BK.%26atitle%3DIntegrating%2520signals%2520from%2520RTKs%2520to%2520ERK%252FMAPK%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26spage%3D3113%26epage%3D3121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Roberts, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Der, C. J.</span><span> </span><span class="NLM_article-title">Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">3291</span><span class="NLM_x">–</span> <span class="NLM_lpage">3310</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm300126x&amp;key=10.1038%2Fsj.onc.1210422" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm300126x&amp;key=17496923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm300126x&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlt1Wktb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=3291-3310&author=P.+J.+Robertsauthor=C.+J.+Der&title=Targeting+the+Raf-MEK-ERK+mitogen-activated+protein+kinase+cascade+for+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer</span></div><div class="casAuthors">Roberts, P. J.; Der, C. J.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">3291-3310</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Mitogen-activated protein kinase (MAPK) cascades are key signaling pathways involved in the regulation of normal cell proliferation, survival and differentiation.  Aberrant regulation of MAPK cascades contribute to cancer and other human diseases.  In particular, the extracellular signal-regulated kinase (ERK) MAPK pathway has been the subject of intense research scrutiny leading to the development of pharmacol. inhibitors for the treatment of cancer.  ERK is a downstream component of an evolutionarily conserved signaling module that is activated by the Raf serine/threonine kinases.  Raf activates the MAPK/ERK kinase (MEK)1/2 dual-specificity protein kinases, which then activate ERK1/2.  The mutational activation of Raf in human cancers supports the important role of this pathway in human oncogenesis.  Addnl., the Raf-MEK-ERK pathway is a key downstream effector of the Ras small GTPase, the most frequently mutated oncogene in human cancers.  Finally, Ras is a key downstream effector of the epidermal growth factor receptor (EGFR), which is mutationally activated and/or overexpressed in a wide variety of human cancers.  ERK activation also promotes upregulated expression of EGFR ligands, promoting an autocrine growth loop crit. for tumor growth.  Thus, the EGFR-Ras-Raf-MEK-ERK signaling network has been the subject of intense research and pharmaceutical scrutiny to identify novel target-based approaches for cancer treatment.  In this review, we summarize the current status of the different approaches and targets that are under evaluation and development for the therapeutic intervention of this key signaling pathway in human disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7hdVDVyRBHrVg90H21EOLACvtfcHk0li8YCLPjnlgEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlt1Wktb4%253D&md5=bf56109e3b4defc12004471da30178c0</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1210422&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1210422%26sid%3Dliteratum%253Aachs%26aulast%3DRoberts%26aufirst%3DP.%2BJ.%26aulast%3DDer%26aufirst%3DC.%2BJ.%26atitle%3DTargeting%2520the%2520Raf-MEK-ERK%2520mitogen-activated%2520protein%2520kinase%2520cascade%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26spage%3D3291%26epage%3D3310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Downward, J.</span><span> </span><span class="NLM_article-title">Targeting RAS signalling pathways in cancer therapy</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">11</span><span class="NLM_x">–</span> <span class="NLM_lpage">22</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm300126x&amp;key=10.1038%2Fnrc969" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm300126x&amp;key=12509763" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm300126x&amp;key=1%3ACAS%3A528%3ADC%252BD38XpvVertbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=11-22&author=J.+Downward&title=Targeting+RAS+signalling+pathways+in+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting RAS signalling pathways in cancer therapy</span></div><div class="casAuthors">Downward, Julian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-22</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The RAS proteins control signaling pathways that are key regulators of several aspects of normal cell growth and malignant transformation.  They are aberrant in most human tumors due to activating mutations in the RAS genes themselves or to alterations in upstream or downstream signaling components.  Rational therapies that target the RAS pathways might inhibit tumor growth, survival and spread.  Several of these new therapeutic agents are showing promise in the clinic and many more are being developed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwKF9JX2sXtbVg90H21EOLACvtfcHk0li8YCLPjnlgEA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XpvVertbo%253D&md5=85ea9312480c3ca01f2a94faae7b84e7</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrc969&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc969%26sid%3Dliteratum%253Aachs%26aulast%3DDownward%26aufirst%3DJ.%26atitle%3DTargeting%2520RAS%2520signalling%2520pathways%2520in%2520cancer%2520therapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2003%26volume%3D3%26spage%3D11%26epage%3D22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Garnett, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marais, R.</span><span> </span><span class="NLM_article-title">Guilty as charged: B-RAF is a human oncogene</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">313</span><span class="NLM_x">–</span> <span class="NLM_lpage">319</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2004&pages=313-319&author=M.+J.+Garnettauthor=R.+Marais&title=Guilty+as+charged%3A+B-RAF+is+a+human+oncogene"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGarnett%26aufirst%3DM.%2BJ.%26aulast%3DMarais%26aufirst%3DR.%26atitle%3DGuilty%2520as%2520charged%253A%2520B-RAF%2520is%2520a%2520human%2520oncogene%26jtitle%3DCancer%2520Cell%26date%3D2004%26volume%3D6%26spage%3D313%26epage%3D319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit4b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Mercer, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pritchard, C. A.</span><span> </span><span class="NLM_article-title">Raf proteins and cancer: B-Raf is identified as a mutational target</span> <span class="citation_source-journal">Biochim. Biophys. Acta</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">1653</span><span class="NLM_x">, </span> <span class="NLM_fpage">25</span><span class="NLM_x">–</span> <span class="NLM_lpage">40</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1653&publication_year=2003&pages=25-40&author=K.+E.+Mercerauthor=C.+A.+Pritchard&title=Raf+proteins+and+cancer%3A+B-Raf+is+identified+as+a+mutational+target"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMercer%26aufirst%3DK.%2BE.%26aulast%3DPritchard%26aufirst%3DC.%2BA.%26atitle%3DRaf%2520proteins%2520and%2520cancer%253A%2520B-Raf%2520is%2520identified%2520as%2520a%2520mutational%2520target%26jtitle%3DBiochim.%2520Biophys.%2520Acta%26date%3D2003%26volume%3D1653%26spage%3D25%26epage%3D40" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Davies, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bignell, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephens, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edkins, S</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clegg, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teague, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woffendin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garnett, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bottomley, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dicks, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ewing, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawes, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kosmidou, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menzies, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mould, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hooper, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayatilake, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gusterson, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shipley, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hargrave, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pritchard-Jones, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maitland, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chenevix-Trench, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riggins, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bigner, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmieri, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cossu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flanagan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, J. W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuen, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seigler, H. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Darrow, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paterson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marais, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wooster, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stratton, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Futreal, P. A.</span><span> </span><span class="NLM_article-title">Mutations of the <i>BRAF</i> gene in human cancer</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">417</span><span class="NLM_x">, </span> <span class="NLM_fpage">949</span><span class="NLM_x">–</span> <span class="NLM_lpage">954</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm300126x&amp;key=10.1038%2Fnature00766" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm300126x&amp;key=12068308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm300126x&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvVagsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=417&publication_year=2002&pages=949-954&author=H.+Daviesauthor=G.+R.+Bignellauthor=C.+Coxauthor=P.+Stephensauthor=S+Edkinsauthor=S.+Cleggauthor=J.+Teagueauthor=H.+Woffendinauthor=M.+J.+Garnettauthor=W.+Bottomleyauthor=N.+Davisauthor=E.+Dicksauthor=R.+Ewingauthor=Y.+Floydauthor=K.+Grayauthor=S.+Hallauthor=R.+Hawesauthor=J.+Hughesauthor=V.+Kosmidouauthor=A.+Menziesauthor=C.+Mouldauthor=A.+Parkerauthor=C.+Stevensauthor=S.+Wattauthor=S.+Hooperauthor=R.+Wilsonauthor=H.+Jayatilakeauthor=B.+A.+Gustersonauthor=C.+Cooperauthor=J.+Shipleyauthor=D.+Hargraveauthor=K.+Pritchard-Jonesauthor=N.+Maitlandauthor=G.+Chenevix-Trenchauthor=G.+J.+Rigginsauthor=D.+D.+Bignerauthor=G.+Palmieriauthor=A.+Cossuauthor=A.+Flanaganauthor=A.+Nicholsonauthor=J.+W.+C.+Hoauthor=S.+Y.+Leungauthor=S.+T.+Yuenauthor=B.+L.+Weberauthor=H.+F.+Seiglerauthor=T.+L.+Darrowauthor=H.+Patersonauthor=R.+Maraisauthor=C.+J.+Marshallauthor=R.+Woosterauthor=M.+R.+Strattonauthor=P.+A.+Futreal&title=Mutations+of+the+BRAF+gene+in+human+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Mutations of the BRAF gene in human cancer</span></div><div class="casAuthors">Davies, Helen; Bignell, Graham R.; Cox, Charles; Stephens, Philip; Edkins, Sarah; Clegg, Sheila; Teague, Jon; Woffendin, Hayley; Garnett, Mathew J.; Bottomley, William; Davis, Neil; Dicks, Ed; Ewing, Rebecca; Floyd, Yvonne; Gray, Kristian; Hall, Sarah; Hawes, Rachel; Hughes, Jaime; Kosmidou, Vivian; Menzies, Andrew; Mould, Catherine; Parker, Adrian; Stevens, Claire; Watt, Stephen; Hooper, Steven; Wilson, Rebecca; Jayatilake, Hiran; Gusterson, Barry A.; Cooper, Colin; Shipley, Janet; Hargrave, Darren; Pritchard-Jones, Katherine; Maitland, Norman; Chenevix-Trench, Georgia; Riggins, Gregory J.; Bigner, Darell D.; Palmieri, Giuseppe; Cossu, Antonio; Flanagan, Adrienne; Nicholson, Andrew; Ho, Judy W. C.; Leung, Suet Y.; Yuen, Siu T.; Weber, Barbara L.; Seigler, Hilliard F.; Darrow, Timothy L.; Paterson, Hugh; Marais, Richard; Marshall, Christopher J.; Wooster, Richard; Stratton, Michael R.; Futreal, P. Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">417</span>
        (<span class="NLM_cas:issue">6892</span>),
    <span class="NLM_cas:pages">949-954</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cancers arise owing to the accumulation of mutations in crit. genes that alter normal programs of cell proliferation, differentiation and death.  As the first stage of a systematic genome-wide screen for these genes, we have prioritized for anal. signalling pathways in which at least one gene is mutated in human cancer.  The RAS-RAF-MEK-ERK-MAP kinase pathway mediates cellular responses to growth signals.  RAS is mutated to an oncogenic form in about 15% of human cancer.  The three RAF genes code for cytoplasmic serine/threonine kinases that are regulated by binding RAS.  Here we report BRAF somatic missense mutations in 66% of malignant melanomas and at lower frequency in a wide range of human cancers.  All mutations are within the kinase domain, with a single substitution (V599E) accounting for 80%.  Mutated BRAF proteins have elevated kinase activity and are transforming in NIH3T3 cells.  Furthermore, RAS function is not required for the growth of cancer cell lines with the V599E mutation.  As BRAF is a serine/threonine kinase that is commonly activated by somatic point mutation in human cancer, it may provide new therapeutic opportunities in malignant melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPBmhJC0GAjrVg90H21EOLACvtfcHk0lijiavJuXv9pw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvVagsLo%253D&md5=4625be53ad9a382d51b6ee753d0c17e8</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnature00766&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature00766%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DH.%26aulast%3DBignell%26aufirst%3DG.%2BR.%26aulast%3DCox%26aufirst%3DC.%26aulast%3DStephens%26aufirst%3DP.%26aulast%3DEdkins%26aufirst%3DS%26aulast%3DClegg%26aufirst%3DS.%26aulast%3DTeague%26aufirst%3DJ.%26aulast%3DWoffendin%26aufirst%3DH.%26aulast%3DGarnett%26aufirst%3DM.%2BJ.%26aulast%3DBottomley%26aufirst%3DW.%26aulast%3DDavis%26aufirst%3DN.%26aulast%3DDicks%26aufirst%3DE.%26aulast%3DEwing%26aufirst%3DR.%26aulast%3DFloyd%26aufirst%3DY.%26aulast%3DGray%26aufirst%3DK.%26aulast%3DHall%26aufirst%3DS.%26aulast%3DHawes%26aufirst%3DR.%26aulast%3DHughes%26aufirst%3DJ.%26aulast%3DKosmidou%26aufirst%3DV.%26aulast%3DMenzies%26aufirst%3DA.%26aulast%3DMould%26aufirst%3DC.%26aulast%3DParker%26aufirst%3DA.%26aulast%3DStevens%26aufirst%3DC.%26aulast%3DWatt%26aufirst%3DS.%26aulast%3DHooper%26aufirst%3DS.%26aulast%3DWilson%26aufirst%3DR.%26aulast%3DJayatilake%26aufirst%3DH.%26aulast%3DGusterson%26aufirst%3DB.%2BA.%26aulast%3DCooper%26aufirst%3DC.%26aulast%3DShipley%26aufirst%3DJ.%26aulast%3DHargrave%26aufirst%3DD.%26aulast%3DPritchard-Jones%26aufirst%3DK.%26aulast%3DMaitland%26aufirst%3DN.%26aulast%3DChenevix-Trench%26aufirst%3DG.%26aulast%3DRiggins%26aufirst%3DG.%2BJ.%26aulast%3DBigner%26aufirst%3DD.%2BD.%26aulast%3DPalmieri%26aufirst%3DG.%26aulast%3DCossu%26aufirst%3DA.%26aulast%3DFlanagan%26aufirst%3DA.%26aulast%3DNicholson%26aufirst%3DA.%26aulast%3DHo%26aufirst%3DJ.%2BW.%2BC.%26aulast%3DLeung%26aufirst%3DS.%2BY.%26aulast%3DYuen%26aufirst%3DS.%2BT.%26aulast%3DWeber%26aufirst%3DB.%2BL.%26aulast%3DSeigler%26aufirst%3DH.%2BF.%26aulast%3DDarrow%26aufirst%3DT.%2BL.%26aulast%3DPaterson%26aufirst%3DH.%26aulast%3DMarais%26aufirst%3DR.%26aulast%3DMarshall%26aufirst%3DC.%2BJ.%26aulast%3DWooster%26aufirst%3DR.%26aulast%3DStratton%26aufirst%3DM.%2BR.%26aulast%3DFutreal%26aufirst%3DP.%2BA.%26atitle%3DMutations%2520of%2520the%2520BRAF%2520gene%2520in%2520human%2520cancer%26jtitle%3DNature%26date%3D2002%26volume%3D417%26spage%3D949%26epage%3D954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Tuveson, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herlyn, M.</span><span> </span><span class="NLM_article-title">BRAF as a potential therapeutic target in melanoma and other malignancies</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">95</span><span class="NLM_x">–</span> <span class="NLM_lpage">98</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2003&pages=95-98&author=D.+A.+Tuvesonauthor=B.+L.+Weberauthor=M.+Herlyn&title=BRAF+as+a+potential+therapeutic+target+in+melanoma+and+other+malignancies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTuveson%26aufirst%3DD.%2BA.%26aulast%3DWeber%26aufirst%3DB.%2BL.%26aulast%3DHerlyn%26aufirst%3DM.%26atitle%3DBRAF%2520as%2520a%2520potential%2520therapeutic%2520target%2520in%2520melanoma%2520and%2520other%2520malignancies%26jtitle%3DCancer%2520Cell%26date%3D2003%26volume%3D4%26spage%3D95%26epage%3D98" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Beeram, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patnaik, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowinsky, E. K.</span><span> </span><span class="NLM_article-title">Raf: a strategic target for therapeutic development against cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">6771</span><span class="NLM_x">–</span> <span class="NLM_lpage">6790</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Fjm300126x&amp;key=10.1200%2FJCO.2005.08.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=8&amp;doi=10.1021%2Fjm300126x&amp;key=16170185" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=32&amp;doi=10.1021%2Fjm300126x&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFWqsb7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=6771-6790&author=M.+Beeramauthor=A.+Patnaikauthor=E.+K.+Rowinsky&title=Raf%3A+a+strategic+target+for+therapeutic+development+against+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7aR"><div class="casContent"><span class="casTitleNuber">7a</span><div class="casTitle"><span class="NLM_cas:atitle">Raf: a strategic target for therapeutic development against cancer</span></div><div class="casAuthors">Beeram, Muralidhar; Patnaik, Amita; Rowinsky, Eric K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">6771-6790</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  The mitogen-activated protein kinase (MARK) signaling pathway plays a crit. role in transmitting proliferative signals generated by cell surface receptors and cytoplasmic signaling elements to the nucleus.  Several important signaling elements of the MARK pathway, particularly Ras and Raf, are encoded by oncogenes, and as such, their structures and functions can be modified, rendering them constitutively active.  Because the MARK pathway is dysregulated in a notable proportion of human malignancies, many of its aberrant and crit. components represent strategic targets for therapeutic development against cancer.  Raf, which is an essential serine/threonine kinase constituent of the MARK pathway and a downstream effector of the central signal transduction mediator Ras, is activated in a wide range of human malignancies by aberrant signaling upstream of the protein (eg, growth factor receptors and mutant Ras) and activating mutations of the protein itself, both of which confer a proliferative advantage.  Three isoforms of Raf have been identified, and therapeutics targeting Raf, including small-mol. inhibitors and antisense oligodeoxyribonucleotides (ASON), are undergoing clin. evaluation.  The outcomes of these investigations may have far-reaching implications in the management of many types of human cancer.  This review outlines the structure and diverse functions of Raf, the rationale for targeting Raf as a therapeutic strategy against cancer, and the present status of various therapeutic approaches including ASONs and small mols., particularly sorafenib (BAY 43-9006).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeXfxCgXq8wbVg90H21EOLACvtfcHk0lgMgx_Mw0VjZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFWqsb7P&md5=8e75a4ac97b6adfe9e1aecf82f3c1825</span></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.1200%2FJCO.2005.08.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2005.08.036%26sid%3Dliteratum%253Aachs%26aulast%3DBeeram%26aufirst%3DM.%26aulast%3DPatnaik%26aufirst%3DA.%26aulast%3DRowinsky%26aufirst%3DE.%2BK.%26atitle%3DRaf%253A%2520a%2520strategic%2520target%2520for%2520therapeutic%2520development%2520against%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2005%26volume%3D23%26spage%3D6771%26epage%3D6790" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit7b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Frasca, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nucera, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellegriti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gangemi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Attard, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stella, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vella, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giordano, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trimarchi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazzon, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belfiore, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vigneri, R.</span><span> </span><span class="NLM_article-title"><i>BRAF</i><sup><i>(V600E)</i></sup> mutation and the biology of papillary thyroid cancer</span> <span class="citation_source-journal">Endocr.-Relat. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">191</span><span class="NLM_x">–</span> <span class="NLM_lpage">205</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2008&pages=191-205&author=F.+Frascaauthor=C.+Nuceraauthor=G.+Pellegritiauthor=P.+Gangemiauthor=M.+Attardauthor=M.+Stellaauthor=M.+Lodaauthor=V.+Vellaauthor=C.+Giordanoauthor=F.+Trimarchiauthor=E.+Mazzonauthor=A.+Belfioreauthor=R.+Vigneri&title=BRAF%28V600E%29+mutation+and+the+biology+of+papillary+thyroid+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFrasca%26aufirst%3DF.%26aulast%3DNucera%26aufirst%3DC.%26aulast%3DPellegriti%26aufirst%3DG.%26aulast%3DGangemi%26aufirst%3DP.%26aulast%3DAttard%26aufirst%3DM.%26aulast%3DStella%26aufirst%3DM.%26aulast%3DLoda%26aufirst%3DM.%26aulast%3DVella%26aufirst%3DV.%26aulast%3DGiordano%26aufirst%3DC.%26aulast%3DTrimarchi%26aufirst%3DF.%26aulast%3DMazzon%26aufirst%3DE.%26aulast%3DBelfiore%26aufirst%3DA.%26aulast%3DVigneri%26aufirst%3DR.%26atitle%3DBRAF%2528V600E%2529%2520mutation%2520and%2520the%2520biology%2520of%2520papillary%2520thyroid%2520cancer%26jtitle%3DEndocr.-Relat.%2520Cancer%26date%3D2008%26volume%3D15%26spage%3D191%26epage%3D205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit7c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Samowitz, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sweeney., C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrick, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albertsen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levin, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murtaugh, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolff, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slattery, M. L.</span><span> </span><span class="NLM_article-title">Poor survival associated with the <i>BRAF</i> V600E mutation in microsatellite-stable colon cancers</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">6063</span><span class="NLM_x">–</span> <span class="NLM_lpage">6070</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=6063-6070&author=W.+S.+Samowitzauthor=C.+Sweeney.author=J.+Herrickauthor=H.+Albertsenauthor=T.+R.+Levinauthor=M.+A.+Murtaughauthor=R.+K.+Wolffauthor=M.+L.+Slattery&title=Poor+survival+associated+with+the+BRAF+V600E+mutation+in+microsatellite-stable+colon+cancers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSamowitz%26aufirst%3DW.%2BS.%26aulast%3DSweeney.%26aufirst%3DC.%26aulast%3DHerrick%26aufirst%3DJ.%26aulast%3DAlbertsen%26aufirst%3DH.%26aulast%3DLevin%26aufirst%3DT.%2BR.%26aulast%3DMurtaugh%26aufirst%3DM.%2BA.%26aulast%3DWolff%26aufirst%3DR.%2BK.%26aulast%3DSlattery%26aufirst%3DM.%2BL.%26atitle%3DPoor%2520survival%2520associated%2520with%2520the%2520BRAF%2520V600E%2520mutation%2520in%2520microsatellite-stable%2520colon%2520cancers%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D6063%26epage%3D6070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Montagut, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span> </span><span class="NLM_article-title">Targeting the RAF-MEK-ERK pathway in cancer therapy</span> <span class="citation_source-journal">Cancer Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">283</span><span class="NLM_x">, </span> <span class="NLM_fpage">125</span><span class="NLM_x">–</span> <span class="NLM_lpage">134</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=16&amp;doi=10.1021%2Fjm300126x&amp;key=10.1016%2Fj.canlet.2009.01.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=8&amp;doi=10.1021%2Fjm300126x&amp;key=19217204" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=32&amp;doi=10.1021%2Fjm300126x&amp;key=1%3ACAS%3A528%3ADC%252BD1MXptlantbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2009&pages=125-134&author=C.+Montagutauthor=J.+Settleman&title=Targeting+the+RAF-MEK-ERK+pathway+in+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8aR"><div class="casContent"><span class="casTitleNuber">8a</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the RAF-MEK-ERK pathway in cancer therapy</span></div><div class="casAuthors">Montagut, Clara; Settleman, Jeff</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (Shannon, Ireland)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">125-134</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">A review.  The clin. success of selective kinase inhibitors, such as imatinib and erlotinib, as therapeutic agents for several human cancers has prompted substantial interest in the further development and clin. testing of such inhibitors for a wide variety of malignancies.  While much of this effort was focused on the receptor tyrosine kinases, including EGFR, HER2, PDGF receptor, c-KIT, and MET, inhibitors of serine/threonine kinases are also beginning to emerge within discovery pipelines.  Among these kinases, the RAF and MEK kinases have received substantial attention, owing largely to the relatively high frequency of activating mutations of RAS (∼20% of all human cancers), an upstream activator of the well established RAF-MEK-ERK signaling cascade, as well as frequent activating mutations in the BRAF kinase (∼7% of all human cancers).  Here, we summarize the current state of development of kinase inhibitors directed at this signaling pathway, a few of which have already demonstrating favorable toxicity profiles as well as promising activity in early phase clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbTpfm5XYkBbVg90H21EOLACvtfcHk0lgMgx_Mw0VjZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXptlantbc%253D&md5=9c5139834b5e347079c212bb312b0b25</span></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2009.01.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2009.01.022%26sid%3Dliteratum%253Aachs%26aulast%3DMontagut%26aufirst%3DC.%26aulast%3DSettleman%26aufirst%3DJ.%26atitle%3DTargeting%2520the%2520RAF-MEK-ERK%2520pathway%2520in%2520cancer%2520therapy%26jtitle%3DCancer%2520Lett.%26date%3D2009%26volume%3D283%26spage%3D125%26epage%3D134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit8b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Chapman, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hauschild, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haanen, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ascierto, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larkin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dummer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garbe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Testori, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hogg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorigan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebbe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jouary, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schadendorf, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Day, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirkwood, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eggermont, A. M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dreno, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolop, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McArthur, G. A.</span><span> </span><span class="NLM_article-title">For the BRIM-3 study group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">364</span><span class="NLM_x">, </span> <span class="NLM_fpage">2507</span><span class="NLM_x">–</span> <span class="NLM_lpage">2516</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=16&amp;doi=10.1021%2Fjm300126x&amp;key=10.1056%2FNEJMoa1103782" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=8&amp;doi=10.1021%2Fjm300126x&amp;key=21639808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=32&amp;doi=10.1021%2Fjm300126x&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosVeitbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2011&pages=2507-2516&author=P.+B.+Chapmanauthor=A.+Hauschildauthor=C.+Robertauthor=J.+B.+Haanenauthor=P.+Asciertoauthor=J.+Larkinauthor=R.+Dummerauthor=C.+Garbeauthor=A.+Testoriauthor=M.+Maioauthor=D.+Hoggauthor=P.+Loriganauthor=C.+Lebbeauthor=T.+Jouaryauthor=D.+Schadendorfauthor=A.+Ribasauthor=S.+J.+O%E2%80%99Dayauthor=J.+A.+Sosmanauthor=J.+M.+Kirkwoodauthor=A.+M.+M.+Eggermontauthor=B.+Drenoauthor=K.+Nolopauthor=J.+Liauthor=B.+Nelsonauthor=J.+Houauthor=R.+J.+Leeauthor=K.+T.+Flahertyauthor=G.+A.+McArthur&title=For+the+BRIM-3+study+group.+Improved+survival+with+vemurafenib+in+melanoma+with+BRAF+V600E+mutation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8bR"><div class="casContent"><span class="casTitleNuber">8b</span><div class="casTitle"><span class="NLM_cas:atitle">Improved survival with vemurafenib in melanoma with BRAF V600E mutation</span></div><div class="casAuthors">Chapman, Paul B.; Hauschild, Axel; Robert, Caroline; Haanen, John B.; Ascierto, Paolo; Larkin, James; Dummer, Reinhard; Garbe, Claus; Testori, Alessandro; Maio, Michele; Hogg, David; Lorigan, Paul; Lebbe, Celeste; Jouary, Thomas; Schadendorf, Dirk; Ribas, Antoni; O'Day, Steven J.; Sosman, Jeffrey A.; Kirkwood, John M.; Eggermont, Alexander M. M.; Dreno, Brigitte; Nolop, Keith; Li, Jiang; Nelson, Betty; Hou, Jeannie; Lee, Richard J.; Flaherty, Keith T.; McArthur, Grant A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">2507-2516</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Phase 1 and 2 clin. trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more than 50% in patients with metastatic melanoma with the BRAF V600E mutation.  METHODS: We conducted a phase 3 randomized clin. trial comparing vemurafenib with dacarbazine in 675 patients with previously untreated, metastatic melanoma with the BRAF V600E mutation.  Patients were randomly assigned to receive either vemurafenib (960 mg orally twice daily) or dacarbazine (1000 mg per square meter of body-surface area i.v. every 3 wk).  Coprimary end points were rates of overall and progression-free survival.  Secondary end points included the response rate, response duration, and safety.  A final anal. was planned after 196 deaths and an interim anal. after 98 deaths.  RESULTS: At 6 mo, overall survival was 840/ (95% confidence interval [CI], 78 to 89) in the vemurafenib group and 64% (95% CI, 56 to 73) in the dacarbazine group.  In the interim anal. for overall survival and final anal. for progression-free survival, vemurafenib was assocd. with a relative redn. of 63% in the risk of death and of 74% in the risk of either death or disease progression, as compared with dacarbazine (P < 0.001 for both comparisons).  After review of the interim anal. by an independent data and safety monitoring board, crossover from dacarbazine to vemurafenib was recommended.  Response rates were 48% for vemurafenib and 5% for dacarbazine.  Common adverse events assocd. with vemurafenib were arthralgia, rash, fatigue, alopecia, keratoacanthoma or squamous-cell carcinoma, photosensitivity, nausea, and diarrhea; 38% of patients required dose modification because of toxic effects.  CONCLUSIONS: Vemurafenib produced improved rates of overall and progression-free survival in patients with previously untreated melanoma with the BRAF V600E mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4NFxmTaDz97Vg90H21EOLACvtfcHk0lgMgx_Mw0VjZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosVeitbs%253D&md5=1a4b4f963221888dc63f620e87408070</span></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1103782&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1103782%26sid%3Dliteratum%253Aachs%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DHauschild%26aufirst%3DA.%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DHaanen%26aufirst%3DJ.%2BB.%26aulast%3DAscierto%26aufirst%3DP.%26aulast%3DLarkin%26aufirst%3DJ.%26aulast%3DDummer%26aufirst%3DR.%26aulast%3DGarbe%26aufirst%3DC.%26aulast%3DTestori%26aufirst%3DA.%26aulast%3DMaio%26aufirst%3DM.%26aulast%3DHogg%26aufirst%3DD.%26aulast%3DLorigan%26aufirst%3DP.%26aulast%3DLebbe%26aufirst%3DC.%26aulast%3DJouary%26aufirst%3DT.%26aulast%3DSchadendorf%26aufirst%3DD.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Day%26aufirst%3DS.%2BJ.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DKirkwood%26aufirst%3DJ.%2BM.%26aulast%3DEggermont%26aufirst%3DA.%2BM.%2BM.%26aulast%3DDreno%26aufirst%3DB.%26aulast%3DNolop%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DNelson%26aufirst%3DB.%26aulast%3DHou%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26atitle%3DFor%2520the%2520BRIM-3%2520study%2520group.%2520Improved%2520survival%2520with%2520vemurafenib%2520in%2520melanoma%2520with%2520BRAF%2520V600E%2520mutation%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D364%26spage%3D2507%26epage%3D2516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Folkman, J.</span><span> </span><span class="NLM_article-title">Angiogenesis: an organizing principle for drug discovery?</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">273</span><span class="NLM_x">–</span> <span class="NLM_lpage">286</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=273-286&author=J.+Folkman&title=Angiogenesis%3A+an+organizing+principle+for+drug+discovery%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFolkman%26aufirst%3DJ.%26atitle%3DAngiogenesis%253A%2520an%2520organizing%2520principle%2520for%2520drug%2520discovery%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D273%26epage%3D286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Holmes, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, O. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cross, M. J.</span><span> </span><span class="NLM_article-title">Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition</span> <span class="citation_source-journal">Cell. Signalling</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">2003</span><span class="NLM_x">–</span> <span class="NLM_lpage">2012</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm300126x&amp;key=10.1016%2Fj.cellsig.2007.05.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm300126x&amp;key=17658244" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm300126x&amp;key=1%3ACAS%3A528%3ADC%252BD2sXovFylsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2007&pages=2003-2012&author=K.+Holmesauthor=O.+L.+Robertsauthor=A.+M.+Thomasauthor=M.+J.+Cross&title=Vascular+endothelial+growth+factor+receptor-2%3A+structure%2C+function%2C+intracellular+signalling+and+therapeutic+inhibition"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition</span></div><div class="casAuthors">Holmes, Katherine; Roberts, Owain Ll; Thomas, Angharad M.; Cross, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Signalling</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2003-2012</span>CODEN:
                <span class="NLM_cas:coden">CESIEY</span>;
        ISSN:<span class="NLM_cas:issn">0898-6568</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Vascular endothelial growth factors (VEGFs) regulate vascular development, angiogenesis and lymphangiogenesis by binding to a no. of receptors.  VEGFR-1 is required for the recruitment of hematopoietic stem cells and the migration of monocytes and macrophages, VEGFR-2 regulates vascular endothelial function and VEGFR-3 regulates lymphatic endothelial cell function.  Over the last decade, considerable progress has been made in delineating the VEGFR-2 specific intracellular signaling cascades leading to proliferation, migration, survival and increased permeability, each of which contributes to the angiogenic response.  Furthermore, therapeutic inhibition of VEGFR-2 action is now having an impact in the clinic for the treatment of a no. of diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTYxPMokVV57Vg90H21EOLACvtfcHk0lh15u0gxjTFcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXovFylsLs%253D&md5=44a935f36d29b000d2a9ff514709e9c2</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.cellsig.2007.05.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cellsig.2007.05.013%26sid%3Dliteratum%253Aachs%26aulast%3DHolmes%26aufirst%3DK.%26aulast%3DRoberts%26aufirst%3DO.%2BL.%26aulast%3DThomas%26aufirst%3DA.%2BM.%26aulast%3DCross%26aufirst%3DM.%2BJ.%26atitle%3DVascular%2520endothelial%2520growth%2520factor%2520receptor-2%253A%2520structure%252C%2520function%252C%2520intracellular%2520signalling%2520and%2520therapeutic%2520inhibition%26jtitle%3DCell.%2520Signalling%26date%3D2007%26volume%3D19%26spage%3D2003%26epage%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Ferrara, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hillan, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerber, H.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Novotny, W.</span><span> </span><span class="NLM_article-title">Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">391</span><span class="NLM_x">–</span> <span class="NLM_lpage">400</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm300126x&amp;key=10.1038%2Fnrd1381" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm300126x&amp;key=15136787" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm300126x&amp;key=1%3ACAS%3A528%3ADC%252BD2cXktlCrt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=391-400&author=N.+Ferraraauthor=K.+J.+Hillanauthor=H.-P.+Gerberauthor=W.+Novotny&title=Discovery+and+development+of+bevacizumab%2C+an+anti-VEGF+antibody+for+treating+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer</span></div><div class="casAuthors">Ferrara, Napoleone; Hillan, Kenneth J.; Gerber, Hans-Peter; Novotny, William</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">391-400</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The existence of factors that stimulate blood vessel growth, thereby recruiting a neovascular supply to nourish a growing tumor, was postulated many decades ago, although the identification and isolation of these factors proved elusive.  Now, vascular endothelial growth factor (VEGF), which was identified in the 1980s, is recognized as an essential regulator of normal and abnormal blood vessel growth.  In 1993, it was shown that a monoclonal antibody that targeted VEGF results in a dramatic suppression of tumor growth in vivo, which led to the development of bevacizumab (Avastin; Genentech), a humanized variant of this anti-VEGF antibody, as an anticancer agent.  The recent approval of bevacizumab by the US FDA as a first-line therapy for metastatic colorectal cancer validates the ideas that VEGF is a key mediator of tumor angiogenesis and that blocking angiogenesis is an effective strategy to treat human cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphaLbfhdBKOLVg90H21EOLACvtfcHk0lh15u0gxjTFcw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXktlCrt78%253D&md5=4b1f647db4dfe2a24449cdf59b874e7c</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fnrd1381&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1381%26sid%3Dliteratum%253Aachs%26aulast%3DFerrara%26aufirst%3DN.%26aulast%3DHillan%26aufirst%3DK.%2BJ.%26aulast%3DGerber%26aufirst%3DH.-P.%26aulast%3DNovotny%26aufirst%3DW.%26atitle%3DDiscovery%2520and%2520development%2520of%2520bevacizumab%252C%2520an%2520anti-VEGF%2520antibody%2520for%2520treating%2520cancer%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26spage%3D391%26epage%3D400" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Faivre, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delbaldo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vera, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lozahic, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lassau, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bello, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deprimo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brega, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Massimini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armand, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scigalla, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raymond, E.</span><span> </span><span class="NLM_article-title">Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">25</span><span class="NLM_x">–</span> <span class="NLM_lpage">35</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=16&amp;doi=10.1021%2Fjm300126x&amp;key=10.1200%2FJCO.2005.02.2194" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=8&amp;doi=10.1021%2Fjm300126x&amp;key=16314617" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=32&amp;doi=10.1021%2Fjm300126x&amp;key=1%3ACAS%3A528%3ADC%252BD28Xot1ChtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=25-35&author=S.+Faivreauthor=C.+Delbaldoauthor=K.+Veraauthor=C.+Robertauthor=S.+Lozahicauthor=N.+Lassauauthor=C.+Belloauthor=S.+Deprimoauthor=N.+Bregaauthor=G.+Massiminiauthor=J.-P.+Armandauthor=P.+Scigallaauthor=E.+Raymond&title=Safety%2C+pharmacokinetic%2C+and+antitumor+activity+of+SU11248%2C+a+novel+oral+multitarget+tyrosine+kinase+inhibitor%2C+in+patients+with+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12aR"><div class="casContent"><span class="casTitleNuber">12a</span><div class="casTitle"><span class="NLM_cas:atitle">Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer</span></div><div class="casAuthors">Faivre, Sandrine; Delbaldo, Catherine; Vera, Karina; Robert, Caroline; Lozahic, Stephanie; Lassau, Nathalie; Bello, Carlo; Deprimo, Samuel; Brega, Nicoletta; Massimini, Giorgio; Armand, Jean-Pierre; Scigalla, Paul; Raymond, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25-35</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose To establish the safety, pharmacokinetics, and recommended dose of sunitinib, a novel oral multitargeting tyrosine kinase inhibitor with antiangiogenic and antitumor properties, in patients with advanced malignancies.  Patients and Methods Sunitinib was given orally for 4 wk every 6 wk.  Results Twenty-eight patients received doses ranging from 15 to 59 mg/m2 (ranging from 50 mg every other day to 150 mg/d).  Dose-limiting toxicities reported at the max.-tolerated doses ≥ 75 mg/d were reversible grade 3 fatigue, grade 3 hypertension, and grade 2 bullous skin toxicity.  Therefore, the recommended dose was 50 mg/d.  At this dose, the main adverse effects were sore mouth, edema, and thrombocytopenia.  Hair discoloration and yellow coloration of the skin were obsd. at doses ≥ 50 mg/d.  Pharmacokinetic data indicate that potentially active target plasma concns. ≥ 50 ng/mL can be achieved with moderate interpatient variability and a long half-life compatible with a single daily dosing.  Six objective responses were obsd. in three renal cell carcinomas, one neuroendocrine tumor, one stromal tumor, and one unknown primary adenocarcinoma patient.  At higher doses (≥ 75 mg/d), tumor responses were often assocd. with reduced intratumoral vascularization and central tumor necrosis, eventually resulting in organ perforation or fistula.  Conclusion At the dose of 50 mg/d (4 wk on, 2 wk off), sunitinib displays manageable toxicity.  Antitumor activity supports further studies in patients with renal cell carcinoma, gastrointestinal, neuroendocrine, and stromal tumors.  Future studies may consider including prospective imaging techniques such as high frequency ultrasound to monitor tumor d.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqleiABO1D2O7Vg90H21EOLACvtfcHk0lgOAf3FQ5qDpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xot1ChtQ%253D%253D&md5=e6c97fab9666b29992414f56a9c63151</span></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=10.1200%2FJCO.2005.02.2194&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2005.02.2194%26sid%3Dliteratum%253Aachs%26aulast%3DFaivre%26aufirst%3DS.%26aulast%3DDelbaldo%26aufirst%3DC.%26aulast%3DVera%26aufirst%3DK.%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DLozahic%26aufirst%3DS.%26aulast%3DLassau%26aufirst%3DN.%26aulast%3DBello%26aufirst%3DC.%26aulast%3DDeprimo%26aufirst%3DS.%26aulast%3DBrega%26aufirst%3DN.%26aulast%3DMassimini%26aufirst%3DG.%26aulast%3DArmand%26aufirst%3DJ.-P.%26aulast%3DScigalla%26aufirst%3DP.%26aulast%3DRaymond%26aufirst%3DE.%26atitle%3DSafety%252C%2520pharmacokinetic%252C%2520and%2520antitumor%2520activity%2520of%2520SU11248%252C%2520a%2520novel%2520oral%2520multitarget%2520tyrosine%2520kinase%2520inhibitor%252C%2520in%2520patients%2520with%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2006%26volume%3D24%26spage%3D25%26epage%3D35" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit12b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Motzer, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michaelson, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Redman, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudes, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilding, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Figlin, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ginsberg, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baum, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DePrimo, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bello, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Theuer, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">George, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rini, B. I.</span><span> </span><span class="NLM_article-title">Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">16</span><span class="NLM_x">–</span> <span class="NLM_lpage">24</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=16&amp;doi=10.1021%2Fjm300126x&amp;key=10.1200%2FJCO.2005.02.2574" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=8&amp;doi=10.1021%2Fjm300126x&amp;key=16330672" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=32&amp;doi=10.1021%2Fjm300126x&amp;key=1%3ACAS%3A528%3ADC%252BD28Xot1ChtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=16-24&author=R.+J.+Motzerauthor=M.+D.+Michaelsonauthor=B.+G.+Redmanauthor=G.+R.+Hudesauthor=G.+Wildingauthor=R.+A.+Figlinauthor=M.+S.+Ginsbergauthor=S.+T.+Kimauthor=C.+M.+Baumauthor=S.+E.+DePrimoauthor=J.+Z.+Liauthor=C.+L.+Belloauthor=C.+P.+Theuerauthor=D.+J.+Georgeauthor=B.+I.+Rini&title=Activity+of+SU11248%2C+a+multitargeted+inhibitor+of+vascular+endothelial+growth+factor+receptor+and+platelet-derived+growth+factor+receptor%2C+in+patients+with+metastatic+renal+cell+carcinoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12bR"><div class="casContent"><span class="casTitleNuber">12b</span><div class="casTitle"><span class="NLM_cas:atitle">Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma</span></div><div class="casAuthors">Motzer, Robert J.; Michaelson, M. Dror; Redman, Bruce G.; Hudes, Gary R.; Wilding, George; Figlin, Robert A.; Ginsberg, Michelle S.; Kim, Sindy T.; Baum, Charles M.; DePrimo, Samuel E.; Li, Jim Z.; Bello, Carlo L.; Theuer, Charles P.; George, Daniel J.; Rini, Brian I.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">16-24</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Renal cell carcinoma (RCC) is characterized by loss of von Hippel Lindau tumor suppressor gene activity, resulting in high expression of pro-angiogenic growth factors: vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF).  SU11248 (sunitinib malate), a small mol. inhibitor with high binding affinity for VEGF and PDGF receptors, was tested for clin. activity in patients with metastatic RCC.  Patients and Methods: Patients with metastatic RCC and progression on first-line cytokine therapy were enrolled onto a multicenter phase II trial.  SU11248 monotherapy was administered in repeated 6-wk cycles of daily oral therapy for 4 wk, followed by 2 wk off.  Overall response rate was the primary end point, and time to progression and safety were secondary end points.  Results: Twenty-five (40%) of 63 patients treated with SU11248 achieved partial responses; 17 addnl. patients (27%) demonstrated stable disease lasting ≥ 3 mo.  Median time to progression in the 63 patients was 8.7 mo.  Dosing was generally tolerated with manageable toxicities.  Conclusion: SU11248, a multitargeted receptor tyrosine kinase inhibitor of VEGF and PDGF receptors, demonstrates antitumor activity in metastatic RCC as second-line therapy, a setting where no effective systemic therapy is presently recognized.  The genetics of RCC and these promising clin. results support the hypothesis that VEGF and PDGF receptor-mediated signaling is an effective therapeutic target in RCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCep3NZbaojLVg90H21EOLACvtfcHk0lgOAf3FQ5qDpw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xot1ChtA%253D%253D&md5=f3304eba449f0ff4ac20ac0cf8a878c5</span></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=10.1200%2FJCO.2005.02.2574&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2005.02.2574%26sid%3Dliteratum%253Aachs%26aulast%3DMotzer%26aufirst%3DR.%2BJ.%26aulast%3DMichaelson%26aufirst%3DM.%2BD.%26aulast%3DRedman%26aufirst%3DB.%2BG.%26aulast%3DHudes%26aufirst%3DG.%2BR.%26aulast%3DWilding%26aufirst%3DG.%26aulast%3DFiglin%26aufirst%3DR.%2BA.%26aulast%3DGinsberg%26aufirst%3DM.%2BS.%26aulast%3DKim%26aufirst%3DS.%2BT.%26aulast%3DBaum%26aufirst%3DC.%2BM.%26aulast%3DDePrimo%26aufirst%3DS.%2BE.%26aulast%3DLi%26aufirst%3DJ.%2BZ.%26aulast%3DBello%26aufirst%3DC.%2BL.%26aulast%3DTheuer%26aufirst%3DC.%2BP.%26aulast%3DGeorge%26aufirst%3DD.%2BJ.%26aulast%3DRini%26aufirst%3DB.%2BI.%26atitle%3DActivity%2520of%2520SU11248%252C%2520a%2520multitargeted%2520inhibitor%2520of%2520vascular%2520endothelial%2520growth%2520factor%2520receptor%2520and%2520platelet-derived%2520growth%2520factor%2520receptor%252C%2520in%2520patients%2520with%2520metastatic%2520renal%2520cell%2520carcinoma%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2006%26volume%3D24%26spage%3D16%26epage%3D24" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit12c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Sun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shirazian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukuda, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, J.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nematalla, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sistla, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luu, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, C.</span><span> </span><span class="NLM_article-title">Discovery of 5-[5-fluoro-2-oxo-1,2-dihydroindol-(3<i>Z</i>)-ylidenemethyl]-2,4-dimethyl-1<i>H</i>-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">1116</span><span class="NLM_x">–</span> <span class="NLM_lpage">1119</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0204183" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=1116-1119&author=L.+Sunauthor=C.+Liangauthor=S.+Shirazianauthor=Y.+Zhouauthor=T.+Millerauthor=J.+Cuiauthor=J.+Y.+Fukudaauthor=J.-Y.+Chuauthor=A.+Nematallaauthor=X.+Wangauthor=H.+Chenauthor=A.+Sistlaauthor=T.+C.+Luuauthor=F.+Tangauthor=J.+Weiauthor=C.+Tang&title=Discovery+of+5-%5B5-fluoro-2-oxo-1%2C2-dihydroindol-%283Z%29-ylidenemethyl%5D-2%2C4-dimethyl-1H-pyrrole-3-carboxylic+acid+%282-diethylaminoethyl%29amide%2C+a+novel+tyrosine+kinase+inhibitor+targeting+vascular+endothelial+and+platelet-derived+growth+factor+receptor+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12c&amp;dbid=16384&amp;doi=10.1021%2Fjm0204183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0204183%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DL.%26aulast%3DLiang%26aufirst%3DC.%26aulast%3DShirazian%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DMiller%26aufirst%3DT.%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DFukuda%26aufirst%3DJ.%2BY.%26aulast%3DChu%26aufirst%3DJ.-Y.%26aulast%3DNematalla%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DSistla%26aufirst%3DA.%26aulast%3DLuu%26aufirst%3DT.%2BC.%26aulast%3DTang%26aufirst%3DF.%26aulast%3DWei%26aufirst%3DJ.%26aulast%3DTang%26aufirst%3DC.%26atitle%3DDiscovery%2520of%25205-%255B5-fluoro-2-oxo-1%252C2-dihydroindol-%25283Z%2529-ylidenemethyl%255D-2%252C4-dimethyl-1H-pyrrole-3-carboxylic%2520acid%2520%25282-diethylaminoethyl%2529amide%252C%2520a%2520novel%2520tyrosine%2520kinase%2520inhibitor%2520targeting%2520vascular%2520endothelial%2520and%2520platelet-derived%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D1116%26epage%3D1119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Hu-Lowe, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grazzini, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallin, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wickman, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amundson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rewolinski, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, E. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kania, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connor, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shalinsky, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, S. L.</span><span> </span><span class="NLM_article-title">Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">7272</span><span class="NLM_x">–</span> <span class="NLM_lpage">7283</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Fjm300126x&amp;key=10.1158%2F1078-0432.CCR-08-0652" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=8&amp;doi=10.1021%2Fjm300126x&amp;key=19010843" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=32&amp;doi=10.1021%2Fjm300126x&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlylur7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=7272-7283&author=D.+D.+Hu-Loweauthor=H.+Y.+Zouauthor=M.+L.+Grazziniauthor=M.+E.+Hallinauthor=G.+R.+Wickmanauthor=K.+Amundsonauthor=J.+H.+Chenauthor=D.+A.+Rewolinskiauthor=S.+Yamazakiauthor=E.+Y.+Wuauthor=M.+A.+McTigueauthor=B.+W.+Murrayauthor=R.+S.+Kaniaauthor=P.+O%E2%80%99Connorauthor=D.+R.+Shalinskyauthor=S.+L.+Bender&title=Nonclinical+antiangiogenesis+and+antitumor+activities+of+axitinib+%28AG-013736%29%2C+an+oral%2C+potent%2C+and+selective+inhibitor+of+vascular+endothelial+growth+factor+receptor+tyrosine+kinases+1%2C+2%2C+3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13aR"><div class="casContent"><span class="casTitleNuber">13a</span><div class="casTitle"><span class="NLM_cas:atitle">Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3</span></div><div class="casAuthors">Hu-Lowe, Dana D.; Zou, Helen Y.; Grazzini, Maren L.; Hallin, Max E.; Wickman, Grant R.; Amundson, Karin; Chen, Jeffrey H.; Rewolinski, David A.; Yamazaki, Shinji; Wu, Ellen Y.; McTigue, Michele A.; Murray, Brion W.; Kania, Robert S.; O'Connor, Patrick; Shalinsky, David R.; Bender, Steve L.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">7272-7283</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Axitinib (AG-013736) is a potent and selective inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases 1 to 3 that is in clin. development for the treatment of solid tumors.  We provide a comprehensive description of its in vitro characteristics and activities, in vivo antiangiogenesis, and antitumor efficacy and translational pharmacol. data.  Exptl. Design: The potency, kinase selectivity, pharmacol. activity, and antitumor efficacy of axitinib were assessed in various nonclin. models.  RESULTS: Axitinib inhibits cellular autophosphorylation of VEGF receptors (VEGFR) with picomolar IC50 values.  Counterscreening across multiple kinase and protein panels shows it is selective for VEGFRs.  Axitinib blocks VEGF-mediated endothelial cell survival, tube formation, and downstream signaling through endothelial nitric oxide synthase, Akt and extracellular signal-regulated kinase.  Following twice daily oral administration, axitinib produces consistent and dose-dependent antitumor efficacy that is assocd. with blocking VEGFR-2 phosphorylation, vascular permeability, angiogenesis, and concomitant induction of tumor cell apoptosis.  Axitinib in combination with chemotherapeutic or targeted agents enhances antitumor efficacy in many tumor models compared with single agent alone.  Dose scheduling studies in a human pancreatic tumor xenograft model show that simultaneous administration of axitinib and gemcitabine without prolonged dose interruption or truncation of axitinib produces the greatest antitumor efficacy.  The efficacious drug concns. predicted in nonclin. studies are consistent with the range achieved in the clinic.  Although axitinib inhibits platelet-derived growth factor receptors and KIT with nanomolar in vitro potencies, based on pharmacokinetic/pharmacodynamic anal., axitinib acts primarily as a VEGFR tyrosine kinase inhibitor at the current clin. exposure.  CONCLUSIONS: The selectivity, potency for VEGFRs, and robust nonclin. activity may afford broad opportunities for axitinib to improve cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhwUJi2tefWrVg90H21EOLACvtfcHk0licQ6QdX6GRWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlylur7I&md5=6a616860756379e85551afe6b9eb750e</span></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-0652&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-0652%26sid%3Dliteratum%253Aachs%26aulast%3DHu-Lowe%26aufirst%3DD.%2BD.%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DGrazzini%26aufirst%3DM.%2BL.%26aulast%3DHallin%26aufirst%3DM.%2BE.%26aulast%3DWickman%26aufirst%3DG.%2BR.%26aulast%3DAmundson%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DJ.%2BH.%26aulast%3DRewolinski%26aufirst%3DD.%2BA.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DE.%2BY.%26aulast%3DMcTigue%26aufirst%3DM.%2BA.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DP.%26aulast%3DShalinsky%26aufirst%3DD.%2BR.%26aulast%3DBender%26aufirst%3DS.%2BL.%26atitle%3DNonclinical%2520antiangiogenesis%2520and%2520antitumor%2520activities%2520of%2520axitinib%2520%2528AG-013736%2529%252C%2520an%2520oral%252C%2520potent%252C%2520and%2520selective%2520inhibitor%2520of%2520vascular%2520endothelial%2520growth%2520factor%2520receptor%2520tyrosine%2520kinases%25201%252C%25202%252C%25203%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26spage%3D7272%26epage%3D7283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit13b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Rugo, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herbst, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kies, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinfeldt, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pithavala, Y. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reich, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freddo, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilding, G.</span><span> </span><span class="NLM_article-title">Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">5474</span><span class="NLM_x">–</span> <span class="NLM_lpage">5483</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=16&amp;doi=10.1021%2Fjm300126x&amp;key=10.1200%2FJCO.2005.04.192" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=8&amp;doi=10.1021%2Fjm300126x&amp;key=16027439" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=32&amp;doi=10.1021%2Fjm300126x&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVersr7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=5474-5483&author=H.+S.+Rugoauthor=R.+S.+Herbstauthor=G.+Liuauthor=J.+W.+Parkauthor=M.+S.+Kiesauthor=H.+M.+Steinfeldtauthor=Y.+K.+Pithavalaauthor=S.+D.+Reichauthor=J.+L.+Freddoauthor=G.+Wilding&title=Phase+I+trial+of+the+oral+antiangiogenesis+agent+AG-013736+in+patients+with+advanced+solid+tumors%3A+pharmacokinetic+and+clinical+results"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13bR"><div class="casContent"><span class="casTitleNuber">13b</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results</span></div><div class="casAuthors">Rugo, Hope S.; Herbst, Roy S.; Liu, Glenn; Park, John W.; Kies, Merrill S.; Steinfeldt, Heidi M.; Pithavala, Yazdi K.; Reich, Steven D.; Freddo, James L.; Wilding, George</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">5474-5483</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: We studied the safety, clin. activity, and pharmacokinetics (PK) of AG-013736, an oral receptor tyrosine kinase inhibitor of vascular endothelial cell growth factor, platelet-derived growth factor, and c-Kit, in patients with advanced cancer.  Patients and Methods: Patients received fixed doses of AG-013736 orally in 28-day cycles.  In the first cohort, patients initially received two single test doses of AG-013736 (10 and 30 mg); subsequent dosing was detd. by individual PK parameters.  Doses in subsequent cohorts were assigned by using a traditional dose-escalation/de-escalation rule based on obsd. toxicities in the current and previous cohorts.  PK anal. included evaluation of the effect of food and antacid.  Results: Thirty-six patients received AG-013736 at doses ranging from 5 to 30 mg by mouth twice daily.  The dose-limiting toxicities obsd. included hypertension, hemoptysis, and stomatitis and were seen primarily at the higher dose levels.  The obsd. hypertension was manageable with medication.  Stomatitis was generally tolerable and managed by dose redn. or drug holidays.  AG-013736 was absorbed rapidly, with peak plasma concns. obsd. within 2 to 6 h after dosing.  The max.-tolerated dose and recommended phase II dose of AG-013736 is 5 mg, twice daily, administered in the fasted state.  No significant drug interaction with antacid was seen.  There were three confirmed partial responses and other evidence of clin. activity.  Conclusion: In this study, we have demonstrated clin. activity and safety of AG-013736 in patients with advanced solid tumors and identified the dose for phase II testing.  The unique phase I study design allowed early identification of important absorption and metabolic issues crit. to phase II testing of this agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUWAS7w-z6TrVg90H21EOLACvtfcHk0licQ6QdX6GRWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVersr7F&md5=09347fe027d10507a3279aa66c2c12a2</span></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1200%2FJCO.2005.04.192&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2005.04.192%26sid%3Dliteratum%253Aachs%26aulast%3DRugo%26aufirst%3DH.%2BS.%26aulast%3DHerbst%26aufirst%3DR.%2BS.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DPark%26aufirst%3DJ.%2BW.%26aulast%3DKies%26aufirst%3DM.%2BS.%26aulast%3DSteinfeldt%26aufirst%3DH.%2BM.%26aulast%3DPithavala%26aufirst%3DY.%2BK.%26aulast%3DReich%26aufirst%3DS.%2BD.%26aulast%3DFreddo%26aufirst%3DJ.%2BL.%26aulast%3DWilding%26aufirst%3DG.%26atitle%3DPhase%2520I%2520trial%2520of%2520the%2520oral%2520antiangiogenesis%2520agent%2520AG-013736%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%253A%2520pharmacokinetic%2520and%2520clinical%2520results%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2005%26volume%3D23%26spage%3D5474%26epage%3D5483" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Bukowski, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yasothan, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirkpatrick, P.</span><span> </span><span class="NLM_article-title">Pazopanib</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">17</span><span class="NLM_x">–</span> <span class="NLM_lpage">18</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=17-18&author=R.+M.+Bukowskiauthor=U.+Yasothanauthor=P.+Kirkpatrick&title=Pazopanib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBukowski%26aufirst%3DR.%2BM.%26aulast%3DYasothan%26aufirst%3DU.%26aulast%3DKirkpatrick%26aufirst%3DP.%26atitle%3DPazopanib%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2010%26volume%3D9%26spage%3D17%26epage%3D18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit14b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Harris, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boloor, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheung, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crosby, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis-Ward, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Epperly, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinkle, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, R. N.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knick, V. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laudeman, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luttrell, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mook, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolte, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudolph, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szewczyk, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Truesdale, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veal, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stafford, J. A.</span><span> </span><span class="NLM_article-title">Discovery of 5-[[4-[(2,3-dimethyl-2<i>H</i>-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">4632</span><span class="NLM_x">–</span> <span class="NLM_lpage">4640</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm800566m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=4632-4640&author=P.+A.+Harrisauthor=A.+Boloorauthor=M.+Cheungauthor=R.+Kumarauthor=R.+M.+Crosbyauthor=R.+G.+Davis-Wardauthor=A.+H.+Epperlyauthor=K.+W.+Hinkleauthor=R.+N.+Hunterauthor=J.+H.+Johnsonauthor=V.+B.+Knickauthor=C.+P.+Laudemanauthor=D.+K.+Luttrellauthor=R.+A.+Mookauthor=R.+T.+Nolteauthor=S.+K.+Rudolphauthor=J.+R.+Szewczykauthor=A.+T.+Truesdaleauthor=J.+M.+Vealauthor=L.+Wangauthor=J.+A.+Stafford&title=Discovery+of+5-%5B%5B4-%5B%282%2C3-dimethyl-2H-indazol-6-yl%29methylamino%5D-2-pyrimidinyl%5Damino%5D-2-methyl-benzenesulfonamide+%28pazopanib%29%2C+a+novel+and+potent+vascular+endothelial+growth+factor+receptor+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=10.1021%2Fjm800566m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800566m%26sid%3Dliteratum%253Aachs%26aulast%3DHarris%26aufirst%3DP.%2BA.%26aulast%3DBoloor%26aufirst%3DA.%26aulast%3DCheung%26aufirst%3DM.%26aulast%3DKumar%26aufirst%3DR.%26aulast%3DCrosby%26aufirst%3DR.%2BM.%26aulast%3DDavis-Ward%26aufirst%3DR.%2BG.%26aulast%3DEpperly%26aufirst%3DA.%2BH.%26aulast%3DHinkle%26aufirst%3DK.%2BW.%26aulast%3DHunter%26aufirst%3DR.%2BN.%26aulast%3DJohnson%26aufirst%3DJ.%2BH.%26aulast%3DKnick%26aufirst%3DV.%2BB.%26aulast%3DLaudeman%26aufirst%3DC.%2BP.%26aulast%3DLuttrell%26aufirst%3DD.%2BK.%26aulast%3DMook%26aufirst%3DR.%2BA.%26aulast%3DNolte%26aufirst%3DR.%2BT.%26aulast%3DRudolph%26aufirst%3DS.%2BK.%26aulast%3DSzewczyk%26aufirst%3DJ.%2BR.%26aulast%3DTruesdale%26aufirst%3DA.%2BT.%26aulast%3DVeal%26aufirst%3DJ.%2BM.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DStafford%26aufirst%3DJ.%2BA.%26atitle%3DDiscovery%2520of%25205-%255B%255B4-%255B%25282%252C3-dimethyl-2H-indazol-6-yl%2529methylamino%255D-2-pyrimidinyl%255Damino%255D-2-methyl-benzenesulfonamide%2520%2528pazopanib%2529%252C%2520a%2520novel%2520and%2520potent%2520vascular%2520endothelial%2520growth%2520factor%2520receptor%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D4632%26epage%3D4640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Wilhelm, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNabola, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHugh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shujath, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gawlak, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eveleigh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowley, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adnane, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Auclair, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gedrich, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voznesensky, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riedl, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Post, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bollag, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trail, P. A.</span><span> </span><span class="NLM_article-title">BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">7099</span><span class="NLM_x">–</span> <span class="NLM_lpage">7109</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=7099-7109&author=S.+M.+Wilhelmauthor=C.+Carterauthor=L.+Tangauthor=D.+Wilkieauthor=A.+McNabolaauthor=H.+Rongauthor=C.+Chenauthor=X.+Zhangauthor=P.+Vincentauthor=M.+McHughauthor=Y.+Caoauthor=J.+Shujathauthor=S.+Gawlakauthor=D.+Eveleighauthor=B.+Rowleyauthor=L.+Liuauthor=L.+Adnaneauthor=M.+Lynchauthor=D.+Auclairauthor=I.+Taylorauthor=R.+Gedrichauthor=A.+Voznesenskyauthor=B.+Riedlauthor=L.+E.+Postauthor=G.+Bollagauthor=P.+A.+Trail&title=BAY+43-9006+exhibits+broad+spectrum+oral+antitumor+activity+and+targets+the+RAF%2FMEK%2FERK+pathway+and+receptor+tyrosine+kinases+involved+in+tumor+progression+and+angiogenesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWilhelm%26aufirst%3DS.%2BM.%26aulast%3DCarter%26aufirst%3DC.%26aulast%3DTang%26aufirst%3DL.%26aulast%3DWilkie%26aufirst%3DD.%26aulast%3DMcNabola%26aufirst%3DA.%26aulast%3DRong%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DVincent%26aufirst%3DP.%26aulast%3DMcHugh%26aufirst%3DM.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DShujath%26aufirst%3DJ.%26aulast%3DGawlak%26aufirst%3DS.%26aulast%3DEveleigh%26aufirst%3DD.%26aulast%3DRowley%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DAdnane%26aufirst%3DL.%26aulast%3DLynch%26aufirst%3DM.%26aulast%3DAuclair%26aufirst%3DD.%26aulast%3DTaylor%26aufirst%3DI.%26aulast%3DGedrich%26aufirst%3DR.%26aulast%3DVoznesensky%26aufirst%3DA.%26aulast%3DRiedl%26aufirst%3DB.%26aulast%3DPost%26aufirst%3DL.%2BE.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DTrail%26aufirst%3DP.%2BA.%26atitle%3DBAY%252043-9006%2520exhibits%2520broad%2520spectrum%2520oral%2520antitumor%2520activity%2520and%2520targets%2520the%2520RAF%252FMEK%252FERK%2520pathway%2520and%2520receptor%2520tyrosine%2520kinases%2520involved%2520in%2520tumor%2520progression%2520and%2520angiogenesis%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D7099%26epage%3D7109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Wilhelm, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lowinger, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dumas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simantov, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelley, S.</span><span> </span><span class="NLM_article-title">Discovery and development of sorafenib: a multikinase inhibitor for treating cancer</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">835</span><span class="NLM_x">–</span> <span class="NLM_lpage">844</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Fjm300126x&amp;key=10.1038%2Fnrd2130" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Fjm300126x&amp;key=17016424" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm300126x&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVajsbbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=835-844&author=S.+Wilhelmauthor=C.+Carterauthor=M.+Lynchauthor=T.+Lowingerauthor=J.+Dumasauthor=R.+A.+Smithauthor=B.+Schwartzauthor=R.+Simantovauthor=S.+Kelley&title=Discovery+and+development+of+sorafenib%3A+a+multikinase+inhibitor+for+treating+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and development of sorafenib: a multikinase inhibitor for treating cancer</span></div><div class="casAuthors">Wilhelm, Scott; Carter, Christopher; Lynch, Mark; Lowinger, Timothy; Dumas, Jacques; Smith, Roger A.; Schwartz, Brian; Simantov, Ronit; Kelley, Susan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">835-844</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Since the mol. revolution of the 1980s, knowledge of the etiol. of cancer has increased considerably, which has led to the discovery and development of targeted therapies tailored to inhibit cancer-specific pathways.  The introduction and refinement of rapid, high-throughput screening technologies over the past decade has greatly facilitated this targeted discovery and development process.  Here, the authors describe the discovery and continuing development of sorafenib (previously known as BAY 43-9006), the first oral multikinase inhibitor that targets Raf and affects tumor signaling and the tumor vasculature.  The discovery cycle of sorafenib (Nexavar; Bayer Pharmaceuticals) - from initial screening for a lead compd. to FDA approval for the treatment of advanced renal cell carcinoma in Dec. 2005 - was completed in just 11 years, with approval being received ∼5 years after the initiation of the first Phase I trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6WjjfgNSCtbVg90H21EOLACvtfcHk0lh6siddQS9y3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVajsbbM&md5=490d4995170f3a7270ae9bbdd24b12e5</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fnrd2130&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2130%26sid%3Dliteratum%253Aachs%26aulast%3DWilhelm%26aufirst%3DS.%26aulast%3DCarter%26aufirst%3DC.%26aulast%3DLynch%26aufirst%3DM.%26aulast%3DLowinger%26aufirst%3DT.%26aulast%3DDumas%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DR.%2BA.%26aulast%3DSchwartz%26aufirst%3DB.%26aulast%3DSimantov%26aufirst%3DR.%26aulast%3DKelley%26aufirst%3DS.%26atitle%3DDiscovery%2520and%2520development%2520of%2520sorafenib%253A%2520a%2520multikinase%2520inhibitor%2520for%2520treating%2520cancer%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D835%26epage%3D844" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span>Food and Drug Administration. Highlights of Prescribing Information. <a href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021923s004s005s006s007lbl.pdf" class="extLink">http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021923s004s005s006s007lbl.pdf</a> (accessed Jan 11,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Food+and+Drug+Administration.+Highlights+of+Prescribing+Information.+http%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2007%2F021923s004s005s006s007lbl.pdf+%28accessed+Jan+11%2C+2012%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Eisen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmad, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gore, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaye, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marais, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbens, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hackett, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuchter, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nathanson, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simantov, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poulin-Costello, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Dwyer, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ratain, M. J.</span><span> </span><span class="NLM_article-title">Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">95</span><span class="NLM_x">, </span> <span class="NLM_fpage">581</span><span class="NLM_x">–</span> <span class="NLM_lpage">586</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm300126x&amp;key=10.1038%2Fsj.bjc.6603291" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm300126x&amp;key=16880785" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm300126x&amp;key=1%3ACAS%3A528%3ADC%252BD28XovVWitLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2006&pages=581-586&author=T.+Eisenauthor=T.+Ahmadauthor=K.+T.+Flahertyauthor=M.+Goreauthor=S.+Kayeauthor=R.+Maraisauthor=I.+Gibbensauthor=S.+Hackettauthor=M.+Jamesauthor=L.+M.+Schuchterauthor=K.+L.+Nathansonauthor=C.+Xiaauthor=R.+Simantovauthor=B.+Schwartzauthor=M.+Poulin-Costelloauthor=P.+J.+O%E2%80%99Dwyerauthor=M.+J.+Ratain&title=Sorafenib+in+advanced+melanoma%3A+a+phase+II+randomised+discontinuation+trial+analysis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis</span></div><div class="casAuthors">Eisen, T.; Ahmad, T.; Flaherty, K. T.; Gore, M.; Kaye, S.; Marais, R.; Gibbens, I.; Hackett, S.; James, M.; Schuchter, L. M.; Nathanson, K. L.; Xia, C.; Simantov, R.; Schwartz, B.; Poulin-Costello, M.; O'Dwyer, P. J.; Ratain, M. J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">581-586</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The effects of sorafenib - an oral multikinase inhibitor targeting the tumor and tumor vasculature - were evaluated in patients with advanced melanoma enrolled in a large multidisease Phase II randomised discontinuation trial (RDT).  Enrolled patients received a 12-wk run-in of sorafenib 400 mg twice daily (b.i.d.).  Patients with changes in bi-dimensional tumor measurements <25% from baseline were then randomised to sorafenib or placebo for a further 12 wk (ie to week 24).  Patients with ≥25% tumor shrinkage after the run-in continued on open-label sorafenib, whereas those with ≥25% tumor growth discontinued treatment.  This anal. focussed on secondary RDT end points: changes in bi-dimensional tumor measurements from baseline after 12 wk and overall tumor responses (WHO criteria) at week 24, progression-free survival (PFS), safety and biomarkers (BRAF, KRAS and NRAS mutational status).  Of 37 melanoma patients treated during the run-in phase, 34 were evaluable for response: one had ≥25% tumor shrinkage and remained on open-label sorafenib; six (16%) had <25% tumor growth and were randomised (placebo, n=3; sorafenib, n=3); and 27 had ≥25% tumor growth and discontinued.  All three randomised sorafenib patients progressed by week 24; one remained on sorafenib for symptomatic relief.  All three placebo patients progressed by week-24 and were re-started on sorafenib; one experienced disease re-stabilization.  Overall, the confirmed best responses for each of the 37 melanoma patients who received sorafenib were 19% stable disease (SD) (ie n=1 open-label; n=6 randomised), 62% (n=23) progressive disease (PD) and 19% (n=7) unevaluable.  The overall median PFS was 11 wk.  The six randomised patients with SD had overall PFS values ranging from 16 to 34 wk.  The most common drug-related adverse events were dermatol. (eg rash/desquamation, 51%; hand-foot skin reaction, 35%).  There was no relationship between V600E BRAF status and disease stability.  DNA was extd. from the biopsies of 17/22 patients.  Six had V600E-pos. tumors (n=4 had PD; n=1 had SD; n=1 unevaluable for response), and 11 had tumors contg. wild-type BRAF (n=9 PD; n=1 SD; n=1 unevaluable for response).  In conclusion, sorafenib is well tolerated but has little or no antitumor activity in advanced melanoma patients as a single agent at the dose evaluated (400 mg b.i.d.).  Ongoing trials in advanced melanoma are evaluating sorafenib combination therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrADSApQdE0pLVg90H21EOLACvtfcHk0lh6siddQS9y3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XovVWitLo%253D&md5=5040c220e2361be41099fe0f42edcb8b</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6603291&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6603291%26sid%3Dliteratum%253Aachs%26aulast%3DEisen%26aufirst%3DT.%26aulast%3DAhmad%26aufirst%3DT.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DGore%26aufirst%3DM.%26aulast%3DKaye%26aufirst%3DS.%26aulast%3DMarais%26aufirst%3DR.%26aulast%3DGibbens%26aufirst%3DI.%26aulast%3DHackett%26aufirst%3DS.%26aulast%3DJames%26aufirst%3DM.%26aulast%3DSchuchter%26aufirst%3DL.%2BM.%26aulast%3DNathanson%26aufirst%3DK.%2BL.%26aulast%3DXia%26aufirst%3DC.%26aulast%3DSimantov%26aufirst%3DR.%26aulast%3DSchwartz%26aufirst%3DB.%26aulast%3DPoulin-Costello%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Dwyer%26aufirst%3DP.%2BJ.%26aulast%3DRatain%26aufirst%3DM.%2BJ.%26atitle%3DSorafenib%2520in%2520advanced%2520melanoma%253A%2520a%2520phase%2520II%2520randomised%2520discontinuation%2520trial%2520analysis%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2006%26volume%3D95%26spage%3D581%26epage%3D586" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Wan, P. T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garnett, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roe, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niculescu-Duvaz, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Good, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springer, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barford, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marais, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cancer Genome Project.</span><span> </span><span class="NLM_article-title">Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">116</span><span class="NLM_x">, </span> <span class="NLM_fpage">855</span><span class="NLM_x">–</span> <span class="NLM_lpage">867</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm300126x&amp;key=10.1016%2FS0092-8674%2804%2900215-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Fjm300126x&amp;key=15035987" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm300126x&amp;key=1%3ACAS%3A528%3ADC%252BD2cXivVyksLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2004&pages=855-867&author=P.+T.+C.+Wanauthor=M.+J.+Garnettauthor=S.+M.+Roeauthor=S.+Leeauthor=D.+Niculescu-Duvazauthor=V.+M.+Goodauthor=C.+M.+Jonesauthor=C.+J.+Marshallauthor=C.+J.+Springerauthor=D.+Barfordauthor=R.+Maraisauthor=Cancer+Genome+Project.&title=Mechanism+of+activation+of+the+RAF-ERK+signaling+pathway+by+oncogenic+mutations+of+B-RAF"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF</span></div><div class="casAuthors">Wan, Paul T. C.; Garnett, Mathew J.; Roe, S. Mark; Lee, Sharlene; Niculescu-Duvaz, Dan; Good, Valerie M.; Project, Cancer Genome; Jones, C. Michael; Marshall, Christopher J.; Springer, Caroline J.; Barford, David; Marais, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">855-867</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Over 30 mutations of the B-RAF gene assocd. with human cancers have been identified, the majority of which are located within the kinase domain.  Here the authors show that of 22 B-RAF mutants analyzed, 18 have elevated kinase activity and signal to ERK in vivo.  Surprisingly, three mutants have reduced kinase activity towards MEK in vitro but, by activating C-RAF in vivo, signal to ERK in cells.  The structures of wild type and oncogenic V599EB-RAF kinase domains in complex with the RAF inhibitor BAY43-9006 show that the activation segment is held in an inactive conformation by assocn. with the P loop.  The clustering of most mutations to these two regions suggests that disruption of this interaction converts B-RAF into its active conformation.  The high activity mutants signal to ERK by directly phosphorylating MEK, whereas the impaired activity mutants stimulate MEK by activating endogenous C-RAF, possibly via an allosteric or transphosphorylation mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYiQicwc1xVLVg90H21EOLACvtfcHk0ljviQL5qdFZew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXivVyksLw%253D&md5=4cc020056c64e514286c000666da1972</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2804%2900215-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252804%252900215-6%26sid%3Dliteratum%253Aachs%26aulast%3DWan%26aufirst%3DP.%2BT.%2BC.%26aulast%3DGarnett%26aufirst%3DM.%2BJ.%26aulast%3DRoe%26aufirst%3DS.%2BM.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DNiculescu-Duvaz%26aufirst%3DD.%26aulast%3DGood%26aufirst%3DV.%2BM.%26aulast%3DJones%26aufirst%3DC.%2BM.%26aulast%3DMarshall%26aufirst%3DC.%2BJ.%26aulast%3DSpringer%26aufirst%3DC.%2BJ.%26aulast%3DBarford%26aufirst%3DD.%26aulast%3DMarais%26aufirst%3DR.%26aulast%3D%26atitle%3DMechanism%2520of%2520activation%2520of%2520the%2520RAF-ERK%2520signaling%2520pathway%2520by%2520oncogenic%2520mutations%2520of%2520B-RAF%26jtitle%3DCell%26date%3D2004%26volume%3D116%26spage%3D855%26epage%3D867" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Venetsanakos, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stuart, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salangsang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aardalen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faure, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heise, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jallal, B.</span><span> </span><span class="NLM_article-title">CHIR-265, a novel inhibitor that targets B-Raf and VEGFR, shows efficacy in a broad range of preclinical models</span> <span class="citation_source-journal">Proc. Am. Assoc. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">4854</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2006&pages=4854&author=E.+Venetsanakosauthor=D.+Stuartauthor=N.+Tanauthor=H.+Yeauthor=F.+Salangsangauthor=K.+Aardalenauthor=M.+Faureauthor=C.+Heiseauthor=D.+Mendelauthor=B.+Jallal&title=CHIR-265%2C+a+novel+inhibitor+that+targets+B-Raf+and+VEGFR%2C+shows+efficacy+in+a+broad+range+of+preclinical+models"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVenetsanakos%26aufirst%3DE.%26aulast%3DStuart%26aufirst%3DD.%26aulast%3DTan%26aufirst%3DN.%26aulast%3DYe%26aufirst%3DH.%26aulast%3DSalangsang%26aufirst%3DF.%26aulast%3DAardalen%26aufirst%3DK.%26aulast%3DFaure%26aufirst%3DM.%26aulast%3DHeise%26aufirst%3DC.%26aulast%3DMendel%26aufirst%3DD.%26aulast%3DJallal%26aufirst%3DB.%26atitle%3DCHIR-265%252C%2520a%2520novel%2520inhibitor%2520that%2520targets%2520B-Raf%2520and%2520VEGFR%252C%2520shows%2520efficacy%2520in%2520a%2520broad%2520range%2520of%2520preclinical%2520models%26jtitle%3DProc.%2520Am.%2520Assoc.%2520Cancer%2520Res.%26date%3D2006%26volume%3D47%26spage%3D4854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Rational design of inhibitors that bind to inactive kinase conformations</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">358</span><span class="NLM_x">–</span> <span class="NLM_lpage">364</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=16&amp;doi=10.1021%2Fjm300126x&amp;key=10.1038%2Fnchembio799" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=8&amp;doi=10.1021%2Fjm300126x&amp;key=16783341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=32&amp;doi=10.1021%2Fjm300126x&amp;key=1%3ACAS%3A528%3ADC%252BD28XlvFGjs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2006&pages=358-364&author=Y.+Liuauthor=N.+S.+Gray&title=Rational+design+of+inhibitors+that+bind+to+inactive+kinase+conformations"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21aR"><div class="casContent"><span class="casTitleNuber">21a</span><div class="casTitle"><span class="NLM_cas:atitle">Rational design of inhibitors that bind to inactive kinase conformations</span></div><div class="casAuthors">Liu, Yi; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">358-364</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The majority of kinase inhibitors, known as type I inhibitors that have been developed so far target the ATP binding site of the kinase in its active conformation, in which the activation loop is phosphorylated.  Recently, crystal structures of inhibitors such as imatinib, BIRB796, and sorafenib (BAY43-9006), known as type II inhibitors, have revealed a new binding mode that exploits an addnl. binding site immediately adjacent to the region occupied by ATP.  This pocket is made accessible by an activation-loop rearrangement that is characteristic of kinases in an inactive conformation.  The examn. of binding features of known type II inhibitors is discussed and a pharmacophore model currently used in the design of a new generation of structurally diverse type II inhibitors is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxahsMPlhgDbVg90H21EOLACvtfcHk0ljviQL5qdFZew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlvFGjs7g%253D&md5=4a9347a44a2cf4a412c9741fdcc5696b</span></div><a href="/servlet/linkout?suffix=cit21a&amp;dbid=16384&amp;doi=10.1038%2Fnchembio799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio799%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DRational%2520design%2520of%2520inhibitors%2520that%2520bind%2520to%2520inactive%2520kinase%2520conformations%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2006%26volume%3D2%26spage%3D358%26epage%3D364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit21b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Backes, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zech, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felber, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klebl, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, G.</span><span> </span><span class="NLM_article-title">Small-molecule inhibitors binding to protein kinase. Part II: The novel pharmacophore approach of type II and type III inhibition</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1427</span><span class="NLM_x">–</span> <span class="NLM_lpage">1449</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=1427-1449&author=A.+C.+Backesauthor=B.+Zechauthor=B.+Felberauthor=B.+Kleblauthor=G.+M%C3%BCller&title=Small-molecule+inhibitors+binding+to+protein+kinase.+Part+II%3A+The+novel+pharmacophore+approach+of+type+II+and+type+III+inhibition"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBackes%26aufirst%3DA.%2BC.%26aulast%3DZech%26aufirst%3DB.%26aulast%3DFelber%26aufirst%3DB.%26aulast%3DKlebl%26aufirst%3DB.%26aulast%3DM%25C3%25BCller%26aufirst%3DG.%26atitle%3DSmall-molecule%2520inhibitors%2520binding%2520to%2520protein%2520kinase.%2520Part%2520II%253A%2520The%2520novel%2520pharmacophore%2520approach%2520of%2520type%2520II%2520and%2520type%2520III%2520inhibition%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2008%26volume%3D3%26spage%3D1427%26epage%3D1449" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Bollag, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirth, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ibrahim, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spevak, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Habets, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burton, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shellooe, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marimuthu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, K. Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Artis, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlessinger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higgins, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iyer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Andrea, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koehler, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stumm, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grippo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puzanov, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McArthur, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nathanson, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolop, K.</span><span> </span><span class="NLM_article-title">Clinical efficacy of a RAF inhibitor needs broad target blockade in <i>BRAF</i>-mutant melanoma</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">467</span><span class="NLM_x">, </span> <span class="NLM_fpage">596</span><span class="NLM_x">–</span> <span class="NLM_lpage">599</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm300126x&amp;key=10.1038%2Fnature09454" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Fjm300126x&amp;key=20823850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm300126x&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1ajtbfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=467&publication_year=2010&pages=596-599&author=G.+Bollagauthor=P.+Hirthauthor=J.+Tsaiauthor=J.+Zhangauthor=P.+N.+Ibrahimauthor=H.+Choauthor=W.+Spevakauthor=C.+Zhangauthor=Y.+Zhangauthor=G.+Habetsauthor=E.+A.+Burtonauthor=B.+Wongauthor=G.+Tsangauthor=B.+L.+Westauthor=B.+Powellauthor=R.+Shellooeauthor=A.+Marimuthuauthor=H.+Nguyenauthor=K.+Y.+J.+Zhangauthor=D.+R.+Artisauthor=J.+Schlessingerauthor=F.+Suauthor=B.+Higginsauthor=R.+Iyerauthor=K.+D%E2%80%99Andreaauthor=A.+Koehlerauthor=M.+Stummauthor=P.+S.+Linauthor=R.+J.+Leeauthor=J.+Grippoauthor=I.+Puzanovauthor=K.+B.+Kimauthor=A.+Ribasauthor=G.+A.+McArthurauthor=J.+A.+Sosmanauthor=P.+B.+Chapmanauthor=K.+T.+Flahertyauthor=X.+Xuauthor=K.+L.+Nathansonauthor=K.+Nolop&title=Clinical+efficacy+of+a+RAF+inhibitor+needs+broad+target+blockade+in+BRAF-mutant+melanoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma</span></div><div class="casAuthors">Bollag, Gideon; Hirth, Peter; Tsai, James; Zhang, Jiazhong; Ibrahim, Prabha N.; Cho, Hanna; Spevak, Wayne; Zhang, Chao; Zhang, Ying; Habets, Gaston; Burton, Elizabeth A.; Wong, Bernice; Tsang, Garson; West, Brian L.; Powell, Ben; Shellooe, Rafe; Marimuthu, Adhirai; Nguyen, Hoa; Zhang, Kam Y. J.; Artis, Dean R.; Schlessinger, Joseph; Su, Fei; Higgins, Brian; Iyer, Raman; D'Andrea, Kurt; Koehler, Astrid; Stumm, Michael; Lin, Paul S.; Lee, Richard J.; Grippo, Joseph; Puzanov, Igor; Kim, Kevin B.; Ribas, Antoni; McArthur, Grant A.; Sosman, Jeffrey A.; Chapman, Paul B.; Flaherty, Keith T.; Xu, Xiaowei; Nathanson, Katherine L.; Nolop, Keith</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">467</span>
        (<span class="NLM_cas:issue">7315</span>),
    <span class="NLM_cas:pages">596-599</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">B-RAF is the most frequently mutated protein kinase in human cancers.  The finding that oncogenic mutations in BRAF are common in melanoma, followed by the demonstration that these tumors are dependent on the RAF/MEK/ERK pathway, offered hope that inhibition of B-RAF kinase activity could benefit melanoma patients.  Herein, we describe the structure-guided discovery of PLX4032 (RG7204), a potent inhibitor of oncogenic B-RAF kinase activity.  Preclin. expts. demonstrated that PLX4032 selectively blocked the RAF/MEK/ERK pathway in BRAF mutant cells and caused regression of BRAF mutant xenografts.  Toxicol. studies confirmed a wide safety margin consistent with the high degree of selectivity, enabling Phase 1 clin. trials using a cryst. formulation of PLX4032 (ref. 5).  In a subset of melanoma patients, pathway inhibition was monitored in paired biopsy specimens collected before treatment initiation and following 2 wk of treatment.  This anal. revealed substantial inhibition of ERK phosphorylation, yet clin. evaluation did not show tumor regressions.  At higher drug exposures afforded by a new amorphous drug formulation, greater than 80% inhibition of ERK phosphorylation in the tumors of patients correlated with clin. response.  Indeed, the Phase 1 clin. data revealed a remarkably high 81% response rate in metastatic melanoma patients treated at an oral dose of 960 mg twice daily.  These data demonstrate that BRAF-mutant melanomas are highly dependent on B-RAF kinase activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpYwlns1EfcLVg90H21EOLACvtfcHk0lh-cUrZ96v3Sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1ajtbfK&md5=8a26d0ab41970f39a109ddafff2f17b4</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fnature09454&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09454%26sid%3Dliteratum%253Aachs%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DHirth%26aufirst%3DP.%26aulast%3DTsai%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DIbrahim%26aufirst%3DP.%2BN.%26aulast%3DCho%26aufirst%3DH.%26aulast%3DSpevak%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHabets%26aufirst%3DG.%26aulast%3DBurton%26aufirst%3DE.%2BA.%26aulast%3DWong%26aufirst%3DB.%26aulast%3DTsang%26aufirst%3DG.%26aulast%3DWest%26aufirst%3DB.%2BL.%26aulast%3DPowell%26aufirst%3DB.%26aulast%3DShellooe%26aufirst%3DR.%26aulast%3DMarimuthu%26aufirst%3DA.%26aulast%3DNguyen%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DK.%2BY.%2BJ.%26aulast%3DArtis%26aufirst%3DD.%2BR.%26aulast%3DSchlessinger%26aufirst%3DJ.%26aulast%3DSu%26aufirst%3DF.%26aulast%3DHiggins%26aufirst%3DB.%26aulast%3DIyer%26aufirst%3DR.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DK.%26aulast%3DKoehler%26aufirst%3DA.%26aulast%3DStumm%26aufirst%3DM.%26aulast%3DLin%26aufirst%3DP.%2BS.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DGrippo%26aufirst%3DJ.%26aulast%3DPuzanov%26aufirst%3DI.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DNathanson%26aufirst%3DK.%2BL.%26aulast%3DNolop%26aufirst%3DK.%26atitle%3DClinical%2520efficacy%2520of%2520a%2520RAF%2520inhibitor%2520needs%2520broad%2520target%2520blockade%2520in%2520BRAF-mutant%2520melanoma%26jtitle%3DNature%26date%3D2010%26volume%3D467%26spage%3D596%26epage%3D599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">King, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patrick, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Batorsky, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Do, H. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusnak, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takle, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hugger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karreth, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lougheed, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chau, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stout, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">May, E. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rominger, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaber, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lakdawala, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Contractor, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smalley, K. S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herlyn, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrissey, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuveson, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, P. S.</span><span> </span><span class="NLM_article-title">Demonstration of a genetic therapeutic index for tumors expressing oncogenic <i>BRAF</i> by the kinase inhibitor SB-590885</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">11100</span><span class="NLM_x">–</span> <span class="NLM_lpage">11105</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=11100-11105&author=A.+J.+Kingauthor=D.+R.+Patrickauthor=R.+S.+Batorskyauthor=M.+L.+Hoauthor=H.+T.+Doauthor=S.+Y.+Zhangauthor=R.+Kumarauthor=D.+W.+Rusnakauthor=A.+K.+Takleauthor=D.+M.+Wilsonauthor=E.+Huggerauthor=L.+Wangauthor=F.+Karrethauthor=J.+C.+Lougheedauthor=J.+Leeauthor=D.+Chauauthor=T.+J.+Stoutauthor=E.+W.+Mayauthor=C.+M.+Romingerauthor=M.+D.+Schaberauthor=L.+Luoauthor=A.+S.+Lakdawalaauthor=J.+L.+Adamsauthor=R.+G.+Contractorauthor=K.+S.+M.+Smalleyauthor=M.+Herlynauthor=M.+M.+Morrisseyauthor=D.+A.+Tuvesonauthor=P.+S.+Huang&title=Demonstration+of+a+genetic+therapeutic+index+for+tumors+expressing+oncogenic+BRAF+by+the+kinase+inhibitor+SB-590885"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKing%26aufirst%3DA.%2BJ.%26aulast%3DPatrick%26aufirst%3DD.%2BR.%26aulast%3DBatorsky%26aufirst%3DR.%2BS.%26aulast%3DHo%26aufirst%3DM.%2BL.%26aulast%3DDo%26aufirst%3DH.%2BT.%26aulast%3DZhang%26aufirst%3DS.%2BY.%26aulast%3DKumar%26aufirst%3DR.%26aulast%3DRusnak%26aufirst%3DD.%2BW.%26aulast%3DTakle%26aufirst%3DA.%2BK.%26aulast%3DWilson%26aufirst%3DD.%2BM.%26aulast%3DHugger%26aufirst%3DE.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DKarreth%26aufirst%3DF.%26aulast%3DLougheed%26aufirst%3DJ.%2BC.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DChau%26aufirst%3DD.%26aulast%3DStout%26aufirst%3DT.%2BJ.%26aulast%3DMay%26aufirst%3DE.%2BW.%26aulast%3DRominger%26aufirst%3DC.%2BM.%26aulast%3DSchaber%26aufirst%3DM.%2BD.%26aulast%3DLuo%26aufirst%3DL.%26aulast%3DLakdawala%26aufirst%3DA.%2BS.%26aulast%3DAdams%26aufirst%3DJ.%2BL.%26aulast%3DContractor%26aufirst%3DR.%2BG.%26aulast%3DSmalley%26aufirst%3DK.%2BS.%2BM.%26aulast%3DHerlyn%26aufirst%3DM.%26aulast%3DMorrissey%26aufirst%3DM.%2BM.%26aulast%3DTuveson%26aufirst%3DD.%2BA.%26aulast%3DHuang%26aufirst%3DP.%2BS.%26atitle%3DDemonstration%2520of%2520a%2520genetic%2520therapeutic%2520index%2520for%2520tumors%2520expressing%2520oncogenic%2520BRAF%2520by%2520the%2520kinase%2520inhibitor%2520SB-590885%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D11100%26epage%3D11105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit23b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Takle, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M. J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dean, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Francis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaiba, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hird, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, F. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovell, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naylor, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reith, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steadman, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, D. M.</span><span> </span><span class="NLM_article-title">The identification of potent and selective imidazole-based inhibitors of B-Raf kinase</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">378</span><span class="NLM_x">–</span> <span class="NLM_lpage">381</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=378-381&author=A.+K.+Takleauthor=M.+J.+B.+Brownauthor=S.+Daviesauthor=D.+K.+Deanauthor=G.+Francisauthor=A.+Gaibaauthor=A.+W.+Hirdauthor=F.+D.+Kingauthor=P.+J.+Lovellauthor=A.+Naylorauthor=A.+D.+Reithauthor=J.+G.+Steadmanauthor=D.+M.+Wilson&title=The+identification+of+potent+and+selective+imidazole-based+inhibitors+of+B-Raf+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTakle%26aufirst%3DA.%2BK.%26aulast%3DBrown%26aufirst%3DM.%2BJ.%2BB.%26aulast%3DDavies%26aufirst%3DS.%26aulast%3DDean%26aufirst%3DD.%2BK.%26aulast%3DFrancis%26aufirst%3DG.%26aulast%3DGaiba%26aufirst%3DA.%26aulast%3DHird%26aufirst%3DA.%2BW.%26aulast%3DKing%26aufirst%3DF.%2BD.%26aulast%3DLovell%26aufirst%3DP.%2BJ.%26aulast%3DNaylor%26aufirst%3DA.%26aulast%3DReith%26aufirst%3DA.%2BD.%26aulast%3DSteadman%26aufirst%3DJ.%2BG.%26aulast%3DWilson%26aufirst%3DD.%2BM.%26atitle%3DThe%2520identification%2520of%2520potent%2520and%2520selective%2520imidazole-based%2520inhibitors%2520of%2520B-Raf%2520kinase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D378%26epage%3D381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Sakai, N.; Imamura, S.; Miyamoto, N.; Hirayama, T.</span><span> </span><span class="NLM_article-title">Fused Heterocyclic Derivative and Use Thereof</span>. WIPO Patent Application WO 2008/016192, Feb 7,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=N.+Sakai&author=S.+Imamura&author=N.+Miyamoto&author=T.+Hirayama&title=Fused+Heterocyclic+Derivative+and+Use+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSakai%26aufirst%3DN.%26atitle%3DFused%2520Heterocyclic%2520Derivative%2520and%2520Use%2520Thereof%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Jones, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willett, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glen, R. C.</span><span> </span><span class="NLM_article-title">Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">245</span><span class="NLM_x">, </span> <span class="NLM_fpage">43</span><span class="NLM_x">–</span> <span class="NLM_lpage">53</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=16&amp;doi=10.1021%2Fjm300126x&amp;key=10.1016%2FS0022-2836%2895%2980037-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=8&amp;doi=10.1021%2Fjm300126x&amp;key=7823319" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=32&amp;doi=10.1021%2Fjm300126x&amp;key=1%3ACAS%3A528%3ADyaK2MXjtVKlsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=245&publication_year=1995&pages=43-53&author=G.+Jonesauthor=P.+Willettauthor=R.+C.+Glen&title=Molecular+recognition+of+receptor+sites+using+a+genetic+algorithm+with+a+description+of+desolvation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25aR"><div class="casContent"><span class="casTitleNuber">25a</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular recognition of a receptor sites using a genetic algorithm with a description of desolvation</span></div><div class="casAuthors">Jones, Gareth; Willett, Peter; Glen, Robert C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">245</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">43-53</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Academic</span>)
        </div><div class="casAbstract">Understanding the principles whereby macromol. biol. receptors can recognize small mol. substrates or inhibitors is the subject of a major effort.  This is of paramount importance in rational drug design where the receptor structure is known (the "docking" problem).  Current theor. approaches utilize models of the steric and electrostatic interaction of bound ligands and recently conformational flexibility has been incorporated.  The authors report results based on software using a genetic algorithm that uses an evolutionary strategy in exploring the full conformational flexibility of the ligand with partial flexibility of the protein, and which satisfies the fundamental requirement that the ligand must displace loosely bound water on binding.  Results are reported on five test systems showing excellent agreement with exptl. data.  The design of the algorithm offers insight into the mol. recognition mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7Xcn7nQyVRLVg90H21EOLACvtfcHk0lh-cUrZ96v3Sw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXjtVKlsbc%253D&md5=bf45edafb986a73c7c1d0ac55e070f28</span></div><a href="/servlet/linkout?suffix=cit25a&amp;dbid=16384&amp;doi=10.1016%2FS0022-2836%2895%2980037-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0022-2836%252895%252980037-9%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DG.%26aulast%3DWillett%26aufirst%3DP.%26aulast%3DGlen%26aufirst%3DR.%2BC.%26atitle%3DMolecular%2520recognition%2520of%2520receptor%2520sites%2520using%2520a%2520genetic%2520algorithm%2520with%2520a%2520description%2520of%2520desolvation%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D1995%26volume%3D245%26spage%3D43%26epage%3D53" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit25b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Halgren, T. A.</span><span> </span><span class="NLM_article-title">MMFF VI, MMFF94s option for energy minimization studies</span> <span class="citation_source-journal">J. Comput. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">720</span><span class="NLM_x">–</span> <span class="NLM_lpage">729</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=1999&pages=720-729&author=T.+A.+Halgren&title=MMFF+VI%2C+MMFF94s+option+for+energy+minimization+studies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHalgren%26aufirst%3DT.%2BA.%26atitle%3DMMFF%2520VI%252C%2520MMFF94s%2520option%2520for%2520energy%2520minimization%2520studies%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D1999%26volume%3D20%26spage%3D720%26epage%3D729" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Mourad, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wise, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Townsend, L. B.</span><span> </span><span class="NLM_article-title">Methyl imidazo[1,2-<i>b</i>]pyridazine-2-carbamates and related compounds as potential antifilarial agents</span> <span class="citation_source-journal">J. Heterocycl. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">1583</span><span class="NLM_x">–</span> <span class="NLM_lpage">1592</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=1992&pages=1583-1592&author=A.+E.+Mouradauthor=D.+S.+Wiseauthor=L.+B.+Townsend&title=Methyl+imidazo%5B1%2C2-b%5Dpyridazine-2-carbamates+and+related+compounds+as+potential+antifilarial+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMourad%26aufirst%3DA.%2BE.%26aulast%3DWise%26aufirst%3DD.%2BS.%26aulast%3DTownsend%26aufirst%3DL.%2BB.%26atitle%3DMethyl%2520imidazo%255B1%252C2-b%255Dpyridazine-2-carbamates%2520and%2520related%2520compounds%2520as%2520potential%2520antifilarial%2520agents%26jtitle%3DJ.%2520Heterocycl.%2520Chem.%26date%3D1992%26volume%3D29%26spage%3D1583%26epage%3D1592" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Yamanaka, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoneda, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohhara, H.</span><span> </span><span class="NLM_article-title">Imidazo[1,2-<i>a</i>]pyridines. II. Ozonolysis of imidazo[1,2-<i>a</i>]pyridines and synthesis of cardiotonic agents</span> <span class="citation_source-journal">Chem. Pharm. Bull.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">666</span><span class="NLM_x">–</span> <span class="NLM_lpage">674</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1992&pages=666-674&author=M.+Yamanakaauthor=S.+Sudaauthor=N.+Yonedaauthor=H.+Ohhara&title=Imidazo%5B1%2C2-a%5Dpyridines.+II.+Ozonolysis+of+imidazo%5B1%2C2-a%5Dpyridines+and+synthesis+of+cardiotonic+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYamanaka%26aufirst%3DM.%26aulast%3DSuda%26aufirst%3DS.%26aulast%3DYoneda%26aufirst%3DN.%26aulast%3DOhhara%26aufirst%3DH.%26atitle%3DImidazo%255B1%252C2-a%255Dpyridines.%2520II.%2520Ozonolysis%2520of%2520imidazo%255B1%252C2-a%255Dpyridines%2520and%2520synthesis%2520of%2520cardiotonic%2520agents%26jtitle%3DChem.%2520Pharm.%2520Bull.%26date%3D1992%26volume%3D40%26spage%3D666%26epage%3D674" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit27b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Hamdouchi, C</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendoza, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaramillo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Diego, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robertson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watkins, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooks, H. B.</span><span> </span><span class="NLM_article-title">Structure-based design of a new class of highly selective aminoimidazo[1,2-<i>a</i>]pyridine-based inhibitors of cyclin dependent kinases</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">1943</span><span class="NLM_x">–</span> <span class="NLM_lpage">1947</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=1943-1947&author=C+Hamdouchiauthor=B.+Zhongauthor=J.+Mendozaauthor=E.+Collinsauthor=C.+Jaramilloauthor=J.+E.+de+Diegoauthor=D.+Robertsonauthor=C.+D.+Spencerauthor=B.+D.+Andersonauthor=S.+A.+Watkinsauthor=F.+Zhangauthor=H.+B.+Brooks&title=Structure-based+design+of+a+new+class+of+highly+selective+aminoimidazo%5B1%2C2-a%5Dpyridine-based+inhibitors+of+cyclin+dependent+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHamdouchi%26aufirst%3DC%26aulast%3DZhong%26aufirst%3DB.%26aulast%3DMendoza%26aufirst%3DJ.%26aulast%3DCollins%26aufirst%3DE.%26aulast%3DJaramillo%26aufirst%3DC.%26aulast%3Dde%2BDiego%26aufirst%3DJ.%2BE.%26aulast%3DRobertson%26aufirst%3DD.%26aulast%3DSpencer%26aufirst%3DC.%2BD.%26aulast%3DAnderson%26aufirst%3DB.%2BD.%26aulast%3DWatkins%26aufirst%3DS.%2BA.%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DBrooks%26aufirst%3DH.%2BB.%26atitle%3DStructure-based%2520design%2520of%2520a%2520new%2520class%2520of%2520highly%2520selective%2520aminoimidazo%255B1%252C2-a%255Dpyridine-based%2520inhibitors%2520of%2520cyclin%2520dependent%2520kinases%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26spage%3D1943%26epage%3D1947" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Alcalde, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinarés, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frigola, J.</span><span> </span><span class="NLM_article-title">NMR studies of <i>N</i>-(benzimidazol-2-yl)pyridinium derivatives: QSAR with the anti-leishmanial activity and their carbon-13 NMR chemical shifts</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">633</span><span class="NLM_x">–</span> <span class="NLM_lpage">642</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=1991&pages=633-642&author=E.+Alcaldeauthor=I.+Dinar%C3%A9sauthor=J.+Frigola&title=NMR+studies+of+N-%28benzimidazol-2-yl%29pyridinium+derivatives%3A+QSAR+with+the+anti-leishmanial+activity+and+their+carbon-13+NMR+chemical+shifts"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAlcalde%26aufirst%3DE.%26aulast%3DDinar%25C3%25A9s%26aufirst%3DI.%26aulast%3DFrigola%26aufirst%3DJ.%26atitle%3DNMR%2520studies%2520of%2520N-%2528benzimidazol-2-yl%2529pyridinium%2520derivatives%253A%2520QSAR%2520with%2520the%2520anti-leishmanial%2520activity%2520and%2520their%2520carbon-13%2520NMR%2520chemical%2520shifts%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D1991%26volume%3D26%26spage%3D633%26epage%3D642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit28b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Hasegawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishigaki, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Washio, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kano, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mori, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, R. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shibahara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toyoda, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolte, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veal, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheung, M.</span><span> </span><span class="NLM_article-title">Discovery of novel benzimidazoles as potent inhibitors of TIE-2 and VEGFR-2 tyrosine kinase receptors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">4453</span><span class="NLM_x">–</span> <span class="NLM_lpage">4470</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0611051" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=4453-4470&author=M.+Hasegawaauthor=N.+Nishigakiauthor=Y.+Washioauthor=K.+Kanoauthor=P.+A.+Harrisauthor=H.+Satoauthor=I.+Moriauthor=R.+I.+Westauthor=M.+Shibaharaauthor=H.+Toyodaauthor=L.+Wangauthor=R.+T.+Nolteauthor=J.+M.+Vealauthor=M.+Cheung&title=Discovery+of+novel+benzimidazoles+as+potent+inhibitors+of+TIE-2+and+VEGFR-2+tyrosine+kinase+receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28b&amp;dbid=16384&amp;doi=10.1021%2Fjm0611051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0611051%26sid%3Dliteratum%253Aachs%26aulast%3DHasegawa%26aufirst%3DM.%26aulast%3DNishigaki%26aufirst%3DN.%26aulast%3DWashio%26aufirst%3DY.%26aulast%3DKano%26aufirst%3DK.%26aulast%3DHarris%26aufirst%3DP.%2BA.%26aulast%3DSato%26aufirst%3DH.%26aulast%3DMori%26aufirst%3DI.%26aulast%3DWest%26aufirst%3DR.%2BI.%26aulast%3DShibahara%26aufirst%3DM.%26aulast%3DToyoda%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DNolte%26aufirst%3DR.%2BT.%26aulast%3DVeal%26aufirst%3DJ.%2BM.%26aulast%3DCheung%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520novel%2520benzimidazoles%2520as%2520potent%2520inhibitors%2520of%2520TIE-2%2520and%2520VEGFR-2%2520tyrosine%2520kinase%2520receptors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D4453%26epage%3D4470" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Mader, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Dios, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shih, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonjouklian, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Uralde, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sánchez-Martinez, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">del Prado, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaramillo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Diego, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cabrejas, L. M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dominguez, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montero, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shepherd, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dally, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toth, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chatterjee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pleite, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanco-Urgoiti, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barberis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorite, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jambrina, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nevill, C. R.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolos, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, B. D.</span><span> </span><span class="NLM_article-title">Imidazolyl benzimidazoles and imidazo[4,5-<i>b</i>]pyridines as potent p38α MAP kinase inhibitors with excellent in vivo antiinflammatory properties</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">179</span><span class="NLM_x">–</span> <span class="NLM_lpage">183</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=179-183&author=M.+Maderauthor=A.+de+Diosauthor=C.+Shihauthor=R.+Bonjouklianauthor=T.+Liauthor=W.+Whiteauthor=B.+L.+de+Uraldeauthor=C.+S%C3%A1nchez-Martinezauthor=M.+del+Pradoauthor=C.+Jaramilloauthor=E.+de+Diegoauthor=L.+M.+M.+Cabrejasauthor=C.+Dominguezauthor=C.+Monteroauthor=T.+Shepherdauthor=R.+Dallyauthor=J.+E.+Tothauthor=A.+Chatterjeeauthor=S.+Pleiteauthor=J.+Blanco-Urgoitiauthor=L.+Perezauthor=M.+Barberisauthor=M.+J.+Loriteauthor=E.+Jambrinaauthor=C.+R.+Nevillauthor=P.+A.+Leeauthor=R.+C.+Schultzauthor=J.+A.+Wolosauthor=L.+C.+Liauthor=R.+M.+Campbellauthor=B.+D.+Anderson&title=Imidazolyl+benzimidazoles+and+imidazo%5B4%2C5-b%5Dpyridines+as+potent+p38%CE%B1+MAP+kinase+inhibitors+with+excellent+in+vivo+antiinflammatory+properties"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMader%26aufirst%3DM.%26aulast%3Dde%2BDios%26aufirst%3DA.%26aulast%3DShih%26aufirst%3DC.%26aulast%3DBonjouklian%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DT.%26aulast%3DWhite%26aufirst%3DW.%26aulast%3Dde%2BUralde%26aufirst%3DB.%2BL.%26aulast%3DS%25C3%25A1nchez-Martinez%26aufirst%3DC.%26aulast%3Ddel%2BPrado%26aufirst%3DM.%26aulast%3DJaramillo%26aufirst%3DC.%26aulast%3Dde%2BDiego%26aufirst%3DE.%26aulast%3DCabrejas%26aufirst%3DL.%2BM.%2BM.%26aulast%3DDominguez%26aufirst%3DC.%26aulast%3DMontero%26aufirst%3DC.%26aulast%3DShepherd%26aufirst%3DT.%26aulast%3DDally%26aufirst%3DR.%26aulast%3DToth%26aufirst%3DJ.%2BE.%26aulast%3DChatterjee%26aufirst%3DA.%26aulast%3DPleite%26aufirst%3DS.%26aulast%3DBlanco-Urgoiti%26aufirst%3DJ.%26aulast%3DPerez%26aufirst%3DL.%26aulast%3DBarberis%26aufirst%3DM.%26aulast%3DLorite%26aufirst%3DM.%2BJ.%26aulast%3DJambrina%26aufirst%3DE.%26aulast%3DNevill%26aufirst%3DC.%2BR.%26aulast%3DLee%26aufirst%3DP.%2BA.%26aulast%3DSchultz%26aufirst%3DR.%2BC.%26aulast%3DWolos%26aufirst%3DJ.%2BA.%26aulast%3DLi%26aufirst%3DL.%2BC.%26aulast%3DCampbell%26aufirst%3DR.%2BM.%26aulast%3DAnderson%26aufirst%3DB.%2BD.%26atitle%3DImidazolyl%2520benzimidazoles%2520and%2520imidazo%255B4%252C5-b%255Dpyridines%2520as%2520potent%2520p38%25CE%25B1%2520MAP%2520kinase%2520inhibitors%2520with%2520excellent%2520in%2520vivo%2520antiinflammatory%2520properties%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D179%26epage%3D183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Kaufmann, H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, E.</span><span> </span><span class="NLM_article-title">Arzneimittelsynthetische studien IV. Synthese schwefelhaltiger verbindungen</span> <span class="citation_source-journal">Arch. Pharm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1929</span><span class="NLM_x">, </span> <span class="NLM_fpage">192</span><span class="NLM_x">–</span> <span class="NLM_lpage">211</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Fjm300126x&amp;key=10.1002%2Fardp.19292670304" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm300126x&amp;key=1%3ACAS%3A528%3ADyaB1MXhvFSnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1929&pages=192-211&author=H.+P.+Kaufmannauthor=E.+Weber&title=Arzneimittelsynthetische+studien+IV.+Synthese+schwefelhaltiger+verbindungen"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic drug studies. IV. Synthesis of sulfur-containing preparations</span></div><div class="casAuthors">Kaufmann, H. P.; Weber, E.</div><div class="citationInfo"><span class="NLM_cas:title">Archiv der Pharmazie und Berichte der Deutschen Pharmazeutischen Gesellschaft</span>
        (<span class="NLM_cas:date">1929</span>),
    <span class="NLM_cas:volume">267</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">192-211</span>CODEN:
                <span class="NLM_cas:coden">APBDAJ</span>;
        ISSN:<span class="NLM_cas:issn">0376-0367</span>.
    </div><div class="casAbstract">An exptl. study confined mainly to the introduction of the SCN group into, and the influence of such groups, on certain antipyretics (aniline, phenetidine and phenylhydrazinc) and disinfectants (thymol, cresols and hydroxyquinolines).  The method of introducing SCN into the above compds. involves treatment in a suitable solvent with NaSCN and Br.  Among the new compds. prepd. and characterized were the following: p-rhodanacelanilide, C9H8ON2S, needles m. 188°;  1-amino-2-rhodan-4-ethoxybenzene, C9H10ON2S, silky needles m. 67-8°, easily convertible to 2-amino-6-ethoxybenzthiazol; C9H10ON2S, needles m. 161°;  2-diacetylamino-6-ethoxybenzthiazol, C13H14O3N2S, m. 245°;  bis(1-amino-4-ethoxy)2-disulfide, C16H20O2S2, m. 101°; sym.-formyl-(p-rhodanphenyl) hydrazine, C8H7ON3S, needles m. 132°; sym.-Ac(p-rhodanphenyl), C9H9ON3S, m. 171°; sym.-benzoyl-(p-rhodanphenyl)hydrazine, C14H11ON3S, m. 164°; sym.-phthalyl-(p-rhodanphenyl)hydrazine, C15H9O2N3S, m. 213°; sym.-acetyl-bis(p-rhodanphenyl)hydrazine, C15H12ON4S2, needles m. 160°; sym.-benzoyl-bis(p-rhodanphenyl)hydrazine, C21H14ON4S2, m. 160°; α-hydroxy-γ-rhodanquinoline (4-rhodancarbostyrile), C10H6ON2S, yellowish needles m. 141°; γ-rhodan-o-hydroxyquinoline, C10H6ON2S, m. 134°; 1-methyl-4-isopropyl-3-hydroxy-6-rhodanbenzene (3-methyl-4-rhodan-6-isopropylphenol), needles m. 105°; 1-methyl-2-hydroxy-5-rhodanbenzene (o-methyl-p-rhodanphenol), C8H7ONS, m. 71°; 1-methyl-3-hydroxy-5-rhodanbenzene (o-methyl-m-rhodanphenol), C8H7ONS, needles m. 76°; 1-methyl-4-hydroxy-3-rhodanbenzene, C8H7ONS, m. 105°, yields with alc.  HCl a N-free compd., C8H6O2S, m. 83°.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRUByAzB_wf7Vg90H21EOLACvtfcHk0li6YqUXS6QE9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaB1MXhvFSnsg%253D%253D&md5=f514b2d36023e1c8ed30c16b08dfeff8</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1002%2Fardp.19292670304&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fardp.19292670304%26sid%3Dliteratum%253Aachs%26aulast%3DKaufmann%26aufirst%3DH.%2BP.%26aulast%3DWeber%26aufirst%3DE.%26atitle%3DArzneimittelsynthetische%2520studien%2520IV.%2520Synthese%2520schwefelhaltiger%2520verbindungen%26jtitle%3DArch.%2520Pharm.%26date%3D1929%26spage%3D192%26epage%3D211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Yamamoto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, T.</span><span> </span><span class="NLM_article-title">Syntheses of pyridothiazoles and pyridoxazoles. Sulfur-containing pyridine derivatives. XXXI</span> <span class="citation_source-journal">Yakugaku Zasshi</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1951</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">169</span><span class="NLM_x">–</span> <span class="NLM_lpage">172</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=1951&pages=169-172&author=Y.+Yamamotoauthor=T.+Takahashi&title=Syntheses+of+pyridothiazoles+and+pyridoxazoles.+Sulfur-containing+pyridine+derivatives.+XXXI"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYamamoto%26aufirst%3DY.%26aulast%3DTakahashi%26aufirst%3DT.%26atitle%3DSyntheses%2520of%2520pyridothiazoles%2520and%2520pyridoxazoles.%2520Sulfur-containing%2520pyridine%2520derivatives.%2520XXXI%26jtitle%3DYakugaku%2520Zasshi%26date%3D1951%26volume%3D71%26spage%3D169%26epage%3D172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit31b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Yamamoto, Y.</span><span> </span><span class="NLM_article-title">Sulfur-containing pyridine derivatives. XXXII. Synthesis of pyridothiazoles</span> <span class="citation_source-journal">Yakugaku Zasshi</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1951</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">662</span><span class="NLM_x">–</span> <span class="NLM_lpage">667</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=1951&pages=662-667&author=Y.+Yamamoto&title=Sulfur-containing+pyridine+derivatives.+XXXII.+Synthesis+of+pyridothiazoles"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYamamoto%26aufirst%3DY.%26atitle%3DSulfur-containing%2520pyridine%2520derivatives.%2520XXXII.%2520Synthesis%2520of%2520pyridothiazoles%26jtitle%3DYakugaku%2520Zasshi%26date%3D1951%26volume%3D71%26spage%3D662%26epage%3D667" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit31c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Okafor, C. O.</span><span> </span><span class="NLM_article-title">Some pyrido[2,3-<i>d</i>]thiazole systems</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1967</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">126</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm00313a039" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1967&pages=126&author=C.+O.+Okafor&title=Some+pyrido%5B2%2C3-d%5Dthiazole+systems"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31c&amp;dbid=16384&amp;doi=10.1021%2Fjm00313a039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00313a039%26sid%3Dliteratum%253Aachs%26aulast%3DOkafor%26aufirst%3DC.%2BO.%26atitle%3DSome%2520pyrido%255B2%252C3-d%255Dthiazole%2520systems%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1967%26volume%3D10%26spage%3D126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Gao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bohl, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalton, J. T.</span><span> </span><span class="NLM_article-title">Characterization of the in vitro metabolism of selective androgen receptor modulator using human, rat, and dog liver enzyme preparations</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">243</span><span class="NLM_x">–</span> <span class="NLM_lpage">253</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2006&pages=243-253&author=W.+Gaoauthor=Z.+Wuauthor=C.+E.+Bohlauthor=J.+Yangauthor=D.+D.+Millerauthor=J.+T.+Dalton&title=Characterization+of+the+in+vitro+metabolism+of+selective+androgen+receptor+modulator+using+human%2C+rat%2C+and+dog+liver+enzyme+preparations"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DBohl%26aufirst%3DC.%2BE.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DMiller%26aufirst%3DD.%2BD.%26aulast%3DDalton%26aufirst%3DJ.%2BT.%26atitle%3DCharacterization%2520of%2520the%2520in%2520vitro%2520metabolism%2520of%2520selective%2520androgen%2520receptor%2520modulator%2520using%2520human%252C%2520rat%252C%2520and%2520dog%2520liver%2520enzyme%2520preparations%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2006%26volume%3D34%26spage%3D243%26epage%3D253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit32b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Okaniwa, M.; Imada, T.; Ohashi, T.; Miyazaki, T.; Arita, T.; Yabuki, M.; Sumita, A.; Tsutsumi, S.; Higashikawa, K.; Takagi, T.; Kawamoto, T.; Inui, Y.; Yoshida, S.; Ishikawa, T.</span><span> </span><span class="NLM_article-title">Design and synthesis of novel DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors: (II) synthesis and characterization of a novel imide-type prodrug for improving oral absorption</span>. Manuscript in preparation.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Okaniwa%2C+M.%3B+Imada%2C+T.%3B+Ohashi%2C+T.%3B+Miyazaki%2C+T.%3B+Arita%2C+T.%3B+Yabuki%2C+M.%3B+Sumita%2C+A.%3B+Tsutsumi%2C+S.%3B+Higashikawa%2C+K.%3B+Takagi%2C+T.%3B+Kawamoto%2C+T.%3B+Inui%2C+Y.%3B+Yoshida%2C+S.%3B+Ishikawa%2C+T.+Design+and+synthesis+of+novel+DFG-out+RAF%2Fvascular+endothelial+growth+factor+receptor+2+%28VEGFR2%29+inhibitors%3A+%28II%29+synthesis+and+characterization+of+a+novel+imide-type+prodrug+for+improving+oral+absorption.+Manuscript+in+preparation."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DOkaniwa%26aufirst%3DM.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520novel%2520DFG-out%2520RAF%252Fvascular%2520endothelial%2520growth%2520factor%2520receptor%25202%2520%2528VEGFR2%2529%2520inhibitors%253A%2520%2528II%2529%2520synthesis%2520and%2520characterization%2520of%2520a%2520novel%2520imide-type%2520prodrug%2520for%2520improving%2520oral%2520absorption" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Remko, M.</span><span> </span><span class="NLM_article-title">Molecular structure, p<i>Ka</i>, lipophilicity, solubility and absorption of biologically active aromatic and heterocyclic sulfonamides</span> <span class="citation_source-journal">J. Mol. Struct.: THEOCHEM</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">944</span><span class="NLM_x">, </span> <span class="NLM_fpage">34</span><span class="NLM_x">–</span> <span class="NLM_lpage">42</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Fjm300126x&amp;key=10.1016%2Fj.theochem.2009.12.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm300126x&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitFylsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=944&publication_year=2010&pages=34-42&author=M.+Remko&title=Molecular+structure%2C+pKa%2C+lipophilicity%2C+solubility+and+absorption+of+biologically+active+aromatic+and+heterocyclic+sulfonamides"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular structure, pKa, lipophilicity, solubility and absorption of biologically active aromatic and heterocyclic sulfonamides</span></div><div class="casAuthors">Remko, Milan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Structure: THEOCHEM</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">944</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">34-42</span>CODEN:
                <span class="NLM_cas:coden">THEODJ</span>;
        ISSN:<span class="NLM_cas:issn">0166-1280</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The methods of theor. chem. have been used to elucidate mol. properties of clin. useful acetazolamide, dorzolamide and brinzolamide and two new arom. sulfonamides in both neutral and deprotonated forms.  The geometries and energies of these drugs have been computed using HF/6-31G(d), Becke3LYP/6-31G(d) and Becke3LYP/6-311+G(d,p) model chemistries.  The equil. structure of the acetazolamide is stabilized via intramol. interaction between non-bonded S···O atoms of the acetylamino group and the thiadiazole ring.  In the case of the arom. sulfonamides (4-sulfamoyl-N-(3-morpholinopropyl) benzamide (P10), and N-(morpholinopropyl)benzene-1,4-bis(sulfonamide) (P20)) the fully optimized most stable conformers possess characteristic L-shape structure stabilized via intramol. hydrogen bonding system of the N-H···N type.  Computed partition coeffs. (XLOGP2 method) for drugs studied varied between -0.3 and -1.8.  Neutral compds. are described as slightly lipophilic drugs.  The calcd. water soly. of dorzolamide and brinzolamide is comparably low.  P10 and P20 are slightly lipophilic sulfonamides with moderate soly.  The calcd. pKa values of -SO2NH2 moiety in the sulfonamides studied are in the range of 7.3-9.7 and are characterized as weak org. acids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrd4gB3TIuauLVg90H21EOLACvtfcHk0li6YqUXS6QE9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitFylsbs%253D&md5=c2d8d1d26507764495fcfdc8efe768f6</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.theochem.2009.12.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.theochem.2009.12.017%26sid%3Dliteratum%253Aachs%26aulast%3DRemko%26aufirst%3DM.%26atitle%3DMolecular%2520structure%252C%2520pKa%252C%2520lipophilicity%252C%2520solubility%2520and%2520absorption%2520of%2520biologically%2520active%2520aromatic%2520and%2520heterocyclic%2520sulfonamides%26jtitle%3DJ.%2520Mol.%2520Struct.%253A%2520THEOCHEM%26date%3D2010%26volume%3D944%26spage%3D34%26epage%3D42" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="note"><p class="first last">The coordinates and structure factors have been deposited with the Protein Data Bank with accession codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4DBN">4DBN</a> for BRAF and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3VNT">3VNT</a> for VEGFR2.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Bondi, A.</span><span> </span><span class="NLM_article-title">van der Waals volumes and radii</span> <span class="citation_source-journal">J. Phys. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1964</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">441</span><span class="NLM_x">–</span> <span class="NLM_lpage">451</span></span><div class="citationLinks">[<a href="/doi/10.1021/j100785a001" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Fjm300126x&amp;key=1%3ACAS%3A528%3ADyaF2cXls1Cgsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=1964&pages=441-451&author=A.+Bondi&title=van+der+Waals+volumes+and+radii"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">van der Waals volumes and radii</span></div><div class="casAuthors">Bondi, A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physical Chemistry</span>
        (<span class="NLM_cas:date">1964</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">441-51</span>CODEN:
                <span class="NLM_cas:coden">JPCHAX</span>;
        ISSN:<span class="NLM_cas:issn">0022-3654</span>.
    </div><div class="casAbstract">Intermol. van der Waals radii of the nonmetallic elements were assembled into a list of recommended values for vol. calcns.  These values were arrived at by selecting from the most reliable x-ray diffraction data those which could be reconciled with crystal d. at 0°K. (to give reasonable packing d.), gas kinetic collision cross section, crit. d., and with liquid state properties.  A qual. understanding of the nature of van der Waals radii is provided by correlation with the de Broglie wavelength of the outermost valence electron.  Tentative values for the van der Waals radii of metallic elements in organometallic compds. are proposed.  A list of increments for the vol. of mols. impenetrable to thermal collision, the so-called van der Waals vol., and of the corresponding increments in area per mol. is given.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHeueZoao997Vg90H21EOLACvtfcHk0lihYReg0bqctw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF2cXls1Cgsg%253D%253D&md5=0f25964afae4e9f761e0d314151444a5</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fj100785a001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fj100785a001%26sid%3Dliteratum%253Aachs%26aulast%3DBondi%26aufirst%3DA.%26atitle%3Dvan%2520der%2520Waals%2520volumes%2520and%2520radii%26jtitle%3DJ.%2520Phys.%2520Chem.%26date%3D1964%26volume%3D68%26spage%3D441%26epage%3D451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Giavazzi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giuliani, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coltrini, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bani, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferri, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sennino, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tosatti, M. P. M</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoppacciaro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Presta, M.</span><span> </span><span class="NLM_article-title">Modulation of tumor angiogenesis by conditional expression of fibroblast growth factor-2 affects early but not established tumors</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">309</span><span class="NLM_x">–</span> <span class="NLM_lpage">317</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=309-317&author=R.+Giavazziauthor=R.+Giulianiauthor=D.+Coltriniauthor=M.+R.+Baniauthor=C.+Ferriauthor=B.+Senninoauthor=M.+P.+M+Tosattiauthor=A.+Stoppacciaroauthor=M.+Presta&title=Modulation+of+tumor+angiogenesis+by+conditional+expression+of+fibroblast+growth+factor-2+affects+early+but+not+established+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGiavazzi%26aufirst%3DR.%26aulast%3DGiuliani%26aufirst%3DR.%26aulast%3DColtrini%26aufirst%3DD.%26aulast%3DBani%26aufirst%3DM.%2BR.%26aulast%3DFerri%26aufirst%3DC.%26aulast%3DSennino%26aufirst%3DB.%26aulast%3DTosatti%26aufirst%3DM.%2BP.%2BM%26aulast%3DStoppacciaro%26aufirst%3DA.%26aulast%3DPresta%26aufirst%3DM.%26atitle%3DModulation%2520of%2520tumor%2520angiogenesis%2520by%2520conditional%2520expression%2520of%2520fibroblast%2520growth%2520factor-2%2520affects%2520early%2520but%2520not%2520established%2520tumors%26jtitle%3DCancer%2520Res.%26date%3D2001%26volume%3D61%26spage%3D309%26epage%3D317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="cit36b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Pietras, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sjöblom, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubin, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heldin, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Östman, A.</span><span> </span><span class="NLM_article-title">PDGF receptors as cancer drug targets</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">439</span><span class="NLM_x">–</span> <span class="NLM_lpage">443</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=439-443&author=K.+Pietrasauthor=T.+Sj%C3%B6blomauthor=K.+Rubinauthor=C.-H.+Heldinauthor=A.+%C3%96stman&title=PDGF+receptors+as+cancer+drug+targets"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPietras%26aufirst%3DK.%26aulast%3DSj%25C3%25B6blom%26aufirst%3DT.%26aulast%3DRubin%26aufirst%3DK.%26aulast%3DHeldin%26aufirst%3DC.-H.%26aulast%3D%25C3%2596stman%26aufirst%3DA.%26atitle%3DPDGF%2520receptors%2520as%2520cancer%2520drug%2520targets%26jtitle%3DCancer%2520Cell%26date%3D2003%26volume%3D3%26spage%3D439%26epage%3D443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Backer, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Backer, J. M.</span><span> </span><span class="NLM_article-title">Functionally active VEGF fusion proteins</span> <span class="citation_source-journal">Protein Expression Purif.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">7</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Fjm300126x&amp;key=10.1006%2Fprep.2001.1472" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Fjm300126x&amp;key=11570839" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Fjm300126x&amp;key=1%3ACAS%3A528%3ADC%252BD3MXmvFymur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2001&pages=1-7&author=M.+V.+Backerauthor=J.+M.+Backer&title=Functionally+active+VEGF+fusion+proteins"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Functionally Active VEGF Fusion Proteins</span></div><div class="casAuthors">Backer, Marina V.; Backer, Joseph M.</div><div class="citationInfo"><span class="NLM_cas:title">Protein Expression and Purification</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-7</span>CODEN:
                <span class="NLM_cas:coden">PEXPEJ</span>;
        ISSN:<span class="NLM_cas:issn">1046-5928</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">Angiogenesis is stimulated by vascular endothelial growth factor (VEGF) acting via endothelial cell-specific receptors, such as VEGFR-2, that are overexpressed at the sites of angiogenesis.  If VEGF retains activity as a fusion protein with a large N-terminal extension, it would facilitate development of VEGF-based vehicles for receptor-mediated delivery of therapeutic and diagnostic agents to the sites of angiogenesis.  We have constructed, expressed in Escherichia coli, and purified VEGF fusion proteins contg. a 158-amino acid N-terminal extension fused to human VEGF121, VEGF165, and VEGF189.  We report here that VEGF fusion proteins induce tyrosine autophosphorylation of VEGFR-2 and its downstream targets, as well as cell contraction in cells overexpressing VEGFR-2.  Although N-terminal extensions decrease the affinity of VEGF fusion proteins to VEGFR-2, at satg. concns. these proteins are as efficient as correct size VEGF165.  We hypothesize that VEGF fusion proteins may be employed for targeting endothelial cells at the sites of angiogenesis.  (c) 2001 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqliXh0Fgp0MbVg90H21EOLACvtfcHk0lihYReg0bqctw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXmvFymur4%253D&md5=4141b8a25070c8092e480ce25a42b252</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1006%2Fprep.2001.1472&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fprep.2001.1472%26sid%3Dliteratum%253Aachs%26aulast%3DBacker%26aufirst%3DM.%2BV.%26aulast%3DBacker%26aufirst%3DJ.%2BM.%26atitle%3DFunctionally%2520active%2520VEGF%2520fusion%2520proteins%26jtitle%3DProtein%2520Expression%2520Purif.%26date%3D2001%26volume%3D23%26spage%3D1%26epage%3D7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Janssens, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van den Mooter, G.</span><span> </span><span class="NLM_article-title">Review: physical chemistry of solid dispersions</span> <span class="citation_source-journal">J. Pharm. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">1571</span><span class="NLM_x">–</span> <span class="NLM_lpage">1586</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Fjm300126x&amp;key=10.1211%2Fjpp.61.12.0001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Fjm300126x&amp;key=19958579" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Fjm300126x&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitFGqsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2009&pages=1571-1586&author=S.+Janssensauthor=G.+Van+den+Mooter&title=Review%3A+physical+chemistry+of+solid+dispersions"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Review: physical chemistry of solid dispersions</span></div><div class="casAuthors">Janssens, Sandrien; Van den Mooter, Guy</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacy and Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1571-1586</span>CODEN:
                <span class="NLM_cas:coden">JPPMAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3573</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Press</span>)
        </div><div class="casAbstract">A review.  With poorly sol. drug candidates emerging in the drug discovery pipeline, the importance of the solid dispersion formulation approach is increasing.  This strategy includes complete removal of drug crystallinity, and mol. dispersion of the poorly sol. compd. in a hydrophilic polymeric carrier.  The potential of this technique to increase oral absorption and hence bioavailability is enormous.  Nevertheless, some issues have to be considered regarding thermodn. instability, as well in supersatd. solns. that are formed upon dissoln. as in the solid state.  After a brief discussion on the historical background of solid dispersions and their current role in formulation, an overview will be given on the phys. chem. and stability of glass solns. as they form supersatd. solns., and during their shelf life.  Thorough understanding of these aspects will elicit conscious evaluation of carrier properties and eventually facilitate rational excipient selection.  Thus, full exploitation of the solid dispersion strategy may provide an appropriate answer to drug attrition due to low aq. soly. in later stages of development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2x4xN6QffoLVg90H21EOLACvtfcHk0lihYReg0bqctw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitFGqsr4%253D&md5=7c8c3efd9cf1fcc162e208ff8ffda813</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1211%2Fjpp.61.12.0001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1211%252Fjpp.61.12.0001%26sid%3Dliteratum%253Aachs%26aulast%3DJanssens%26aufirst%3DS.%26aulast%3DVan%2Bden%2BMooter%26aufirst%3DG.%26atitle%3DReview%253A%2520physical%2520chemistry%2520of%2520solid%2520dispersions%26jtitle%3DJ.%2520Pharm.%2520Pharmacol.%26date%3D2009%26volume%3D61%26spage%3D1571%26epage%3D1586" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1a','cit1b','cit1c'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4a','cit4b'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7a','cit7b','cit7c'],'ref8':['cit8a','cit8b'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12a','cit12b','cit12c'],'ref13':['cit13a','cit13b'],'ref14':['cit14a','cit14b'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21a','cit21b'],'ref22':['cit22'],'ref23':['cit23a','cit23b'],'ref24':['cit24'],'ref25':['cit25a','cit25b'],'ref26':['cit26'],'ref27':['cit27a','cit27b'],'ref28':['cit28a','cit28b'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31a','cit31b','cit31c'],'ref32':['cit32a','cit32b'],'ref33':['cit33'],'ref34':[],'ref35':['cit35'],'ref36':['cit36a','cit36b'],'ref37':['cit37'],'ref38':['cit38']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 41 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Andrea  Volkamer</span>, <span class="hlFld-ContribAuthor ">Sameh  Eid</span>, <span class="hlFld-ContribAuthor ">Samo  Turk</span>, <span class="hlFld-ContribAuthor ">Friedrich  Rippmann</span>, and <span class="hlFld-ContribAuthor ">Simone  Fulle</span>  . </span><span class="cited-content_cbyCitation_article-title">Identification and Visualization of Kinase-Specific Subpockets. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2016,</strong> <em>56 </em>
                                    (2)
                                     , 335-346. <a href="https://doi.org/10.1021/acs.jcim.5b00627" title="DOI URL">https://doi.org/10.1021/acs.jcim.5b00627</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.5b00627&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.5b00627%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DIdentification%252Band%252BVisualization%252Bof%252BKinase-Specific%252BSubpockets%26aulast%3DVolkamer%26aufirst%3DAndrea%26date%3D2016%26date%3D2016%26date%3D2015%26date%3D15102015%26date%3D29012016%26date%3D22022016%26date%3D06012016%26volume%3D56%26issue%3D2%26spage%3D335%26epage%3D346" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Brett R.  Beno</span>, <span class="hlFld-ContribAuthor ">Kap-Sun  Yeung</span>, <span class="hlFld-ContribAuthor ">Michael D.  Bartberger</span>, <span class="hlFld-ContribAuthor ">Lewis D.  Pennington</span>, and <span class="hlFld-ContribAuthor ">Nicholas A.  Meanwell</span>  . </span><span class="cited-content_cbyCitation_article-title">A Survey of the Role of Noncovalent Sulfur Interactions in Drug Design. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (11)
                                     , 4383-4438. <a href="https://doi.org/10.1021/jm501853m" title="DOI URL">https://doi.org/10.1021/jm501853m</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm501853m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm501853m%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DA%252BSurvey%252Bof%252Bthe%252BRole%252Bof%252BNoncovalent%252BSulfur%252BInteractions%252Bin%252BDrug%252BDesign%26aulast%3DBeno%26aufirst%3DBrett%2BR.%26date%3D2015%26date%3D2015%26date%3D2014%26date%3D01122014%26date%3D03032015%26date%3D11062015%26volume%3D58%26issue%3D11%26spage%3D4383%26epage%3D4438" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kristen A.  Marino</span>, <span class="hlFld-ContribAuthor ">Ludovico  Sutto</span>, and <span class="hlFld-ContribAuthor ">Francesco Luigi  Gervasio</span>  . </span><span class="cited-content_cbyCitation_article-title">The Effect of a Widespread Cancer-Causing Mutation on the Inactive to Active Dynamics of the B-Raf Kinase. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2015,</strong> <em>137 </em>
                                    (16)
                                     , 5280-5283. <a href="https://doi.org/10.1021/jacs.5b01421" title="DOI URL">https://doi.org/10.1021/jacs.5b01421</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jacs.5b01421&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjacs.5b01421%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DThe%252BEffect%252Bof%252Ba%252BWidespread%252BCancer-Causing%252BMutation%252Bon%252Bthe%252BInactive%252Bto%252BActive%252BDynamics%252Bof%252Bthe%252BB-Raf%252BKinase%26aulast%3DMarino%26aufirst%3DKristen%2BA.%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D09022015%26date%3D17042015%26date%3D29042015%26date%3D13042015%26volume%3D137%26issue%3D16%26spage%3D5280%26epage%3D5283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nicole C.  Goodwin</span>, <span class="hlFld-ContribAuthor ">Giovanni  Cianchetta</span>, <span class="hlFld-ContribAuthor ">Hugh A.  Burgoon</span>, <span class="hlFld-ContribAuthor ">Jason  Healy</span>, <span class="hlFld-ContribAuthor ">Ross  Mabon</span>, <span class="hlFld-ContribAuthor ">Eric D.  Strobel</span>, <span class="hlFld-ContribAuthor ">Jason  Allen</span>, <span class="hlFld-ContribAuthor ">Shuli  Wang</span>, <span class="hlFld-ContribAuthor ">Brian D.  Hamman</span>, and <span class="hlFld-ContribAuthor ">David B.  Rawlins</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of a Type III Inhibitor of LIM Kinase 2 That Binds in a DFG-Out Conformation. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2015,</strong> <em>6 </em>
                                    (1)
                                     , 53-57. <a href="https://doi.org/10.1021/ml500242y" title="DOI URL">https://doi.org/10.1021/ml500242y</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ml500242y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fml500242y%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Ba%252BType%252BIII%252BInhibitor%252Bof%252BLIM%252BKinase%252B2%252BThat%252BBinds%252Bin%252Ba%252BDFG-Out%252BConformation%26aulast%3DGoodwin%26aufirst%3DNicole%2BC.%26date%3D2015%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D10062014%26date%3D07082014%26date%3D12082014%26date%3D08012015%26date%3D07082014%26volume%3D6%26issue%3D1%26spage%3D53%26epage%3D57" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Janos  Sapi</span>, <span class="hlFld-ContribAuthor ">Frédéric  Schmidt</span>, <span class="hlFld-ContribAuthor ">Luc  Van Hijfte</span>, and <span class="hlFld-ContribAuthor ">Pascal  George</span>  . </span><span class="cited-content_cbyCitation_article-title">Interfacing Chemical Biology and Drug Discovery: Report from the 50th International Conference on Medicinal Chemistry of the SCT (French Medicinal Chemistry Society), July 2–4, 2014, Rouen, France. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Biology</span><span> <strong>2014,</strong> <em>9 </em>
                                    (12)
                                     , 2702-2707. <a href="https://doi.org/10.1021/cb5009469" title="DOI URL">https://doi.org/10.1021/cb5009469</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/cb5009469&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fcb5009469%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Biology%26atitle%3DInterfacing%252BChemical%252BBiology%252Band%252BDrug%252BDiscovery%25253A%252BReport%252Bfrom%252Bthe%252B50th%252BInternational%252BConference%252Bon%252BMedicinal%252BChemistry%252Bof%252Bthe%252BSCT%252B%252528French%252BMedicinal%252BChemistry%252BSociety%252529%25252C%252BJuly%252B2%2525E2%252580%2525934%25252C%252B2014%25252C%252BRouen%25252C%252BFrance%26aulast%3DSapi%26aufirst%3DJanos%26date%3D2014%26date%3D2014%26date%3D02122014%26date%3D05122014%26date%3D19122014%26volume%3D9%26issue%3D12%26spage%3D2702%26epage%3D2707" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Oscar P. J.  van Linden</span>, <span class="hlFld-ContribAuthor ">Albert J.  Kooistra</span>, <span class="hlFld-ContribAuthor ">Rob  Leurs</span>, <span class="hlFld-ContribAuthor ">Iwan J. P.  de Esch</span>, and <span class="hlFld-ContribAuthor ">Chris  de Graaf</span>  . </span><span class="cited-content_cbyCitation_article-title">KLIFS: A Knowledge-Based Structural Database To Navigate Kinase–Ligand Interaction Space. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>57 </em>
                                    (2)
                                     , 249-277. <a href="https://doi.org/10.1021/jm400378w" title="DOI URL">https://doi.org/10.1021/jm400378w</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm400378w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm400378w%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DKLIFS%25253A%252BA%252BKnowledge-Based%252BStructural%252BDatabase%252BTo%252BNavigate%252BKinase%2525E2%252580%252593Ligand%252BInteraction%252BSpace%26aulast%3Dvan%2BLinden%26aufirst%3DOscar%2BP.%2BJ.%26date%3D2014%26date%3D2013%26date%3D2013%26date%3D14032013%26date%3D20092013%26date%3D23012014%26date%3D13082013%26volume%3D57%26issue%3D2%26spage%3D249%26epage%3D277" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Masanori  Okaniwa</span>, <span class="hlFld-ContribAuthor ">Masaaki  Hirose</span>, <span class="hlFld-ContribAuthor ">Takeo  Arita</span>, <span class="hlFld-ContribAuthor ">Masato  Yabuki</span>, <span class="hlFld-ContribAuthor ">Akito  Nakamura</span>, <span class="hlFld-ContribAuthor ">Terufumi  Takagi</span>, <span class="hlFld-ContribAuthor ">Tomohiro  Kawamoto</span>, <span class="hlFld-ContribAuthor ">Noriko  Uchiyama</span>, <span class="hlFld-ContribAuthor ">Akihiko  Sumita</span>, <span class="hlFld-ContribAuthor ">Shunichirou  Tsutsumi</span>, <span class="hlFld-ContribAuthor ">Tsuneaki  Tottori</span>, <span class="hlFld-ContribAuthor ">Yoshitaka  Inui</span>, <span class="hlFld-ContribAuthor ">Bi-Ching  Sang</span>, <span class="hlFld-ContribAuthor ">Jason  Yano</span>, <span class="hlFld-ContribAuthor ">Kathleen  Aertgeerts</span>, <span class="hlFld-ContribAuthor ">Sei  Yoshida</span>, and <span class="hlFld-ContribAuthor ">Tomoyasu  Ishikawa</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of a Selective Kinase Inhibitor (TAK-632) Targeting Pan-RAF Inhibition: Design, Synthesis, and Biological Evaluation of C-7-Substituted 1,3-Benzothiazole Derivatives. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2013,</strong> <em>56 </em>
                                    (16)
                                     , 6478-6494. <a href="https://doi.org/10.1021/jm400778d" title="DOI URL">https://doi.org/10.1021/jm400778d</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm400778d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm400778d%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Ba%252BSelective%252BKinase%252BInhibitor%252B%252528TAK-632%252529%252BTargeting%252BPan-RAF%252BInhibition%25253A%252BDesign%25252C%252BSynthesis%25252C%252Band%252BBiological%252BEvaluation%252Bof%252BC-7-Substituted%252B1%25252C3-Benzothiazole%252BDerivatives%26aulast%3DOkaniwa%26aufirst%3DMasanori%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D26052013%26date%3D01082013%26date%3D22082013%26volume%3D56%26issue%3D16%26spage%3D6478%26epage%3D6494" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xun  Ji</span>, <span class="hlFld-ContribAuthor ">Yu  Zhou</span>, <span class="hlFld-ContribAuthor ">Jinfang  Wang</span>, <span class="hlFld-ContribAuthor ">Linxiang  Zhao</span>, <span class="hlFld-ContribAuthor ">Hualiang  Jiang</span>, and <span class="hlFld-ContribAuthor ">Hong  Liu</span>  . </span><span class="cited-content_cbyCitation_article-title">Au(I)/Ag(I)-Catalyzed Cascade Approach for the Synthesis of Benzo[4,5]imidazo[1,2-c]pyrrolo[1,2-a]quinazolinones. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2013,</strong> <em>78 </em>
                                    (9)
                                     , 4312-4318. <a href="https://doi.org/10.1021/jo400228g" title="DOI URL">https://doi.org/10.1021/jo400228g</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jo400228g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjo400228g%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DAu%252528I%252529%25252FAg%252528I%252529-Catalyzed%252BCascade%252BApproach%252Bfor%252Bthe%252BSynthesis%252Bof%252BBenzo%25255B4%25252C5%25255Dimidazo%25255B1%25252C2-c%25255Dpyrrolo%25255B1%25252C2-a%25255Dquinazolinones%26aulast%3DJi%26aufirst%3DXun%26date%3D2013%26date%3D2013%26date%3D2013%26date%3D08022013%26date%3D19042013%26date%3D03052013%26date%3D04042013%26volume%3D78%26issue%3D9%26spage%3D4312%26epage%3D4318" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bing  Yang</span>, <span class="hlFld-ContribAuthor ">Jiahua  Zhou</span>, <span class="hlFld-ContribAuthor ">Fa  Wang</span>, <span class="hlFld-ContribAuthor ">Xiao-Wei  Hu</span>, <span class="hlFld-ContribAuthor ">Yujun  Shi</span>. </span><span class="cited-content_cbyCitation_article-title">Pyrazoline derivatives as tubulin polymerization inhibitors with one hit for Vascular Endothelial Growth Factor Receptor 2 inhibition. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>114 </em>, 105134. <a href="https://doi.org/10.1016/j.bioorg.2021.105134" title="DOI URL">https://doi.org/10.1016/j.bioorg.2021.105134</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2021.105134&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2021.105134%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DPyrazoline%252Bderivatives%252Bas%252Btubulin%252Bpolymerization%252Binhibitors%252Bwith%252Bone%252Bhit%252Bfor%252BVascular%252BEndothelial%252BGrowth%252BFactor%252BReceptor%252B2%252Binhibition%26aulast%3DYang%26aufirst%3DBing%26date%3D2021%26volume%3D114%26spage%3D105134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Saad R.  Atta-Allah</span>, <span class="hlFld-ContribAuthor ">Asmaa M.  AboulMagd</span>, <span class="hlFld-ContribAuthor ">Paula S.  Farag</span>. </span><span class="cited-content_cbyCitation_article-title">Design, microwave assisted synthesis, and molecular modeling study of some new 1,3,4-thiadiazole derivatives as potent anticancer agents and potential VEGFR-2 inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2021,</strong> <em>112 </em>, 104923. <a href="https://doi.org/10.1016/j.bioorg.2021.104923" title="DOI URL">https://doi.org/10.1016/j.bioorg.2021.104923</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2021.104923&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2021.104923%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDesign%25252C%252Bmicrowave%252Bassisted%252Bsynthesis%25252C%252Band%252Bmolecular%252Bmodeling%252Bstudy%252Bof%252Bsome%252Bnew%252B1%25252C3%25252C4-thiadiazole%252Bderivatives%252Bas%252Bpotent%252Banticancer%252Bagents%252Band%252Bpotential%252BVEGFR-2%252Binhibitors%26aulast%3DAtta-Allah%26aufirst%3DSaad%2BR.%26date%3D2021%26volume%3D112%26spage%3D104923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Helen S.  Beeston</span>, <span class="hlFld-ContribAuthor ">Tobias  Klein</span>, <span class="hlFld-ContribAuthor ">Richard A.  Norman</span>, <span class="hlFld-ContribAuthor ">Julie A.  Tucker</span>, <span class="hlFld-ContribAuthor ">Malcolm  Anderson</span>, <span class="hlFld-ContribAuthor ">Alison E.  Ashcroft</span>, <span class="hlFld-ContribAuthor ">Geoffrey A.  Holdgate</span>. </span><span class="cited-content_cbyCitation_article-title">Validation of ion mobility spectrometry ‐ mass spectrometry as a screening tool to identify type II kinase inhibitors of FGFR1 kinase. </span><span class="cited-content_cbyCitation_journal-name">Rapid Communications in Mass Spectrometry</span><span> <strong>2021,</strong> <em>6 </em><a href="https://doi.org/10.1002/rcm.9130" title="DOI URL">https://doi.org/10.1002/rcm.9130</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/rcm.9130&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Frcm.9130%26sid%3Dliteratum%253Aachs%26jtitle%3DRapid%2520Communications%2520in%2520Mass%2520Spectrometry%26atitle%3DValidation%252Bof%252Bion%252Bmobility%252Bspectrometry%252B%2525E2%252580%252590%252Bmass%252Bspectrometry%252Bas%252Ba%252Bscreening%252Btool%252Bto%252Bidentify%252Btype%252BII%252Bkinase%252Binhibitors%252Bof%252BFGFR1%252Bkinase%26aulast%3DBeeston%26aufirst%3DHelen%2BS.%26date%3D2021%26date%3D2021%26volume%3D6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Viola  Previtali</span>, <span class="hlFld-ContribAuthor ">Helene B.  Mihigo</span>, <span class="hlFld-ContribAuthor ">Rebecca  Amet</span>, <span class="hlFld-ContribAuthor ">Anthony M.  McElligott</span>, <span class="hlFld-ContribAuthor ">Daniela M.  Zisterer</span>, <span class="hlFld-ContribAuthor ">Isabel  Rozas</span>. </span><span class="cited-content_cbyCitation_article-title">Exploring the Anti-Cancer Mechanism of Novel 3,4′-Substituted Diaryl Guanidinium Derivatives. </span><span class="cited-content_cbyCitation_journal-name">Pharmaceuticals</span><span> <strong>2020,</strong> <em>13 </em>
                                    (12)
                                     , 485. <a href="https://doi.org/10.3390/ph13120485" title="DOI URL">https://doi.org/10.3390/ph13120485</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ph13120485&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fph13120485%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmaceuticals%26atitle%3DExploring%252Bthe%252BAnti-Cancer%252BMechanism%252Bof%252BNovel%252B3%25252C4%2525E2%252580%2525B2-Substituted%252BDiaryl%252BGuanidinium%252BDerivatives%26aulast%3DPrevitali%26aufirst%3DViola%26date%3D2020%26date%3D2020%26volume%3D13%26issue%3D12%26spage%3D485" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lamya H.  Al-Wahaibi</span>, <span class="hlFld-ContribAuthor ">Ahmed M.  Gouda</span>, <span class="hlFld-ContribAuthor ">Ola F.  Abou-Ghadir</span>, <span class="hlFld-ContribAuthor ">Ola I.A.  Salem</span>, <span class="hlFld-ContribAuthor ">Asmaa T.  Ali</span>, <span class="hlFld-ContribAuthor ">Hatem S.  Farghaly</span>, <span class="hlFld-ContribAuthor ">Mostafa H.  Abdelrahman</span>, <span class="hlFld-ContribAuthor ">Laurent  Trembleau</span>, <span class="hlFld-ContribAuthor ">Hajjaj H.M.  Abdu-Allah</span>, <span class="hlFld-ContribAuthor ">Bahaa G.M.  Youssif</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of novel 2,3-dihydropyrazino[1,2-a]indole-1,4-dione derivatives as antiproliferative EGFR and BRAFV600E dual inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>104 </em>, 104260. <a href="https://doi.org/10.1016/j.bioorg.2020.104260" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.104260</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.104260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.104260%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252Bnovel%252B2%25252C3-dihydropyrazino%25255B1%25252C2-a%25255Dindole-1%25252C4-dione%252Bderivatives%252Bas%252Bantiproliferative%252BEGFR%252Band%252BBRAFV600E%252Bdual%252Binhibitors%26aulast%3DAl-Wahaibi%26aufirst%3DLamya%2BH.%26date%3D2020%26volume%3D104%26spage%3D104260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chelliah  Selvam</span>, <span class="hlFld-ContribAuthor ">Charlotta D.  Mock</span>, <span class="hlFld-ContribAuthor ">Omana P.  Mathew</span>, <span class="hlFld-ContribAuthor ">Kasturi  Ranganna</span>, <span class="hlFld-ContribAuthor ">Ramasamy  Thilagavathi</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Vascular Endothelial Growth Factor Receptor‐2 (VEGFR‐2) Inhibitors by Ligand‐based Virtual High Throughput Screening. </span><span class="cited-content_cbyCitation_journal-name">Molecular Informatics</span><span> <strong>2020,</strong> <em>39 </em>
                                    (7)
                                     , 1900150. <a href="https://doi.org/10.1002/minf.201900150" title="DOI URL">https://doi.org/10.1002/minf.201900150</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/minf.201900150&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fminf.201900150%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Informatics%26atitle%3DDiscovery%252Bof%252BVascular%252BEndothelial%252BGrowth%252BFactor%252BReceptor%2525E2%252580%2525902%252B%252528VEGFR%2525E2%252580%2525902%252529%252BInhibitors%252Bby%252BLigand%2525E2%252580%252590based%252BVirtual%252BHigh%252BThroughput%252BScreening%26aulast%3DSelvam%26aufirst%3DChelliah%26date%3D2020%26date%3D2020%26volume%3D39%26issue%3D7%26spage%3D1900150" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Janos  Sapi</span>, <span class="hlFld-ContribAuthor ">Stéphane  Gérard</span>. </span><span class="cited-content_cbyCitation_article-title">Bicyclic 5-6 Systems: Three Heteroatoms 2:1. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2020,</strong>,<a href="https://doi.org/10.1016/B978-0-12-818655-8.00021-4" title="DOI URL">https://doi.org/10.1016/B978-0-12-818655-8.00021-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-818655-8.00021-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-818655-8.00021-4%26sid%3Dliteratum%253Aachs%26atitle%3DBicyclic%252B5-6%252BSystems%25253A%252BThree%252BHeteroatoms%252B2%25253A1%26aulast%3DSapi%26aufirst%3DJanos%26date%3D2020%26pub%3DElsevier%26atitle%3DReference%252BModule%252Bin%252BChemistry%25252C%252BMolecular%252BSciences%252Band%252BChemical%252BEngineering%26date%3D2020%26volume%3Dvol.%252010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xu  Yuan</span>, <span class="hlFld-ContribAuthor ">Qingyi  Yang</span>, <span class="hlFld-ContribAuthor ">Tongyan  Liu</span>, <span class="hlFld-ContribAuthor ">Ke  Li</span>, <span class="hlFld-ContribAuthor ">Yuwen  Liu</span>, <span class="hlFld-ContribAuthor ">Changcheng  Zhu</span>, <span class="hlFld-ContribAuthor ">Zhiyun  Zhang</span>, <span class="hlFld-ContribAuthor ">Linghua  Li</span>, <span class="hlFld-ContribAuthor ">Conghai  Zhang</span>, <span class="hlFld-ContribAuthor ">Mingjin  Xie</span>, <span class="hlFld-ContribAuthor ">Jun  Lin</span>, <span class="hlFld-ContribAuthor ">Jihong  Zhang</span>, <span class="hlFld-ContribAuthor ">Yi  Jin</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and in vitro evaluation of 6-amide-2-aryl benzoxazole/benzimidazole derivatives against tumor cells by inhibiting VEGFR-2 kinase. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>179 </em>, 147-165. <a href="https://doi.org/10.1016/j.ejmech.2019.06.054" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.06.054</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.06.054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.06.054%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bin%2525C2%2525A0vitro%252Bevaluation%252Bof%252B6-amide-2-aryl%252Bbenzoxazole%25252Fbenzimidazole%252Bderivatives%252Bagainst%252Btumor%252Bcells%252Bby%252Binhibiting%252BVEGFR-2%252Bkinase%26aulast%3DYuan%26aufirst%3DXu%26date%3D2019%26volume%3D179%26spage%3D147%26epage%3D165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Heba T.  Abdel-Mohsen</span>, <span class="hlFld-ContribAuthor ">Mohamed A.  Omar</span>, <span class="hlFld-ContribAuthor ">Ahmed M.  El Kerdawy</span>, <span class="hlFld-ContribAuthor ">Abeer E.E.  Mahmoud</span>, <span class="hlFld-ContribAuthor ">Mamdouh M.  Ali</span>, <span class="hlFld-ContribAuthor ">Hoda I.  El Diwani</span>. </span><span class="cited-content_cbyCitation_article-title">Novel potent substituted 4-amino-2-thiopyrimidines as dual VEGFR-2 and BRAF kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>179 </em>, 707-722. <a href="https://doi.org/10.1016/j.ejmech.2019.06.063" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.06.063</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.06.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.06.063%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DNovel%252Bpotent%252Bsubstituted%252B4-amino-2-thiopyrimidines%252Bas%252Bdual%252BVEGFR-2%252Band%252BBRAF%252Bkinase%252Binhibitors%26aulast%3DAbdel-Mohsen%26aufirst%3DHeba%2BT.%26date%3D2019%26volume%3D179%26spage%3D707%26epage%3D722" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anuprita  Turwankar</span>, <span class="hlFld-ContribAuthor ">Surendra  Ghaskadbi</span>. </span><span class="cited-content_cbyCitation_article-title">VEGF and FGF signaling during head regeneration in hydra. </span><span class="cited-content_cbyCitation_journal-name">Gene</span><span> <strong>2019,</strong> <em>717 </em>, 144047. <a href="https://doi.org/10.1016/j.gene.2019.144047" title="DOI URL">https://doi.org/10.1016/j.gene.2019.144047</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.gene.2019.144047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.gene.2019.144047%26sid%3Dliteratum%253Aachs%26jtitle%3DGene%26atitle%3DVEGF%252Band%252BFGF%252Bsignaling%252Bduring%252Bhead%252Bregeneration%252Bin%252Bhydra%26aulast%3DTurwankar%26aufirst%3DAnuprita%26date%3D2019%26volume%3D717%26spage%3D144047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Siddharth J.  Modi</span>, <span class="hlFld-ContribAuthor ">Vithal M.  Kulkarni</span>. </span><span class="cited-content_cbyCitation_article-title">Vascular Endothelial Growth Factor Receptor (VEGFR-2)/KDR Inhibitors: Medicinal Chemistry Perspective. </span><span class="cited-content_cbyCitation_journal-name">Medicine in Drug Discovery</span><span> <strong>2019,</strong> <em>2 </em>, 100009. <a href="https://doi.org/10.1016/j.medidd.2019.100009" title="DOI URL">https://doi.org/10.1016/j.medidd.2019.100009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.medidd.2019.100009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.medidd.2019.100009%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicine%2520in%2520Drug%2520Discovery%26atitle%3DVascular%252BEndothelial%252BGrowth%252BFactor%252BReceptor%252B%252528VEGFR-2%252529%25252FKDR%252BInhibitors%25253A%252BMedicinal%252BChemistry%252BPerspective%26aulast%3DModi%26aufirst%3DSiddharth%2BJ.%26date%3D2019%26volume%3D2%26spage%3D100009" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yu  Wang</span>, <span class="hlFld-ContribAuthor ">Cheng  Peng</span>, <span class="hlFld-ContribAuthor ">Guimin  Wang</span>, <span class="hlFld-ContribAuthor ">Zhijian  Xu</span>, <span class="hlFld-ContribAuthor ">Yongfeng  Luo</span>, <span class="hlFld-ContribAuthor ">Jinan  Wang</span>, <span class="hlFld-ContribAuthor ">Weiliang  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Exploring binding mechanisms of VEGFR2 with three drugs lenvatinib, sorafenib, and sunitinib by molecular dynamics simulation and free energy calculation. </span><span class="cited-content_cbyCitation_journal-name">Chemical Biology & Drug Design</span><span> <strong>2019,</strong> <em>93 </em>
                                    (5)
                                     , 934-948. <a href="https://doi.org/10.1111/cbdd.13493" title="DOI URL">https://doi.org/10.1111/cbdd.13493</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cbdd.13493&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcbdd.13493%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Biology%2520%2526%2520Drug%2520Design%26atitle%3DExploring%252Bbinding%252Bmechanisms%252Bof%252BVEGFR2%252Bwith%252Bthree%252Bdrugs%252Blenvatinib%25252C%252Bsorafenib%25252C%252Band%252Bsunitinib%252Bby%252Bmolecular%252Bdynamics%252Bsimulation%252Band%252Bfree%252Benergy%252Bcalculation%26aulast%3DWang%26aufirst%3DYu%26date%3D2019%26date%3D2019%26volume%3D93%26issue%3D5%26spage%3D934%26epage%3D948" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Arun K.  Ghosh</span>, <span class="hlFld-ContribAuthor ">Margherita  Brindisi</span>, <span class="hlFld-ContribAuthor ">Anindya  Sarkar</span>. </span><span class="cited-content_cbyCitation_article-title">The Curtius Rearrangement: Applications in Modern Drug Discovery and Medicinal Chemistry. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2018,</strong> <em>13 </em>
                                    (22)
                                     , 2351-2373. <a href="https://doi.org/10.1002/cmdc.201800518" title="DOI URL">https://doi.org/10.1002/cmdc.201800518</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201800518&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201800518%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DThe%252BCurtius%252BRearrangement%25253A%252BApplications%252Bin%252BModern%252BDrug%252BDiscovery%252Band%252BMedicinal%252BChemistry%26aulast%3DGhosh%26aufirst%3DArun%2BK.%26date%3D2018%26date%3D2018%26volume%3D13%26issue%3D22%26spage%3D2351%26epage%3D2373" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shelli M.  Morris</span>, <span class="hlFld-ContribAuthor ">Andrew J.  Mhyre</span>, <span class="hlFld-ContribAuthor ">Savanna S.  Carmack</span>, <span class="hlFld-ContribAuthor ">Carrie H.  Myers</span>, <span class="hlFld-ContribAuthor ">Connor  Burns</span>, <span class="hlFld-ContribAuthor ">Wenjuan  Ye</span>, <span class="hlFld-ContribAuthor ">Marc  Ferrer</span>, <span class="hlFld-ContribAuthor ">James M.  Olson</span>, <span class="hlFld-ContribAuthor ">Richard A.  Klinghoffer</span>. </span><span class="cited-content_cbyCitation_article-title">A modified gene trap approach for improved high-throughput cancer drug discovery. </span><span class="cited-content_cbyCitation_journal-name">Oncogene</span><span> <strong>2018,</strong> <em>37 </em>
                                    (31)
                                     , 4226-4238. <a href="https://doi.org/10.1038/s41388-018-0274-4" title="DOI URL">https://doi.org/10.1038/s41388-018-0274-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41388-018-0274-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41388-018-0274-4%26sid%3Dliteratum%253Aachs%26jtitle%3DOncogene%26atitle%3DA%252Bmodified%252Bgene%252Btrap%252Bapproach%252Bfor%252Bimproved%252Bhigh-throughput%252Bcancer%252Bdrug%252Bdiscovery%26aulast%3DMorris%26aufirst%3DShelli%2BM.%26date%3D2018%26date%3D2018%26volume%3D37%26issue%3D31%26spage%3D4226%26epage%3D4238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wuji  Sun</span>, <span class="hlFld-ContribAuthor ">Shubiao  Fang</span>, <span class="hlFld-ContribAuthor ">Hong  Yan</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel picolinamide-based derivatives as novel VEGFR-2 kinase inhibitors: synthesis,
              in vitro
              biological evaluation and molecular docking. </span><span class="cited-content_cbyCitation_journal-name">MedChemComm</span><span> <strong>2018,</strong> <em>9 </em>
                                    (6)
                                     , 1054-1058. <a href="https://doi.org/10.1039/C8MD00057C" title="DOI URL">https://doi.org/10.1039/C8MD00057C</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C8MD00057C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC8MD00057C%26sid%3Dliteratum%253Aachs%26jtitle%3DMedChemComm%26atitle%3DDiscovery%252Bof%252Bnovel%252Bpicolinamide-based%252Bderivatives%252Bas%252Bnovel%252BVEGFR-2%252Bkinase%252Binhibitors%25253A%252Bsynthesis%25252C%252Bin%252Bvitro%252Bbiological%252Bevaluation%252Band%252Bmolecular%252Bdocking%26aulast%3DSun%26aufirst%3DWuji%26date%3D2018%26date%3D2018%26volume%3D9%26issue%3D6%26spage%3D1054%26epage%3D1058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ashraf Kareem  El-Damasy</span>, <span class="hlFld-ContribAuthor ">Ju-Hyeon  Lee</span>, <span class="hlFld-ContribAuthor ">Seon Hee  Seo</span>, <span class="hlFld-ContribAuthor ">Nam-Chul  Cho</span>, <span class="hlFld-ContribAuthor ">Ae Nim  Pae</span>, <span class="hlFld-ContribAuthor ">Gyochang  Keum</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of new potent anticancer benzothiazole amides and ureas featuring pyridylamide moiety and possessing dual B-RafV600E and C-Raf kinase inhibitory activities. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>115 </em>, 201-216. <a href="https://doi.org/10.1016/j.ejmech.2016.02.039" title="DOI URL">https://doi.org/10.1016/j.ejmech.2016.02.039</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2016.02.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2016.02.039%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252Bnew%252Bpotent%252Banticancer%252Bbenzothiazole%252Bamides%252Band%252Bureas%252Bfeaturing%252Bpyridylamide%252Bmoiety%252Band%252Bpossessing%252Bdual%252BB-RafV600E%252Band%252BC-Raf%252Bkinase%252Binhibitory%252Bactivities%26aulast%3DEl-Damasy%26aufirst%3DAshraf%2BKareem%26date%3D2016%26volume%3D115%26spage%3D201%26epage%3D216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jingya  Zhang</span>, <span class="hlFld-ContribAuthor ">Linna  Zhang</span>, <span class="hlFld-ContribAuthor ">Yuanyou  Wang</span>, <span class="hlFld-ContribAuthor ">Guisen  Zhao</span>. </span><span class="cited-content_cbyCitation_article-title">Development of anti-angiogenic tyrosine kinases inhibitors: molecular structures and binding modes. </span><span class="cited-content_cbyCitation_journal-name">Cancer Chemotherapy and Pharmacology</span><span> <strong>2016,</strong> <em>77 </em>
                                    (5)
                                     , 905-926. <a href="https://doi.org/10.1007/s00280-016-2961-6" title="DOI URL">https://doi.org/10.1007/s00280-016-2961-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00280-016-2961-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00280-016-2961-6%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Chemotherapy%2520and%2520Pharmacology%26atitle%3DDevelopment%252Bof%252Banti-angiogenic%252Btyrosine%252Bkinases%252Binhibitors%25253A%252Bmolecular%252Bstructures%252Band%252Bbinding%252Bmodes%26aulast%3DZhang%26aufirst%3DJingya%26date%3D2016%26date%3D2016%26volume%3D77%26issue%3D5%26spage%3D905%26epage%3D926" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Silvia  Salerno</span>, <span class="hlFld-ContribAuthor ">Anna Maria  Marini</span>, <span class="hlFld-ContribAuthor ">Giacomo  Fornaciari</span>, <span class="hlFld-ContribAuthor ">Francesca  Simorini</span>, <span class="hlFld-ContribAuthor ">Concettina  La Motta</span>, <span class="hlFld-ContribAuthor ">Sabrina  Taliani</span>, <span class="hlFld-ContribAuthor ">Stefania  Sartini</span>, <span class="hlFld-ContribAuthor ">Federico  Da Settimo</span>, <span class="hlFld-ContribAuthor ">Aída Nelly  García-Argáez</span>, <span class="hlFld-ContribAuthor ">Ornella  Gia</span>, <span class="hlFld-ContribAuthor ">Sandro  Cosconati</span>, <span class="hlFld-ContribAuthor ">Ettore  Novellino</span>, <span class="hlFld-ContribAuthor ">Pilar  D'Ocon</span>, <span class="hlFld-ContribAuthor ">Anna  Fioravanti</span>, <span class="hlFld-ContribAuthor ">Paola  Orlandi</span>, <span class="hlFld-ContribAuthor ">Guido  Bocci</span>, <span class="hlFld-ContribAuthor ">Lisa  Dalla Via</span>. </span><span class="cited-content_cbyCitation_article-title">Investigation of new 2-aryl substituted Benzothiopyrano[4,3-d]pyrimidines as kinase inhibitors targeting vascular endothelial growth factor receptor 2. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>103 </em>, 29-43. <a href="https://doi.org/10.1016/j.ejmech.2015.08.027" title="DOI URL">https://doi.org/10.1016/j.ejmech.2015.08.027</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2015.08.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2015.08.027%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DInvestigation%252Bof%252Bnew%252B2-aryl%252Bsubstituted%252BBenzothiopyrano%25255B4%25252C3-d%25255Dpyrimidines%252Bas%252Bkinase%252Binhibitors%252Btargeting%252Bvascular%252Bendothelial%252Bgrowth%252Bfactor%252Breceptor%252B2%26aulast%3DSalerno%26aufirst%3DSilvia%26date%3D2015%26volume%3D103%26spage%3D29%26epage%3D43" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hai-Chun  Liu</span>, <span class="hlFld-ContribAuthor ">San-Zhi  Tang</span>, <span class="hlFld-ContribAuthor ">Shuai  Lu</span>, <span class="hlFld-ContribAuthor ">Ting  Ran</span>, <span class="hlFld-ContribAuthor ">Jian  Wang</span>, <span class="hlFld-ContribAuthor ">Yan-Min  Zhang</span>, <span class="hlFld-ContribAuthor ">An-Yang  Xu</span>, <span class="hlFld-ContribAuthor ">Tao  Lu</span>, <span class="hlFld-ContribAuthor ">Ya-Dong  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Studies on [5,6]-Fused Bicyclic Scaffolds Derivatives as  Potent Dual B-RafV600E/KDR Inhibitors Using Docking  and 3D-QSAR Approaches. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2015,</strong> <em>16 </em>
                                    (10)
                                     , 24451-24474. <a href="https://doi.org/10.3390/ijms161024451" title="DOI URL">https://doi.org/10.3390/ijms161024451</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms161024451&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms161024451%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DStudies%252Bon%252B%25255B5%25252C6%25255D-Fused%252BBicyclic%252BScaffolds%252BDerivatives%252Bas%252BPotent%252BDual%252BB-RafV600E%25252FKDR%252BInhibitors%252BUsing%252BDocking%252Band%252B3D-QSAR%252BApproaches%26aulast%3DLiu%26aufirst%3DHai-Chun%26date%3D2015%26date%3D2015%26volume%3D16%26issue%3D10%26spage%3D24451%26epage%3D24474" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ping  Su</span>, <span class="hlFld-ContribAuthor ">Jinfeng  Wang</span>, <span class="hlFld-ContribAuthor ">Yaling  Shi</span>, <span class="hlFld-ContribAuthor ">Xiaoyan  Pan</span>, <span class="hlFld-ContribAuthor ">Ruili  Shao</span>, <span class="hlFld-ContribAuthor ">Jie  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of biphenyl-aryl ureas as novel VEGFR-2 inhibitors. Part 4: Exploration of diverse hinge-binding fragments. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2015,</strong> <em>23 </em>
                                    (13)
                                     , 3228-3236. <a href="https://doi.org/10.1016/j.bmc.2015.04.071" title="DOI URL">https://doi.org/10.1016/j.bmc.2015.04.071</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2015.04.071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2015.04.071%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bbiphenyl-aryl%252Bureas%252Bas%252Bnovel%252BVEGFR-2%252Binhibitors.%252BPart%252B4%25253A%252BExploration%252Bof%252Bdiverse%252Bhinge-binding%252Bfragments%26aulast%3DSu%26aufirst%3DPing%26date%3D2015%26volume%3D23%26issue%3D13%26spage%3D3228%26epage%3D3236" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rangappa S.  Keri</span>, <span class="hlFld-ContribAuthor ">Mahadeo R.  Patil</span>, <span class="hlFld-ContribAuthor ">Siddappa A.  Patil</span>, <span class="hlFld-ContribAuthor ">Srinivasa  Budagumpi</span>. </span><span class="cited-content_cbyCitation_article-title">A comprehensive review in current developments of benzothiazole-based molecules in medicinal chemistry. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>89 </em>, 207-251. <a href="https://doi.org/10.1016/j.ejmech.2014.10.059" title="DOI URL">https://doi.org/10.1016/j.ejmech.2014.10.059</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2014.10.059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2014.10.059%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DA%252Bcomprehensive%252Breview%252Bin%252Bcurrent%252Bdevelopments%252Bof%252Bbenzothiazole-based%252Bmolecules%252Bin%252Bmedicinal%252Bchemistry%26aulast%3DKeri%26aufirst%3DRangappa%2BS.%26date%3D2015%26volume%3D89%26spage%3D207%26epage%3D251" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Carolina  Hertzman Johansson</span>, <span class="hlFld-ContribAuthor ">Suzanne  Egyhazi Brage</span>. </span><span class="cited-content_cbyCitation_article-title">BRAF inhibitors in cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">Pharmacology & Therapeutics</span><span> <strong>2014,</strong> <em>142 </em>
                                    (2)
                                     , 176-182. <a href="https://doi.org/10.1016/j.pharmthera.2013.11.011" title="DOI URL">https://doi.org/10.1016/j.pharmthera.2013.11.011</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.pharmthera.2013.11.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.pharmthera.2013.11.011%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacology%2520%2526%2520Therapeutics%26atitle%3DBRAF%252Binhibitors%252Bin%252Bcancer%252Btherapy%26aulast%3DHertzman%2BJohansson%26aufirst%3DCarolina%26date%3D2014%26volume%3D142%26issue%3D2%26spage%3D176%26epage%3D182" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kin-Chun  Luk</span>, <span class="hlFld-ContribAuthor ">Alexander Lee  Satz</span>. </span><span class="cited-content_cbyCitation_article-title">DNA-Compatible Chemistry. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2014,</strong>,, 67-98. <a href="https://doi.org/10.1002/9781118832738.ch4" title="DOI URL">https://doi.org/10.1002/9781118832738.ch4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9781118832738.ch4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9781118832738.ch4%26sid%3Dliteratum%253Aachs%26atitle%3DDNA-Compatible%252BChemistry%26aulast%3DLuk%26aufirst%3DKin-Chun%26date%3D2014%26date%3D2014%26spage%3D67%26epage%3D98%26pub%3DJohn%2520Wiley%2520%2526%2520Sons%252C%2520Inc%26atitle%3DA%252BHandbook%252Bfor%252BDNA-Encoded%252BChemistry%26aulast%3DGoodnow%26aufirst%3DRobert%2BA.%26date%3D2014%26volume%3D7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Siddaiah  Vidavalur</span>, <span class="hlFld-ContribAuthor ">Mahaboob Basha  Gajula</span>, <span class="hlFld-ContribAuthor ">Ramu  Tadikonda</span>, <span class="hlFld-ContribAuthor ">Mangarao  Nakka</span>, <span class="hlFld-ContribAuthor ">Sudhakar  Dega</span>, <span class="hlFld-ContribAuthor ">Santosh Kumar  Yadav</span>, <span class="hlFld-ContribAuthor ">Christopher  Voosala</span>. </span><span class="cited-content_cbyCitation_article-title">PTSA catalyzed straightforward protocol for the synthesis of 2-(N-acyl)aminobenzimidazoles and 2-(N-acyl)aminobenzothiazoles in PEG. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron Letters</span><span> <strong>2014,</strong> <em>55 </em>
                                    (16)
                                     , 2691-2694. <a href="https://doi.org/10.1016/j.tetlet.2014.03.040" title="DOI URL">https://doi.org/10.1016/j.tetlet.2014.03.040</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetlet.2014.03.040&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetlet.2014.03.040%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%2520Letters%26atitle%3DPTSA%252Bcatalyzed%252Bstraightforward%252Bprotocol%252Bfor%252Bthe%252Bsynthesis%252Bof%252B2-%252528N-acyl%252529aminobenzimidazoles%252Band%252B2-%252528N-acyl%252529aminobenzothiazoles%252Bin%252BPEG%26aulast%3DVidavalur%26aufirst%3DSiddaiah%26date%3D2014%26volume%3D55%26issue%3D16%26spage%3D2691%26epage%3D2694" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hala Bakr  El-Nassan</span>. </span><span class="cited-content_cbyCitation_article-title">Recent progress in the identification of BRAF inhibitors as anti-cancer agents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>72 </em>, 170-205. <a href="https://doi.org/10.1016/j.ejmech.2013.11.018" title="DOI URL">https://doi.org/10.1016/j.ejmech.2013.11.018</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2013.11.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2013.11.018%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Bprogress%252Bin%252Bthe%252Bidentification%252Bof%252BBRAF%252Binhibitors%252Bas%252Banti-cancer%252Bagents%26aulast%3DEl-Nassan%26aufirst%3DHala%2BBakr%26date%3D2014%26volume%3D72%26spage%3D170%26epage%3D205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaoyun  Chai</span>, <span class="hlFld-ContribAuthor ">Shichong  Yu</span>, <span class="hlFld-ContribAuthor ">Xiaoyan  Wang</span>, <span class="hlFld-ContribAuthor ">Nan  Wang</span>, <span class="hlFld-ContribAuthor ">Zhanzhou  Zhu</span>, <span class="hlFld-ContribAuthor ">Dazhi  Zhang</span>, <span class="hlFld-ContribAuthor ">Qiuye  Wu</span>, <span class="hlFld-ContribAuthor ">Yongbing  Cao</span>, <span class="hlFld-ContribAuthor ">Qingyan  Sun</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and antifungal activity of novel 7-O-substituted pyridyl-4-methyl coumarin derivatives. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Chemistry Research</span><span> <strong>2013,</strong> <em>22 </em>
                                    (10)
                                     , 4654-4662. <a href="https://doi.org/10.1007/s00044-013-0470-2" title="DOI URL">https://doi.org/10.1007/s00044-013-0470-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00044-013-0470-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00044-013-0470-2%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Chemistry%2520Research%26atitle%3DSynthesis%252Band%252Bantifungal%252Bactivity%252Bof%252Bnovel%252B7-O-substituted%252Bpyridyl-4-methyl%252Bcoumarin%252Bderivatives%26aulast%3DChai%26aufirst%3DXiaoyun%26date%3D2013%26date%3D2013%26volume%3D22%26issue%3D10%26spage%3D4654%26epage%3D4662" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yunfeng  Xie</span>, <span class="hlFld-ContribAuthor ">Xianjie  Chen</span>, <span class="hlFld-ContribAuthor ">Jie  Qin</span>, <span class="hlFld-ContribAuthor ">Xiangqian  Kong</span>, <span class="hlFld-ContribAuthor ">Fei  Ye</span>, <span class="hlFld-ContribAuthor ">Yuren  Jiang</span>, <span class="hlFld-ContribAuthor ">Hong  Liu</span>, <span class="hlFld-ContribAuthor ">Hualiang  Jiang</span>, <span class="hlFld-ContribAuthor ">Ronen  Marmorstein</span>, <span class="hlFld-ContribAuthor ">Cheng  Luo</span>. </span><span class="cited-content_cbyCitation_article-title">Identification and synthesis of N-(thiophen-2-yl) benzamide derivatives as BRAFV600E inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2013,</strong> <em>23 </em>
                                    (8)
                                     , 2306-2312. <a href="https://doi.org/10.1016/j.bmcl.2013.02.072" title="DOI URL">https://doi.org/10.1016/j.bmcl.2013.02.072</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2013.02.072&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2013.02.072%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DIdentification%252Band%252Bsynthesis%252Bof%252BN-%252528thiophen-2-yl%252529%252Bbenzamide%252Bderivatives%252Bas%252BBRAFV600E%252Binhibitors%26aulast%3DXie%26aufirst%3DYunfeng%26date%3D2013%26volume%3D23%26issue%3D8%26spage%3D2306%26epage%3D2312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaolun  Wang</span>, <span class="hlFld-ContribAuthor ">Kristin  Schleicher</span>. </span><span class="cited-content_cbyCitation_article-title">Conformation-Specific Inhibitors of Raf Kinases. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2013,</strong>,, 41-66. <a href="https://doi.org/10.1016/B978-0-12-420146-0.00003-2" title="DOI URL">https://doi.org/10.1016/B978-0-12-420146-0.00003-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-420146-0.00003-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-420146-0.00003-2%26sid%3Dliteratum%253Aachs%26atitle%3DConformation-Specific%252BInhibitors%252Bof%252BRaf%252BKinases%26aulast%3DWang%26aufirst%3DXiaolun%26date%3D2013%26spage%3D41%26epage%3D66%26pub%3DElsevier%26atitle%3DInhibitors%252Bof%252Bthe%252BRas%252Bsuperfamily%252BG-proteins%25252C%252BPart%252BB%26date%3D2013%26volume%3D34" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Se Hun  Kwak</span>, <span class="hlFld-ContribAuthor ">Gee-Hyung  Lee</span>, <span class="hlFld-ContribAuthor ">Young-Dae  Gong</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis of N-Substituted-2-Aminothiazolo[4,5-b]pyrazines by Tandem Reaction of o-Aminohalopyrazines with Isothiocyanates. </span><span class="cited-content_cbyCitation_journal-name">Bulletin of the Korean Chemical Society</span><span> <strong>2012,</strong> <em>33 </em>
                                    (12)
                                     , 4271-4274. <a href="https://doi.org/10.5012/bkcs.2012.33.12.4271" title="DOI URL">https://doi.org/10.5012/bkcs.2012.33.12.4271</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.5012/bkcs.2012.33.12.4271&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.5012%2Fbkcs.2012.33.12.4271%26sid%3Dliteratum%253Aachs%26jtitle%3DBulletin%2520of%2520the%2520Korean%2520Chemical%2520Society%26atitle%3DSynthesis%252Bof%252BN-Substituted-2-Aminothiazolo%25255B4%25252C5-b%25255Dpyrazines%252Bby%252BTandem%252BReaction%252Bof%252Bo-Aminohalopyrazines%252Bwith%252BIsothiocyanates%26aulast%3DKwak%26aufirst%3DSe%2BHun%26date%3D2012%26volume%3D33%26issue%3D12%26spage%3D4271%26epage%3D4274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hassen  Bel Abed</span>, <span class="hlFld-ContribAuthor ">Oscar  Mammoliti</span>, <span class="hlFld-ContribAuthor ">Guy  Van Lommen</span>, <span class="hlFld-ContribAuthor ">Piet  Herdewijn</span>. </span><span class="cited-content_cbyCitation_article-title">A short and convenient strategy for the synthesis of pyridazines via Diaza–Wittig reaction. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron Letters</span><span> <strong>2012,</strong> <em>53 </em>
                                    (48)
                                     , 6489-6491. <a href="https://doi.org/10.1016/j.tetlet.2012.09.059" title="DOI URL">https://doi.org/10.1016/j.tetlet.2012.09.059</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetlet.2012.09.059&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetlet.2012.09.059%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%2520Letters%26atitle%3DA%252Bshort%252Band%252Bconvenient%252Bstrategy%252Bfor%252Bthe%252Bsynthesis%252Bof%252Bpyridazines%252Bvia%252BDiaza%2525E2%252580%252593Wittig%252Breaction%26aulast%3DBel%2BAbed%26aufirst%3DHassen%26date%3D2012%26volume%3D53%26issue%3D48%26spage%3D6489%26epage%3D6491" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Masaaki  Hirose</span>, <span class="hlFld-ContribAuthor ">Masanori  Okaniwa</span>, <span class="hlFld-ContribAuthor ">Tohru  Miyazaki</span>, <span class="hlFld-ContribAuthor ">Takashi  Imada</span>, <span class="hlFld-ContribAuthor ">Tomohiro  Ohashi</span>, <span class="hlFld-ContribAuthor ">Yuta  Tanaka</span>, <span class="hlFld-ContribAuthor ">Takeo  Arita</span>, <span class="hlFld-ContribAuthor ">Masato  Yabuki</span>, <span class="hlFld-ContribAuthor ">Tomohiro  Kawamoto</span>, <span class="hlFld-ContribAuthor ">Shunichirou  Tsutsumi</span>, <span class="hlFld-ContribAuthor ">Akihiko  Sumita</span>, <span class="hlFld-ContribAuthor ">Terufumi  Takagi</span>, <span class="hlFld-ContribAuthor ">Bi-Ching  Sang</span>, <span class="hlFld-ContribAuthor ">Jason  Yano</span>, <span class="hlFld-ContribAuthor ">Kathleen  Aertgeerts</span>, <span class="hlFld-ContribAuthor ">Sei  Yoshida</span>, <span class="hlFld-ContribAuthor ">Tomoyasu  Ishikawa</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of novel DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors: 3. Evaluation of 5-amino-linked thiazolo[5,4-d]pyrimidine and thiazolo[5,4-b]pyridine derivatives. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2012,</strong> <em>20 </em>
                                    (18)
                                     , 5600-5615. <a href="https://doi.org/10.1016/j.bmc.2012.07.032" title="DOI URL">https://doi.org/10.1016/j.bmc.2012.07.032</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2012.07.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2012.07.032%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252Bnovel%252BDFG-out%252BRAF%25252Fvascular%252Bendothelial%252Bgrowth%252Bfactor%252Breceptor%252B2%252B%252528VEGFR2%252529%252Binhibitors%25253A%252B3.%252BEvaluation%252Bof%252B5-amino-linked%252Bthiazolo%25255B5%25252C4-d%25255Dpyrimidine%252Band%252Bthiazolo%25255B5%25252C4-b%25255Dpyridine%252Bderivatives%26aulast%3DHirose%26aufirst%3DMasaaki%26date%3D2012%26volume%3D20%26issue%3D18%26spage%3D5600%26epage%3D5615" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lingyi  Huang</span>, <span class="hlFld-ContribAuthor ">Zhengui  Huang</span>, <span class="hlFld-ContribAuthor ">Zhiqiang  Bai</span>, <span class="hlFld-ContribAuthor ">Rui  Xie</span>, <span class="hlFld-ContribAuthor ">Liping  Sun</span>, <span class="hlFld-ContribAuthor ">Kejiang  Lin</span>. </span><span class="cited-content_cbyCitation_article-title">Development and strategies of VEGFR-2/KDR inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Future Medicinal Chemistry</span><span> <strong>2012,</strong> <em>4 </em>
                                    (14)
                                     , 1839-1852. <a href="https://doi.org/10.4155/fmc.12.121" title="DOI URL">https://doi.org/10.4155/fmc.12.121</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.4155/fmc.12.121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.4155%2Ffmc.12.121%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Medicinal%2520Chemistry%26atitle%3DDevelopment%252Band%252Bstrategies%252Bof%252BVEGFR-2%25252FKDR%252Binhibitors%26aulast%3DHuang%26aufirst%3DLingyi%26date%3D2012%26volume%3D4%26issue%3D14%26spage%3D1839%26epage%3D1852" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Masanori  Okaniwa</span>, <span class="hlFld-ContribAuthor ">Takashi  Imada</span>, <span class="hlFld-ContribAuthor ">Tomohiro  Ohashi</span>, <span class="hlFld-ContribAuthor ">Tohru  Miyazaki</span>, <span class="hlFld-ContribAuthor ">Takeo  Arita</span>, <span class="hlFld-ContribAuthor ">Masato  Yabuki</span>, <span class="hlFld-ContribAuthor ">Akihiko  Sumita</span>, <span class="hlFld-ContribAuthor ">Shunichirou  Tsutsumi</span>, <span class="hlFld-ContribAuthor ">Keiko  Higashikawa</span>, <span class="hlFld-ContribAuthor ">Terufumi  Takagi</span>, <span class="hlFld-ContribAuthor ">Tomohiro  Kawamoto</span>, <span class="hlFld-ContribAuthor ">Yoshitaka  Inui</span>, <span class="hlFld-ContribAuthor ">Sei  Yoshida</span>, <span class="hlFld-ContribAuthor ">Tomoyasu  Ishikawa</span>. </span><span class="cited-content_cbyCitation_article-title">Design and synthesis of novel DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors: 2. Synthesis and characterization of a novel imide-type prodrug for improving oral absorption. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2012,</strong> <em>20 </em>
                                    (15)
                                     , 4680-4692. <a href="https://doi.org/10.1016/j.bmc.2012.06.015" title="DOI URL">https://doi.org/10.1016/j.bmc.2012.06.015</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2012.06.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2012.06.015%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252Bsynthesis%252Bof%252Bnovel%252BDFG-out%252BRAF%25252Fvascular%252Bendothelial%252Bgrowth%252Bfactor%252Breceptor%252B2%252B%252528VEGFR2%252529%252Binhibitors%25253A%252B2.%252BSynthesis%252Band%252Bcharacterization%252Bof%252Ba%252Bnovel%252Bimide-type%252Bprodrug%252Bfor%252Bimproving%252Boral%252Babsorption%26aulast%3DOkaniwa%26aufirst%3DMasanori%26date%3D2012%26volume%3D20%26issue%3D15%26spage%3D4680%26epage%3D4692" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_null" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/medium/jm-2012-00126x_0028.gif" alt="" id="_i1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0028.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300126x&amp;id=f_null"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/medium/jm-2012-00126x_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Various BRAF inhibitors and their binding to the BRAF protein.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300126x&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/medium/jm-2012-00126x_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Design concept: (A) structures of hit compound <b>1a</b> and its analogue <b>1b</b>; (B) overlap modeling of <b>1b</b> (yellow) and sorafenib (purple) bound to BRAF(V600E) (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1UWJ">1UWJ</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300126x&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/medium/jm-2012-00126x_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Design of our DFG-out-type RAF inhibitors (left). Design of the [5,6]-fused bicyclic ring A (right).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300126x&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/medium/jm-2012-00126x_0018.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0018.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of N-Acylated 2-Aminoimidazo[1,2-<i>b</i>]pyridazines <b>1a</b>–<b>f</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300126x&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 3-aminophenol, K<sub>2</sub>CO<sub>3</sub>, DMF, 150 °C, 5 h (50%); (b) 3-(trifluoromethyl)benzoic acid, EDCI·HCl, HOBt, DMF, room temp, 3 h (86%); (c) 8 N NaOH aq, MeOH, H<sub>2</sub>O, room temp, 4 h (91%); (d) DPPA, Et<sub>3</sub>N, <sup><i>t</i></sup>BuOH, 100 °C, 14 h (89%); (e) 4 N HCl/EtOAc, MeOH, room temp, 14 h (67%); (f) R<sup>1</sup>CO<sub>2</sub>H (<b>a</b>, <b>c</b>, and <b>d</b>), EDCI·HCl, HOBt, DMF, room temp (42–81%); (g) R<sup>1</sup>COCl (<b>b</b>, <b>e</b>, <b>f</b>, and <b>g</b>), Et<sub>3</sub>N, THF, room temp (54–75%).</p></p></figure><figure data-id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/medium/jm-2012-00126x_0019.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0019.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Cyclopropyl Carbonylated 2-Aminoimidazo[1,2-<i>b</i>]pyridazines <b>1g</b>–<b>n</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0019.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300126x&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) ethyl (chloroacetyl)carbamate, Na<sub>2</sub>HPO<sub>4</sub>, DMF, 110 °C, 4 h (76%); (b) Ba(OH)<sub>2</sub>·8H<sub>2</sub>O, H<sub>2</sub>O, NMP, 120 °C, 12 h (71%); (c) cyclopropanecarbonyl chloride, DMA, room temp, 16 h (98%); (d) 3-aminophenol, K<sub>2</sub>CO<sub>3</sub>, DMF, 150 °C, 24 h (80%); (e) R<sup>3</sup>-C<sub>6</sub>H<sub>4</sub>CO<sub>2</sub>H (<b>h</b>, <b>l</b>, and <b>n</b>), EDCI, HOBt, DMF, room temp (68–77%); (f) R<sup>3</sup>-C<sub>6</sub>H<sub>4</sub>COCl (<b>i</b>, <b>j</b>, and <b>k</b>), NMP, room temp (43–75%); (g) 1.4 M methylmagnesium bromide in THF, toluene, room temp, 12 h (19%).</p></p></figure><figure data-id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/medium/jm-2012-00126x_0020.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0020.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Benzoic Acids <b>15n</b>–<b>q</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0020.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300126x&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) potassium cyanide, 18-crown-6, CH<sub>3</sub>CN, room temp, 3 days (91%) or sodium cyanide, DMF, 80 °C, 1 h (79%); (b) NaH, DMSO, room temp, then MeI, room temp (79–88%); (c) NaH, DMSO, room temp, then 1,2-dibromoethane, room temp (57–76%); (d) LiOH·H<sub>2</sub>O, THF, MeOH, H<sub>2</sub>O, room temp (61–98%); (e) NBS, AIBN, CH<sub>3</sub>CN, 90 °C, 26 h (66%).</p></p></figure><figure data-id="sch4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/medium/jm-2012-00126x_0021.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0021.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of Imidazo[1,2-<i>a</i>]pyridine <b>2</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0021.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300126x&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 3-nitrophenol, Cs<sub>2</sub>CO<sub>3</sub>, DMF, room temp, 12 h (54%); (b) H<sub>2</sub>, 10% Pd/C, MeOH, THF, EtOAc, room temp, 20 h, then 4 N HCl/EtOAc (quant); (c) 3-(1-cyano-1-methylethyl)benzoyl chloride, DMA, room temp, 18 h (66%); (d) 4-methylbenzenesulfonyl chloride, pyridine, 80 °C, 2 days (99%); (e) 2-iodoacetamide, DIEA, DMF, room temp, 48 h (63%); (f) TFAA, CH<sub>2</sub>Cl<sub>2</sub>, room temp, 16 h (52%); (g) 1 N NaOH aq, EtOH, 45 °C, 12 h (quant); (h) cyclopropanecarbonyl chloride, DMA, room temp, 8 h (43%).</p></p></figure><figure data-id="sch5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/medium/jm-2012-00126x_0022.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0022.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of 1<i>H</i>-Benzimidazole <b>3a</b>,<b>b</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0022.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300126x&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 40% methylamine solution, 0 °C, 1.5 h (99%); (b) <i>tert</i>-butyl (3-hydroxyphenyl)carbamate, K<sub>2</sub>CO<sub>3</sub>, DMF, 80–100 °C (69–100%); (c) H<sub>2</sub>, 10% Pd/C, THF, MeOH, room temp (quant); (d) BrCN, THF, room temp (69–100%); (e) cyclopropanecarbonyl chloride, DMAP, pyridine, room temp (65–98%); (f) TFA, reflux (88%); (g) <b>15n</b>, EDCI·HCl, DMAP, pyridine (38–69%).</p></p></figure><figure data-id="sch6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/medium/jm-2012-00126x_0023.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0023.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of Imidazo[4,5-<i>b</i>]pyridine <b>4</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0023.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300126x&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (COCl)<sub>2</sub>, cat. DMF, THF, room temp; (b) 3-aminophenol, NaHCO<sub>3</sub>, H<sub>2</sub>O, THF, room temp (96% in two steps); (c) <i>tert</i>-butylamine, toluene, or methylamine, THF, room temp (78–99%); (d) <b>30</b>, K<sub>2</sub>CO<sub>3</sub>, DMF, room temp, 18 h (72–88%); (e) H<sub>2</sub>, 10% Pd/C, MeOH, THF, room temp, 12 h; (f) BrCN, THF, room temp, 18 h (80–82% in two steps); (g) cyclopropanecarbonyl chloride, DMAP, pyridine, room temp (56–96%); (h) TFA, 80 °C, 2 h (82%).</p></p></figure><figure data-id="sch7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/medium/jm-2012-00126x_0024.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0024.jpeg" id="rightTab-gr16" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. Synthesis of 1,3-Benzothiazole <b>5</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0024.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300126x&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 3-aminophenol, K<sub>2</sub>CO<sub>3</sub>, DMF, 80 °C, 8 h (95%); (b) <b>15n</b>, EDCI·HCl, DMAP, pyridine, room temp, 4 h (99%); (c) H<sub>2</sub>, 10% Pd/C, THF, MeOH, room temp, 14 h (98%); (d) KSCN, Br<sub>2</sub>, AcOH, room temp, 4 h (87%); (e) cyclopropanecarbonyl chloride, DMAP, pyridine, room temp, 6 h (88%).</p></p></figure><figure data-id="sch8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/medium/jm-2012-00126x_0025.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0025.jpeg" id="rightTab-gr17" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthesis of [1,3]Thiazolo[5,4-<i>b</i>]pyridine <b>6a</b>–<b>c</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0025.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300126x&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) <i>tert</i>-butyl (3-hydroxyphenyl)carbamate, K<sub>2</sub>CO<sub>3</sub>, DMF, 70 °C, 2 h; (b) H<sub>2</sub>, 10% Pd/C, EtOH, THF, room temp, 7 h (77% in two steps); (c) KSCN, Br<sub>2</sub>, AcOH, room temp, 1.5 h (88%); (d) cyclopropanecarbonyl chloride, pyridine, room temp, 1 h (86%); (e) TFA, anisole, 0 °C, 1 h (79%); (f) <b>15n</b>,<b>o</b>, SOCl<sub>2</sub>, DMAP, toluene, then pyridine (46–58%), or <b>15p</b>, HATU, pyridine, room temp (87%).</p></p></figure><figure data-id="sch9" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/medium/jm-2012-00126x_0026.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0026.jpeg" id="rightTab-gr18" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Synthesis of [1,3]Thiazolo[5,4-<i>b</i>]pyridine <b>6d</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0026.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300126x&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) (COCl)<sub>2</sub>, cat. DMF, THF, room temp, 2.5 h, then 3-amino-4-fluorophenol, NaHCO<sub>3</sub>, THF, H<sub>2</sub>O, room temp, 1 h (100%); (b) <b>39</b>, K<sub>2</sub>CO<sub>3</sub>, DMF, room temp, 4 h (93%); (c) Fe(0), CaCl<sub>2</sub>, EtOH, H<sub>2</sub>O, 80 °C, 18 h (69%); (d) KSCN, Br<sub>2</sub>, AcOH, room temp, 6 h (69%); (e) cyclopropanecarbonyl chloride, pyridine, THF, room temp, 3 h (96%).</p></p></figure><figure data-id="sch10" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Scheme 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/medium/jm-2012-00126x_0027.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0027.jpeg" id="rightTab-gr19" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 10. Synthesis of [1,3]Thiazolo[5,4-<i>b</i>]pyridine <b>6e</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0027.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300126x&amp;id=sch10"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 3-amino-4-chlorophenol, K<sub>2</sub>CO<sub>3</sub>, DMF, room temp, 16 h (85%); (b) TFAA, THF, room temp, 1 h (87%); (c) Fe(0), AcOH, 60 °C, 3 h (91%); (d) KSCN, Br<sub>2</sub>, AcOH, room temp, 16 h (72%); (e) cyclopropanecarbonyl chloride, pyridine, room temp, 1 h (59%); (f) NaBH<sub>4</sub>, MeOH, EtOH, room temp, 1 h (75%); (g) <b>15q</b>, (COCl)<sub>2</sub>, DMF, THF, then DMA, room temp, 2 h (64%).</p></p></figure><figure data-id="fig4" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/medium/jm-2012-00126x_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Stable dihedral angles of amides linked to ring A (<b>3</b>, <b>4</b>) are calculated using ligand-based analysis to determine their minimal potential energies. Compounds calculated are simplified analogues without the phenoxy moiety. Fused imidazoles without the methyl group (<b>3a</b>, <b>4a</b>) are categorized in the planar group. Fused imidazoles with a methyl group (<b>3b</b>, <b>4b</b>) are categorized in the torsional group owing to steric hindrance between 3-methyl and carbonyl. Dihedral angles (deg) and their internal energy gains (Δ<i>E</i>*) from their planar conformations are shown.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300126x&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/medium/jm-2012-00126x_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Cocrystal structure of <b>6d</b> with BRAF (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4DBN">4DBN</a>, 3.1 Å resolution) and VEGFR2 (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3VNT">3VNT</a>, 1.64 Å resolution): (A) DFG-out conformation of BRAF (green cartoon) is stabilized by <b>6d</b>; (B) back pocket region of BRAF (surface); (C) DFG-out conformation of VEGFR2 (magenta cartoon) is stabilized by <b>6d</b>; (D) back pocket region of VEGFR2 (surface).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300126x&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="16" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/medium/jm-2012-00126x_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. MAPK signal suppression effect by 2 h treatment of <b>6d</b> (Western blotting) and its antiproliferative activity (GI<sub>50</sub>) in various cancer cell lines possessing the <i>BRAF</i><sup>V600E</sup> mutated gene.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300126x&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="17" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/medium/jm-2012-00126x_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. VEGF signal suppression effect by 2 h treatment of <b>6d</b> (Western blotting) in 293/KDR cell lines. The 293/KDR cells were untreated (−) or treated (+) with VEGF-A (final concentration of 50 ng/mL) for 10 min.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300126x&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="18" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/medium/jm-2012-00126x_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Mean (<i>n</i> = 2) phosphorylated ERK1/2 levels in F344 nude rats bearing A375 (<i>BRAF</i><sup>V600E</sup> mutant) human melanoma xenograft tumors after treatment with single dose of <b>6d-SD</b>. Footnotes in the table portion indicate the following: (b) detected by Western blotting; (c) delivered in distilled water; (d) solid dispersion formulation was delivered in distilled water; (e) dose of <b>6d</b> is described.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300126x&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="19" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/medium/jm-2012-00126x_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Mean (<i>n</i> = 3) tumor volumes and body weights in F344 nude rats bearing A375 human melanoma xenograft tumors dosed with <b>6d-SD</b> or vehicle. Footnotes in the table portion indicate the following: (b) compound <b>6d-SD</b> was administered orally twice daily for 14 days; (c) delivered in distilled water; (d) dolid dispersion formulation was delivered in distilled water; (e) dose of <b>6d</b> is described. <i>P</i> ≤ 0.05 vs control at day 14 (<i>t</i>-test).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2012/jmcmar.2012.55.issue-7/jm300126x/production/images/large/jm-2012-00126x_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm300126x&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i99">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28848" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28848" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 38 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Kolch, W.</span><span> </span><span class="NLM_article-title">Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">351</span><span class="NLM_x">, </span> <span class="NLM_fpage">289</span><span class="NLM_x">–</span> <span class="NLM_lpage">305</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=351&publication_year=2000&pages=289-305&author=W.+Kolch&title=Meaningful+relationships%3A+the+regulation+of+the+Ras%2FRaf%2FMEK%2FERK+pathway+by+protein+interactions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKolch%26aufirst%3DW.%26atitle%3DMeaningful%2520relationships%253A%2520the%2520regulation%2520of%2520the%2520Ras%252FRaf%252FMEK%252FERK%2520pathway%2520by%2520protein%2520interactions%26jtitle%3DBiochem.%2520J.%26date%3D2000%26volume%3D351%26spage%3D289%26epage%3D305" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit1b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Peyssonnaux, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eychène, A.</span><span> </span><span class="NLM_article-title">The Raf/MEK/ERK pathway: new concepts of activation</span> <span class="citation_source-journal">Biol. Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">93</span><span class="NLM_x">, </span> <span class="NLM_fpage">53</span><span class="NLM_x">–</span> <span class="NLM_lpage">62</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=16&amp;doi=10.1021%2Fjm300126x&amp;key=10.1016%2FS0248-4900%2801%2901125-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=8&amp;doi=10.1021%2Fjm300126x&amp;key=11730323" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1b&amp;dbid=32&amp;doi=10.1021%2Fjm300126x&amp;key=1%3ACAS%3A528%3ADC%252BD3MXptVOju7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=93&publication_year=2001&pages=53-62&author=C.+Peyssonnauxauthor=A.+Eych%C3%A8ne&title=The+Raf%2FMEK%2FERK+pathway%3A+new+concepts+of+activation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1bR"><div class="casContent"><span class="casTitleNuber">1b</span><div class="casTitle"><span class="NLM_cas:atitle">The Raf/MEK/ERK pathway: New concepts of activation</span></div><div class="casAuthors">Peyssonnaux, Carole; Eychene, Alain</div><div class="citationInfo"><span class="NLM_cas:title">Biology of the Cell</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">93</span>
        (<span class="NLM_cas:issue">1/2</span>),
    <span class="NLM_cas:pages">53-62</span>CODEN:
                <span class="NLM_cas:coden">BCELDF</span>;
        ISSN:<span class="NLM_cas:issn">0248-4900</span>.
    
            (<span class="NLM_cas:orgname">Editions Scientifiques et Medicales Elsevier</span>)
        </div><div class="casAbstract">A review.  The Raf/MEK/ERK signaling was the first MAP kinase cascade to be characterized.  It is probably one of the most well known signal transduction pathways among biologists because of its implication in a wide variety of cellular functions as diverse -and occasionally contradictory- as cell proliferation, cell-cycle arrest, terminal differentiation and apoptosis.  Discovery and understanding of this pathway have benefited from the combination of both genetic studies in worms and flies and biochem. studies in mammalian cells.  However, ten years after, this field is still under debate and new mol. partners in the cascade continue to increase the complexity of its regulation.  This review deals with the emergence of new concepts in the activation and regulation of the Raf/MEK/ERK module.  In particular, the preponderant role of B-Raf is underlined, and the role of novel regulators such as KSR is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpyjiXSFlBQ6rVg90H21EOLACvtfcHk0lhONhWW3VtfSQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXptVOju7s%253D&md5=cde3db5b205a1305dc2e6262deea65ec</span></div><a href="/servlet/linkout?suffix=cit1b&amp;dbid=16384&amp;doi=10.1016%2FS0248-4900%2801%2901125-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0248-4900%252801%252901125-X%26sid%3Dliteratum%253Aachs%26aulast%3DPeyssonnaux%26aufirst%3DC.%26aulast%3DEych%25C3%25A8ne%26aufirst%3DA.%26atitle%3DThe%2520Raf%252FMEK%252FERK%2520pathway%253A%2520new%2520concepts%2520of%2520activation%26jtitle%3DBiol.%2520Cell%26date%3D2001%26volume%3D93%26spage%3D53%26epage%3D62" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit1c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">McKay, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrison, D. K.</span><span> </span><span class="NLM_article-title">Integrating signals from RTKs to ERK/MAPK</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">3113</span><span class="NLM_x">–</span> <span class="NLM_lpage">3121</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=3113-3121&author=M.+M.+McKayauthor=D.+K.+Morrison&title=Integrating+signals+from+RTKs+to+ERK%2FMAPK"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMcKay%26aufirst%3DM.%2BM.%26aulast%3DMorrison%26aufirst%3DD.%2BK.%26atitle%3DIntegrating%2520signals%2520from%2520RTKs%2520to%2520ERK%252FMAPK%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26spage%3D3113%26epage%3D3121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Roberts, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Der, C. J.</span><span> </span><span class="NLM_article-title">Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">3291</span><span class="NLM_x">–</span> <span class="NLM_lpage">3310</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm300126x&amp;key=10.1038%2Fsj.onc.1210422" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm300126x&amp;key=17496923" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm300126x&amp;key=1%3ACAS%3A528%3ADC%252BD2sXlt1Wktb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=3291-3310&author=P.+J.+Robertsauthor=C.+J.+Der&title=Targeting+the+Raf-MEK-ERK+mitogen-activated+protein+kinase+cascade+for+the+treatment+of+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer</span></div><div class="casAuthors">Roberts, P. J.; Der, C. J.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">3291-3310</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Mitogen-activated protein kinase (MAPK) cascades are key signaling pathways involved in the regulation of normal cell proliferation, survival and differentiation.  Aberrant regulation of MAPK cascades contribute to cancer and other human diseases.  In particular, the extracellular signal-regulated kinase (ERK) MAPK pathway has been the subject of intense research scrutiny leading to the development of pharmacol. inhibitors for the treatment of cancer.  ERK is a downstream component of an evolutionarily conserved signaling module that is activated by the Raf serine/threonine kinases.  Raf activates the MAPK/ERK kinase (MEK)1/2 dual-specificity protein kinases, which then activate ERK1/2.  The mutational activation of Raf in human cancers supports the important role of this pathway in human oncogenesis.  Addnl., the Raf-MEK-ERK pathway is a key downstream effector of the Ras small GTPase, the most frequently mutated oncogene in human cancers.  Finally, Ras is a key downstream effector of the epidermal growth factor receptor (EGFR), which is mutationally activated and/or overexpressed in a wide variety of human cancers.  ERK activation also promotes upregulated expression of EGFR ligands, promoting an autocrine growth loop crit. for tumor growth.  Thus, the EGFR-Ras-Raf-MEK-ERK signaling network has been the subject of intense research and pharmaceutical scrutiny to identify novel target-based approaches for cancer treatment.  In this review, we summarize the current status of the different approaches and targets that are under evaluation and development for the therapeutic intervention of this key signaling pathway in human disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7hdVDVyRBHrVg90H21EOLACvtfcHk0lhra5EO8kJczA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXlt1Wktb4%253D&md5=bf56109e3b4defc12004471da30178c0</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1210422&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1210422%26sid%3Dliteratum%253Aachs%26aulast%3DRoberts%26aufirst%3DP.%2BJ.%26aulast%3DDer%26aufirst%3DC.%2BJ.%26atitle%3DTargeting%2520the%2520Raf-MEK-ERK%2520mitogen-activated%2520protein%2520kinase%2520cascade%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26spage%3D3291%26epage%3D3310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Downward, J.</span><span> </span><span class="NLM_article-title">Targeting RAS signalling pathways in cancer therapy</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">11</span><span class="NLM_x">–</span> <span class="NLM_lpage">22</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm300126x&amp;key=10.1038%2Fnrc969" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm300126x&amp;key=12509763" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm300126x&amp;key=1%3ACAS%3A528%3ADC%252BD38XpvVertbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=11-22&author=J.+Downward&title=Targeting+RAS+signalling+pathways+in+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting RAS signalling pathways in cancer therapy</span></div><div class="casAuthors">Downward, Julian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">11-22</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The RAS proteins control signaling pathways that are key regulators of several aspects of normal cell growth and malignant transformation.  They are aberrant in most human tumors due to activating mutations in the RAS genes themselves or to alterations in upstream or downstream signaling components.  Rational therapies that target the RAS pathways might inhibit tumor growth, survival and spread.  Several of these new therapeutic agents are showing promise in the clinic and many more are being developed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpwKF9JX2sXtbVg90H21EOLACvtfcHk0lhra5EO8kJczA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XpvVertbo%253D&md5=85ea9312480c3ca01f2a94faae7b84e7</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrc969&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc969%26sid%3Dliteratum%253Aachs%26aulast%3DDownward%26aufirst%3DJ.%26atitle%3DTargeting%2520RAS%2520signalling%2520pathways%2520in%2520cancer%2520therapy%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2003%26volume%3D3%26spage%3D11%26epage%3D22" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Garnett, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marais, R.</span><span> </span><span class="NLM_article-title">Guilty as charged: B-RAF is a human oncogene</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">313</span><span class="NLM_x">–</span> <span class="NLM_lpage">319</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2004&pages=313-319&author=M.+J.+Garnettauthor=R.+Marais&title=Guilty+as+charged%3A+B-RAF+is+a+human+oncogene"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGarnett%26aufirst%3DM.%2BJ.%26aulast%3DMarais%26aufirst%3DR.%26atitle%3DGuilty%2520as%2520charged%253A%2520B-RAF%2520is%2520a%2520human%2520oncogene%26jtitle%3DCancer%2520Cell%26date%3D2004%26volume%3D6%26spage%3D313%26epage%3D319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit4b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Mercer, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pritchard, C. A.</span><span> </span><span class="NLM_article-title">Raf proteins and cancer: B-Raf is identified as a mutational target</span> <span class="citation_source-journal">Biochim. Biophys. Acta</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">1653</span><span class="NLM_x">, </span> <span class="NLM_fpage">25</span><span class="NLM_x">–</span> <span class="NLM_lpage">40</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1653&publication_year=2003&pages=25-40&author=K.+E.+Mercerauthor=C.+A.+Pritchard&title=Raf+proteins+and+cancer%3A+B-Raf+is+identified+as+a+mutational+target"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit4b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMercer%26aufirst%3DK.%2BE.%26aulast%3DPritchard%26aufirst%3DC.%2BA.%26atitle%3DRaf%2520proteins%2520and%2520cancer%253A%2520B-Raf%2520is%2520identified%2520as%2520a%2520mutational%2520target%26jtitle%3DBiochim.%2520Biophys.%2520Acta%26date%3D2003%26volume%3D1653%26spage%3D25%26epage%3D40" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Davies, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bignell, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cox, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephens, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edkins, S</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clegg, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teague, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woffendin, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garnett, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bottomley, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dicks, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ewing, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hall, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawes, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hughes, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kosmidou, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menzies, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mould, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stevens, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hooper, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayatilake, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gusterson, B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooper, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shipley, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hargrave, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pritchard-Jones, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maitland, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chenevix-Trench, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riggins, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bigner, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmieri, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cossu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flanagan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nicholson, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, J. W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leung, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuen, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seigler, H. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Darrow, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paterson, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marais, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wooster, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stratton, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Futreal, P. A.</span><span> </span><span class="NLM_article-title">Mutations of the <i>BRAF</i> gene in human cancer</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">417</span><span class="NLM_x">, </span> <span class="NLM_fpage">949</span><span class="NLM_x">–</span> <span class="NLM_lpage">954</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm300126x&amp;key=10.1038%2Fnature00766" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm300126x&amp;key=12068308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm300126x&amp;key=1%3ACAS%3A528%3ADC%252BD38XkvVagsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=417&publication_year=2002&pages=949-954&author=H.+Daviesauthor=G.+R.+Bignellauthor=C.+Coxauthor=P.+Stephensauthor=S+Edkinsauthor=S.+Cleggauthor=J.+Teagueauthor=H.+Woffendinauthor=M.+J.+Garnettauthor=W.+Bottomleyauthor=N.+Davisauthor=E.+Dicksauthor=R.+Ewingauthor=Y.+Floydauthor=K.+Grayauthor=S.+Hallauthor=R.+Hawesauthor=J.+Hughesauthor=V.+Kosmidouauthor=A.+Menziesauthor=C.+Mouldauthor=A.+Parkerauthor=C.+Stevensauthor=S.+Wattauthor=S.+Hooperauthor=R.+Wilsonauthor=H.+Jayatilakeauthor=B.+A.+Gustersonauthor=C.+Cooperauthor=J.+Shipleyauthor=D.+Hargraveauthor=K.+Pritchard-Jonesauthor=N.+Maitlandauthor=G.+Chenevix-Trenchauthor=G.+J.+Rigginsauthor=D.+D.+Bignerauthor=G.+Palmieriauthor=A.+Cossuauthor=A.+Flanaganauthor=A.+Nicholsonauthor=J.+W.+C.+Hoauthor=S.+Y.+Leungauthor=S.+T.+Yuenauthor=B.+L.+Weberauthor=H.+F.+Seiglerauthor=T.+L.+Darrowauthor=H.+Patersonauthor=R.+Maraisauthor=C.+J.+Marshallauthor=R.+Woosterauthor=M.+R.+Strattonauthor=P.+A.+Futreal&title=Mutations+of+the+BRAF+gene+in+human+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Mutations of the BRAF gene in human cancer</span></div><div class="casAuthors">Davies, Helen; Bignell, Graham R.; Cox, Charles; Stephens, Philip; Edkins, Sarah; Clegg, Sheila; Teague, Jon; Woffendin, Hayley; Garnett, Mathew J.; Bottomley, William; Davis, Neil; Dicks, Ed; Ewing, Rebecca; Floyd, Yvonne; Gray, Kristian; Hall, Sarah; Hawes, Rachel; Hughes, Jaime; Kosmidou, Vivian; Menzies, Andrew; Mould, Catherine; Parker, Adrian; Stevens, Claire; Watt, Stephen; Hooper, Steven; Wilson, Rebecca; Jayatilake, Hiran; Gusterson, Barry A.; Cooper, Colin; Shipley, Janet; Hargrave, Darren; Pritchard-Jones, Katherine; Maitland, Norman; Chenevix-Trench, Georgia; Riggins, Gregory J.; Bigner, Darell D.; Palmieri, Giuseppe; Cossu, Antonio; Flanagan, Adrienne; Nicholson, Andrew; Ho, Judy W. C.; Leung, Suet Y.; Yuen, Siu T.; Weber, Barbara L.; Seigler, Hilliard F.; Darrow, Timothy L.; Paterson, Hugh; Marais, Richard; Marshall, Christopher J.; Wooster, Richard; Stratton, Michael R.; Futreal, P. Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">417</span>
        (<span class="NLM_cas:issue">6892</span>),
    <span class="NLM_cas:pages">949-954</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cancers arise owing to the accumulation of mutations in crit. genes that alter normal programs of cell proliferation, differentiation and death.  As the first stage of a systematic genome-wide screen for these genes, we have prioritized for anal. signalling pathways in which at least one gene is mutated in human cancer.  The RAS-RAF-MEK-ERK-MAP kinase pathway mediates cellular responses to growth signals.  RAS is mutated to an oncogenic form in about 15% of human cancer.  The three RAF genes code for cytoplasmic serine/threonine kinases that are regulated by binding RAS.  Here we report BRAF somatic missense mutations in 66% of malignant melanomas and at lower frequency in a wide range of human cancers.  All mutations are within the kinase domain, with a single substitution (V599E) accounting for 80%.  Mutated BRAF proteins have elevated kinase activity and are transforming in NIH3T3 cells.  Furthermore, RAS function is not required for the growth of cancer cell lines with the V599E mutation.  As BRAF is a serine/threonine kinase that is commonly activated by somatic point mutation in human cancer, it may provide new therapeutic opportunities in malignant melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPBmhJC0GAjrVg90H21EOLACvtfcHk0lj4iz3sItfZVg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkvVagsLo%253D&md5=4625be53ad9a382d51b6ee753d0c17e8</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fnature00766&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature00766%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DH.%26aulast%3DBignell%26aufirst%3DG.%2BR.%26aulast%3DCox%26aufirst%3DC.%26aulast%3DStephens%26aufirst%3DP.%26aulast%3DEdkins%26aufirst%3DS%26aulast%3DClegg%26aufirst%3DS.%26aulast%3DTeague%26aufirst%3DJ.%26aulast%3DWoffendin%26aufirst%3DH.%26aulast%3DGarnett%26aufirst%3DM.%2BJ.%26aulast%3DBottomley%26aufirst%3DW.%26aulast%3DDavis%26aufirst%3DN.%26aulast%3DDicks%26aufirst%3DE.%26aulast%3DEwing%26aufirst%3DR.%26aulast%3DFloyd%26aufirst%3DY.%26aulast%3DGray%26aufirst%3DK.%26aulast%3DHall%26aufirst%3DS.%26aulast%3DHawes%26aufirst%3DR.%26aulast%3DHughes%26aufirst%3DJ.%26aulast%3DKosmidou%26aufirst%3DV.%26aulast%3DMenzies%26aufirst%3DA.%26aulast%3DMould%26aufirst%3DC.%26aulast%3DParker%26aufirst%3DA.%26aulast%3DStevens%26aufirst%3DC.%26aulast%3DWatt%26aufirst%3DS.%26aulast%3DHooper%26aufirst%3DS.%26aulast%3DWilson%26aufirst%3DR.%26aulast%3DJayatilake%26aufirst%3DH.%26aulast%3DGusterson%26aufirst%3DB.%2BA.%26aulast%3DCooper%26aufirst%3DC.%26aulast%3DShipley%26aufirst%3DJ.%26aulast%3DHargrave%26aufirst%3DD.%26aulast%3DPritchard-Jones%26aufirst%3DK.%26aulast%3DMaitland%26aufirst%3DN.%26aulast%3DChenevix-Trench%26aufirst%3DG.%26aulast%3DRiggins%26aufirst%3DG.%2BJ.%26aulast%3DBigner%26aufirst%3DD.%2BD.%26aulast%3DPalmieri%26aufirst%3DG.%26aulast%3DCossu%26aufirst%3DA.%26aulast%3DFlanagan%26aufirst%3DA.%26aulast%3DNicholson%26aufirst%3DA.%26aulast%3DHo%26aufirst%3DJ.%2BW.%2BC.%26aulast%3DLeung%26aufirst%3DS.%2BY.%26aulast%3DYuen%26aufirst%3DS.%2BT.%26aulast%3DWeber%26aufirst%3DB.%2BL.%26aulast%3DSeigler%26aufirst%3DH.%2BF.%26aulast%3DDarrow%26aufirst%3DT.%2BL.%26aulast%3DPaterson%26aufirst%3DH.%26aulast%3DMarais%26aufirst%3DR.%26aulast%3DMarshall%26aufirst%3DC.%2BJ.%26aulast%3DWooster%26aufirst%3DR.%26aulast%3DStratton%26aufirst%3DM.%2BR.%26aulast%3DFutreal%26aufirst%3DP.%2BA.%26atitle%3DMutations%2520of%2520the%2520BRAF%2520gene%2520in%2520human%2520cancer%26jtitle%3DNature%26date%3D2002%26volume%3D417%26spage%3D949%26epage%3D954" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Tuveson, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herlyn, M.</span><span> </span><span class="NLM_article-title">BRAF as a potential therapeutic target in melanoma and other malignancies</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">95</span><span class="NLM_x">–</span> <span class="NLM_lpage">98</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2003&pages=95-98&author=D.+A.+Tuvesonauthor=B.+L.+Weberauthor=M.+Herlyn&title=BRAF+as+a+potential+therapeutic+target+in+melanoma+and+other+malignancies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTuveson%26aufirst%3DD.%2BA.%26aulast%3DWeber%26aufirst%3DB.%2BL.%26aulast%3DHerlyn%26aufirst%3DM.%26atitle%3DBRAF%2520as%2520a%2520potential%2520therapeutic%2520target%2520in%2520melanoma%2520and%2520other%2520malignancies%26jtitle%3DCancer%2520Cell%26date%3D2003%26volume%3D4%26spage%3D95%26epage%3D98" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Beeram, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patnaik, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowinsky, E. K.</span><span> </span><span class="NLM_article-title">Raf: a strategic target for therapeutic development against cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">6771</span><span class="NLM_x">–</span> <span class="NLM_lpage">6790</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=16&amp;doi=10.1021%2Fjm300126x&amp;key=10.1200%2FJCO.2005.08.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=8&amp;doi=10.1021%2Fjm300126x&amp;key=16170185" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7a&amp;dbid=32&amp;doi=10.1021%2Fjm300126x&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtFWqsb7P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=6771-6790&author=M.+Beeramauthor=A.+Patnaikauthor=E.+K.+Rowinsky&title=Raf%3A+a+strategic+target+for+therapeutic+development+against+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7aR"><div class="casContent"><span class="casTitleNuber">7a</span><div class="casTitle"><span class="NLM_cas:atitle">Raf: a strategic target for therapeutic development against cancer</span></div><div class="casAuthors">Beeram, Muralidhar; Patnaik, Amita; Rowinsky, Eric K.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">6771-6790</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  The mitogen-activated protein kinase (MARK) signaling pathway plays a crit. role in transmitting proliferative signals generated by cell surface receptors and cytoplasmic signaling elements to the nucleus.  Several important signaling elements of the MARK pathway, particularly Ras and Raf, are encoded by oncogenes, and as such, their structures and functions can be modified, rendering them constitutively active.  Because the MARK pathway is dysregulated in a notable proportion of human malignancies, many of its aberrant and crit. components represent strategic targets for therapeutic development against cancer.  Raf, which is an essential serine/threonine kinase constituent of the MARK pathway and a downstream effector of the central signal transduction mediator Ras, is activated in a wide range of human malignancies by aberrant signaling upstream of the protein (eg, growth factor receptors and mutant Ras) and activating mutations of the protein itself, both of which confer a proliferative advantage.  Three isoforms of Raf have been identified, and therapeutics targeting Raf, including small-mol. inhibitors and antisense oligodeoxyribonucleotides (ASON), are undergoing clin. evaluation.  The outcomes of these investigations may have far-reaching implications in the management of many types of human cancer.  This review outlines the structure and diverse functions of Raf, the rationale for targeting Raf as a therapeutic strategy against cancer, and the present status of various therapeutic approaches including ASONs and small mols., particularly sorafenib (BAY 43-9006).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqeXfxCgXq8wbVg90H21EOLACvtfcHk0lgy45EHnqEGPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtFWqsb7P&md5=8e75a4ac97b6adfe9e1aecf82f3c1825</span></div><a href="/servlet/linkout?suffix=cit7a&amp;dbid=16384&amp;doi=10.1200%2FJCO.2005.08.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2005.08.036%26sid%3Dliteratum%253Aachs%26aulast%3DBeeram%26aufirst%3DM.%26aulast%3DPatnaik%26aufirst%3DA.%26aulast%3DRowinsky%26aufirst%3DE.%2BK.%26atitle%3DRaf%253A%2520a%2520strategic%2520target%2520for%2520therapeutic%2520development%2520against%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2005%26volume%3D23%26spage%3D6771%26epage%3D6790" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit7b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Frasca, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nucera, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pellegriti, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gangemi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Attard, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stella, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loda, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vella, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giordano, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trimarchi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mazzon, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belfiore, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vigneri, R.</span><span> </span><span class="NLM_article-title"><i>BRAF</i><sup><i>(V600E)</i></sup> mutation and the biology of papillary thyroid cancer</span> <span class="citation_source-journal">Endocr.-Relat. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">191</span><span class="NLM_x">–</span> <span class="NLM_lpage">205</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2008&pages=191-205&author=F.+Frascaauthor=C.+Nuceraauthor=G.+Pellegritiauthor=P.+Gangemiauthor=M.+Attardauthor=M.+Stellaauthor=M.+Lodaauthor=V.+Vellaauthor=C.+Giordanoauthor=F.+Trimarchiauthor=E.+Mazzonauthor=A.+Belfioreauthor=R.+Vigneri&title=BRAF%28V600E%29+mutation+and+the+biology+of+papillary+thyroid+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFrasca%26aufirst%3DF.%26aulast%3DNucera%26aufirst%3DC.%26aulast%3DPellegriti%26aufirst%3DG.%26aulast%3DGangemi%26aufirst%3DP.%26aulast%3DAttard%26aufirst%3DM.%26aulast%3DStella%26aufirst%3DM.%26aulast%3DLoda%26aufirst%3DM.%26aulast%3DVella%26aufirst%3DV.%26aulast%3DGiordano%26aufirst%3DC.%26aulast%3DTrimarchi%26aufirst%3DF.%26aulast%3DMazzon%26aufirst%3DE.%26aulast%3DBelfiore%26aufirst%3DA.%26aulast%3DVigneri%26aufirst%3DR.%26atitle%3DBRAF%2528V600E%2529%2520mutation%2520and%2520the%2520biology%2520of%2520papillary%2520thyroid%2520cancer%26jtitle%3DEndocr.-Relat.%2520Cancer%26date%3D2008%26volume%3D15%26spage%3D191%26epage%3D205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit7c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Samowitz, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sweeney., C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrick, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Albertsen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levin, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murtaugh, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolff, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slattery, M. L.</span><span> </span><span class="NLM_article-title">Poor survival associated with the <i>BRAF</i> V600E mutation in microsatellite-stable colon cancers</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">6063</span><span class="NLM_x">–</span> <span class="NLM_lpage">6070</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=6063-6070&author=W.+S.+Samowitzauthor=C.+Sweeney.author=J.+Herrickauthor=H.+Albertsenauthor=T.+R.+Levinauthor=M.+A.+Murtaughauthor=R.+K.+Wolffauthor=M.+L.+Slattery&title=Poor+survival+associated+with+the+BRAF+V600E+mutation+in+microsatellite-stable+colon+cancers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7c&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSamowitz%26aufirst%3DW.%2BS.%26aulast%3DSweeney.%26aufirst%3DC.%26aulast%3DHerrick%26aufirst%3DJ.%26aulast%3DAlbertsen%26aufirst%3DH.%26aulast%3DLevin%26aufirst%3DT.%2BR.%26aulast%3DMurtaugh%26aufirst%3DM.%2BA.%26aulast%3DWolff%26aufirst%3DR.%2BK.%26aulast%3DSlattery%26aufirst%3DM.%2BL.%26atitle%3DPoor%2520survival%2520associated%2520with%2520the%2520BRAF%2520V600E%2520mutation%2520in%2520microsatellite-stable%2520colon%2520cancers%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D6063%26epage%3D6070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Montagut, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span> </span><span class="NLM_article-title">Targeting the RAF-MEK-ERK pathway in cancer therapy</span> <span class="citation_source-journal">Cancer Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">283</span><span class="NLM_x">, </span> <span class="NLM_fpage">125</span><span class="NLM_x">–</span> <span class="NLM_lpage">134</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=16&amp;doi=10.1021%2Fjm300126x&amp;key=10.1016%2Fj.canlet.2009.01.022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=8&amp;doi=10.1021%2Fjm300126x&amp;key=19217204" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8a&amp;dbid=32&amp;doi=10.1021%2Fjm300126x&amp;key=1%3ACAS%3A528%3ADC%252BD1MXptlantbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=283&publication_year=2009&pages=125-134&author=C.+Montagutauthor=J.+Settleman&title=Targeting+the+RAF-MEK-ERK+pathway+in+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8aR"><div class="casContent"><span class="casTitleNuber">8a</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the RAF-MEK-ERK pathway in cancer therapy</span></div><div class="casAuthors">Montagut, Clara; Settleman, Jeff</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (Shannon, Ireland)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">283</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">125-134</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">A review.  The clin. success of selective kinase inhibitors, such as imatinib and erlotinib, as therapeutic agents for several human cancers has prompted substantial interest in the further development and clin. testing of such inhibitors for a wide variety of malignancies.  While much of this effort was focused on the receptor tyrosine kinases, including EGFR, HER2, PDGF receptor, c-KIT, and MET, inhibitors of serine/threonine kinases are also beginning to emerge within discovery pipelines.  Among these kinases, the RAF and MEK kinases have received substantial attention, owing largely to the relatively high frequency of activating mutations of RAS (∼20% of all human cancers), an upstream activator of the well established RAF-MEK-ERK signaling cascade, as well as frequent activating mutations in the BRAF kinase (∼7% of all human cancers).  Here, we summarize the current state of development of kinase inhibitors directed at this signaling pathway, a few of which have already demonstrating favorable toxicity profiles as well as promising activity in early phase clin. studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbTpfm5XYkBbVg90H21EOLACvtfcHk0lgy45EHnqEGPw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXptlantbc%253D&md5=9c5139834b5e347079c212bb312b0b25</span></div><a href="/servlet/linkout?suffix=cit8a&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2009.01.022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2009.01.022%26sid%3Dliteratum%253Aachs%26aulast%3DMontagut%26aufirst%3DC.%26aulast%3DSettleman%26aufirst%3DJ.%26atitle%3DTargeting%2520the%2520RAF-MEK-ERK%2520pathway%2520in%2520cancer%2520therapy%26jtitle%3DCancer%2520Lett.%26date%3D2009%26volume%3D283%26spage%3D125%26epage%3D134" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit8b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Chapman, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hauschild, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haanen, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ascierto, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Larkin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dummer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garbe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Testori, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hogg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorigan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebbe, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jouary, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schadendorf, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Day, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirkwood, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eggermont, A. M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dreno, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolop, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hou, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McArthur, G. A.</span><span> </span><span class="NLM_article-title">For the BRIM-3 study group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">364</span><span class="NLM_x">, </span> <span class="NLM_fpage">2507</span><span class="NLM_x">–</span> <span class="NLM_lpage">2516</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=16&amp;doi=10.1021%2Fjm300126x&amp;key=10.1056%2FNEJMoa1103782" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=8&amp;doi=10.1021%2Fjm300126x&amp;key=21639808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8b&amp;dbid=32&amp;doi=10.1021%2Fjm300126x&amp;key=1%3ACAS%3A528%3ADC%252BC3MXosVeitbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=364&publication_year=2011&pages=2507-2516&author=P.+B.+Chapmanauthor=A.+Hauschildauthor=C.+Robertauthor=J.+B.+Haanenauthor=P.+Asciertoauthor=J.+Larkinauthor=R.+Dummerauthor=C.+Garbeauthor=A.+Testoriauthor=M.+Maioauthor=D.+Hoggauthor=P.+Loriganauthor=C.+Lebbeauthor=T.+Jouaryauthor=D.+Schadendorfauthor=A.+Ribasauthor=S.+J.+O%E2%80%99Dayauthor=J.+A.+Sosmanauthor=J.+M.+Kirkwoodauthor=A.+M.+M.+Eggermontauthor=B.+Drenoauthor=K.+Nolopauthor=J.+Liauthor=B.+Nelsonauthor=J.+Houauthor=R.+J.+Leeauthor=K.+T.+Flahertyauthor=G.+A.+McArthur&title=For+the+BRIM-3+study+group.+Improved+survival+with+vemurafenib+in+melanoma+with+BRAF+V600E+mutation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8bR"><div class="casContent"><span class="casTitleNuber">8b</span><div class="casTitle"><span class="NLM_cas:atitle">Improved survival with vemurafenib in melanoma with BRAF V600E mutation</span></div><div class="casAuthors">Chapman, Paul B.; Hauschild, Axel; Robert, Caroline; Haanen, John B.; Ascierto, Paolo; Larkin, James; Dummer, Reinhard; Garbe, Claus; Testori, Alessandro; Maio, Michele; Hogg, David; Lorigan, Paul; Lebbe, Celeste; Jouary, Thomas; Schadendorf, Dirk; Ribas, Antoni; O'Day, Steven J.; Sosman, Jeffrey A.; Kirkwood, John M.; Eggermont, Alexander M. M.; Dreno, Brigitte; Nolop, Keith; Li, Jiang; Nelson, Betty; Hou, Jeannie; Lee, Richard J.; Flaherty, Keith T.; McArthur, Grant A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">364</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">2507-2516</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Phase 1 and 2 clin. trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more than 50% in patients with metastatic melanoma with the BRAF V600E mutation.  METHODS: We conducted a phase 3 randomized clin. trial comparing vemurafenib with dacarbazine in 675 patients with previously untreated, metastatic melanoma with the BRAF V600E mutation.  Patients were randomly assigned to receive either vemurafenib (960 mg orally twice daily) or dacarbazine (1000 mg per square meter of body-surface area i.v. every 3 wk).  Coprimary end points were rates of overall and progression-free survival.  Secondary end points included the response rate, response duration, and safety.  A final anal. was planned after 196 deaths and an interim anal. after 98 deaths.  RESULTS: At 6 mo, overall survival was 840/ (95% confidence interval [CI], 78 to 89) in the vemurafenib group and 64% (95% CI, 56 to 73) in the dacarbazine group.  In the interim anal. for overall survival and final anal. for progression-free survival, vemurafenib was assocd. with a relative redn. of 63% in the risk of death and of 74% in the risk of either death or disease progression, as compared with dacarbazine (P < 0.001 for both comparisons).  After review of the interim anal. by an independent data and safety monitoring board, crossover from dacarbazine to vemurafenib was recommended.  Response rates were 48% for vemurafenib and 5% for dacarbazine.  Common adverse events assocd. with vemurafenib were arthralgia, rash, fatigue, alopecia, keratoacanthoma or squamous-cell carcinoma, photosensitivity, nausea, and diarrhea; 38% of patients required dose modification because of toxic effects.  CONCLUSIONS: Vemurafenib produced improved rates of overall and progression-free survival in patients with previously untreated melanoma with the BRAF V600E mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4NFxmTaDz97Vg90H21EOLACvtfcHk0lhB83CRjtzHfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXosVeitbs%253D&md5=1a4b4f963221888dc63f620e87408070</span></div><a href="/servlet/linkout?suffix=cit8b&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1103782&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1103782%26sid%3Dliteratum%253Aachs%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DHauschild%26aufirst%3DA.%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DHaanen%26aufirst%3DJ.%2BB.%26aulast%3DAscierto%26aufirst%3DP.%26aulast%3DLarkin%26aufirst%3DJ.%26aulast%3DDummer%26aufirst%3DR.%26aulast%3DGarbe%26aufirst%3DC.%26aulast%3DTestori%26aufirst%3DA.%26aulast%3DMaio%26aufirst%3DM.%26aulast%3DHogg%26aufirst%3DD.%26aulast%3DLorigan%26aufirst%3DP.%26aulast%3DLebbe%26aufirst%3DC.%26aulast%3DJouary%26aufirst%3DT.%26aulast%3DSchadendorf%26aufirst%3DD.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DO%25E2%2580%2599Day%26aufirst%3DS.%2BJ.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DKirkwood%26aufirst%3DJ.%2BM.%26aulast%3DEggermont%26aufirst%3DA.%2BM.%2BM.%26aulast%3DDreno%26aufirst%3DB.%26aulast%3DNolop%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DNelson%26aufirst%3DB.%26aulast%3DHou%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26atitle%3DFor%2520the%2520BRIM-3%2520study%2520group.%2520Improved%2520survival%2520with%2520vemurafenib%2520in%2520melanoma%2520with%2520BRAF%2520V600E%2520mutation%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2011%26volume%3D364%26spage%3D2507%26epage%3D2516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Folkman, J.</span><span> </span><span class="NLM_article-title">Angiogenesis: an organizing principle for drug discovery?</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">273</span><span class="NLM_x">–</span> <span class="NLM_lpage">286</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=273-286&author=J.+Folkman&title=Angiogenesis%3A+an+organizing+principle+for+drug+discovery%3F"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DFolkman%26aufirst%3DJ.%26atitle%3DAngiogenesis%253A%2520an%2520organizing%2520principle%2520for%2520drug%2520discovery%253F%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D273%26epage%3D286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Holmes, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roberts, O. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cross, M. J.</span><span> </span><span class="NLM_article-title">Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition</span> <span class="citation_source-journal">Cell. Signalling</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">2003</span><span class="NLM_x">–</span> <span class="NLM_lpage">2012</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Fjm300126x&amp;key=10.1016%2Fj.cellsig.2007.05.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Fjm300126x&amp;key=17658244" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm300126x&amp;key=1%3ACAS%3A528%3ADC%252BD2sXovFylsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2007&pages=2003-2012&author=K.+Holmesauthor=O.+L.+Robertsauthor=A.+M.+Thomasauthor=M.+J.+Cross&title=Vascular+endothelial+growth+factor+receptor-2%3A+structure%2C+function%2C+intracellular+signalling+and+therapeutic+inhibition"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Vascular endothelial growth factor receptor-2: structure, function, intracellular signalling and therapeutic inhibition</span></div><div class="casAuthors">Holmes, Katherine; Roberts, Owain Ll; Thomas, Angharad M.; Cross, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Signalling</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2003-2012</span>CODEN:
                <span class="NLM_cas:coden">CESIEY</span>;
        ISSN:<span class="NLM_cas:issn">0898-6568</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Vascular endothelial growth factors (VEGFs) regulate vascular development, angiogenesis and lymphangiogenesis by binding to a no. of receptors.  VEGFR-1 is required for the recruitment of hematopoietic stem cells and the migration of monocytes and macrophages, VEGFR-2 regulates vascular endothelial function and VEGFR-3 regulates lymphatic endothelial cell function.  Over the last decade, considerable progress has been made in delineating the VEGFR-2 specific intracellular signaling cascades leading to proliferation, migration, survival and increased permeability, each of which contributes to the angiogenic response.  Furthermore, therapeutic inhibition of VEGFR-2 action is now having an impact in the clinic for the treatment of a no. of diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqTYxPMokVV57Vg90H21EOLACvtfcHk0lhB83CRjtzHfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXovFylsLs%253D&md5=44a935f36d29b000d2a9ff514709e9c2</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1016%2Fj.cellsig.2007.05.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cellsig.2007.05.013%26sid%3Dliteratum%253Aachs%26aulast%3DHolmes%26aufirst%3DK.%26aulast%3DRoberts%26aufirst%3DO.%2BL.%26aulast%3DThomas%26aufirst%3DA.%2BM.%26aulast%3DCross%26aufirst%3DM.%2BJ.%26atitle%3DVascular%2520endothelial%2520growth%2520factor%2520receptor-2%253A%2520structure%252C%2520function%252C%2520intracellular%2520signalling%2520and%2520therapeutic%2520inhibition%26jtitle%3DCell.%2520Signalling%26date%3D2007%26volume%3D19%26spage%3D2003%26epage%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Ferrara, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hillan, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gerber, H.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Novotny, W.</span><span> </span><span class="NLM_article-title">Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">391</span><span class="NLM_x">–</span> <span class="NLM_lpage">400</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm300126x&amp;key=10.1038%2Fnrd1381" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Fjm300126x&amp;key=15136787" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm300126x&amp;key=1%3ACAS%3A528%3ADC%252BD2cXktlCrt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=391-400&author=N.+Ferraraauthor=K.+J.+Hillanauthor=H.-P.+Gerberauthor=W.+Novotny&title=Discovery+and+development+of+bevacizumab%2C+an+anti-VEGF+antibody+for+treating+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer</span></div><div class="casAuthors">Ferrara, Napoleone; Hillan, Kenneth J.; Gerber, Hans-Peter; Novotny, William</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">391-400</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The existence of factors that stimulate blood vessel growth, thereby recruiting a neovascular supply to nourish a growing tumor, was postulated many decades ago, although the identification and isolation of these factors proved elusive.  Now, vascular endothelial growth factor (VEGF), which was identified in the 1980s, is recognized as an essential regulator of normal and abnormal blood vessel growth.  In 1993, it was shown that a monoclonal antibody that targeted VEGF results in a dramatic suppression of tumor growth in vivo, which led to the development of bevacizumab (Avastin; Genentech), a humanized variant of this anti-VEGF antibody, as an anticancer agent.  The recent approval of bevacizumab by the US FDA as a first-line therapy for metastatic colorectal cancer validates the ideas that VEGF is a key mediator of tumor angiogenesis and that blocking angiogenesis is an effective strategy to treat human cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGphaLbfhdBKOLVg90H21EOLACvtfcHk0lhB83CRjtzHfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXktlCrt78%253D&md5=4b1f647db4dfe2a24449cdf59b874e7c</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fnrd1381&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1381%26sid%3Dliteratum%253Aachs%26aulast%3DFerrara%26aufirst%3DN.%26aulast%3DHillan%26aufirst%3DK.%2BJ.%26aulast%3DGerber%26aufirst%3DH.-P.%26aulast%3DNovotny%26aufirst%3DW.%26atitle%3DDiscovery%2520and%2520development%2520of%2520bevacizumab%252C%2520an%2520anti-VEGF%2520antibody%2520for%2520treating%2520cancer%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2004%26volume%3D3%26spage%3D391%26epage%3D400" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Faivre, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delbaldo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vera, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robert, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lozahic, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lassau, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bello, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deprimo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brega, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Massimini, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Armand, J.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scigalla, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Raymond, E.</span><span> </span><span class="NLM_article-title">Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">25</span><span class="NLM_x">–</span> <span class="NLM_lpage">35</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=16&amp;doi=10.1021%2Fjm300126x&amp;key=10.1200%2FJCO.2005.02.2194" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=8&amp;doi=10.1021%2Fjm300126x&amp;key=16314617" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12a&amp;dbid=32&amp;doi=10.1021%2Fjm300126x&amp;key=1%3ACAS%3A528%3ADC%252BD28Xot1ChtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=25-35&author=S.+Faivreauthor=C.+Delbaldoauthor=K.+Veraauthor=C.+Robertauthor=S.+Lozahicauthor=N.+Lassauauthor=C.+Belloauthor=S.+Deprimoauthor=N.+Bregaauthor=G.+Massiminiauthor=J.-P.+Armandauthor=P.+Scigallaauthor=E.+Raymond&title=Safety%2C+pharmacokinetic%2C+and+antitumor+activity+of+SU11248%2C+a+novel+oral+multitarget+tyrosine+kinase+inhibitor%2C+in+patients+with+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12aR"><div class="casContent"><span class="casTitleNuber">12a</span><div class="casTitle"><span class="NLM_cas:atitle">Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer</span></div><div class="casAuthors">Faivre, Sandrine; Delbaldo, Catherine; Vera, Karina; Robert, Caroline; Lozahic, Stephanie; Lassau, Nathalie; Bello, Carlo; Deprimo, Samuel; Brega, Nicoletta; Massimini, Giorgio; Armand, Jean-Pierre; Scigalla, Paul; Raymond, Eric</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">25-35</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose To establish the safety, pharmacokinetics, and recommended dose of sunitinib, a novel oral multitargeting tyrosine kinase inhibitor with antiangiogenic and antitumor properties, in patients with advanced malignancies.  Patients and Methods Sunitinib was given orally for 4 wk every 6 wk.  Results Twenty-eight patients received doses ranging from 15 to 59 mg/m2 (ranging from 50 mg every other day to 150 mg/d).  Dose-limiting toxicities reported at the max.-tolerated doses ≥ 75 mg/d were reversible grade 3 fatigue, grade 3 hypertension, and grade 2 bullous skin toxicity.  Therefore, the recommended dose was 50 mg/d.  At this dose, the main adverse effects were sore mouth, edema, and thrombocytopenia.  Hair discoloration and yellow coloration of the skin were obsd. at doses ≥ 50 mg/d.  Pharmacokinetic data indicate that potentially active target plasma concns. ≥ 50 ng/mL can be achieved with moderate interpatient variability and a long half-life compatible with a single daily dosing.  Six objective responses were obsd. in three renal cell carcinomas, one neuroendocrine tumor, one stromal tumor, and one unknown primary adenocarcinoma patient.  At higher doses (≥ 75 mg/d), tumor responses were often assocd. with reduced intratumoral vascularization and central tumor necrosis, eventually resulting in organ perforation or fistula.  Conclusion At the dose of 50 mg/d (4 wk on, 2 wk off), sunitinib displays manageable toxicity.  Antitumor activity supports further studies in patients with renal cell carcinoma, gastrointestinal, neuroendocrine, and stromal tumors.  Future studies may consider including prospective imaging techniques such as high frequency ultrasound to monitor tumor d.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqleiABO1D2O7Vg90H21EOLACvtfcHk0liA4tj2hCZyQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xot1ChtQ%253D%253D&md5=e6c97fab9666b29992414f56a9c63151</span></div><a href="/servlet/linkout?suffix=cit12a&amp;dbid=16384&amp;doi=10.1200%2FJCO.2005.02.2194&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2005.02.2194%26sid%3Dliteratum%253Aachs%26aulast%3DFaivre%26aufirst%3DS.%26aulast%3DDelbaldo%26aufirst%3DC.%26aulast%3DVera%26aufirst%3DK.%26aulast%3DRobert%26aufirst%3DC.%26aulast%3DLozahic%26aufirst%3DS.%26aulast%3DLassau%26aufirst%3DN.%26aulast%3DBello%26aufirst%3DC.%26aulast%3DDeprimo%26aufirst%3DS.%26aulast%3DBrega%26aufirst%3DN.%26aulast%3DMassimini%26aufirst%3DG.%26aulast%3DArmand%26aufirst%3DJ.-P.%26aulast%3DScigalla%26aufirst%3DP.%26aulast%3DRaymond%26aufirst%3DE.%26atitle%3DSafety%252C%2520pharmacokinetic%252C%2520and%2520antitumor%2520activity%2520of%2520SU11248%252C%2520a%2520novel%2520oral%2520multitarget%2520tyrosine%2520kinase%2520inhibitor%252C%2520in%2520patients%2520with%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2006%26volume%3D24%26spage%3D25%26epage%3D35" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit12b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Motzer, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Michaelson, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Redman, B. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudes, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilding, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Figlin, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ginsberg, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baum, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DePrimo, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bello, C. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Theuer, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">George, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rini, B. I.</span><span> </span><span class="NLM_article-title">Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">24</span><span class="NLM_x">, </span> <span class="NLM_fpage">16</span><span class="NLM_x">–</span> <span class="NLM_lpage">24</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=16&amp;doi=10.1021%2Fjm300126x&amp;key=10.1200%2FJCO.2005.02.2574" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=8&amp;doi=10.1021%2Fjm300126x&amp;key=16330672" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12b&amp;dbid=32&amp;doi=10.1021%2Fjm300126x&amp;key=1%3ACAS%3A528%3ADC%252BD28Xot1ChtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2006&pages=16-24&author=R.+J.+Motzerauthor=M.+D.+Michaelsonauthor=B.+G.+Redmanauthor=G.+R.+Hudesauthor=G.+Wildingauthor=R.+A.+Figlinauthor=M.+S.+Ginsbergauthor=S.+T.+Kimauthor=C.+M.+Baumauthor=S.+E.+DePrimoauthor=J.+Z.+Liauthor=C.+L.+Belloauthor=C.+P.+Theuerauthor=D.+J.+Georgeauthor=B.+I.+Rini&title=Activity+of+SU11248%2C+a+multitargeted+inhibitor+of+vascular+endothelial+growth+factor+receptor+and+platelet-derived+growth+factor+receptor%2C+in+patients+with+metastatic+renal+cell+carcinoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12bR"><div class="casContent"><span class="casTitleNuber">12b</span><div class="casTitle"><span class="NLM_cas:atitle">Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma</span></div><div class="casAuthors">Motzer, Robert J.; Michaelson, M. Dror; Redman, Bruce G.; Hudes, Gary R.; Wilding, George; Figlin, Robert A.; Ginsberg, Michelle S.; Kim, Sindy T.; Baum, Charles M.; DePrimo, Samuel E.; Li, Jim Z.; Bello, Carlo L.; Theuer, Charles P.; George, Daniel J.; Rini, Brian I.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">16-24</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Renal cell carcinoma (RCC) is characterized by loss of von Hippel Lindau tumor suppressor gene activity, resulting in high expression of pro-angiogenic growth factors: vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF).  SU11248 (sunitinib malate), a small mol. inhibitor with high binding affinity for VEGF and PDGF receptors, was tested for clin. activity in patients with metastatic RCC.  Patients and Methods: Patients with metastatic RCC and progression on first-line cytokine therapy were enrolled onto a multicenter phase II trial.  SU11248 monotherapy was administered in repeated 6-wk cycles of daily oral therapy for 4 wk, followed by 2 wk off.  Overall response rate was the primary end point, and time to progression and safety were secondary end points.  Results: Twenty-five (40%) of 63 patients treated with SU11248 achieved partial responses; 17 addnl. patients (27%) demonstrated stable disease lasting ≥ 3 mo.  Median time to progression in the 63 patients was 8.7 mo.  Dosing was generally tolerated with manageable toxicities.  Conclusion: SU11248, a multitargeted receptor tyrosine kinase inhibitor of VEGF and PDGF receptors, demonstrates antitumor activity in metastatic RCC as second-line therapy, a setting where no effective systemic therapy is presently recognized.  The genetics of RCC and these promising clin. results support the hypothesis that VEGF and PDGF receptor-mediated signaling is an effective therapeutic target in RCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoCep3NZbaojLVg90H21EOLACvtfcHk0liA4tj2hCZyQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xot1ChtA%253D%253D&md5=f3304eba449f0ff4ac20ac0cf8a878c5</span></div><a href="/servlet/linkout?suffix=cit12b&amp;dbid=16384&amp;doi=10.1200%2FJCO.2005.02.2574&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2005.02.2574%26sid%3Dliteratum%253Aachs%26aulast%3DMotzer%26aufirst%3DR.%2BJ.%26aulast%3DMichaelson%26aufirst%3DM.%2BD.%26aulast%3DRedman%26aufirst%3DB.%2BG.%26aulast%3DHudes%26aufirst%3DG.%2BR.%26aulast%3DWilding%26aufirst%3DG.%26aulast%3DFiglin%26aufirst%3DR.%2BA.%26aulast%3DGinsberg%26aufirst%3DM.%2BS.%26aulast%3DKim%26aufirst%3DS.%2BT.%26aulast%3DBaum%26aufirst%3DC.%2BM.%26aulast%3DDePrimo%26aufirst%3DS.%2BE.%26aulast%3DLi%26aufirst%3DJ.%2BZ.%26aulast%3DBello%26aufirst%3DC.%2BL.%26aulast%3DTheuer%26aufirst%3DC.%2BP.%26aulast%3DGeorge%26aufirst%3DD.%2BJ.%26aulast%3DRini%26aufirst%3DB.%2BI.%26atitle%3DActivity%2520of%2520SU11248%252C%2520a%2520multitargeted%2520inhibitor%2520of%2520vascular%2520endothelial%2520growth%2520factor%2520receptor%2520and%2520platelet-derived%2520growth%2520factor%2520receptor%252C%2520in%2520patients%2520with%2520metastatic%2520renal%2520cell%2520carcinoma%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2006%26volume%3D24%26spage%3D16%26epage%3D24" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit12c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Sun, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shirazian, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fukuda, J. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, J.-Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nematalla, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sistla, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luu, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, C.</span><span> </span><span class="NLM_article-title">Discovery of 5-[5-fluoro-2-oxo-1,2-dihydroindol-(3<i>Z</i>)-ylidenemethyl]-2,4-dimethyl-1<i>H</i>-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">46</span><span class="NLM_x">, </span> <span class="NLM_fpage">1116</span><span class="NLM_x">–</span> <span class="NLM_lpage">1119</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0204183" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=1116-1119&author=L.+Sunauthor=C.+Liangauthor=S.+Shirazianauthor=Y.+Zhouauthor=T.+Millerauthor=J.+Cuiauthor=J.+Y.+Fukudaauthor=J.-Y.+Chuauthor=A.+Nematallaauthor=X.+Wangauthor=H.+Chenauthor=A.+Sistlaauthor=T.+C.+Luuauthor=F.+Tangauthor=J.+Weiauthor=C.+Tang&title=Discovery+of+5-%5B5-fluoro-2-oxo-1%2C2-dihydroindol-%283Z%29-ylidenemethyl%5D-2%2C4-dimethyl-1H-pyrrole-3-carboxylic+acid+%282-diethylaminoethyl%29amide%2C+a+novel+tyrosine+kinase+inhibitor+targeting+vascular+endothelial+and+platelet-derived+growth+factor+receptor+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12c&amp;dbid=16384&amp;doi=10.1021%2Fjm0204183&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0204183%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DL.%26aulast%3DLiang%26aufirst%3DC.%26aulast%3DShirazian%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DMiller%26aufirst%3DT.%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DFukuda%26aufirst%3DJ.%2BY.%26aulast%3DChu%26aufirst%3DJ.-Y.%26aulast%3DNematalla%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DH.%26aulast%3DSistla%26aufirst%3DA.%26aulast%3DLuu%26aufirst%3DT.%2BC.%26aulast%3DTang%26aufirst%3DF.%26aulast%3DWei%26aufirst%3DJ.%26aulast%3DTang%26aufirst%3DC.%26atitle%3DDiscovery%2520of%25205-%255B5-fluoro-2-oxo-1%252C2-dihydroindol-%25283Z%2529-ylidenemethyl%255D-2%252C4-dimethyl-1H-pyrrole-3-carboxylic%2520acid%2520%25282-diethylaminoethyl%2529amide%252C%2520a%2520novel%2520tyrosine%2520kinase%2520inhibitor%2520targeting%2520vascular%2520endothelial%2520and%2520platelet-derived%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D1116%26epage%3D1119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Hu-Lowe, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grazzini, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallin, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wickman, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Amundson, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rewolinski, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, E. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murray, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kania, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Connor, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shalinsky, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, S. L.</span><span> </span><span class="NLM_article-title">Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">7272</span><span class="NLM_x">–</span> <span class="NLM_lpage">7283</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=16&amp;doi=10.1021%2Fjm300126x&amp;key=10.1158%2F1078-0432.CCR-08-0652" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=8&amp;doi=10.1021%2Fjm300126x&amp;key=19010843" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13a&amp;dbid=32&amp;doi=10.1021%2Fjm300126x&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlylur7I" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=7272-7283&author=D.+D.+Hu-Loweauthor=H.+Y.+Zouauthor=M.+L.+Grazziniauthor=M.+E.+Hallinauthor=G.+R.+Wickmanauthor=K.+Amundsonauthor=J.+H.+Chenauthor=D.+A.+Rewolinskiauthor=S.+Yamazakiauthor=E.+Y.+Wuauthor=M.+A.+McTigueauthor=B.+W.+Murrayauthor=R.+S.+Kaniaauthor=P.+O%E2%80%99Connorauthor=D.+R.+Shalinskyauthor=S.+L.+Bender&title=Nonclinical+antiangiogenesis+and+antitumor+activities+of+axitinib+%28AG-013736%29%2C+an+oral%2C+potent%2C+and+selective+inhibitor+of+vascular+endothelial+growth+factor+receptor+tyrosine+kinases+1%2C+2%2C+3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13aR"><div class="casContent"><span class="casTitleNuber">13a</span><div class="casTitle"><span class="NLM_cas:atitle">Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3</span></div><div class="casAuthors">Hu-Lowe, Dana D.; Zou, Helen Y.; Grazzini, Maren L.; Hallin, Max E.; Wickman, Grant R.; Amundson, Karin; Chen, Jeffrey H.; Rewolinski, David A.; Yamazaki, Shinji; Wu, Ellen Y.; McTigue, Michele A.; Murray, Brion W.; Kania, Robert S.; O'Connor, Patrick; Shalinsky, David R.; Bender, Steve L.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">7272-7283</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Axitinib (AG-013736) is a potent and selective inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases 1 to 3 that is in clin. development for the treatment of solid tumors.  We provide a comprehensive description of its in vitro characteristics and activities, in vivo antiangiogenesis, and antitumor efficacy and translational pharmacol. data.  Exptl. Design: The potency, kinase selectivity, pharmacol. activity, and antitumor efficacy of axitinib were assessed in various nonclin. models.  RESULTS: Axitinib inhibits cellular autophosphorylation of VEGF receptors (VEGFR) with picomolar IC50 values.  Counterscreening across multiple kinase and protein panels shows it is selective for VEGFRs.  Axitinib blocks VEGF-mediated endothelial cell survival, tube formation, and downstream signaling through endothelial nitric oxide synthase, Akt and extracellular signal-regulated kinase.  Following twice daily oral administration, axitinib produces consistent and dose-dependent antitumor efficacy that is assocd. with blocking VEGFR-2 phosphorylation, vascular permeability, angiogenesis, and concomitant induction of tumor cell apoptosis.  Axitinib in combination with chemotherapeutic or targeted agents enhances antitumor efficacy in many tumor models compared with single agent alone.  Dose scheduling studies in a human pancreatic tumor xenograft model show that simultaneous administration of axitinib and gemcitabine without prolonged dose interruption or truncation of axitinib produces the greatest antitumor efficacy.  The efficacious drug concns. predicted in nonclin. studies are consistent with the range achieved in the clinic.  Although axitinib inhibits platelet-derived growth factor receptors and KIT with nanomolar in vitro potencies, based on pharmacokinetic/pharmacodynamic anal., axitinib acts primarily as a VEGFR tyrosine kinase inhibitor at the current clin. exposure.  CONCLUSIONS: The selectivity, potency for VEGFRs, and robust nonclin. activity may afford broad opportunities for axitinib to improve cancer therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhwUJi2tefWrVg90H21EOLACvtfcHk0ljjO1LOkj9xEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlylur7I&md5=6a616860756379e85551afe6b9eb750e</span></div><a href="/servlet/linkout?suffix=cit13a&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-08-0652&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-08-0652%26sid%3Dliteratum%253Aachs%26aulast%3DHu-Lowe%26aufirst%3DD.%2BD.%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DGrazzini%26aufirst%3DM.%2BL.%26aulast%3DHallin%26aufirst%3DM.%2BE.%26aulast%3DWickman%26aufirst%3DG.%2BR.%26aulast%3DAmundson%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DJ.%2BH.%26aulast%3DRewolinski%26aufirst%3DD.%2BA.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DWu%26aufirst%3DE.%2BY.%26aulast%3DMcTigue%26aufirst%3DM.%2BA.%26aulast%3DMurray%26aufirst%3DB.%2BW.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DP.%26aulast%3DShalinsky%26aufirst%3DD.%2BR.%26aulast%3DBender%26aufirst%3DS.%2BL.%26atitle%3DNonclinical%2520antiangiogenesis%2520and%2520antitumor%2520activities%2520of%2520axitinib%2520%2528AG-013736%2529%252C%2520an%2520oral%252C%2520potent%252C%2520and%2520selective%2520inhibitor%2520of%2520vascular%2520endothelial%2520growth%2520factor%2520receptor%2520tyrosine%2520kinases%25201%252C%25202%252C%25203%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26spage%3D7272%26epage%3D7283" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit13b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Rugo, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herbst, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kies, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steinfeldt, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pithavala, Y. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reich, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freddo, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilding, G.</span><span> </span><span class="NLM_article-title">Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">5474</span><span class="NLM_x">–</span> <span class="NLM_lpage">5483</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=16&amp;doi=10.1021%2Fjm300126x&amp;key=10.1200%2FJCO.2005.04.192" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=8&amp;doi=10.1021%2Fjm300126x&amp;key=16027439" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13b&amp;dbid=32&amp;doi=10.1021%2Fjm300126x&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVersr7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2005&pages=5474-5483&author=H.+S.+Rugoauthor=R.+S.+Herbstauthor=G.+Liuauthor=J.+W.+Parkauthor=M.+S.+Kiesauthor=H.+M.+Steinfeldtauthor=Y.+K.+Pithavalaauthor=S.+D.+Reichauthor=J.+L.+Freddoauthor=G.+Wilding&title=Phase+I+trial+of+the+oral+antiangiogenesis+agent+AG-013736+in+patients+with+advanced+solid+tumors%3A+pharmacokinetic+and+clinical+results"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13bR"><div class="casContent"><span class="casTitleNuber">13b</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results</span></div><div class="casAuthors">Rugo, Hope S.; Herbst, Roy S.; Liu, Glenn; Park, John W.; Kies, Merrill S.; Steinfeldt, Heidi M.; Pithavala, Yazdi K.; Reich, Steven D.; Freddo, James L.; Wilding, George</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">5474-5483</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: We studied the safety, clin. activity, and pharmacokinetics (PK) of AG-013736, an oral receptor tyrosine kinase inhibitor of vascular endothelial cell growth factor, platelet-derived growth factor, and c-Kit, in patients with advanced cancer.  Patients and Methods: Patients received fixed doses of AG-013736 orally in 28-day cycles.  In the first cohort, patients initially received two single test doses of AG-013736 (10 and 30 mg); subsequent dosing was detd. by individual PK parameters.  Doses in subsequent cohorts were assigned by using a traditional dose-escalation/de-escalation rule based on obsd. toxicities in the current and previous cohorts.  PK anal. included evaluation of the effect of food and antacid.  Results: Thirty-six patients received AG-013736 at doses ranging from 5 to 30 mg by mouth twice daily.  The dose-limiting toxicities obsd. included hypertension, hemoptysis, and stomatitis and were seen primarily at the higher dose levels.  The obsd. hypertension was manageable with medication.  Stomatitis was generally tolerable and managed by dose redn. or drug holidays.  AG-013736 was absorbed rapidly, with peak plasma concns. obsd. within 2 to 6 h after dosing.  The max.-tolerated dose and recommended phase II dose of AG-013736 is 5 mg, twice daily, administered in the fasted state.  No significant drug interaction with antacid was seen.  There were three confirmed partial responses and other evidence of clin. activity.  Conclusion: In this study, we have demonstrated clin. activity and safety of AG-013736 in patients with advanced solid tumors and identified the dose for phase II testing.  The unique phase I study design allowed early identification of important absorption and metabolic issues crit. to phase II testing of this agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrUWAS7w-z6TrVg90H21EOLACvtfcHk0ljjO1LOkj9xEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVersr7F&md5=09347fe027d10507a3279aa66c2c12a2</span></div><a href="/servlet/linkout?suffix=cit13b&amp;dbid=16384&amp;doi=10.1200%2FJCO.2005.04.192&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2005.04.192%26sid%3Dliteratum%253Aachs%26aulast%3DRugo%26aufirst%3DH.%2BS.%26aulast%3DHerbst%26aufirst%3DR.%2BS.%26aulast%3DLiu%26aufirst%3DG.%26aulast%3DPark%26aufirst%3DJ.%2BW.%26aulast%3DKies%26aufirst%3DM.%2BS.%26aulast%3DSteinfeldt%26aufirst%3DH.%2BM.%26aulast%3DPithavala%26aufirst%3DY.%2BK.%26aulast%3DReich%26aufirst%3DS.%2BD.%26aulast%3DFreddo%26aufirst%3DJ.%2BL.%26aulast%3DWilding%26aufirst%3DG.%26atitle%3DPhase%2520I%2520trial%2520of%2520the%2520oral%2520antiangiogenesis%2520agent%2520AG-013736%2520in%2520patients%2520with%2520advanced%2520solid%2520tumors%253A%2520pharmacokinetic%2520and%2520clinical%2520results%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2005%26volume%3D23%26spage%3D5474%26epage%3D5483" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Bukowski, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yasothan, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirkpatrick, P.</span><span> </span><span class="NLM_article-title">Pazopanib</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">17</span><span class="NLM_x">–</span> <span class="NLM_lpage">18</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=17-18&author=R.+M.+Bukowskiauthor=U.+Yasothanauthor=P.+Kirkpatrick&title=Pazopanib"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBukowski%26aufirst%3DR.%2BM.%26aulast%3DYasothan%26aufirst%3DU.%26aulast%3DKirkpatrick%26aufirst%3DP.%26atitle%3DPazopanib%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2010%26volume%3D9%26spage%3D17%26epage%3D18" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit14b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Harris, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boloor, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheung, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crosby, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis-Ward, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Epperly, A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinkle, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, R. N.,  III</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knick, V. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laudeman, C. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luttrell, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mook, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolte, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rudolph, S. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szewczyk, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Truesdale, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veal, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stafford, J. A.</span><span> </span><span class="NLM_article-title">Discovery of 5-[[4-[(2,3-dimethyl-2<i>H</i>-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">4632</span><span class="NLM_x">–</span> <span class="NLM_lpage">4640</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm800566m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=4632-4640&author=P.+A.+Harrisauthor=A.+Boloorauthor=M.+Cheungauthor=R.+Kumarauthor=R.+M.+Crosbyauthor=R.+G.+Davis-Wardauthor=A.+H.+Epperlyauthor=K.+W.+Hinkleauthor=R.+N.+Hunterauthor=J.+H.+Johnsonauthor=V.+B.+Knickauthor=C.+P.+Laudemanauthor=D.+K.+Luttrellauthor=R.+A.+Mookauthor=R.+T.+Nolteauthor=S.+K.+Rudolphauthor=J.+R.+Szewczykauthor=A.+T.+Truesdaleauthor=J.+M.+Vealauthor=L.+Wangauthor=J.+A.+Stafford&title=Discovery+of+5-%5B%5B4-%5B%282%2C3-dimethyl-2H-indazol-6-yl%29methylamino%5D-2-pyrimidinyl%5Damino%5D-2-methyl-benzenesulfonamide+%28pazopanib%29%2C+a+novel+and+potent+vascular+endothelial+growth+factor+receptor+inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14b&amp;dbid=16384&amp;doi=10.1021%2Fjm800566m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800566m%26sid%3Dliteratum%253Aachs%26aulast%3DHarris%26aufirst%3DP.%2BA.%26aulast%3DBoloor%26aufirst%3DA.%26aulast%3DCheung%26aufirst%3DM.%26aulast%3DKumar%26aufirst%3DR.%26aulast%3DCrosby%26aufirst%3DR.%2BM.%26aulast%3DDavis-Ward%26aufirst%3DR.%2BG.%26aulast%3DEpperly%26aufirst%3DA.%2BH.%26aulast%3DHinkle%26aufirst%3DK.%2BW.%26aulast%3DHunter%26aufirst%3DR.%2BN.%26aulast%3DJohnson%26aufirst%3DJ.%2BH.%26aulast%3DKnick%26aufirst%3DV.%2BB.%26aulast%3DLaudeman%26aufirst%3DC.%2BP.%26aulast%3DLuttrell%26aufirst%3DD.%2BK.%26aulast%3DMook%26aufirst%3DR.%2BA.%26aulast%3DNolte%26aufirst%3DR.%2BT.%26aulast%3DRudolph%26aufirst%3DS.%2BK.%26aulast%3DSzewczyk%26aufirst%3DJ.%2BR.%26aulast%3DTruesdale%26aufirst%3DA.%2BT.%26aulast%3DVeal%26aufirst%3DJ.%2BM.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DStafford%26aufirst%3DJ.%2BA.%26atitle%3DDiscovery%2520of%25205-%255B%255B4-%255B%25282%252C3-dimethyl-2H-indazol-6-yl%2529methylamino%255D-2-pyrimidinyl%255Damino%255D-2-methyl-benzenesulfonamide%2520%2528pazopanib%2529%252C%2520a%2520novel%2520and%2520potent%2520vascular%2520endothelial%2520growth%2520factor%2520receptor%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D4632%26epage%3D4640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Wilhelm, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilkie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNabola, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rong, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vincent, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McHugh, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cao, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shujath, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gawlak, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eveleigh, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rowley, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adnane, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Auclair, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gedrich, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Voznesensky, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riedl, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Post, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bollag, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trail, P. A.</span><span> </span><span class="NLM_article-title">BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">64</span><span class="NLM_x">, </span> <span class="NLM_fpage">7099</span><span class="NLM_x">–</span> <span class="NLM_lpage">7109</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=7099-7109&author=S.+M.+Wilhelmauthor=C.+Carterauthor=L.+Tangauthor=D.+Wilkieauthor=A.+McNabolaauthor=H.+Rongauthor=C.+Chenauthor=X.+Zhangauthor=P.+Vincentauthor=M.+McHughauthor=Y.+Caoauthor=J.+Shujathauthor=S.+Gawlakauthor=D.+Eveleighauthor=B.+Rowleyauthor=L.+Liuauthor=L.+Adnaneauthor=M.+Lynchauthor=D.+Auclairauthor=I.+Taylorauthor=R.+Gedrichauthor=A.+Voznesenskyauthor=B.+Riedlauthor=L.+E.+Postauthor=G.+Bollagauthor=P.+A.+Trail&title=BAY+43-9006+exhibits+broad+spectrum+oral+antitumor+activity+and+targets+the+RAF%2FMEK%2FERK+pathway+and+receptor+tyrosine+kinases+involved+in+tumor+progression+and+angiogenesis"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWilhelm%26aufirst%3DS.%2BM.%26aulast%3DCarter%26aufirst%3DC.%26aulast%3DTang%26aufirst%3DL.%26aulast%3DWilkie%26aufirst%3DD.%26aulast%3DMcNabola%26aufirst%3DA.%26aulast%3DRong%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DVincent%26aufirst%3DP.%26aulast%3DMcHugh%26aufirst%3DM.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DShujath%26aufirst%3DJ.%26aulast%3DGawlak%26aufirst%3DS.%26aulast%3DEveleigh%26aufirst%3DD.%26aulast%3DRowley%26aufirst%3DB.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DAdnane%26aufirst%3DL.%26aulast%3DLynch%26aufirst%3DM.%26aulast%3DAuclair%26aufirst%3DD.%26aulast%3DTaylor%26aufirst%3DI.%26aulast%3DGedrich%26aufirst%3DR.%26aulast%3DVoznesensky%26aufirst%3DA.%26aulast%3DRiedl%26aufirst%3DB.%26aulast%3DPost%26aufirst%3DL.%2BE.%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DTrail%26aufirst%3DP.%2BA.%26atitle%3DBAY%252043-9006%2520exhibits%2520broad%2520spectrum%2520oral%2520antitumor%2520activity%2520and%2520targets%2520the%2520RAF%252FMEK%252FERK%2520pathway%2520and%2520receptor%2520tyrosine%2520kinases%2520involved%2520in%2520tumor%2520progression%2520and%2520angiogenesis%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D7099%26epage%3D7109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Wilhelm, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carter, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lowinger, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dumas, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simantov, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kelley, S.</span><span> </span><span class="NLM_article-title">Discovery and development of sorafenib: a multikinase inhibitor for treating cancer</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">835</span><span class="NLM_x">–</span> <span class="NLM_lpage">844</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Fjm300126x&amp;key=10.1038%2Fnrd2130" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Fjm300126x&amp;key=17016424" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm300126x&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtVajsbbM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2006&pages=835-844&author=S.+Wilhelmauthor=C.+Carterauthor=M.+Lynchauthor=T.+Lowingerauthor=J.+Dumasauthor=R.+A.+Smithauthor=B.+Schwartzauthor=R.+Simantovauthor=S.+Kelley&title=Discovery+and+development+of+sorafenib%3A+a+multikinase+inhibitor+for+treating+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and development of sorafenib: a multikinase inhibitor for treating cancer</span></div><div class="casAuthors">Wilhelm, Scott; Carter, Christopher; Lynch, Mark; Lowinger, Timothy; Dumas, Jacques; Smith, Roger A.; Schwartz, Brian; Simantov, Ronit; Kelley, Susan</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">835-844</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Since the mol. revolution of the 1980s, knowledge of the etiol. of cancer has increased considerably, which has led to the discovery and development of targeted therapies tailored to inhibit cancer-specific pathways.  The introduction and refinement of rapid, high-throughput screening technologies over the past decade has greatly facilitated this targeted discovery and development process.  Here, the authors describe the discovery and continuing development of sorafenib (previously known as BAY 43-9006), the first oral multikinase inhibitor that targets Raf and affects tumor signaling and the tumor vasculature.  The discovery cycle of sorafenib (Nexavar; Bayer Pharmaceuticals) - from initial screening for a lead compd. to FDA approval for the treatment of advanced renal cell carcinoma in Dec. 2005 - was completed in just 11 years, with approval being received ∼5 years after the initiation of the first Phase I trial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6WjjfgNSCtbVg90H21EOLACvtfcHk0ljEOZiZ10mTbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtVajsbbM&md5=490d4995170f3a7270ae9bbdd24b12e5</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1038%2Fnrd2130&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2130%26sid%3Dliteratum%253Aachs%26aulast%3DWilhelm%26aufirst%3DS.%26aulast%3DCarter%26aufirst%3DC.%26aulast%3DLynch%26aufirst%3DM.%26aulast%3DLowinger%26aufirst%3DT.%26aulast%3DDumas%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DR.%2BA.%26aulast%3DSchwartz%26aufirst%3DB.%26aulast%3DSimantov%26aufirst%3DR.%26aulast%3DKelley%26aufirst%3DS.%26atitle%3DDiscovery%2520and%2520development%2520of%2520sorafenib%253A%2520a%2520multikinase%2520inhibitor%2520for%2520treating%2520cancer%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2006%26volume%3D5%26spage%3D835%26epage%3D844" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span>Food and Drug Administration. Highlights of Prescribing Information. <a href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021923s004s005s006s007lbl.pdf" class="extLink">http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021923s004s005s006s007lbl.pdf</a> (accessed Jan 11,<span class="NLM_x"> </span><span class="NLM_year">2012</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Food+and+Drug+Administration.+Highlights+of+Prescribing+Information.+http%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2007%2F021923s004s005s006s007lbl.pdf+%28accessed+Jan+11%2C+2012%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Eisen, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmad, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gore, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaye, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marais, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gibbens, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hackett, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">James, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuchter, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nathanson, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simantov, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwartz, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poulin-Costello, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Dwyer, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ratain, M. J.</span><span> </span><span class="NLM_article-title">Sorafenib in advanced melanoma: a phase II randomised discontinuation trial analysis</span> <span class="citation_source-journal">Br. J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">95</span><span class="NLM_x">, </span> <span class="NLM_fpage">581</span><span class="NLM_x">–</span> <span class="NLM_lpage">586</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm300126x&amp;key=10.1038%2Fsj.bjc.6603291" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm300126x&amp;key=16880785" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm300126x&amp;key=1%3ACAS%3A528%3ADC%252BD28XovVWitLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=2006&pages=581-586&author=T.+Eisenauthor=T.+Ahmadauthor=K.+T.+Flahertyauthor=M.+Goreauthor=S.+Kayeauthor=R.+Maraisauthor=I.+Gibbensauthor=S.+Hackettauthor=M.+Jamesauthor=L.+M.+Schuchterauthor=K.+L.+Nathansonauthor=C.+Xiaauthor=R.+Simantovauthor=B.+Schwartzauthor=M.+Poulin-Costelloauthor=P.+J.+O%E2%80%99Dwyerauthor=M.+J.+Ratain&title=Sorafenib+in+advanced+melanoma%3A+a+phase+II+randomised+discontinuation+trial+analysis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis</span></div><div class="casAuthors">Eisen, T.; Ahmad, T.; Flaherty, K. T.; Gore, M.; Kaye, S.; Marais, R.; Gibbens, I.; Hackett, S.; James, M.; Schuchter, L. M.; Nathanson, K. L.; Xia, C.; Simantov, R.; Schwartz, B.; Poulin-Costello, M.; O'Dwyer, P. J.; Ratain, M. J.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">581-586</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The effects of sorafenib - an oral multikinase inhibitor targeting the tumor and tumor vasculature - were evaluated in patients with advanced melanoma enrolled in a large multidisease Phase II randomised discontinuation trial (RDT).  Enrolled patients received a 12-wk run-in of sorafenib 400 mg twice daily (b.i.d.).  Patients with changes in bi-dimensional tumor measurements <25% from baseline were then randomised to sorafenib or placebo for a further 12 wk (ie to week 24).  Patients with ≥25% tumor shrinkage after the run-in continued on open-label sorafenib, whereas those with ≥25% tumor growth discontinued treatment.  This anal. focussed on secondary RDT end points: changes in bi-dimensional tumor measurements from baseline after 12 wk and overall tumor responses (WHO criteria) at week 24, progression-free survival (PFS), safety and biomarkers (BRAF, KRAS and NRAS mutational status).  Of 37 melanoma patients treated during the run-in phase, 34 were evaluable for response: one had ≥25% tumor shrinkage and remained on open-label sorafenib; six (16%) had <25% tumor growth and were randomised (placebo, n=3; sorafenib, n=3); and 27 had ≥25% tumor growth and discontinued.  All three randomised sorafenib patients progressed by week 24; one remained on sorafenib for symptomatic relief.  All three placebo patients progressed by week-24 and were re-started on sorafenib; one experienced disease re-stabilization.  Overall, the confirmed best responses for each of the 37 melanoma patients who received sorafenib were 19% stable disease (SD) (ie n=1 open-label; n=6 randomised), 62% (n=23) progressive disease (PD) and 19% (n=7) unevaluable.  The overall median PFS was 11 wk.  The six randomised patients with SD had overall PFS values ranging from 16 to 34 wk.  The most common drug-related adverse events were dermatol. (eg rash/desquamation, 51%; hand-foot skin reaction, 35%).  There was no relationship between V600E BRAF status and disease stability.  DNA was extd. from the biopsies of 17/22 patients.  Six had V600E-pos. tumors (n=4 had PD; n=1 had SD; n=1 unevaluable for response), and 11 had tumors contg. wild-type BRAF (n=9 PD; n=1 SD; n=1 unevaluable for response).  In conclusion, sorafenib is well tolerated but has little or no antitumor activity in advanced melanoma patients as a single agent at the dose evaluated (400 mg b.i.d.).  Ongoing trials in advanced melanoma are evaluating sorafenib combination therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrADSApQdE0pLVg90H21EOLACvtfcHk0lh7FFFOhSnUQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XovVWitLo%253D&md5=5040c220e2361be41099fe0f42edcb8b</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjc.6603291&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjc.6603291%26sid%3Dliteratum%253Aachs%26aulast%3DEisen%26aufirst%3DT.%26aulast%3DAhmad%26aufirst%3DT.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DGore%26aufirst%3DM.%26aulast%3DKaye%26aufirst%3DS.%26aulast%3DMarais%26aufirst%3DR.%26aulast%3DGibbens%26aufirst%3DI.%26aulast%3DHackett%26aufirst%3DS.%26aulast%3DJames%26aufirst%3DM.%26aulast%3DSchuchter%26aufirst%3DL.%2BM.%26aulast%3DNathanson%26aufirst%3DK.%2BL.%26aulast%3DXia%26aufirst%3DC.%26aulast%3DSimantov%26aufirst%3DR.%26aulast%3DSchwartz%26aufirst%3DB.%26aulast%3DPoulin-Costello%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Dwyer%26aufirst%3DP.%2BJ.%26aulast%3DRatain%26aufirst%3DM.%2BJ.%26atitle%3DSorafenib%2520in%2520advanced%2520melanoma%253A%2520a%2520phase%2520II%2520randomised%2520discontinuation%2520trial%2520analysis%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2006%26volume%3D95%26spage%3D581%26epage%3D586" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Wan, P. T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garnett, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roe, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niculescu-Duvaz, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Good, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springer, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barford, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marais, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cancer Genome Project.</span><span> </span><span class="NLM_article-title">Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">116</span><span class="NLM_x">, </span> <span class="NLM_fpage">855</span><span class="NLM_x">–</span> <span class="NLM_lpage">867</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm300126x&amp;key=10.1016%2FS0092-8674%2804%2900215-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Fjm300126x&amp;key=15035987" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm300126x&amp;key=1%3ACAS%3A528%3ADC%252BD2cXivVyksLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=116&publication_year=2004&pages=855-867&author=P.+T.+C.+Wanauthor=M.+J.+Garnettauthor=S.+M.+Roeauthor=S.+Leeauthor=D.+Niculescu-Duvazauthor=V.+M.+Goodauthor=C.+M.+Jonesauthor=C.+J.+Marshallauthor=C.+J.+Springerauthor=D.+Barfordauthor=R.+Maraisauthor=Cancer+Genome+Project.&title=Mechanism+of+activation+of+the+RAF-ERK+signaling+pathway+by+oncogenic+mutations+of+B-RAF"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF</span></div><div class="casAuthors">Wan, Paul T. C.; Garnett, Mathew J.; Roe, S. Mark; Lee, Sharlene; Niculescu-Duvaz, Dan; Good, Valerie M.; Project, Cancer Genome; Jones, C. Michael; Marshall, Christopher J.; Springer, Caroline J.; Barford, David; Marais, Richard</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">116</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">855-867</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Over 30 mutations of the B-RAF gene assocd. with human cancers have been identified, the majority of which are located within the kinase domain.  Here the authors show that of 22 B-RAF mutants analyzed, 18 have elevated kinase activity and signal to ERK in vivo.  Surprisingly, three mutants have reduced kinase activity towards MEK in vitro but, by activating C-RAF in vivo, signal to ERK in cells.  The structures of wild type and oncogenic V599EB-RAF kinase domains in complex with the RAF inhibitor BAY43-9006 show that the activation segment is held in an inactive conformation by assocn. with the P loop.  The clustering of most mutations to these two regions suggests that disruption of this interaction converts B-RAF into its active conformation.  The high activity mutants signal to ERK by directly phosphorylating MEK, whereas the impaired activity mutants stimulate MEK by activating endogenous C-RAF, possibly via an allosteric or transphosphorylation mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoYiQicwc1xVLVg90H21EOLACvtfcHk0lh7FFFOhSnUQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXivVyksLw%253D&md5=4cc020056c64e514286c000666da1972</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1016%2FS0092-8674%2804%2900215-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0092-8674%252804%252900215-6%26sid%3Dliteratum%253Aachs%26aulast%3DWan%26aufirst%3DP.%2BT.%2BC.%26aulast%3DGarnett%26aufirst%3DM.%2BJ.%26aulast%3DRoe%26aufirst%3DS.%2BM.%26aulast%3DLee%26aufirst%3DS.%26aulast%3DNiculescu-Duvaz%26aufirst%3DD.%26aulast%3DGood%26aufirst%3DV.%2BM.%26aulast%3DJones%26aufirst%3DC.%2BM.%26aulast%3DMarshall%26aufirst%3DC.%2BJ.%26aulast%3DSpringer%26aufirst%3DC.%2BJ.%26aulast%3DBarford%26aufirst%3DD.%26aulast%3DMarais%26aufirst%3DR.%26aulast%3D%26atitle%3DMechanism%2520of%2520activation%2520of%2520the%2520RAF-ERK%2520signaling%2520pathway%2520by%2520oncogenic%2520mutations%2520of%2520B-RAF%26jtitle%3DCell%26date%3D2004%26volume%3D116%26spage%3D855%26epage%3D867" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Venetsanakos, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stuart, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salangsang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aardalen, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faure, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heise, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendel, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jallal, B.</span><span> </span><span class="NLM_article-title">CHIR-265, a novel inhibitor that targets B-Raf and VEGFR, shows efficacy in a broad range of preclinical models</span> <span class="citation_source-journal">Proc. Am. Assoc. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">4854</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2006&pages=4854&author=E.+Venetsanakosauthor=D.+Stuartauthor=N.+Tanauthor=H.+Yeauthor=F.+Salangsangauthor=K.+Aardalenauthor=M.+Faureauthor=C.+Heiseauthor=D.+Mendelauthor=B.+Jallal&title=CHIR-265%2C+a+novel+inhibitor+that+targets+B-Raf+and+VEGFR%2C+shows+efficacy+in+a+broad+range+of+preclinical+models"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DVenetsanakos%26aufirst%3DE.%26aulast%3DStuart%26aufirst%3DD.%26aulast%3DTan%26aufirst%3DN.%26aulast%3DYe%26aufirst%3DH.%26aulast%3DSalangsang%26aufirst%3DF.%26aulast%3DAardalen%26aufirst%3DK.%26aulast%3DFaure%26aufirst%3DM.%26aulast%3DHeise%26aufirst%3DC.%26aulast%3DMendel%26aufirst%3DD.%26aulast%3DJallal%26aufirst%3DB.%26atitle%3DCHIR-265%252C%2520a%2520novel%2520inhibitor%2520that%2520targets%2520B-Raf%2520and%2520VEGFR%252C%2520shows%2520efficacy%2520in%2520a%2520broad%2520range%2520of%2520preclinical%2520models%26jtitle%3DProc.%2520Am.%2520Assoc.%2520Cancer%2520Res.%26date%3D2006%26volume%3D47%26spage%3D4854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Rational design of inhibitors that bind to inactive kinase conformations</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">358</span><span class="NLM_x">–</span> <span class="NLM_lpage">364</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=16&amp;doi=10.1021%2Fjm300126x&amp;key=10.1038%2Fnchembio799" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=8&amp;doi=10.1021%2Fjm300126x&amp;key=16783341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21a&amp;dbid=32&amp;doi=10.1021%2Fjm300126x&amp;key=1%3ACAS%3A528%3ADC%252BD28XlvFGjs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2006&pages=358-364&author=Y.+Liuauthor=N.+S.+Gray&title=Rational+design+of+inhibitors+that+bind+to+inactive+kinase+conformations"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21aR"><div class="casContent"><span class="casTitleNuber">21a</span><div class="casTitle"><span class="NLM_cas:atitle">Rational design of inhibitors that bind to inactive kinase conformations</span></div><div class="casAuthors">Liu, Yi; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">358-364</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The majority of kinase inhibitors, known as type I inhibitors that have been developed so far target the ATP binding site of the kinase in its active conformation, in which the activation loop is phosphorylated.  Recently, crystal structures of inhibitors such as imatinib, BIRB796, and sorafenib (BAY43-9006), known as type II inhibitors, have revealed a new binding mode that exploits an addnl. binding site immediately adjacent to the region occupied by ATP.  This pocket is made accessible by an activation-loop rearrangement that is characteristic of kinases in an inactive conformation.  The examn. of binding features of known type II inhibitors is discussed and a pharmacophore model currently used in the design of a new generation of structurally diverse type II inhibitors is presented.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrxahsMPlhgDbVg90H21EOLACvtfcHk0lh7FFFOhSnUQg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XlvFGjs7g%253D&md5=4a9347a44a2cf4a412c9741fdcc5696b</span></div><a href="/servlet/linkout?suffix=cit21a&amp;dbid=16384&amp;doi=10.1038%2Fnchembio799&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio799%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DRational%2520design%2520of%2520inhibitors%2520that%2520bind%2520to%2520inactive%2520kinase%2520conformations%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2006%26volume%3D2%26spage%3D358%26epage%3D364" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit21b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Backes, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zech, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felber, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klebl, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, G.</span><span> </span><span class="NLM_article-title">Small-molecule inhibitors binding to protein kinase. Part II: The novel pharmacophore approach of type II and type III inhibition</span> <span class="citation_source-journal">Expert Opin. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1427</span><span class="NLM_x">–</span> <span class="NLM_lpage">1449</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2008&pages=1427-1449&author=A.+C.+Backesauthor=B.+Zechauthor=B.+Felberauthor=B.+Kleblauthor=G.+M%C3%BCller&title=Small-molecule+inhibitors+binding+to+protein+kinase.+Part+II%3A+The+novel+pharmacophore+approach+of+type+II+and+type+III+inhibition"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit21b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBackes%26aufirst%3DA.%2BC.%26aulast%3DZech%26aufirst%3DB.%26aulast%3DFelber%26aufirst%3DB.%26aulast%3DKlebl%26aufirst%3DB.%26aulast%3DM%25C3%25BCller%26aufirst%3DG.%26atitle%3DSmall-molecule%2520inhibitors%2520binding%2520to%2520protein%2520kinase.%2520Part%2520II%253A%2520The%2520novel%2520pharmacophore%2520approach%2520of%2520type%2520II%2520and%2520type%2520III%2520inhibition%26jtitle%3DExpert%2520Opin.%2520Drug%2520Discovery%26date%3D2008%26volume%3D3%26spage%3D1427%26epage%3D1449" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Bollag, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirth, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ibrahim, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spevak, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Habets, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burton, E. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tsang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shellooe, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marimuthu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nguyen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, K. Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Artis, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlessinger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Higgins, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iyer, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Andrea, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koehler, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stumm, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grippo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Puzanov, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ribas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McArthur, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sosman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chapman, P. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Flaherty, K. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nathanson, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolop, K.</span><span> </span><span class="NLM_article-title">Clinical efficacy of a RAF inhibitor needs broad target blockade in <i>BRAF</i>-mutant melanoma</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">467</span><span class="NLM_x">, </span> <span class="NLM_fpage">596</span><span class="NLM_x">–</span> <span class="NLM_lpage">599</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Fjm300126x&amp;key=10.1038%2Fnature09454" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Fjm300126x&amp;key=20823850" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Fjm300126x&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht1ajtbfK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=467&publication_year=2010&pages=596-599&author=G.+Bollagauthor=P.+Hirthauthor=J.+Tsaiauthor=J.+Zhangauthor=P.+N.+Ibrahimauthor=H.+Choauthor=W.+Spevakauthor=C.+Zhangauthor=Y.+Zhangauthor=G.+Habetsauthor=E.+A.+Burtonauthor=B.+Wongauthor=G.+Tsangauthor=B.+L.+Westauthor=B.+Powellauthor=R.+Shellooeauthor=A.+Marimuthuauthor=H.+Nguyenauthor=K.+Y.+J.+Zhangauthor=D.+R.+Artisauthor=J.+Schlessingerauthor=F.+Suauthor=B.+Higginsauthor=R.+Iyerauthor=K.+D%E2%80%99Andreaauthor=A.+Koehlerauthor=M.+Stummauthor=P.+S.+Linauthor=R.+J.+Leeauthor=J.+Grippoauthor=I.+Puzanovauthor=K.+B.+Kimauthor=A.+Ribasauthor=G.+A.+McArthurauthor=J.+A.+Sosmanauthor=P.+B.+Chapmanauthor=K.+T.+Flahertyauthor=X.+Xuauthor=K.+L.+Nathansonauthor=K.+Nolop&title=Clinical+efficacy+of+a+RAF+inhibitor+needs+broad+target+blockade+in+BRAF-mutant+melanoma"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma</span></div><div class="casAuthors">Bollag, Gideon; Hirth, Peter; Tsai, James; Zhang, Jiazhong; Ibrahim, Prabha N.; Cho, Hanna; Spevak, Wayne; Zhang, Chao; Zhang, Ying; Habets, Gaston; Burton, Elizabeth A.; Wong, Bernice; Tsang, Garson; West, Brian L.; Powell, Ben; Shellooe, Rafe; Marimuthu, Adhirai; Nguyen, Hoa; Zhang, Kam Y. J.; Artis, Dean R.; Schlessinger, Joseph; Su, Fei; Higgins, Brian; Iyer, Raman; D'Andrea, Kurt; Koehler, Astrid; Stumm, Michael; Lin, Paul S.; Lee, Richard J.; Grippo, Joseph; Puzanov, Igor; Kim, Kevin B.; Ribas, Antoni; McArthur, Grant A.; Sosman, Jeffrey A.; Chapman, Paul B.; Flaherty, Keith T.; Xu, Xiaowei; Nathanson, Katherine L.; Nolop, Keith</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">467</span>
        (<span class="NLM_cas:issue">7315</span>),
    <span class="NLM_cas:pages">596-599</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">B-RAF is the most frequently mutated protein kinase in human cancers.  The finding that oncogenic mutations in BRAF are common in melanoma, followed by the demonstration that these tumors are dependent on the RAF/MEK/ERK pathway, offered hope that inhibition of B-RAF kinase activity could benefit melanoma patients.  Herein, we describe the structure-guided discovery of PLX4032 (RG7204), a potent inhibitor of oncogenic B-RAF kinase activity.  Preclin. expts. demonstrated that PLX4032 selectively blocked the RAF/MEK/ERK pathway in BRAF mutant cells and caused regression of BRAF mutant xenografts.  Toxicol. studies confirmed a wide safety margin consistent with the high degree of selectivity, enabling Phase 1 clin. trials using a cryst. formulation of PLX4032 (ref. 5).  In a subset of melanoma patients, pathway inhibition was monitored in paired biopsy specimens collected before treatment initiation and following 2 wk of treatment.  This anal. revealed substantial inhibition of ERK phosphorylation, yet clin. evaluation did not show tumor regressions.  At higher drug exposures afforded by a new amorphous drug formulation, greater than 80% inhibition of ERK phosphorylation in the tumors of patients correlated with clin. response.  Indeed, the Phase 1 clin. data revealed a remarkably high 81% response rate in metastatic melanoma patients treated at an oral dose of 960 mg twice daily.  These data demonstrate that BRAF-mutant melanomas are highly dependent on B-RAF kinase activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpYwlns1EfcLVg90H21EOLACvtfcHk0li6PK8fTfyKNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht1ajtbfK&md5=8a26d0ab41970f39a109ddafff2f17b4</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fnature09454&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature09454%26sid%3Dliteratum%253Aachs%26aulast%3DBollag%26aufirst%3DG.%26aulast%3DHirth%26aufirst%3DP.%26aulast%3DTsai%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DIbrahim%26aufirst%3DP.%2BN.%26aulast%3DCho%26aufirst%3DH.%26aulast%3DSpevak%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHabets%26aufirst%3DG.%26aulast%3DBurton%26aufirst%3DE.%2BA.%26aulast%3DWong%26aufirst%3DB.%26aulast%3DTsang%26aufirst%3DG.%26aulast%3DWest%26aufirst%3DB.%2BL.%26aulast%3DPowell%26aufirst%3DB.%26aulast%3DShellooe%26aufirst%3DR.%26aulast%3DMarimuthu%26aufirst%3DA.%26aulast%3DNguyen%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DK.%2BY.%2BJ.%26aulast%3DArtis%26aufirst%3DD.%2BR.%26aulast%3DSchlessinger%26aufirst%3DJ.%26aulast%3DSu%26aufirst%3DF.%26aulast%3DHiggins%26aufirst%3DB.%26aulast%3DIyer%26aufirst%3DR.%26aulast%3DD%25E2%2580%2599Andrea%26aufirst%3DK.%26aulast%3DKoehler%26aufirst%3DA.%26aulast%3DStumm%26aufirst%3DM.%26aulast%3DLin%26aufirst%3DP.%2BS.%26aulast%3DLee%26aufirst%3DR.%2BJ.%26aulast%3DGrippo%26aufirst%3DJ.%26aulast%3DPuzanov%26aufirst%3DI.%26aulast%3DKim%26aufirst%3DK.%2BB.%26aulast%3DRibas%26aufirst%3DA.%26aulast%3DMcArthur%26aufirst%3DG.%2BA.%26aulast%3DSosman%26aufirst%3DJ.%2BA.%26aulast%3DChapman%26aufirst%3DP.%2BB.%26aulast%3DFlaherty%26aufirst%3DK.%2BT.%26aulast%3DXu%26aufirst%3DX.%26aulast%3DNathanson%26aufirst%3DK.%2BL.%26aulast%3DNolop%26aufirst%3DK.%26atitle%3DClinical%2520efficacy%2520of%2520a%2520RAF%2520inhibitor%2520needs%2520broad%2520target%2520blockade%2520in%2520BRAF-mutant%2520melanoma%26jtitle%3DNature%26date%3D2010%26volume%3D467%26spage%3D596%26epage%3D599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">King, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patrick, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Batorsky, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ho, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Do, H. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumar, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rusnak, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takle, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, D. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hugger, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karreth, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lougheed, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chau, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stout, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">May, E. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rominger, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaber, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lakdawala, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Contractor, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smalley, K. S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herlyn, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrissey, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tuveson, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, P. S.</span><span> </span><span class="NLM_article-title">Demonstration of a genetic therapeutic index for tumors expressing oncogenic <i>BRAF</i> by the kinase inhibitor SB-590885</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">11100</span><span class="NLM_x">–</span> <span class="NLM_lpage">11105</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2006&pages=11100-11105&author=A.+J.+Kingauthor=D.+R.+Patrickauthor=R.+S.+Batorskyauthor=M.+L.+Hoauthor=H.+T.+Doauthor=S.+Y.+Zhangauthor=R.+Kumarauthor=D.+W.+Rusnakauthor=A.+K.+Takleauthor=D.+M.+Wilsonauthor=E.+Huggerauthor=L.+Wangauthor=F.+Karrethauthor=J.+C.+Lougheedauthor=J.+Leeauthor=D.+Chauauthor=T.+J.+Stoutauthor=E.+W.+Mayauthor=C.+M.+Romingerauthor=M.+D.+Schaberauthor=L.+Luoauthor=A.+S.+Lakdawalaauthor=J.+L.+Adamsauthor=R.+G.+Contractorauthor=K.+S.+M.+Smalleyauthor=M.+Herlynauthor=M.+M.+Morrisseyauthor=D.+A.+Tuvesonauthor=P.+S.+Huang&title=Demonstration+of+a+genetic+therapeutic+index+for+tumors+expressing+oncogenic+BRAF+by+the+kinase+inhibitor+SB-590885"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DKing%26aufirst%3DA.%2BJ.%26aulast%3DPatrick%26aufirst%3DD.%2BR.%26aulast%3DBatorsky%26aufirst%3DR.%2BS.%26aulast%3DHo%26aufirst%3DM.%2BL.%26aulast%3DDo%26aufirst%3DH.%2BT.%26aulast%3DZhang%26aufirst%3DS.%2BY.%26aulast%3DKumar%26aufirst%3DR.%26aulast%3DRusnak%26aufirst%3DD.%2BW.%26aulast%3DTakle%26aufirst%3DA.%2BK.%26aulast%3DWilson%26aufirst%3DD.%2BM.%26aulast%3DHugger%26aufirst%3DE.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DKarreth%26aufirst%3DF.%26aulast%3DLougheed%26aufirst%3DJ.%2BC.%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DChau%26aufirst%3DD.%26aulast%3DStout%26aufirst%3DT.%2BJ.%26aulast%3DMay%26aufirst%3DE.%2BW.%26aulast%3DRominger%26aufirst%3DC.%2BM.%26aulast%3DSchaber%26aufirst%3DM.%2BD.%26aulast%3DLuo%26aufirst%3DL.%26aulast%3DLakdawala%26aufirst%3DA.%2BS.%26aulast%3DAdams%26aufirst%3DJ.%2BL.%26aulast%3DContractor%26aufirst%3DR.%2BG.%26aulast%3DSmalley%26aufirst%3DK.%2BS.%2BM.%26aulast%3DHerlyn%26aufirst%3DM.%26aulast%3DMorrissey%26aufirst%3DM.%2BM.%26aulast%3DTuveson%26aufirst%3DD.%2BA.%26aulast%3DHuang%26aufirst%3DP.%2BS.%26atitle%3DDemonstration%2520of%2520a%2520genetic%2520therapeutic%2520index%2520for%2520tumors%2520expressing%2520oncogenic%2520BRAF%2520by%2520the%2520kinase%2520inhibitor%2520SB-590885%26jtitle%3DCancer%2520Res.%26date%3D2006%26volume%3D66%26spage%3D11100%26epage%3D11105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit23b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Takle, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, M. J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dean, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Francis, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gaiba, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hird, A. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">King, F. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovell, P. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naylor, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reith, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steadman, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, D. M.</span><span> </span><span class="NLM_article-title">The identification of potent and selective imidazole-based inhibitors of B-Raf kinase</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">378</span><span class="NLM_x">–</span> <span class="NLM_lpage">381</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2006&pages=378-381&author=A.+K.+Takleauthor=M.+J.+B.+Brownauthor=S.+Daviesauthor=D.+K.+Deanauthor=G.+Francisauthor=A.+Gaibaauthor=A.+W.+Hirdauthor=F.+D.+Kingauthor=P.+J.+Lovellauthor=A.+Naylorauthor=A.+D.+Reithauthor=J.+G.+Steadmanauthor=D.+M.+Wilson&title=The+identification+of+potent+and+selective+imidazole-based+inhibitors+of+B-Raf+kinase"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DTakle%26aufirst%3DA.%2BK.%26aulast%3DBrown%26aufirst%3DM.%2BJ.%2BB.%26aulast%3DDavies%26aufirst%3DS.%26aulast%3DDean%26aufirst%3DD.%2BK.%26aulast%3DFrancis%26aufirst%3DG.%26aulast%3DGaiba%26aufirst%3DA.%26aulast%3DHird%26aufirst%3DA.%2BW.%26aulast%3DKing%26aufirst%3DF.%2BD.%26aulast%3DLovell%26aufirst%3DP.%2BJ.%26aulast%3DNaylor%26aufirst%3DA.%26aulast%3DReith%26aufirst%3DA.%2BD.%26aulast%3DSteadman%26aufirst%3DJ.%2BG.%26aulast%3DWilson%26aufirst%3DD.%2BM.%26atitle%3DThe%2520identification%2520of%2520potent%2520and%2520selective%2520imidazole-based%2520inhibitors%2520of%2520B-Raf%2520kinase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2006%26volume%3D16%26spage%3D378%26epage%3D381" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Sakai, N.; Imamura, S.; Miyamoto, N.; Hirayama, T.</span><span> </span><span class="NLM_article-title">Fused Heterocyclic Derivative and Use Thereof</span>. WIPO Patent Application WO 2008/016192, Feb 7,<span class="NLM_x"> </span><span class="NLM_year">2008</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&author=N.+Sakai&author=S.+Imamura&author=N.+Miyamoto&author=T.+Hirayama&title=Fused+Heterocyclic+Derivative+and+Use+Thereof"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSakai%26aufirst%3DN.%26atitle%3DFused%2520Heterocyclic%2520Derivative%2520and%2520Use%2520Thereof%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Jones, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Willett, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glen, R. C.</span><span> </span><span class="NLM_article-title">Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation</span> <span class="citation_source-journal">J. Mol. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">245</span><span class="NLM_x">, </span> <span class="NLM_fpage">43</span><span class="NLM_x">–</span> <span class="NLM_lpage">53</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=16&amp;doi=10.1021%2Fjm300126x&amp;key=10.1016%2FS0022-2836%2895%2980037-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=8&amp;doi=10.1021%2Fjm300126x&amp;key=7823319" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25a&amp;dbid=32&amp;doi=10.1021%2Fjm300126x&amp;key=1%3ACAS%3A528%3ADyaK2MXjtVKlsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=245&publication_year=1995&pages=43-53&author=G.+Jonesauthor=P.+Willettauthor=R.+C.+Glen&title=Molecular+recognition+of+receptor+sites+using+a+genetic+algorithm+with+a+description+of+desolvation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25aR"><div class="casContent"><span class="casTitleNuber">25a</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular recognition of a receptor sites using a genetic algorithm with a description of desolvation</span></div><div class="casAuthors">Jones, Gareth; Willett, Peter; Glen, Robert C.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Biology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">245</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">43-53</span>CODEN:
                <span class="NLM_cas:coden">JMOBAK</span>;
        ISSN:<span class="NLM_cas:issn">0022-2836</span>.
    
            (<span class="NLM_cas:orgname">Academic</span>)
        </div><div class="casAbstract">Understanding the principles whereby macromol. biol. receptors can recognize small mol. substrates or inhibitors is the subject of a major effort.  This is of paramount importance in rational drug design where the receptor structure is known (the "docking" problem).  Current theor. approaches utilize models of the steric and electrostatic interaction of bound ligands and recently conformational flexibility has been incorporated.  The authors report results based on software using a genetic algorithm that uses an evolutionary strategy in exploring the full conformational flexibility of the ligand with partial flexibility of the protein, and which satisfies the fundamental requirement that the ligand must displace loosely bound water on binding.  Results are reported on five test systems showing excellent agreement with exptl. data.  The design of the algorithm offers insight into the mol. recognition mechanism.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7Xcn7nQyVRLVg90H21EOLACvtfcHk0lhvkcK74hwqqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXjtVKlsbc%253D&md5=bf45edafb986a73c7c1d0ac55e070f28</span></div><a href="/servlet/linkout?suffix=cit25a&amp;dbid=16384&amp;doi=10.1016%2FS0022-2836%2895%2980037-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0022-2836%252895%252980037-9%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DG.%26aulast%3DWillett%26aufirst%3DP.%26aulast%3DGlen%26aufirst%3DR.%2BC.%26atitle%3DMolecular%2520recognition%2520of%2520receptor%2520sites%2520using%2520a%2520genetic%2520algorithm%2520with%2520a%2520description%2520of%2520desolvation%26jtitle%3DJ.%2520Mol.%2520Biol.%26date%3D1995%26volume%3D245%26spage%3D43%26epage%3D53" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit25b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Halgren, T. A.</span><span> </span><span class="NLM_article-title">MMFF VI, MMFF94s option for energy minimization studies</span> <span class="citation_source-journal">J. Comput. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">720</span><span class="NLM_x">–</span> <span class="NLM_lpage">729</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=1999&pages=720-729&author=T.+A.+Halgren&title=MMFF+VI%2C+MMFF94s+option+for+energy+minimization+studies"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit25b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHalgren%26aufirst%3DT.%2BA.%26atitle%3DMMFF%2520VI%252C%2520MMFF94s%2520option%2520for%2520energy%2520minimization%2520studies%26jtitle%3DJ.%2520Comput.%2520Chem.%26date%3D1999%26volume%3D20%26spage%3D720%26epage%3D729" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Mourad, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wise, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Townsend, L. B.</span><span> </span><span class="NLM_article-title">Methyl imidazo[1,2-<i>b</i>]pyridazine-2-carbamates and related compounds as potential antifilarial agents</span> <span class="citation_source-journal">J. Heterocycl. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">1583</span><span class="NLM_x">–</span> <span class="NLM_lpage">1592</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=1992&pages=1583-1592&author=A.+E.+Mouradauthor=D.+S.+Wiseauthor=L.+B.+Townsend&title=Methyl+imidazo%5B1%2C2-b%5Dpyridazine-2-carbamates+and+related+compounds+as+potential+antifilarial+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMourad%26aufirst%3DA.%2BE.%26aulast%3DWise%26aufirst%3DD.%2BS.%26aulast%3DTownsend%26aufirst%3DL.%2BB.%26atitle%3DMethyl%2520imidazo%255B1%252C2-b%255Dpyridazine-2-carbamates%2520and%2520related%2520compounds%2520as%2520potential%2520antifilarial%2520agents%26jtitle%3DJ.%2520Heterocycl.%2520Chem.%26date%3D1992%26volume%3D29%26spage%3D1583%26epage%3D1592" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Yamanaka, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Suda, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoneda, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohhara, H.</span><span> </span><span class="NLM_article-title">Imidazo[1,2-<i>a</i>]pyridines. II. Ozonolysis of imidazo[1,2-<i>a</i>]pyridines and synthesis of cardiotonic agents</span> <span class="citation_source-journal">Chem. Pharm. Bull.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1992</span><span class="NLM_x">, </span> <span class="NLM_volume">40</span><span class="NLM_x">, </span> <span class="NLM_fpage">666</span><span class="NLM_x">–</span> <span class="NLM_lpage">674</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=1992&pages=666-674&author=M.+Yamanakaauthor=S.+Sudaauthor=N.+Yonedaauthor=H.+Ohhara&title=Imidazo%5B1%2C2-a%5Dpyridines.+II.+Ozonolysis+of+imidazo%5B1%2C2-a%5Dpyridines+and+synthesis+of+cardiotonic+agents"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYamanaka%26aufirst%3DM.%26aulast%3DSuda%26aufirst%3DS.%26aulast%3DYoneda%26aufirst%3DN.%26aulast%3DOhhara%26aufirst%3DH.%26atitle%3DImidazo%255B1%252C2-a%255Dpyridines.%2520II.%2520Ozonolysis%2520of%2520imidazo%255B1%252C2-a%255Dpyridines%2520and%2520synthesis%2520of%2520cardiotonic%2520agents%26jtitle%3DChem.%2520Pharm.%2520Bull.%26date%3D1992%26volume%3D40%26spage%3D666%26epage%3D674" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit27b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Hamdouchi, C</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mendoza, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaramillo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Diego, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robertson, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Watkins, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brooks, H. B.</span><span> </span><span class="NLM_article-title">Structure-based design of a new class of highly selective aminoimidazo[1,2-<i>a</i>]pyridine-based inhibitors of cyclin dependent kinases</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">1943</span><span class="NLM_x">–</span> <span class="NLM_lpage">1947</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2005&pages=1943-1947&author=C+Hamdouchiauthor=B.+Zhongauthor=J.+Mendozaauthor=E.+Collinsauthor=C.+Jaramilloauthor=J.+E.+de+Diegoauthor=D.+Robertsonauthor=C.+D.+Spencerauthor=B.+D.+Andersonauthor=S.+A.+Watkinsauthor=F.+Zhangauthor=H.+B.+Brooks&title=Structure-based+design+of+a+new+class+of+highly+selective+aminoimidazo%5B1%2C2-a%5Dpyridine-based+inhibitors+of+cyclin+dependent+kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit27b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHamdouchi%26aufirst%3DC%26aulast%3DZhong%26aufirst%3DB.%26aulast%3DMendoza%26aufirst%3DJ.%26aulast%3DCollins%26aufirst%3DE.%26aulast%3DJaramillo%26aufirst%3DC.%26aulast%3Dde%2BDiego%26aufirst%3DJ.%2BE.%26aulast%3DRobertson%26aufirst%3DD.%26aulast%3DSpencer%26aufirst%3DC.%2BD.%26aulast%3DAnderson%26aufirst%3DB.%2BD.%26aulast%3DWatkins%26aufirst%3DS.%2BA.%26aulast%3DZhang%26aufirst%3DF.%26aulast%3DBrooks%26aufirst%3DH.%2BB.%26atitle%3DStructure-based%2520design%2520of%2520a%2520new%2520class%2520of%2520highly%2520selective%2520aminoimidazo%255B1%252C2-a%255Dpyridine-based%2520inhibitors%2520of%2520cyclin%2520dependent%2520kinases%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2005%26volume%3D15%26spage%3D1943%26epage%3D1947" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Alcalde, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinarés, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frigola, J.</span><span> </span><span class="NLM_article-title">NMR studies of <i>N</i>-(benzimidazol-2-yl)pyridinium derivatives: QSAR with the anti-leishmanial activity and their carbon-13 NMR chemical shifts</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">633</span><span class="NLM_x">–</span> <span class="NLM_lpage">642</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=1991&pages=633-642&author=E.+Alcaldeauthor=I.+Dinar%C3%A9sauthor=J.+Frigola&title=NMR+studies+of+N-%28benzimidazol-2-yl%29pyridinium+derivatives%3A+QSAR+with+the+anti-leishmanial+activity+and+their+carbon-13+NMR+chemical+shifts"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAlcalde%26aufirst%3DE.%26aulast%3DDinar%25C3%25A9s%26aufirst%3DI.%26aulast%3DFrigola%26aufirst%3DJ.%26atitle%3DNMR%2520studies%2520of%2520N-%2528benzimidazol-2-yl%2529pyridinium%2520derivatives%253A%2520QSAR%2520with%2520the%2520anti-leishmanial%2520activity%2520and%2520their%2520carbon-13%2520NMR%2520chemical%2520shifts%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D1991%26volume%3D26%26spage%3D633%26epage%3D642" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit28b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Hasegawa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nishigaki, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Washio, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kano, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harris, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mori, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">West, R. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shibahara, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toyoda, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolte, R. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veal, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheung, M.</span><span> </span><span class="NLM_article-title">Discovery of novel benzimidazoles as potent inhibitors of TIE-2 and VEGFR-2 tyrosine kinase receptors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">50</span><span class="NLM_x">, </span> <span class="NLM_fpage">4453</span><span class="NLM_x">–</span> <span class="NLM_lpage">4470</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0611051" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2007&pages=4453-4470&author=M.+Hasegawaauthor=N.+Nishigakiauthor=Y.+Washioauthor=K.+Kanoauthor=P.+A.+Harrisauthor=H.+Satoauthor=I.+Moriauthor=R.+I.+Westauthor=M.+Shibaharaauthor=H.+Toyodaauthor=L.+Wangauthor=R.+T.+Nolteauthor=J.+M.+Vealauthor=M.+Cheung&title=Discovery+of+novel+benzimidazoles+as+potent+inhibitors+of+TIE-2+and+VEGFR-2+tyrosine+kinase+receptors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28b&amp;dbid=16384&amp;doi=10.1021%2Fjm0611051&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0611051%26sid%3Dliteratum%253Aachs%26aulast%3DHasegawa%26aufirst%3DM.%26aulast%3DNishigaki%26aufirst%3DN.%26aulast%3DWashio%26aufirst%3DY.%26aulast%3DKano%26aufirst%3DK.%26aulast%3DHarris%26aufirst%3DP.%2BA.%26aulast%3DSato%26aufirst%3DH.%26aulast%3DMori%26aufirst%3DI.%26aulast%3DWest%26aufirst%3DR.%2BI.%26aulast%3DShibahara%26aufirst%3DM.%26aulast%3DToyoda%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DNolte%26aufirst%3DR.%2BT.%26aulast%3DVeal%26aufirst%3DJ.%2BM.%26aulast%3DCheung%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520novel%2520benzimidazoles%2520as%2520potent%2520inhibitors%2520of%2520TIE-2%2520and%2520VEGFR-2%2520tyrosine%2520kinase%2520receptors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2007%26volume%3D50%26spage%3D4453%26epage%3D4470" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Mader, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Dios, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shih, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonjouklian, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">White, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Uralde, B. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sánchez-Martinez, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">del Prado, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaramillo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">de Diego, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cabrejas, L. M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dominguez, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Montero, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shepherd, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dally, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toth, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chatterjee, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pleite, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blanco-Urgoiti, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perez, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barberis, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorite, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jambrina, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nevill, C. R.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolos, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, B. D.</span><span> </span><span class="NLM_article-title">Imidazolyl benzimidazoles and imidazo[4,5-<i>b</i>]pyridines as potent p38α MAP kinase inhibitors with excellent in vivo antiinflammatory properties</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">179</span><span class="NLM_x">–</span> <span class="NLM_lpage">183</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=179-183&author=M.+Maderauthor=A.+de+Diosauthor=C.+Shihauthor=R.+Bonjouklianauthor=T.+Liauthor=W.+Whiteauthor=B.+L.+de+Uraldeauthor=C.+S%C3%A1nchez-Martinezauthor=M.+del+Pradoauthor=C.+Jaramilloauthor=E.+de+Diegoauthor=L.+M.+M.+Cabrejasauthor=C.+Dominguezauthor=C.+Monteroauthor=T.+Shepherdauthor=R.+Dallyauthor=J.+E.+Tothauthor=A.+Chatterjeeauthor=S.+Pleiteauthor=J.+Blanco-Urgoitiauthor=L.+Perezauthor=M.+Barberisauthor=M.+J.+Loriteauthor=E.+Jambrinaauthor=C.+R.+Nevillauthor=P.+A.+Leeauthor=R.+C.+Schultzauthor=J.+A.+Wolosauthor=L.+C.+Liauthor=R.+M.+Campbellauthor=B.+D.+Anderson&title=Imidazolyl+benzimidazoles+and+imidazo%5B4%2C5-b%5Dpyridines+as+potent+p38%CE%B1+MAP+kinase+inhibitors+with+excellent+in+vivo+antiinflammatory+properties"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMader%26aufirst%3DM.%26aulast%3Dde%2BDios%26aufirst%3DA.%26aulast%3DShih%26aufirst%3DC.%26aulast%3DBonjouklian%26aufirst%3DR.%26aulast%3DLi%26aufirst%3DT.%26aulast%3DWhite%26aufirst%3DW.%26aulast%3Dde%2BUralde%26aufirst%3DB.%2BL.%26aulast%3DS%25C3%25A1nchez-Martinez%26aufirst%3DC.%26aulast%3Ddel%2BPrado%26aufirst%3DM.%26aulast%3DJaramillo%26aufirst%3DC.%26aulast%3Dde%2BDiego%26aufirst%3DE.%26aulast%3DCabrejas%26aufirst%3DL.%2BM.%2BM.%26aulast%3DDominguez%26aufirst%3DC.%26aulast%3DMontero%26aufirst%3DC.%26aulast%3DShepherd%26aufirst%3DT.%26aulast%3DDally%26aufirst%3DR.%26aulast%3DToth%26aufirst%3DJ.%2BE.%26aulast%3DChatterjee%26aufirst%3DA.%26aulast%3DPleite%26aufirst%3DS.%26aulast%3DBlanco-Urgoiti%26aufirst%3DJ.%26aulast%3DPerez%26aufirst%3DL.%26aulast%3DBarberis%26aufirst%3DM.%26aulast%3DLorite%26aufirst%3DM.%2BJ.%26aulast%3DJambrina%26aufirst%3DE.%26aulast%3DNevill%26aufirst%3DC.%2BR.%26aulast%3DLee%26aufirst%3DP.%2BA.%26aulast%3DSchultz%26aufirst%3DR.%2BC.%26aulast%3DWolos%26aufirst%3DJ.%2BA.%26aulast%3DLi%26aufirst%3DL.%2BC.%26aulast%3DCampbell%26aufirst%3DR.%2BM.%26aulast%3DAnderson%26aufirst%3DB.%2BD.%26atitle%3DImidazolyl%2520benzimidazoles%2520and%2520imidazo%255B4%252C5-b%255Dpyridines%2520as%2520potent%2520p38%25CE%25B1%2520MAP%2520kinase%2520inhibitors%2520with%2520excellent%2520in%2520vivo%2520antiinflammatory%2520properties%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D179%26epage%3D183" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Kaufmann, H. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weber, E.</span><span> </span><span class="NLM_article-title">Arzneimittelsynthetische studien IV. Synthese schwefelhaltiger verbindungen</span> <span class="citation_source-journal">Arch. Pharm.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1929</span><span class="NLM_x">, </span> <span class="NLM_fpage">192</span><span class="NLM_x">–</span> <span class="NLM_lpage">211</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Fjm300126x&amp;key=10.1002%2Fardp.19292670304" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm300126x&amp;key=1%3ACAS%3A528%3ADyaB1MXhvFSnsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=1929&pages=192-211&author=H.+P.+Kaufmannauthor=E.+Weber&title=Arzneimittelsynthetische+studien+IV.+Synthese+schwefelhaltiger+verbindungen"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic drug studies. IV. Synthesis of sulfur-containing preparations</span></div><div class="casAuthors">Kaufmann, H. P.; Weber, E.</div><div class="citationInfo"><span class="NLM_cas:title">Archiv der Pharmazie und Berichte der Deutschen Pharmazeutischen Gesellschaft</span>
        (<span class="NLM_cas:date">1929</span>),
    <span class="NLM_cas:volume">267</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">192-211</span>CODEN:
                <span class="NLM_cas:coden">APBDAJ</span>;
        ISSN:<span class="NLM_cas:issn">0376-0367</span>.
    </div><div class="casAbstract">An exptl. study confined mainly to the introduction of the SCN group into, and the influence of such groups, on certain antipyretics (aniline, phenetidine and phenylhydrazinc) and disinfectants (thymol, cresols and hydroxyquinolines).  The method of introducing SCN into the above compds. involves treatment in a suitable solvent with NaSCN and Br.  Among the new compds. prepd. and characterized were the following: p-rhodanacelanilide, C9H8ON2S, needles m. 188°;  1-amino-2-rhodan-4-ethoxybenzene, C9H10ON2S, silky needles m. 67-8°, easily convertible to 2-amino-6-ethoxybenzthiazol; C9H10ON2S, needles m. 161°;  2-diacetylamino-6-ethoxybenzthiazol, C13H14O3N2S, m. 245°;  bis(1-amino-4-ethoxy)2-disulfide, C16H20O2S2, m. 101°; sym.-formyl-(p-rhodanphenyl) hydrazine, C8H7ON3S, needles m. 132°; sym.-Ac(p-rhodanphenyl), C9H9ON3S, m. 171°; sym.-benzoyl-(p-rhodanphenyl)hydrazine, C14H11ON3S, m. 164°; sym.-phthalyl-(p-rhodanphenyl)hydrazine, C15H9O2N3S, m. 213°; sym.-acetyl-bis(p-rhodanphenyl)hydrazine, C15H12ON4S2, needles m. 160°; sym.-benzoyl-bis(p-rhodanphenyl)hydrazine, C21H14ON4S2, m. 160°; α-hydroxy-γ-rhodanquinoline (4-rhodancarbostyrile), C10H6ON2S, yellowish needles m. 141°; γ-rhodan-o-hydroxyquinoline, C10H6ON2S, m. 134°; 1-methyl-4-isopropyl-3-hydroxy-6-rhodanbenzene (3-methyl-4-rhodan-6-isopropylphenol), needles m. 105°; 1-methyl-2-hydroxy-5-rhodanbenzene (o-methyl-p-rhodanphenol), C8H7ONS, m. 71°; 1-methyl-3-hydroxy-5-rhodanbenzene (o-methyl-m-rhodanphenol), C8H7ONS, needles m. 76°; 1-methyl-4-hydroxy-3-rhodanbenzene, C8H7ONS, m. 105°, yields with alc.  HCl a N-free compd., C8H6O2S, m. 83°.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoRUByAzB_wf7Vg90H21EOLACvtfcHk0ligUlFKIoA0Gg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaB1MXhvFSnsg%253D%253D&md5=f514b2d36023e1c8ed30c16b08dfeff8</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1002%2Fardp.19292670304&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fardp.19292670304%26sid%3Dliteratum%253Aachs%26aulast%3DKaufmann%26aufirst%3DH.%2BP.%26aulast%3DWeber%26aufirst%3DE.%26atitle%3DArzneimittelsynthetische%2520studien%2520IV.%2520Synthese%2520schwefelhaltiger%2520verbindungen%26jtitle%3DArch.%2520Pharm.%26date%3D1929%26spage%3D192%26epage%3D211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Yamamoto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takahashi, T.</span><span> </span><span class="NLM_article-title">Syntheses of pyridothiazoles and pyridoxazoles. Sulfur-containing pyridine derivatives. XXXI</span> <span class="citation_source-journal">Yakugaku Zasshi</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1951</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">169</span><span class="NLM_x">–</span> <span class="NLM_lpage">172</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=1951&pages=169-172&author=Y.+Yamamotoauthor=T.+Takahashi&title=Syntheses+of+pyridothiazoles+and+pyridoxazoles.+Sulfur-containing+pyridine+derivatives.+XXXI"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYamamoto%26aufirst%3DY.%26aulast%3DTakahashi%26aufirst%3DT.%26atitle%3DSyntheses%2520of%2520pyridothiazoles%2520and%2520pyridoxazoles.%2520Sulfur-containing%2520pyridine%2520derivatives.%2520XXXI%26jtitle%3DYakugaku%2520Zasshi%26date%3D1951%26volume%3D71%26spage%3D169%26epage%3D172" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit31b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Yamamoto, Y.</span><span> </span><span class="NLM_article-title">Sulfur-containing pyridine derivatives. XXXII. Synthesis of pyridothiazoles</span> <span class="citation_source-journal">Yakugaku Zasshi</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1951</span><span class="NLM_x">, </span> <span class="NLM_volume">71</span><span class="NLM_x">, </span> <span class="NLM_fpage">662</span><span class="NLM_x">–</span> <span class="NLM_lpage">667</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=1951&pages=662-667&author=Y.+Yamamoto&title=Sulfur-containing+pyridine+derivatives.+XXXII.+Synthesis+of+pyridothiazoles"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DYamamoto%26aufirst%3DY.%26atitle%3DSulfur-containing%2520pyridine%2520derivatives.%2520XXXII.%2520Synthesis%2520of%2520pyridothiazoles%26jtitle%3DYakugaku%2520Zasshi%26date%3D1951%26volume%3D71%26spage%3D662%26epage%3D667" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit31c"><span><span class="NLM_label">(c) </span><span class="NLM_contrib-group">Okafor, C. O.</span><span> </span><span class="NLM_article-title">Some pyrido[2,3-<i>d</i>]thiazole systems</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1967</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">126</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm00313a039" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=1967&pages=126&author=C.+O.+Okafor&title=Some+pyrido%5B2%2C3-d%5Dthiazole+systems"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31c&amp;dbid=16384&amp;doi=10.1021%2Fjm00313a039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm00313a039%26sid%3Dliteratum%253Aachs%26aulast%3DOkafor%26aufirst%3DC.%2BO.%26atitle%3DSome%2520pyrido%255B2%252C3-d%255Dthiazole%2520systems%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D1967%26volume%3D10%26spage%3D126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Gao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bohl, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, D. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dalton, J. T.</span><span> </span><span class="NLM_article-title">Characterization of the in vitro metabolism of selective androgen receptor modulator using human, rat, and dog liver enzyme preparations</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">34</span><span class="NLM_x">, </span> <span class="NLM_fpage">243</span><span class="NLM_x">–</span> <span class="NLM_lpage">253</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2006&pages=243-253&author=W.+Gaoauthor=Z.+Wuauthor=C.+E.+Bohlauthor=J.+Yangauthor=D.+D.+Millerauthor=J.+T.+Dalton&title=Characterization+of+the+in+vitro+metabolism+of+selective+androgen+receptor+modulator+using+human%2C+rat%2C+and+dog+liver+enzyme+preparations"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DW.%26aulast%3DWu%26aufirst%3DZ.%26aulast%3DBohl%26aufirst%3DC.%2BE.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DMiller%26aufirst%3DD.%2BD.%26aulast%3DDalton%26aufirst%3DJ.%2BT.%26atitle%3DCharacterization%2520of%2520the%2520in%2520vitro%2520metabolism%2520of%2520selective%2520androgen%2520receptor%2520modulator%2520using%2520human%252C%2520rat%252C%2520and%2520dog%2520liver%2520enzyme%2520preparations%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D2006%26volume%3D34%26spage%3D243%26epage%3D253" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit32b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Okaniwa, M.; Imada, T.; Ohashi, T.; Miyazaki, T.; Arita, T.; Yabuki, M.; Sumita, A.; Tsutsumi, S.; Higashikawa, K.; Takagi, T.; Kawamoto, T.; Inui, Y.; Yoshida, S.; Ishikawa, T.</span><span> </span><span class="NLM_article-title">Design and synthesis of novel DFG-out RAF/vascular endothelial growth factor receptor 2 (VEGFR2) inhibitors: (II) synthesis and characterization of a novel imide-type prodrug for improving oral absorption</span>. Manuscript in preparation.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Okaniwa%2C+M.%3B+Imada%2C+T.%3B+Ohashi%2C+T.%3B+Miyazaki%2C+T.%3B+Arita%2C+T.%3B+Yabuki%2C+M.%3B+Sumita%2C+A.%3B+Tsutsumi%2C+S.%3B+Higashikawa%2C+K.%3B+Takagi%2C+T.%3B+Kawamoto%2C+T.%3B+Inui%2C+Y.%3B+Yoshida%2C+S.%3B+Ishikawa%2C+T.+Design+and+synthesis+of+novel+DFG-out+RAF%2Fvascular+endothelial+growth+factor+receptor+2+%28VEGFR2%29+inhibitors%3A+%28II%29+synthesis+and+characterization+of+a+novel+imide-type+prodrug+for+improving+oral+absorption.+Manuscript+in+preparation."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DOkaniwa%26aufirst%3DM.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520novel%2520DFG-out%2520RAF%252Fvascular%2520endothelial%2520growth%2520factor%2520receptor%25202%2520%2528VEGFR2%2529%2520inhibitors%253A%2520%2528II%2529%2520synthesis%2520and%2520characterization%2520of%2520a%2520novel%2520imide-type%2520prodrug%2520for%2520improving%2520oral%2520absorption" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Remko, M.</span><span> </span><span class="NLM_article-title">Molecular structure, p<i>Ka</i>, lipophilicity, solubility and absorption of biologically active aromatic and heterocyclic sulfonamides</span> <span class="citation_source-journal">J. Mol. Struct.: THEOCHEM</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">944</span><span class="NLM_x">, </span> <span class="NLM_fpage">34</span><span class="NLM_x">–</span> <span class="NLM_lpage">42</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Fjm300126x&amp;key=10.1016%2Fj.theochem.2009.12.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Fjm300126x&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitFylsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=944&publication_year=2010&pages=34-42&author=M.+Remko&title=Molecular+structure%2C+pKa%2C+lipophilicity%2C+solubility+and+absorption+of+biologically+active+aromatic+and+heterocyclic+sulfonamides"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular structure, pKa, lipophilicity, solubility and absorption of biologically active aromatic and heterocyclic sulfonamides</span></div><div class="casAuthors">Remko, Milan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Molecular Structure: THEOCHEM</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">944</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">34-42</span>CODEN:
                <span class="NLM_cas:coden">THEODJ</span>;
        ISSN:<span class="NLM_cas:issn">0166-1280</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The methods of theor. chem. have been used to elucidate mol. properties of clin. useful acetazolamide, dorzolamide and brinzolamide and two new arom. sulfonamides in both neutral and deprotonated forms.  The geometries and energies of these drugs have been computed using HF/6-31G(d), Becke3LYP/6-31G(d) and Becke3LYP/6-311+G(d,p) model chemistries.  The equil. structure of the acetazolamide is stabilized via intramol. interaction between non-bonded S···O atoms of the acetylamino group and the thiadiazole ring.  In the case of the arom. sulfonamides (4-sulfamoyl-N-(3-morpholinopropyl) benzamide (P10), and N-(morpholinopropyl)benzene-1,4-bis(sulfonamide) (P20)) the fully optimized most stable conformers possess characteristic L-shape structure stabilized via intramol. hydrogen bonding system of the N-H···N type.  Computed partition coeffs. (XLOGP2 method) for drugs studied varied between -0.3 and -1.8.  Neutral compds. are described as slightly lipophilic drugs.  The calcd. water soly. of dorzolamide and brinzolamide is comparably low.  P10 and P20 are slightly lipophilic sulfonamides with moderate soly.  The calcd. pKa values of -SO2NH2 moiety in the sulfonamides studied are in the range of 7.3-9.7 and are characterized as weak org. acids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrd4gB3TIuauLVg90H21EOLACvtfcHk0ljndfhnEoJ7Eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitFylsbs%253D&md5=c2d8d1d26507764495fcfdc8efe768f6</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.theochem.2009.12.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.theochem.2009.12.017%26sid%3Dliteratum%253Aachs%26aulast%3DRemko%26aufirst%3DM.%26atitle%3DMolecular%2520structure%252C%2520pKa%252C%2520lipophilicity%252C%2520solubility%2520and%2520absorption%2520of%2520biologically%2520active%2520aromatic%2520and%2520heterocyclic%2520sulfonamides%26jtitle%3DJ.%2520Mol.%2520Struct.%253A%2520THEOCHEM%26date%3D2010%26volume%3D944%26spage%3D34%26epage%3D42" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="note"><p class="first last">The coordinates and structure factors have been deposited with the Protein Data Bank with accession codes <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4DBN">4DBN</a> for BRAF and <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3VNT">3VNT</a> for VEGFR2.</p></div><div class="citationLinks"><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Bondi, A.</span><span> </span><span class="NLM_article-title">van der Waals volumes and radii</span> <span class="citation_source-journal">J. Phys. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1964</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">441</span><span class="NLM_x">–</span> <span class="NLM_lpage">451</span></span><div class="citationLinks">[<a href="/doi/10.1021/j100785a001" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Fjm300126x&amp;key=1%3ACAS%3A528%3ADyaF2cXls1Cgsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=1964&pages=441-451&author=A.+Bondi&title=van+der+Waals+volumes+and+radii"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">van der Waals volumes and radii</span></div><div class="casAuthors">Bondi, A.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Physical Chemistry</span>
        (<span class="NLM_cas:date">1964</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">441-51</span>CODEN:
                <span class="NLM_cas:coden">JPCHAX</span>;
        ISSN:<span class="NLM_cas:issn">0022-3654</span>.
    </div><div class="casAbstract">Intermol. van der Waals radii of the nonmetallic elements were assembled into a list of recommended values for vol. calcns.  These values were arrived at by selecting from the most reliable x-ray diffraction data those which could be reconciled with crystal d. at 0°K. (to give reasonable packing d.), gas kinetic collision cross section, crit. d., and with liquid state properties.  A qual. understanding of the nature of van der Waals radii is provided by correlation with the de Broglie wavelength of the outermost valence electron.  Tentative values for the van der Waals radii of metallic elements in organometallic compds. are proposed.  A list of increments for the vol. of mols. impenetrable to thermal collision, the so-called van der Waals vol., and of the corresponding increments in area per mol. is given.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrHeueZoao997Vg90H21EOLACvtfcHk0ljndfhnEoJ7Eg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF2cXls1Cgsg%253D%253D&md5=0f25964afae4e9f761e0d314151444a5</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fj100785a001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fj100785a001%26sid%3Dliteratum%253Aachs%26aulast%3DBondi%26aufirst%3DA.%26atitle%3Dvan%2520der%2520Waals%2520volumes%2520and%2520radii%26jtitle%3DJ.%2520Phys.%2520Chem.%26date%3D1964%26volume%3D68%26spage%3D441%26epage%3D451" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36a"><span><span class="NLM_label">(a) </span><span class="NLM_contrib-group">Giavazzi, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giuliani, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coltrini, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bani, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferri, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sennino, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tosatti, M. P. M</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoppacciaro, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Presta, M.</span><span> </span><span class="NLM_article-title">Modulation of tumor angiogenesis by conditional expression of fibroblast growth factor-2 affects early but not established tumors</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">309</span><span class="NLM_x">–</span> <span class="NLM_lpage">317</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2001&pages=309-317&author=R.+Giavazziauthor=R.+Giulianiauthor=D.+Coltriniauthor=M.+R.+Baniauthor=C.+Ferriauthor=B.+Senninoauthor=M.+P.+M+Tosattiauthor=A.+Stoppacciaroauthor=M.+Presta&title=Modulation+of+tumor+angiogenesis+by+conditional+expression+of+fibroblast+growth+factor-2+affects+early+but+not+established+tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36a&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DGiavazzi%26aufirst%3DR.%26aulast%3DGiuliani%26aufirst%3DR.%26aulast%3DColtrini%26aufirst%3DD.%26aulast%3DBani%26aufirst%3DM.%2BR.%26aulast%3DFerri%26aufirst%3DC.%26aulast%3DSennino%26aufirst%3DB.%26aulast%3DTosatti%26aufirst%3DM.%2BP.%2BM%26aulast%3DStoppacciaro%26aufirst%3DA.%26aulast%3DPresta%26aufirst%3DM.%26atitle%3DModulation%2520of%2520tumor%2520angiogenesis%2520by%2520conditional%2520expression%2520of%2520fibroblast%2520growth%2520factor-2%2520affects%2520early%2520but%2520not%2520established%2520tumors%26jtitle%3DCancer%2520Res.%26date%3D2001%26volume%3D61%26spage%3D309%26epage%3D317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div><div class="NLM_citation" id="rightTab-cit36b"><span><span class="NLM_label">(b) </span><span class="NLM_contrib-group">Pietras, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sjöblom, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rubin, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heldin, C.-H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Östman, A.</span><span> </span><span class="NLM_article-title">PDGF receptors as cancer drug targets</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">439</span><span class="NLM_x">–</span> <span class="NLM_lpage">443</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2003&pages=439-443&author=K.+Pietrasauthor=T.+Sj%C3%B6blomauthor=K.+Rubinauthor=C.-H.+Heldinauthor=A.+%C3%96stman&title=PDGF+receptors+as+cancer+drug+targets"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36b&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPietras%26aufirst%3DK.%26aulast%3DSj%25C3%25B6blom%26aufirst%3DT.%26aulast%3DRubin%26aufirst%3DK.%26aulast%3DHeldin%26aufirst%3DC.-H.%26aulast%3D%25C3%2596stman%26aufirst%3DA.%26atitle%3DPDGF%2520receptors%2520as%2520cancer%2520drug%2520targets%26jtitle%3DCancer%2520Cell%26date%3D2003%26volume%3D3%26spage%3D439%26epage%3D443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Backer, M. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Backer, J. M.</span><span> </span><span class="NLM_article-title">Functionally active VEGF fusion proteins</span> <span class="citation_source-journal">Protein Expression Purif.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">7</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Fjm300126x&amp;key=10.1006%2Fprep.2001.1472" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Fjm300126x&amp;key=11570839" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Fjm300126x&amp;key=1%3ACAS%3A528%3ADC%252BD3MXmvFymur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2001&pages=1-7&author=M.+V.+Backerauthor=J.+M.+Backer&title=Functionally+active+VEGF+fusion+proteins"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Functionally Active VEGF Fusion Proteins</span></div><div class="casAuthors">Backer, Marina V.; Backer, Joseph M.</div><div class="citationInfo"><span class="NLM_cas:title">Protein Expression and Purification</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-7</span>CODEN:
                <span class="NLM_cas:coden">PEXPEJ</span>;
        ISSN:<span class="NLM_cas:issn">1046-5928</span>.
    
            (<span class="NLM_cas:orgname">Academic Press</span>)
        </div><div class="casAbstract">Angiogenesis is stimulated by vascular endothelial growth factor (VEGF) acting via endothelial cell-specific receptors, such as VEGFR-2, that are overexpressed at the sites of angiogenesis.  If VEGF retains activity as a fusion protein with a large N-terminal extension, it would facilitate development of VEGF-based vehicles for receptor-mediated delivery of therapeutic and diagnostic agents to the sites of angiogenesis.  We have constructed, expressed in Escherichia coli, and purified VEGF fusion proteins contg. a 158-amino acid N-terminal extension fused to human VEGF121, VEGF165, and VEGF189.  We report here that VEGF fusion proteins induce tyrosine autophosphorylation of VEGFR-2 and its downstream targets, as well as cell contraction in cells overexpressing VEGFR-2.  Although N-terminal extensions decrease the affinity of VEGF fusion proteins to VEGFR-2, at satg. concns. these proteins are as efficient as correct size VEGF165.  We hypothesize that VEGF fusion proteins may be employed for targeting endothelial cells at the sites of angiogenesis.  (c) 2001 Academic Press.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqliXh0Fgp0MbVg90H21EOLACvtfcHk0lgAWOTtRccfPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXmvFymur4%253D&md5=4141b8a25070c8092e480ce25a42b252</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1006%2Fprep.2001.1472&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1006%252Fprep.2001.1472%26sid%3Dliteratum%253Aachs%26aulast%3DBacker%26aufirst%3DM.%2BV.%26aulast%3DBacker%26aufirst%3DJ.%2BM.%26atitle%3DFunctionally%2520active%2520VEGF%2520fusion%2520proteins%26jtitle%3DProtein%2520Expression%2520Purif.%26date%3D2001%26volume%3D23%26spage%3D1%26epage%3D7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Janssens, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van den Mooter, G.</span><span> </span><span class="NLM_article-title">Review: physical chemistry of solid dispersions</span> <span class="citation_source-journal">J. Pharm. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">1571</span><span class="NLM_x">–</span> <span class="NLM_lpage">1586</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Fjm300126x&amp;key=10.1211%2Fjpp.61.12.0001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Fjm300126x&amp;key=19958579" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Fjm300126x&amp;key=1%3ACAS%3A528%3ADC%252BC3cXitFGqsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2009&pages=1571-1586&author=S.+Janssensauthor=G.+Van+den+Mooter&title=Review%3A+physical+chemistry+of+solid+dispersions"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Review: physical chemistry of solid dispersions</span></div><div class="casAuthors">Janssens, Sandrien; Van den Mooter, Guy</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacy and Pharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1571-1586</span>CODEN:
                <span class="NLM_cas:coden">JPPMAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3573</span>.
    
            (<span class="NLM_cas:orgname">Pharmaceutical Press</span>)
        </div><div class="casAbstract">A review.  With poorly sol. drug candidates emerging in the drug discovery pipeline, the importance of the solid dispersion formulation approach is increasing.  This strategy includes complete removal of drug crystallinity, and mol. dispersion of the poorly sol. compd. in a hydrophilic polymeric carrier.  The potential of this technique to increase oral absorption and hence bioavailability is enormous.  Nevertheless, some issues have to be considered regarding thermodn. instability, as well in supersatd. solns. that are formed upon dissoln. as in the solid state.  After a brief discussion on the historical background of solid dispersions and their current role in formulation, an overview will be given on the phys. chem. and stability of glass solns. as they form supersatd. solns., and during their shelf life.  Thorough understanding of these aspects will elicit conscious evaluation of carrier properties and eventually facilitate rational excipient selection.  Thus, full exploitation of the solid dispersion strategy may provide an appropriate answer to drug attrition due to low aq. soly. in later stages of development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2x4xN6QffoLVg90H21EOLACvtfcHk0lgAWOTtRccfPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXitFGqsr4%253D&md5=7c8c3efd9cf1fcc162e208ff8ffda813</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1211%2Fjpp.61.12.0001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1211%252Fjpp.61.12.0001%26sid%3Dliteratum%253Aachs%26aulast%3DJanssens%26aufirst%3DS.%26aulast%3DVan%2Bden%2BMooter%26aufirst%3DG.%26atitle%3DReview%253A%2520physical%2520chemistry%2520of%2520solid%2520dispersions%26jtitle%3DJ.%2520Pharm.%2520Pharmacol.%26date%3D2009%26volume%3D61%26spage%3D1571%26epage%3D1586" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4DBN" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4DBN','PDB','4DBN'); return false;">PDB: 4DBN</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3VNT" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3VNT','PDB','3VNT'); return false;">PDB: 3VNT</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1UWJ" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1UWJ','PDB','1UWJ'); return false;">PDB: 1UWJ</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i95"><a href="/doi/suppl/10.1021/jm300126x">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_16512"></div></div></div></div></div><hr /></hr><p class="last">Information methods used in kinase enzyme assays, cellular assays, in vivo studies, computational studies, structural biology studies, solubility study, microsomal study, and pharmacokinetic studies. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm300126x/suppl_file/jm300126x_si_001.pdf">jm300126x_si_001.pdf (224.67 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm300126x&amp;pbContext=%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2012.55.issue-7%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3Barticle%3Aarticle%3A10.1021%2Fjm300126x%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm300126x" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677b781dea3c2367","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
